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Neonatal respiratory insufficiency and failure are common problems for many
infants in the intensive care unit, and respiratory therapies in the immediate
newborn period typically focus on the lung parenchyma.1 Because the lung matures
relatively late in gestation, immaturity of respiratory function is a significant
problem among premature infants. Term infants may also suffer from damage to
the normally structured and fully developed lung, such as in case of meconium
aspiration syndrome and pneumonia.2,3 Compromised lung function can also be due
to structural abnormalities of the lung, exemplified by congenital diaphragmatic
hernia of other major congenital anomalies such as congenital cystic adenomatoid
malformation of the lung (CCAM) and congenital lobar emphysema.4-6 In addition,
immaturity of the lung's type II cells, surfactant insufficiency or inactivation, fluid
filled parenchyma from retained fluid or infiltrate, and terminal air sacs or canaliculi
instead of alveoli result in diminished compliance and need for respiratory support.7
Mechanical ventilation of a developing lung can lead to chronic lung disease
characterized by arrest of alveolar and vascular development.8 Understanding how
alveoli and the underlying capillary network develop and how these mechanisms are
disrupted in the above mentioned conditions is crucial to develop efficient and
effective therapies for lung disease characterized by alveolar damage.
One such therapy is treatment with surfactant, and this has significantly reduced
neonatal mortality for premature infants with lung immaturity and respiratory
distress2 It is also successfully used for near-term infants with severe respiratory
distress, along with others therapies such as "gentle ventilation".9 Surfactant
treatment may greatly benefit newborn infants with respiratory compromise
secondary to a number of insults, but further prospective evidence of its efficacy in
such disorders is needed.
Late Lung development
The lung is composed of branched tubes that conduct air to a vast gas-exchange
system. The terminal gas-exchange surface is composed of sacs called alveoli,
which are lined by blood capillaries.10 Development of the lung involves complex
mesenchymal-epithelial interactions.11,12 Based on the formation of key
components, three distinct stages of lung development are identified: initial bud
formation, dichotomous branching, which produces the air conducting systems, and
formation and maturation of the terminal elements to produce the gas-exchange
surface.10 Based on histological features, lung development can be classified into
different stages. The embryonic stage is characterized by the formation of the lung
bud as a simple budding of the epithelium from the ventral diverticulum of the
foregut into the surrounding mesenchyme. Then, the resulting lung bud undergoes
rapid dichotomous branching via a complex epithelium-mesenchyme interaction.
This is the pseudoglandular stage, characterized by the formation of the conductive
airway tree down to the terminal bronchioles.13,14 Next, the canalicular stage shows
expansion of the airway tree and massive organ growth along with differentiation of
the air space epithelium cell types. This stage is also marked by massive increase in
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the number of capillaries in the primitive mesenchyme.10 The main gas exchange
surface is formed in the next periods, the saccular and alveolar stages.
Transformation of the immature saccular lung, with a limited gas exchange area, to
a mature lung with a large internal surface area entails thinning of alveolar walls,
growth of a capillary network, and extensive subdivision of gas exchange units. This
period is marked by interstitial fibroblast proliferation while epithelial cells flatten
and decrease in number, resulting in a net thinning of distal airspace walls.15
Concurrently, the alveolar capillary network becomes more complex. Alveolar
septation begins as secondary crests that extend from the primary alveolar
walls.10,16-18 These crests, or septa develop through deposition of new basement
membranes, outgrowth of epithelial cells and myofibroblasts at the tips of septa,
and elastin deposition.19,20 Septation is developmentally regulated, occurring
primarily from postnatal day 4 through 14 in rats and mice and during the last
month of gestation and the first postnatal years in humans. Septum formation
seems to involve mechanisms that are different from those implicated in the
preceding steps in lung development.10,21,22
Septum differentiation
Little is known about the signals for the selection of a specific septation initiation
site over others. A number of theories have been put forward to explain the crucial
steps. Various stimuli, including genetic factors, oxygen tension, nutrition and
hormones, have been shown to modulate distal growth of the lung.23,24 These
stimuli exert their effects via interaction with specific developmentally regulated
molecular pathways that have been evolutionarily conserved.
Many investigators agree that the initial deposition of elastin at specific sites in the
walls of the developing sacculae marks the onset of septa formation.25,26 First
expressed near airway branching points during the pseudoglandular stage, elastin
gene expression peaks during alveolarization when elastin fibers localize to the tips
of the alveolar secondary crest, forming rings that surround the alveolar
entrances.26 The elastin fibers deposit in bundles within alveolar walls.19,20 As elastic
fibers are the primary tissue components in which the energy of mechanical stretch
is stored and released in the septum, these fibers and the elastin-expressing cells
(myofibroblast, fibroblasts) fundamentally determine septal mechanical properties
and strain-related signal transduction. Mechanical stresses provide signals for the
orientation and differentiation of alveolar myofibroblasts as well as for directional
organization of a complex elastic fiber network. Elastin expression in alveolar
myofibroblast is upregulated by transforming growth factor-ǃ (TGF-ǃ) and
downregulated by fibroblast growth factor (FGF).27-32 Inhibition of lysyl oxidase-
mediated crosslinking, exposure to hyperoxia, dexamethasone, depletion of alveolar
myofibroblast, or targeted ablation of the elastin gene all result in decreased
alveolar deposition and enlarged emphysema-like alveoli containing fewer septa.
Moreover, there is a link between retinoids and lung elastin.29,33 A subset of lipid-
laden alveolar myofibroblasts metabolizes retinoids, which upregulate elastin
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expression. Deletion of retinoic acid receptors leads to reduced lung elastin and
alveolar numbers.34-36
During transition from the saccular to the alveolar stage, the walls of the terminal
respiratory units become thinner by apoptosis, and a single layer of capillaries
replaces the double-capillary network found in rudimentary alveolar walls.15 For the
septum to achieve its final mature morphology and role, two preconditions are
critical, namely the presence of a mature microvasculature and the thinning of the
septal mesenchyme, which provides the shortest distance for gas exchange.
Thinning of the mesenchymal tissue involves apoptosis.15 Postnatally, there is a
substantial reduction in the number of interstitial myofibroblasts resulting from
increased apoptosis during alveolarization.
Vascular development
Vascular development occurs via two processes: (1) vasculogenesis, the
development of blood vessels from the differentiation of angioblasts in the
mesoderm, and (2) angiogenesis, which is classically described as sprouting of
blood vessels from existing vessels, but can also occur by "intussusception", i.e. the
formation and growth of a transcapillary tissue pillar that eventually divides an
existing capillary segment into two parts.37-40,41 The bronchial vessels develop with
preacinar airways; development is complete by approximately 16 weeks gestation
with further growth in size to match lung growth. Bronchial vessels are generally
not found in the peripheral acinar region and thus do not normally participate in
alveolar gas exchange. Preacinar pulmonary arteries, supplied by the right heart,
grow simultaneously with the airways into the intra-acinar region and fuse with the
peripherial microvasculature that has arisen from the mesenchyme by
vasculogenesis.42,43 It is not yet fully understood how capillary invasion and alveolar
septation interact with each other. The importance of vascular supply to
alveolarization was demonstrated by studies using antiangiogenic agents, e.g.
inhibitors of the vascular endothelial growth factor (VEGF) receptor.44,45 In the
developing lungs, VEGF isoforms and its receptors have been identified as being
important for endothelial survival and proliferation in the alveolar wall. Other than
VEGF, growth factors like platelet derived growth factor-B (PDGF-B) and its
receptors are crucial for vascular growth and integrity during the alveolar phase by
promoting angiogenesis via upregulation of VEGF and basic fibroblast growth factor
(FGF).46 Furthermore, sonic hedgehog (shh), which is known to be expressed in
developing lungs, has been shown to act on fibroblasts to induce an array of
angiogenic factors like VEGF, angiopoietin-1 and -2 (Ang-1 and Ang-2).46
Animal studies suggest that normal pulmonary vascular growth depends on complex
signaling between the developing alveolar epithelium and the adjacent pulmonary
capillaries. In particular, the mitogenic peptide VEGF is secreted by alveolar
epithelial cells and promotes endothelial cell migration and differentiation.
Disturbances of these complex signaling systems in humans may result in
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disturbance of normal lung growth and development, such as in the case of
bronchopulmonary dysplasia.47,48
Bronchopulmonary Dysplasia
Bronchopulmonary dysplasia (BPD) is a chronic lung disease that most commonly
occurs in premature infants who have needed mechanical ventilation and oxygen
therapy for acute respiratory distress. It may also occur, however, in premature
infants who have had few signs of initial lung disease.8 The definition and exact
clinical criteria of BPD have undergone several changes over the last 30 years.
Currently, many neonatologists use the following criterion: oxygen dependency at
36 weeks postconceptional age in children with a history of assisted ventilation and
characteristic radiographic abnormalities.8 Infants at risk for BPD are born at below
28 weeks' gestation, at a stage when the parallel processes of alveolarization of the
distal lung saccules and development of the capillary bed are just beginning.
Although the disorder is most often associated with premature birth, it is also seen
in infants born at term who needed aggressive ventilation for severe acute lung
disease.49 For these children, alternative diagnostic criteria have to be used, which
regrettably have not been clearly defined. The best available definition is that of
Bancalari et al from 1979, which includes assisted ventilation for at least 3 days,
continuing respiratory symptoms and continued oxygen dependency at 28 days
postnatal age, as well as typical radiographic abnormalities.50,51 Although surfactant
therapy, antenatal steroids, and advances in neonatal intensive care and other
treatments have greatly improved the outcomes, the overall incidence of BPD has
not changed over the past decade. Nevertheless, the severity of this disorder has
been modulated by changes in clinical practice.52 The overall incidence of BPD is
reported to be about 20% of ventilated newborns, with variability between
centers.53 Classically, BPD occurs in the preterm infant lung exposed to hyperoxia
and mechanical ventilation, resulting in extensive alveolar fibroproliferation,
bronchovascular smooth muscle cell hyperplasia and inhibition of distal lung
formation leading to long term pulmonary dysfunction persisting into adolescence
and adulthood.
The "new BPD", lacks the severe bronchovascular lesions and interstitial fibrosis,
and shows abnormal lung development with simplified acinar structure, poorly
formed secundary crests, dysmorphic alveolar capillaries and expression of
angiogenic factors and their receptors.23
In a primate model of BPD induced by mechanical ventilation of premature
baboons, decreased lung capillary density was associated with a reduction in lung
VEGF.48 The lungs of human infants who died with BPD show reduced VEGF
expression as well.54-58
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Inflammation
A number of studies over the past few years have implicated inflammatory
mediators in the development of BPD. Epidemiologic studies suggest that either
pre- or postnatal exposure to these mediators may predispose to the development
of BPD. These mediators may be released in response to infectious
(chorioamnionitis, sepsis, pneumonia) and non-infectious (oxygen, mechanical
ventilation) stimuli.59,60 Increasing evidence indicates that BPD results, at least in
part, from a persistent imbalance between pro-inflammatory and anti-inflammatory
mechanisms which favors pro-inflammatory mechanisms.61 Neutrophils and
macrophages play a crucial role in pulmonary inflammation. Infants at various
stages of developing BPD have much higher and persisting numbers of neutrophils
and macrophages in their bronchoalveolar lavage fluid compared to infants who
have recovered from respiratory distress syndrome (RDS) without developing RDS.
The initiation of mechanical ventilation is followed by a neutrophil influx into the
airways within minutes. The inflammatory response to injury due to mechanical
ventilation may include activation of macrophages that generate early reponse
cytokines like Tumor Necrosis Factor-Į (TNF-Į) and interleukin-1 (IL-1). Increased
protein levels and high mRNA expression of pro-inflammatory cytokines and
chemokines (TNF-Į, IL-1, IL-6, CXCL8) have been detected in airway secretions and
bronchoalveolar cells of infants with developing BPD.62 These cytokines stimulate
vascular endothelial cells to express vascular adhesion molecules, such as
intercellular adhesion molecule-1 (ICAM-1), and E-selectin. Blood neutrophils
adhere to endothelial cells and transmigrate into the interstial and alveolar
compartments. The increased levels and enhanced mRNA expression of pro-
inflammatory cytokines present in the airways and pulmonary tissue reflect the
inability to regulate inflammation through an adequate expression of the anti-
inflammatory cytokines e.g. IL-4, IL-10, IL-12, IL-13 and IL-18.63,64 Cellular IL-10
mRNA is undetectable in most airway samples of preterm infants with RDS, but is
expressed in samples from term infants. Injury to the lung is related to generation
of oxidants by phagocyte cells and the release of proteases.65,66
Proteases and protease inhibitors
Data from in vitro studies, animal experiments and observations in preterm infants
with BPD clearly indicate that an imbalance between proteases and protease
inhibitors may contribute to the pathogenesis of BPD.66-70 Neutrophils and
macrophages present at sites of inflammation release various potent proteases that
are thought to play essential roles in the destruction of the alveolar-capillary unit
and/or the extracellular matrix. An imbalance between elastase and antiproteases
has clearly been demonstrated in preterm infants with RDS and BPD. An imbalance
between the cystein proteases cathepsin B, H, L and S and their inhibitors has been
described in animal models and infants with BPD.
The matrix metalloproteinases (MMPs) process a large array of extracellular and cell
surface proteins under normal and pathological conditions. MMPs and their tissue
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inhibitors (TIMP) play a key role in epithelial-mesenchymal interactions that are
essential for lung development. Infants who develop BPD show an increased
amount of MMP 2 and a higher ratio of MMP 9 to TIMP 1 in the first days of life.67,69
A study of the pathology of BPD using immunohistochemical detection of MMPs and
TIMPs from lung sections of preterm infants in various stages of BPD revealed
changing concentration of TIMP 1 from acute to chronic stages, which was mostly
associated with differentiation of fibroblasts.67
The interactions between the surfactant proteins and MMPs and TIMPs in the
alveolar space most likely play an important role in the lung maturation process,
but more information is needed to identify the exact nature of these interactions in
newborns undergoing ventilatory support using different modalities, such as
conventional mechanical ventilation, oscillation, and other.71-73
Ventilator-induced lung injury
Mechanical ventilation may injure the lungs or exacerbate the pre-existing condition
that necessitated mechanical ventilation. Ventilator-induced lung injury (VILI) may
be associated with alveolar structural damage, pulmonary edema, inflammation and
fibrosis.74 Recovery from VILI requires clearance of pulmonary edema and alveolar
structural repair. The pathogenetic mechanisms for the development of VILI include
high airway pressure (barotrauma), large gas volumes (volutrauma), alveolar
collapse and re-expansion (atelectrauma) and increased inflammation
(biotrauma).75-77 Oxygen toxicity, barotrauma but also volutrauma and oxygen
toxicity induce an infammatory response, which persists in infants who develop
BPD. Ventilator- induced lung injury itself is multifactorial.
Volutrauma refers to a more subtle type of lung injury that can occur secondary to
pulmonary over-distention induced by mechanical ventilation. Excessive inspiratory
lung- stretch can lead to the development of pulmonary edema, diffuse alveolar
damage, increased epithelial permeability, and increased microvascular
permeability. The term volutrauma indicates that the critical variable for injury is
not the airway pressure per se, but rather lung volume or end-inspiratory
stretch.63,64,78
Atelectrauma refers to the damage that can occur when lungs are allowed to
become atelectatic and then are reexpanded. Studies performed during
conventional mechanical ventilation of surfactant-depleted lungs with various levels
of PEEP support the concept that repeated opening and closing of terminal units
causes additional injury. It seems likely that unstable lung units may be damaged
by repeated opening and closing tidal ventilation. Keeping end-expiratory lung
volumes high enough to prevent atelectasis, and using small tidal volumes to
prevent overdistension, improved surfactant efficacy, at least in premature
rabbits.79-81
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Biotrauma, a relatively newly described response to mechanical stress, is
characterized by the release of inflammatory mediators from cells within the lung.
These mediators can cause further injury to lung tissue and to other organ systems.
A number of studies have provided evidence that mechanical ventilation of injured
lungs can exacerbate lung injury and lead to an additional inflammatory response.64
Although subject to some debate, most experimental studies demonstrate that
overstretching lung cells can lead to an increase in lung cytokines.82 Under
conditions of increased lung permeability, these cytokines may translocate from the
alveolar space to the systemic circulation. Within this context, conventional
ventilation in a rabbit model of lung injury produced severe hypoxemia and
pathologic evidence of an influx of large numbers of neutrophils into the lung.83,84
This was in marked contrast to findings in animals that were neutrophil-depleted
with nitrogen mustard prior to lung lavage: the absence of neutrophilic infiltration
was associated with increased PaO2.85-87 These results suggest a key role for
neutrophil-released mediators in ventilator-induced lung injury.
High frequency oscillation in a similar lung lavage model significantly decreased the
concentrations of inflammatory mediators, including thromboxane B2 and platelet
activating factor, when compared to conventional mechanical ventilation.88 Injurious
forms of mechanical ventilation can also lead to higher cytokine concentrations in
previously healthy lungs. These higher concentration are associated with an
increase in c-fos mRNA, an early response gene. This would seem to suggest that
the concept of mechano-transduction (the conversion of cell or receptor
deformation into biochemical responses) might be crucial in activating intracellular
signal transduction pathways and lead to biotrauma.89-91 In experiments in which
isolated lung cells were submitted to cyclic stretch, increasing cell stretch resulted
in an increased release of variuos inflammatory mediators, including TNF-alpha, IL-
6, IL-8, and MMP-9.92-95 Lung macrophages were the main source of these
cytokines, which is associated with up-regulation of the nuclear factor kappa B (NF-
kB) transcription factor. Cytokines found in the lavage fluid may not stay in the lung
but also reach the systemic circulation.96-99 In an isolated perfused mouse model,
ventilation with high end-inspiratory stretch produced higher cytokines levels in the
perfusate of the lungs.97 Another group found that application of zero PEEP with a
moderately large tidal volume (16 mL/kg) in an acid aspiration lung injury model in
the rat resulted in higher serum TNF-alpha and macrophage inflammatory protein-2
(MIP-2) concentration over a four hour period. When the same tidal volume was
used with a higher PEEP level (5 cmH20), there was no significant increase in serum
TNF-alpha. These data suggest a mechanism (release of cytokines and/or
inflammatory mediators into the systemic circulation) by which mechanical
ventilation might have systemic consequences leading to end-organ failure.97
Further evidence for this comes from a rabbit acid aspiration model, in which an
injurious ventilatory strategy induced epithelial cell apoptosis in the kidney. Using
the kidney cells in culture the researchers went on to suggest that apoptosis might
have been mediated by a circulating factor, - soluble Fas Ligand (sFasL).98,100,101
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Finally, they demonstrated a relevance to humans: patients with acute respiratory
distress syndrome (ARDS) who were ventilated with a lung protective strategy had
lower levels of sFasL than those ventilated using a standard ventilatory approach.100
There are other mechanisms by which mechanical ventilation could produce
systemic effects such as translocation of bacteria or endotoxins from the lungs into
the systemic circulation.102,103
Pulmonary surfactant
Surfactant replacement therapy has now become the standard therapy for the
premature infant with respiratory distress.104 There is a significant body of evidence
for profound functional surfactant deficiency in near-term infants with respiratory
failure requiring mechanical ventilation with high mean airway pressure and high
FiO2.105 This may either represent a primary deficiency such as occurs in hyaline
membrane disease (HMD) or be a result of surfactant inhibition or inactivation.
Surfactant composition and function
Pulmonary surfactant is critical for normal lung functioning and survival after birth.
Natural surfactant consists of 80% phospholipids, 8% neutral lipids, and 12%
proteins, including both surfactant-associated proteins and proteins from plasma
and lung tissue. Saturated phosphatidylcholines, most of which is dipalmitoyl
phosphatidylcholine, comprise 60% of the phospholipids. Unsaturated
phosphatidylcholine species comprise another 25%, and the remaining 15% is
phosphatidylglycerol.106,107 Surfactant is synthesized by type II alveolar cells, stored
in lamellar bodies, and eventually secreted into the airspaces as tubular myelin,
which then forms a monolayer at the air-fluid interface. Surfactant reduces surface
tension and inhibits lung vascular injury and edema.108
There are four surfactant-associated proteins: surfactant proteins (SP) A, B, C, and
D. Two of these, SP-A and SP-D, are hydrophobic oligomers of trimeric subunits and
are members of the collectin superfamily, containing a collagen-like domain as well
as a carbohydrate-binding region.109-112 Found in both pulmonary and
extrapulmonary tissue, they are involved in the immune response to microbial
challenges. In this process they bind microorganisms, and modulate various
leukocyte functions including chemotaxis, cytokine production, and phagocytosis.113
In vitro studies suggest a role for SP-A in the formation and maintenance of the
tubular myelin structure as well as regulation of surfactant metabolism in the
alveolus.109
The other two, SP- B and SP-C, are hydrophobic surfactant associated proteins that
facilitate adsorption and spread of phospholipids to form a monolayer at the air-
liquid interface. SP- B is required for proper packaging of surfactant into lamellar
bodies and so very essential for good lung functioning.110
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Surfactant inhibition
There is increasing evidence suggesting that surfactant deficiency may coexist with
other lung disorders.105,111,114-117 An example is meconium aspiration syndrome
(MAS), characterized by lung hyperinflation and acute pneumonitis. Abnormal
pulmonary function in MAS may be caused in part by disorders of surfactant
metabolism.118 Animal models of meconium aspiration demonstrate inactivation of
surfactant with higher surface tension and lower lung volume, compliance, and
oxygenation.118-121 In human infants, concentrations of surfactant inhibitors (e.g.
total protein, albumin, membrane-derived phospholipid) were higher in lung lavage
fluid of infants with MAS than in controls, but concentrations of surfactant
phospholipid and surfactant protein A did not differ.122 In a small study, there was a
trend toward lower surfactant synthesis in neonates with MAS or persistent
pulmonary hypertension (PPHN), who required extracorporeal membrane
oxygenation (ECMO), compared to control infants who required ventilatory support
for non-pulmonary indications.123 Lower tracheal aspirate concentrations of
phosphatidylcholine (PC) and lower incorporation of radiolabeled carbon in PC were
seen in infants with MAS or PPHN compared to controls.106 Cleary et al. found
qualitative decreases in surfactant proteins A and B in meconium-installed animals
compared with controls. This suggests that exudative lung injury with meconium
instillation is associated with lower levels of SP-A and SP-B in the large aggregate
fraction of lung surfactant.124 The authors speculated that less secretion and/or
more degradation account for lower levels of SP-B in bronchoalveolar fluid.
Meconium aspiration syndrome
Meconium aspiration syndrome (MAS) is a respiratory disorder caused by inhalation
of meconium in amniotic fluid into the tracheobronchial tree. Aspiration can occur
before, during, or immediately after delivery. Most cases of severe MAS appear to
result from pathologic intrauterine processes, primarily chronic asphyxia and
infection. Meconium-stained amniotic fluid (MSAF) is seen in a median of 14 percent
of deliveries (range 6 to 25 percent) and is associated with higher risk of respiratory
disorders. MAS occurs in around 11 percent of newborns delivered through MSAF. It
occurs more frequently in infants who are postmature and/or small for gestational
age. The incidence of MAS may be decreasing due to changes in obstetric practice.
In a prospective study of 1365 infants  37 weeks gestational age born through
MSAF, the incidence of MAS decreased nearly four-fold over a period of 8 years.
This was associated with a significant reduction in births  41 weeks gestation (42
to 28 percent), as well as increased use of amnioinfusion, diagnosis of non-
reassuring fetal heart rate patterns, and cesarean delivery.125-128
Normally, fetal breathing activity moves lung fluid out of the trachea. However, as
shown in animals, prolonged hypoxia stimulates fetal breathing and gasping, which
may then lead to inhalation of amniotic fluid. This process also occurs in humans.
Aspirated meconium can interfere with normal breathing in several ways.129 These
include airway obstruction, chemical irritation, infection, and surfactant inactivation
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as described above. Nevertheless, most cases of severe MAS are probably related to
intrauterine pathologic processes, primarily asphyxia and infection, rather than to
the aspiration of meconium itself.129 Components of meconium, including bile salts,
cause inflammation of the lung that is apparent 24 to 48 hours after inhalation. This
produces an exudative and inflammatory pneumonitis with epithelial disruption,
proteinaceous exudation with alveolar collapse, and cellular necrosis. Stimulation of
polymorphonuclear leukocytes (PMN) may play a role in the pathogenesis of
pneumonitis. In in vitro studies, MSAF had chemotactic activity for PMNs that was
likely mediated through interleukin-8. This activity appears to come from the MSAF
and not from the meconium itself. MSAF appears to be a risk factor for bacterial
infection of the amniotic cavity and should alert the clinician to higher risk of
neonatal morbidity. Although meconium is sterile, the mucopolysaccharide
component provides an excellent growth medium for microorganisms, especially
Escherichia coli.130-139
Hypoxemia results from several causes, including decreased alveolar ventilation
related to lung injury and ventilation-perfusion imbalance with continued perfusion
of poorly ventilated lung units. Persistent pulmonary hypertension (PPHN)
frequently accompanies MAS, with right-to-left shunting caused by increased
pulmonary vascular resistance, and resultant hypoxemia.
The management of MAS is largely supportive. The general approach is similar for
all infants and begins with identification of risk factors and anticipation of potential
illness. Infants at risk for MAS should be monitored closely to ensure adequate
oxygenation and ventilation. All ill newborns should be cared for in a neutral
thermal environment to minimize oxygen consumption. Handling of the infant
should be limited to avoid agitation and exacerbation of PPHN, if present. ECMO
may be life-saving in infants who do not respond to mechanical ventilation,
surfactant therapy, and/or iNO.140-142
Lung Hypoplasia
The true incidence of lung hypoplasia is unknown, but the etiologies include
prolonged rupture of membranes, fetal renal dysplasias and obstruction, and fetal
neuromuscular diseases. In cases of premature rupture of membranes at 15 - 28
weeks' gestation, the reported incidence of pulmonary hypoplasia ranges from
9 - 28%.143 Lung hypoplasia also occurs in association with congenital
diaphragmatic hernia and congenital cystic lung lesions such as cystic adenomatoid
malformation. High-risk congenital diaphragmatic hernia survivors, who were
mechanically ventilated, show an incidence of BPD of more than 30%.144
Pulmonary hypoplasia or aplasia is part of the spectrum of malformations
characterized by incomplete development of lung tissue.145 The severity of the
lesion depends on the timing of the insult in relation to the stage of lung
development and the presence of other anatomic anomalies. The hypoplastic lung
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consists of a carina, a malformed bronchial stump, and absent or poorly
differentiated distal lung tissue. In more than 50% of these cases, coexisting
cardiac, gastrointestinal, genitourinary, and skeletal malformations are present, as
well as variations in the bronchopulmonary vasculature.6,146-148 For lung
development to proceed normally, physical space in the fetal thorax must be
adequate, and amniotic fluid must be brought into the lung by fetal breathing
movements, leading to distension of the developing lung.149 Several factors affect
the volume and composition of the fluid in the fetal lung. For example, the volume
of liquid in the lung is determined by the net rate at which liquid is secreted across
the pulmonary epithelium (4 - 5 mL/kg/h) and by the rate at which it flows from the
trachea into the fetal pharynx.150-153 The pressure in the fetal trachea is normally
about 2 mm Hg higher than in the amniotic fluid, thus preventing outflow of fetal
lung fluid. Any alteration in the critical volume and pressure relationships of
amniotic fluid in the trachea and lung during the canalicular stage of fetal lung
development at 15 - 28 weeks' gestation can induce hypoplasia.149 Lung
development is regulated by several transcription factors, such as thyroid
transcription factor 1 (TTF-1), member of the hepatocyte nuclear family, and
peptide growth factors. Signals from these growth factors are integrated with
environmental influences, such as lung fluid volume and hypoxia, to cause cellular
proliferation and differentiation.149,154 A key component of lung development is the
branching morphogenesis that results from interaction between the epithelial and
mesenchymal components. Growth factors are produced by mesenchymal tissue in
the lung and are present in amniotic fluid. A number of growth factors and their
receptors, all of which affect fetal lung development, show temporally and spatially
regulated expression.14
Lung development starts with branching morphogenesis and is completed
postnatally with the development of alveoli.14 Fetal urine is an important component
of amniotic fluid during late gestation and contributes to lung growth.143 During
fetal development, the kidney is also a major source of proline. Proline aids in the
formation of collagen and mesenchyme in the lung, thus explaining the severe
pulmonary hypoplasia in renal agenesis and dysplasia.155-158 Pathologically, the
hypoplastic lung has reduced weight, alveolar number, fewer generations of
airways, and hypoplasia of the corresponding pulmonary arteries. Epithelial
differentiation is delayed, and is associated with surfactant deficiency.159-161
OUTLINE OF THE THESIS
This thesis contains different studies describing clinical and experimental aspects of
lung development and therapy of acute lung injury. The findings may lead to better
understanding of the processes underlying acute and chronic lung injury and may
help develop of new therapeutic and possible preventive strategies.
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There are seven parts to this thesis. Part I gives an overview of the subject.
Chapter 1 is a general introduction. We describe late lung development and
vascular development, as well as the development of BPD and aspects involved in
the pathogenesis of this chronic lung disease. Chapter 2 describes ventilator
management of children with congenital lung abnormalities.
In Part II, Part III, Part IV, and Part IV, the main research questions are
addressed:
- Which regulatory mechanisms are involved in normal and abnormal late lung
development? (Part II)
- What are possible risk factors for the development of BPD? (Part III)
- What is the role of natural and synthetic surfactant in acute pulmonary
disease in childhood? (Part IV and Part V)
In more detail, Part II and Part III describe several aspects of BPD. In chapter
3, we characterize the role of TGF-E signalling during alveolarization in the normal
rodent and human lungs. In chapter 4, the effects of hyperoxia on the TGF-E/BMP
(bone morphogenetic protein) system in an animal models of BPD are investigated.
Chapter 5 describes how hyperoxia regulates Hypoxia-Inducible Factors-1Į and -
2Į, prolylhydroxylases, vascular endothelial growth factor and its receptors Flt-1
and Flk-1, as well as nitric oxide synthetase-1, -2, and -3, dimethylarginine
dimethylaminohydrolase, the cytokines TNF-Į, IL-6, and the surfactant proteins SP-
B and SP-C. Also, their interrelations are described. In chapter 6, we describe
pulmonary development and surfactant protein transcription in an animal model of
hypoxia-induced intrauterine growth retardation. Chapter 7 is a study into the risk
of BPD in a group of very preterm, small for gestational age infants. Chapter 8 is a
short letter, based on the results of chapters 6 and 7, written as a comment on a
review article on BPD. Chapter 9 describes a clinical study into pulmonary
inflammation as an effect of prolonged mechanical ventilation. In chapter 10, the
results of a prospective study into the NO-system in BPD are reported.
Part IV and V describe the surfactant system and its role in therapy of acute
pulmonary diseases. Chapter 11 is a multicenter randomized study into surfactant
treatment in severe acute respiratory distress syndrome in children. Chapter 12
shows the effects of synthetic and natural surfactant on the interaction of TNF-Į-
activated endothelial cells and neutrophils in vitro. In chapters 13 and 14, an
animal model of meconium aspiration is used to study the effects of natural bovine
and synthetic SP-C surfactant on pulmonary inflammatory processes, lung function
and the pulmonary surfactant system. In chapter 15, we investigate how positive
end-expiratory pressure affects the response to natural and synthetic surfactant in
ventilated immature newborn rabbits. Chapter 16 compares a ventilation strategy
(Open Lung Concept) with surfactant replacement therapy in a piglet model of
neonatal ARDS.
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consists of a carina, a malformed bronchial stump, and absent or poorly
differentiated distal lung tissue. In more than 50% of these cases, coexisting
cardiac, gastrointestinal, genitourinary, and skeletal malformations are present, as
well as variations in the bronchopulmonary vasculature.6,146-148 For lung
development to proceed normally, physical space in the fetal thorax must be
adequate, and amniotic fluid must be brought into the lung by fetal breathing
movements, leading to distension of the developing lung.149 Several factors affect
the volume and composition of the fluid in the fetal lung. For example, the volume
of liquid in the lung is determined by the net rate at which liquid is secreted across
the pulmonary epithelium (4 - 5 mL/kg/h) and by the rate at which it flows from the
trachea into the fetal pharynx.150-153 The pressure in the fetal trachea is normally
about 2 mm Hg higher than in the amniotic fluid, thus preventing outflow of fetal
lung fluid. Any alteration in the critical volume and pressure relationships of
amniotic fluid in the trachea and lung during the canalicular stage of fetal lung
development at 15 - 28 weeks' gestation can induce hypoplasia.149 Lung
development is regulated by several transcription factors, such as thyroid
transcription factor 1 (TTF-1), member of the hepatocyte nuclear family, and
peptide growth factors. Signals from these growth factors are integrated with
environmental influences, such as lung fluid volume and hypoxia, to cause cellular
proliferation and differentiation.149,154 A key component of lung development is the
branching morphogenesis that results from interaction between the epithelial and
mesenchymal components. Growth factors are produced by mesenchymal tissue in
the lung and are present in amniotic fluid. A number of growth factors and their
receptors, all of which affect fetal lung development, show temporally and spatially
regulated expression.14
Lung development starts with branching morphogenesis and is completed
postnatally with the development of alveoli.14 Fetal urine is an important component
of amniotic fluid during late gestation and contributes to lung growth.143 During
fetal development, the kidney is also a major source of proline. Proline aids in the
formation of collagen and mesenchyme in the lung, thus explaining the severe
pulmonary hypoplasia in renal agenesis and dysplasia.155-158 Pathologically, the
hypoplastic lung has reduced weight, alveolar number, fewer generations of
airways, and hypoplasia of the corresponding pulmonary arteries. Epithelial
differentiation is delayed, and is associated with surfactant deficiency.159-161
OUTLINE OF THE THESIS
This thesis contains different studies describing clinical and experimental aspects of
lung development and therapy of acute lung injury. The findings may lead to better
understanding of the processes underlying acute and chronic lung injury and may
help develop of new therapeutic and possible preventive strategies.
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vascular development, as well as the development of BPD and aspects involved in
the pathogenesis of this chronic lung disease. Chapter 2 describes ventilator
management of children with congenital lung abnormalities.
In Part II, Part III, Part IV, and Part IV, the main research questions are
addressed:
- Which regulatory mechanisms are involved in normal and abnormal late lung
development? (Part II)
- What are possible risk factors for the development of BPD? (Part III)
- What is the role of natural and synthetic surfactant in acute pulmonary
disease in childhood? (Part IV and Part V)
In more detail, Part II and Part III describe several aspects of BPD. In chapter
3, we characterize the role of TGF-E signalling during alveolarization in the normal
rodent and human lungs. In chapter 4, the effects of hyperoxia on the TGF-E/BMP
(bone morphogenetic protein) system in an animal models of BPD are investigated.
Chapter 5 describes how hyperoxia regulates Hypoxia-Inducible Factors-1Į and -
2Į, prolylhydroxylases, vascular endothelial growth factor and its receptors Flt-1
and Flk-1, as well as nitric oxide synthetase-1, -2, and -3, dimethylarginine
dimethylaminohydrolase, the cytokines TNF-Į, IL-6, and the surfactant proteins SP-
B and SP-C. Also, their interrelations are described. In chapter 6, we describe
pulmonary development and surfactant protein transcription in an animal model of
hypoxia-induced intrauterine growth retardation. Chapter 7 is a study into the risk
of BPD in a group of very preterm, small for gestational age infants. Chapter 8 is a
short letter, based on the results of chapters 6 and 7, written as a comment on a
review article on BPD. Chapter 9 describes a clinical study into pulmonary
inflammation as an effect of prolonged mechanical ventilation. In chapter 10, the
results of a prospective study into the NO-system in BPD are reported.
Part IV and V describe the surfactant system and its role in therapy of acute
pulmonary diseases. Chapter 11 is a multicenter randomized study into surfactant
treatment in severe acute respiratory distress syndrome in children. Chapter 12
shows the effects of synthetic and natural surfactant on the interaction of TNF-Į-
activated endothelial cells and neutrophils in vitro. In chapters 13 and 14, an
animal model of meconium aspiration is used to study the effects of natural bovine
and synthetic SP-C surfactant on pulmonary inflammatory processes, lung function
and the pulmonary surfactant system. In chapter 15, we investigate how positive
end-expiratory pressure affects the response to natural and synthetic surfactant in
ventilated immature newborn rabbits. Chapter 16 compares a ventilation strategy
(Open Lung Concept) with surfactant replacement therapy in a piglet model of
neonatal ARDS.
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Part VI discusses some of our results and reviews aspects of disturbances of late
lung development in chapter 17. Part VII, Chapters 18 and 19 contain the
general conclusions of the thesis and describes future research perspectives in this
field. In chapter 20, the results of this thesis are summarized.
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Ventilator Management for 
Congenital Abnormalities
Irwin Reiss, Robert-Jan Houmes, and Dick Tibboel
CONGENITAL LUNG ABNORMALITIES
Congenital lung anomalies are increasingly discovered
on routine prenatal ultrasound or incidentally during
postnatal imaging for respiratory insufficiency of unknown
origin.1 Infants born with compromised respiratory
status, whether due to immaturity or other conditions
such as congenital lung hypoplasia or space-occupying
processes including lobar emphysema, often require
mechanical ventilation and supplemental oxygen to main-
tain adequate oxygenation and ventilation. Individually
and in combination, oxygen and mechanical ventilation
predispose the newborn to ventilator-induced lung
injury (VILI).2 For years, VILI was synonymous with
barotrauma/volutrauma.
VENTILATOR-INDUCED LUNG INJURY 
OF THE DEVELOPING LUNG
Maturation in the human lung continues well after the
newborn period and through childhood. Compared with
adults, pediatric patients show a spectrum raging from
neonatal to infant and adult stages of lung develop-
ment.3 Important differences between infant and adult
lungs include a different alveolar structure, matrix com-
position, and angiogenesis, especially in the phase in
which new alveoli are formed and septa differentiate
(mainly during the first few years of life).4–6
The effect of mechanical ventilation on the develop-
ing lung cannot be fully understood without considering
the effects of intubation and endotracheal suctioning,
which are integral components of the ventilation process.
Both interventions contribute to injury to the tracheo-
bronchial tree and damage to the ciliated cells of the tra-
cheal epithelium and mucociliary transport system.7,8
Disruption of the epithelium results in retained secre-
tions and debris, thus setting the stage for inflammation
and pulmonary infection.
In addition to intubation and endotracheal suctioning,
high concentrations of oxygen also disrupt the epithelial
cells and cilia activity. When the tracheal epithelium is
exposed to high concentrations of oxygen, the cilia cavity
stops.9 Initiation of mechanical ventilation with high
oxygen concentrations causes injury to the lung through
various inflammatory mediators.10 Pulmonary macrophages
are activated and release substances that cause an accu-
mulation of polymorphonuclear cells in the alveolar
compartment. These leukocytes contain elastases and
collagenases that can further damage the lung connective
tissue.11,12 Elastase is known to play an essential role in
the pathogenesis of acute and chronic lung disease in the
immature lung. Although still controversial, it is gener-
ally accepted that increased production of cytokines,
chemokines, and other inflammatory mediators is one of
the major mechanisms of VILI in the immature and
hypoplastic lung.13–16 Inflammatory cytokines and other
inflammatory mediators appear to influence the severity
of lung injury and the risk for chronic lung disease 
(as has been reviewed by several authors) for the premature
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lung, the so-called bronchopulmonary dysplasia
(BPD).17,18 The concept of VILI must be regarded much
more as a secondary than a primary injury in a struc-
turally immature lung that is fluid filled and hypoplastic.
Ongoing exposure to potentially noxious stimuli, such as
mechanical forces, infectious agents, or toxic agents,
together with the need for endotracheal suctioning, may
cause further damage.19 The individual response and 
susceptibility to lung injury may vary extensively. Previous
lung damage seems to be essential for ventilation to
cause an increased systemic inflammatory response in
normal humans. However, VILI is not only caused by
classic barotraumas (air leaks), but also by more subtle
forms of lung injury such as epithelial and endothelial
damage leading to fluid and protein leak into airways,
alveoli, and interstitium; surfactant disruption and inac-
tivation; and mediator-induced airway and systemic
inflammation (biotrauma).2 The process of inflamma-
tion is a vital response to injury whereby blood leuko-
cytes recruit into the alveolar compartment, activate
tissue macrophages, and produce a series of inflamma-
tory mediators. The inflammatory process may trigger
events that lead to cell regeneration and healing, or 
progression of the inflammatory response, which often
lead to progressive organ dysfunction. Schultz et al.
demonstrated an association between prolonged
mechanical ventilation and pulmonary inflammation in
ventilated infants with an immature lung by inducing
proinflammatory cytokines and by failing to stimulate
the anti-inflammatory cytokine IL-10.15
The injury caused by ventilation has been attributed
to two major mechanisms: (1) overdistension of terminal
airways (volutrauma) and (2) shear stress forces on the
epithelial layer of small airways and terminal lung units
during closing and cyclic reopening of these units
(atelectrauma).20–22
Results of a number of animal studies have shown that
peak inspiratory pressure (PIP) above 30 cm H2O can
produce injury in normal lungs after relatively short peri-
ods of mechanical ventilation. Dreyfuss et al. have shown
that ventilation at a PIP of 45 cmH2O, together with a
low positive end-expiratory pressure (PEEP), can pro-
duce pulmonary edema and protein leakage in about 
20 minutes.23 This ventilation-induced protein leak results
in denaturation of surfactant and loss of surfactant func-
tions24,25; this pattern may develop early in postnatal life.
Bjorklund et al. have shown that as few as five high-peak
airway pressure breaths immediately after birth in the
premature lamb model are sufficient to cause diffuse
alveolar damage and hyaline membrane formation.26
Lung injury secondary to mechanical ventilation is
certainly one of the major contributors to mortality 
in cases of lung hypolasia and is a major risk factor for 
the bad outcome following acute respiratory failure, 
particularly in neonates with congenital diaphragmatic
hernia (CDH).27–29 Experimental data have resulted in a
trend toward using a lung protective strategy in patients
with acute respiratory failure by ventilating with reduced
tidal volumes and the introduction of pressure-limited
“permissive hypercapnia” ventilation in the treatment of
adults and children with acute respiratory failure. This
concept of “gentle ventilation” was introduced by Wung
et al. and is characterized by preservation of spontaneous
breathing, permissive levels of hypercapnia (PaCO2, 
60 to 65 mmHg or 9 kPa), and avoidance of high inspi-
ratory airway pressures.30 Iatrogenic lung injury is
avoided where possible. Retrospective series have shown
improved survival in infants with persistent pulmonary
hypertension of the newborn (PPHN) when hyperventi-
lation was not used.27 In addition, improved survival and
reduced need for extracorporeal membrane oxygenation
(ECMO) support was shown when PIP was limited to
30 cmH2O or less without attempts to correct hypercarbia
in infants with lung hypoplasia.31–33
CONGENITAL DIAPHRAGMATIC HERNIA
Over the past 20 years, pulmonary hypoplasia and pul-
monary hypertension have been recognized as the two
cornerstones of the pathophysiology of CDH, while
more recently VILI has been recognized as a contribut-
ing iatrogenic factor for the development of chronic lung
disease.34,35
The degree of pulmonary hypoplasia was initially
thought to correlate directly with survival, although this
may not be true in most infants. With the advent of
neonatal mechanical ventilation in the 1960s, many CDH
patients with previously fatal respiratory failure were 
surviving long enough to undergo surgical repair.36,37
Pathologic examination of the hypoplastic lungs 
from patients with CDH revealed a marked reduction 
in the number of bronchial branchings, but the develop-
ment of pulmonary acini and alveoli was relatively less
affected. The lung injury secondary to mechanical venti-
lation in these patients was characterized by hyaline
membrane formation, parenchymal hemorrhage pneu-
mothorax, and pulmonary interstitial emphysema. Lung
injury in patients with CDH was microscopically 
more evident in the ipsilateral lung. Regarding the 
relationship between respiratory measurements and 
lung injury, a clinical study on barotrauma in lung
hypoplasia found evidence of pulmonary hemorrhage in
lungs that were ventilated with high peak pressure of 
50 cmH2O.38
Mechanical ventilation is the initial therapy for infants
with respiratory failure due to CDH. In the delivery
room, infants with CDH should immediately be intubated
to prevent hypoxia-induced pulmonary vasoconstriction.
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Because of gastric and abdominal distension and com-
pression of the lung, supply of oxygen by bag-masking
must be avoided. To minimize lung injury, the newborn
should be ventilated initially with peak pressure below 
25 cmH2O.32,33 Any delay in obtaining an airway can
intensify acidosis and hypoxia, which triggers pulmonary
hypertension. For decompression of the abdominal con-
tents in the thorax and thus to help the available lung
tissue to expand, early use of a nasogastric tube and con-
tinuous suctioning of the stomach are warranted. For
optimal mechanical ventilation, blood pressure support
by isotonic fluid and inotropic drugs such as dopamine
and/or dobutamine should be given to maintain arterial
mean blood pressure levels at 50 mmHg and thus to
minimize any right to left shunting.
The aim of mechanical ventilation is to administer peak
pressure to maintain preductal oxygen saturations above
80% or preductal partial oxygen pressure (PaO2) above 
60 mmHg. Initiation of conventional ventilator manage-
ment includes pressure-limited ventilation at rates of 
30 to 100 breaths per minute at peak pressures of 20 to 
25 cmH2O. Peak inspiratory pressures that exceed 
28 cmH2O are used only for a short period as a bridge to
ECMO. The early institution of high-frequency oscillation
(HFO), especially in case of CO2 retention, should be con-
sidered. PEEP should be maintained at physiologic levels 
(3 to 5 cmH2O) whenever possible. Hyperventilation,
hypocarbia, and alkalosis may decrease ductal shunting and
control pulmonary hypertension in CDH, but do so at the
expense of increased barotrauma.39 Permissive hypercapnia,
the so-called gentle ventilation approach, is now commonly
used in neonates with CDH, with increased survival 
compared with hyperventilation and alkalization.27,28,40,41
HFO is reserved for neonates who continue to have
hypoxia and hypercarbia refractory to conventional ven-
tilation. Although the indications for HFO are not
clearly defined, there are observational reports of effec-
tive PCO2 reduction and increased survival in neonates
with CDH.42–44 In one such study, the use of HFO
avoided hyperventilation as well as the need for ECMO.
Although there are no randomized controlled studies
(RCTs), HFO may have a role in managing neonates,
especially in avoiding the need for ECMO.45 Clinical
studies of HFO and mean airway pressure (MAP) in
lung injury found that HFO provides better oxygenation
and higher MAP without increasing the incidence of
barotrauma. On the other hand, low MAP settings do
not allow the alveoli to open in the low-compliance lung,
which leads to the development of atelectasis and an
increase in the amplitude of swing pressure, resulting in
excessive expression of cytokines in the airway. At pres-
ent, no available RCTs show the benefit of HFO as an
initial ventilation modality in CDH.
To adjust the ventilator settings, frequent preductal arte-
rial blood gases are important parameters to be determined.
FiO2 should only be weaned after a period of stabilization
and should be done very slowly to prevent (recurrent) pul-
monary hypertension. Deep analgosedation and some-
times even the use of muscle paralysis may enhance
compliance and reduce vasoconstriction, potentially lead-
ing to lower ventilator settings. However, the loss of the
spontaneous contribution to minute ventilation increases
the third space edema and negates the benefits of paralysis
and therefore should be avoided.46,47 In summary,
although the optimal mode of ventilation in CDH remains
controversial, clinical data suggest that management strate-
gies designed to limit lung distension and barotrauma
result in improved survival.27,28
Surfactant
Studies of different animals models have shown that the
lungs of animals with CDH are surfactant deficient.
Surfactant phospholipids and apoprotein SP-A were
decreased in nitrofen CDH rats.48,49 However, their syn-
thetic capacity to produce surfactant was equal to that in
controls. The administration of surfactant therapy has
been suggested in the treatment of infants with CDH.44,50
A body of data demonstrates that the lungs of infants with
CDH are surfactant deficient.51,52 Whether a primary sur-
factant deficiency truly exists or whether secondary inacti-
vation of surfactant is the underlying problem is the
subject of ongoing debate. A report from the Congenital
Diaphragmatic Hernia Registry did not find that surfac-
tant therapy improved outcome.49 As a consequence, the
routine giving of surfactant to infants with CDH initially
is not recommended. Using surfactant in neonates with a
gestational age of 34 weeks can be considered in the event
that clinical radiologic findings of alveolar atelectasis are
suggestive of respiratory distress syndrome. Cogo et al.
studied the surfactant phosphatidylcholine (PC) kinetics
in CDH patients who did not require ECMO by using
stable istopes.53 Although the amounts of surfactant disat-
urated surfactant synthesis (DSPC) and SP-A in the 
tracheal aspirates of CDH patients were reduced, these
patients had rates of endogenous surfactant DSPC synthe-
sis comparable to control patients.54,55 The decreased sur-
factant PC synthesis in CDH patients who require ECMO
could serve as a rationale for the need for ECMO in this
particular group and might be a result of lung damage by
VILI. Nevertheless, because of several side effects (e.g.,
bronchus obstruction, hypoxia), surfactant administration
should be used with caution in infants with CDH.
Persistent Pulmonary Hypertension 
of the Newborn in Lung Hypoplasia
In many neonates with respiratory insufficiency, 
pulmonary hypertension (PPHN) complicates the clini-
cal presentation.39 PPHN is defined as failure of the 
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pulmonary circulation to adapt normally to extrauterine
life, resulting in unoxygenated blood shunting to the
systemic circulation.56 PPHN remains a significant prob-
lem in infants with CDH.57 Multiple factors, including
decreased cross-sectional area of the pulmonary arteries
due to lung hypoplasia, increased media thickness of the
pulmonary arteries, adventitial thickening, blunted
oxygen-induced vasodilatation, and increased endothe-
lin-A receptor expression, are thought to contribute to
the pulmonary hypertension seen in CDH.58 The diag-
nosis of PPHN should be considered in any infant with
CDH and other cases of pulmonary hypertension in
which a difference in pre- and postductal saturations
exists. The diagnosis of PPHN should be confirmed by
cardiac ultrasound.
The management of PPHN in infants with CDH is
largely supportive. It is directed toward promoting a
progressive decline in the ratio of pulmonary vascular
resistance (PVR) to systemic vascular resistance (SVR) to
maintain adequate tissue oxygenation until PVR falls.
The initial treatment of the newborn with PPHN
includes correction of hypothermia, hypoglycemia,
hypocalcemia, anemia, hypovolemia, and stress.
Although the use of alkalinizing agents is controversial,
correction of metabolic acidosis is standard.39 Because
PVR is elevated in PPHN, decreased SVR or poor car-
diac output result in decreased mean systemic blood
pressure, which can increase right-to-left shunting.
Therapy of elevated PVR includes aggressive support of
cardiac function and perfusion with volume and
inotropic agents to maintain the mean arterial blood
pressure at a level that minimizes right-to-left shunting
(>50 mmHg).
Inhaled Nitric Oxide
Inhaled nitric oxide (iNO) is a selective pulmonary
vasodilator and is widely accepted as the gold standard
treatment in PPHN.59,60 Its use has contributed to
reduced rates of ECMO. Nitric oxide (NO) is produced
in endothelial cells during conversion of L-argine to 
L-citrulline by NO-synthetase. NO diffuses from endothe-
lial cells into adjacent smooth muscle cells to cause
vasodilatation through activation of soluble guanylate
cyclase (sGC) and the production of cyclic guanosine
monophosphate (cGMP). cGMP stimulates a cGMP-
dependent kinase, causing vasodilation through myosin
phosphorylation. To date, results of iNO therapy in
patients with CDH have been poor. In CDH, iNO does
not appear to be of long-term benefit. In the one trial
that specifically addressed this issue, 53 infants with
CDH and hypoxemic respiratory failure (gestational age,
34 weeks) were randomly assigned to receive either iNO
(20 ppm) or 100% oxygen. Death before 120 days or
need for ECMO was not significantly different in iNO or
control groups.61 ECMO use occurred significantly
more in the iNO group, although the percentage of
infants who died was not different. Although a transient
improvement occurred in approximately 50% of the
infants treated with iNO, it did not consistently improve
oxygenation, nor did it decrease the use of ECMO. With
the increasing use of iNO and HFO, the absolute
number of non-CDH, noncardiac neonates with hypox-
emic respiratory failure requiring ECMO has decreased.
Initiation of ECMO has become progressively later,
likely because of the use of these rescue therapies, but
the overall mortality rate remains unchanged despite 
this delay. Inhaled therapy with NO might be helpful 
in stabilizing some patients for transport and initiation 
of ECMO.
Phosphodiesterase Inhibitors
Approximately 30% of patients with PPHN do not
respond to iNO and require alternative treatments.
Substances that stimulate the formation of the second
messengers cyclic adenosine monophosphate (cAMP) or
cGMP have proved useful in the treatment of various
forms of precapillary pulmonary hypertension.62 Milrinone
is a bipyridine compound that selectively inhibits phos-
phodiesterase type 3 (PDE3) and may lead to early and
sustained improvements in oxygenation without com-
promising hemodynamic status. Prospective evaluation
of the acute clinical and physiologic effects and long-
term outcome of intravenous milrinone therapy as an
alternative cardiotrophic agent or as a combination ther-
apy with iNO in neonates with PPHN in lung hyoplasia
is required.63
Sildenafil (Viagra), a phosphodiesterase type 5
inhibitor (PDE5), is an oral agent that has been shown
to selectively reduce pulmonary vascular resistance in
both animal models and adult humans and produced
vasodilation by increasing cGMP through inhibition of
the phosphodiesterase involved in the degradation of
cGMP to guanosine monophosphate. PDE5 is a key reg-
ulator of NO-induced vasodilation in the postnatal pul-
monary arteries. PDE5 inhibitors were shown to be
effective in decreasing pulmonary arterial pressure and
pulmonary vascular resistance in several neonatal models
of acute pulmonary hypertension. One of the recent
adult randomized studies in humans shows that oral
sildenafil significantly improves exercise tolerance, car-
diac index, and quality of life in adult patients with 
primary pulmonary hypertension.64–66
Prostacyclin
Prostacyclin (PGI2) stimulates membrane-bound adeny-
late cyclase, increases cAMP, and inhibits pulmonary
artery smooth muscle cell proliferation in vitro.
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Although the use of systemic infusions of PGI2 may be lim-
ited by the development of systemic hypotension, inhaled
PGI2 has been shown to have vasodilator effects limited to
the pulmonary circulation. Reports in children have been
encouraging, but to date there have been few reports of
inhaled PGI2 use in neonates with PPHN. The actions of
inhaled PGI2 and iNO appear to be additive in humans and
even synergistic in animal studies. Rebound PPHN follow-
ing withdrawal of iNO has been mitigated by intravenous
PGI2 in children with PPHN following CDH.67
PULMONARY HYPOPLASIA 
DUE TO OTHER CAUSES
Pulmonary hypoplasia is part of the spectrum of anom-
alies characterized by incomplete development of lung
tissue. The severity of the lesion depends on the timing
of the insult in relation to the stage of lung development
and the presence of other anatomic anomalies. The
hypoplastic lung consists of a carina, a malformed bronchial
stump, and absent or poorly differentiated distal lung
tissue. In more than 50% of these cases, coexisting 
cardiac, gastrointestinal, genitourinary, and skeletal 
malformations are present, as well as variations in the bron-
chopulmonary vasculature. Isolated primary pulmonary
hypoplasia is rare but in its milder forms can present a
diagnostic dilemma. It usually presents at or shortly after
delivery fo a child in varying degrees of respiratory dis-
tress who may require high ventilatory pressures and has
noncompliant lungs. There may be a genetic compo-
nent, but more commonly pulmonary hypoplasia is sec-
ondary to an underlying abnormality such as restrictive
malformation of the chest wall and decreased fetal
breathing (fetal neuromuscular disease), decreased 
fetal lung fluid (prolonged rupture of membrane, fetal
renal dysplasias and obstruction), and decreased vascular
supply (tetralogy of Fallot, interrupted pulmonary
artery).68 In cases of premature rupture of membranes at
15 to 28 weeks’ gestation, the reported incidence of pul-
monary hypoplasia ranges from 9% to 28% (13% in most
studies).69 In different studies, mortality rates of 71% to
95% have been reported during the perinatal period in
patients with pulmonary hypoplasia. Even after correc-
tion of the underlying abnormality (if possible), the pul-
monary hypoplasia may be so severe as to be incompatible
with life. Postnatal growth of the lung can occur, but in
severely affected children, even newer technologies (such
as ECMO) have contributed little to an improved out-
come. In milder cases (e.g., certain instances of primary
pulmonary hypertension or children who have had matura-
tion arrest due to oligohydramnion following premature
rupture of membranes), artificial pulmonary support may
maintain oxygenation while alveolar growth occurs.
Ventilatory strategies have changed in the last decade
toward use of permissive hypercapnia and gentle ventilation.
Partial liquid ventilation has also been tried in individual
cases, but without definite advantages.70 The concept of a
liquid tissue interface is still very promising, and phase I
clinical trials have recently begun. A decreased response to
NO is believed to occur with pulmonary hypertension asso-
ciated with hypoplasia. Apart from respiratory insufficiency
in premature infants, no appropriate RCTs are available that
evaluate HFO versus conventional ventilation.71
CONGENITAL CYSTIC LUNG LESION
Lesions such as congenital cystic adenomatoid malfor-
mations (CCAMs), sequestrations, bronchogenic cysts,
and congenital lobar emphysema may be asymptomatic
at birth or at the time of discovery later in life.72 Some
authors advocate simple observation because of the lack of
data regarding the incidence of long-term complications.72
However, there are very few described cases in which
CCAM and intralobar sequestration have remained
asymptomatic throughout life; complications eventually
develop in nearly all patients. The most common compli-
cation is pneumonia, which may respond poorly to med-
ical treatment. Other complications include the
development of malignancies (carcinomas and pleuropul-
monary blastomas), pneumothorax, and hemoptysis or
hemothorax. Because lung resection will be required
sooner or later for CCAM, intralobar sequestration, and
intrapulmonary bronchogenic cysts, our approach is to
not wait until complications occur. For patients diag-
nosed prenatally, we recommend surgery at 3 to 6 months
of life at the latest so that compensatory lung growth
may occur. At this age the postoperative course is usually
smooth, with a low risk of complicating pulmonary hyper-
tension, and long-term follow-up has shown normal res-
piratory function. Mediastinal bronchogenic cysts also
tend to become symptomatic, and elective resection is rec-
ommended. On the other hand, asymptomatic congenital
lobar emphysema may regress spontaneously, and obser-
vation is justified. The management of small noncommu-
nicating extralobar sequestrations is more controversial; it is
known that these lesions can remain asymptomatic
throughout life, but complications may develop and they
are sometimes difficult to differentiate from neuroblastoma.
Congenital cystic lung lesions (especially CCAM
and/or pulmonary sequestration) often present as a
benign pulmonary mass in infants and children and are
traditionally described as a multicystic lung mass result-
ing from a proliferation of terminal bronchiolar struc-
tures with an associated suppression of alveolar growth.
Death in utero or at birth in such fetuses and neonates is
often due to hydrops and pulmonary hypoplasia.
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Hydrops occurs in 45% of fetuses with CCAM and is
reported to be associated with combined fetal and post-
natal mortality rates of 68% to 89%. The mortality rate is
less than 10% when fetal hydrops is not present.72,73
The presentation of congenital cystic lung lesions is
variable. Many patients with congenital lung cystic lesions
are identified by routine prenatal ultrasound examination.
Controversy exists as to the management of newborns
with asymptomatic congenital lung cyst lesions. In case of
isolated cystic lesions with overt mediastinal shift, drainage
during fetal life by placement of a pigtail to guarantee flow
of fluid may be considered. In the management of infants
with congenital cyst lung lesion, the same therapeutic
approach as that in patients with hypoplastic lungs with
persistent pulmonary hypertension and poor compliance
with increased pulmonary vascular resistance has to be
considered. Postnatally some patients with CCAM may
even need ECMO, either due to respiratory insufficiency
or postsurgically after pneumectomy resulting from
increased blood flow to the remaining lung.74,75
CONGENITAL LOBAR EMPHYSEMA
Congenital lobar emphysema (CLE) is a developmental
anomaly of the lower respiratory tract that is characterized
by overexpansion of a pulmonary lobe with resultant com-
pression of the remaining ipsilateral lung, and it is a poten-
tially reversible cause of respiratory distress in the neonate.76
Mediastinal shifting away from the increased-volume lung
can also compress the contralateral lung. The abnormality is
related to a congenital bronchial narrowing. In these cases
weakened or absent bronchial cartilage is present, such that
there is inspiratory air entry but collapse of the narrow
bronchial lumen during expiration. This bronchial defect
results in lobar air trapping. In case of congenital extrinsic
compression, such as by a large pulmonary artery, affected
cartilage rings are malformed, soft, and collapsible as a result
of the long-term in utero extrinsic effect.77
Emergency surgical lobectomy was once considered
the only treatment for CLE, but appropriate care may 
be nonsurgical in some infants with only moderate 
respiratory distress. Prevention of endotracheal intuba-
tion should be considered to diminish the risk of 
progressive hyperinflation. Maintaining ventilatory pres-
sures and volume as low as possible avoids producing 
ventilator-related hyperexpansion of an affected lobe.
Management by a more conservative gentle ventilation
technique is often successful. Fewer surgeries result
because the affected lobe only occasionally continues to
expand after diagnosis and initial treatment. Infants with
CLE who are not clinically in respiratory distress and
who are able to feed and grow do not necessarily need
surgery. Lobar emphysema can occur in hypoalveolar
(fewer than the expected number of alveoli) and polyalve-
olar (more than the expected number of alveoli) forms.
CONGENITAL TRACHEAL OBSTRUCTION
Laryngotracheal stenosis is a congenital or acquired 
narrowing of the airway that may affect the glottis, subglot-
tis, or trachea. It causes severe symptoms and should be
suspected in children less than 1 year of age with either
multiple episodes of croup or croup that fails to respond
to medical management or requires endotracheal intuba-
tion. The trachea and the upper airway, although consid-
ered to be relatively rigid conducting airways, do show
some changes in caliber during the normal respiratory
cycle. There is expansion of the intrathoracic airways
along with the expanding lungs, while the extrathoracic
airways diminish in caliber due to their intraluminal pres-
sure being lower than atmospheric pressure. The reverse
of this process occurs during expiration. If the intratho-
racic trachea is soft, the narrowing will accentuate during
expiration due to positive intrathoracic pressure. The
mechanics of critical tracheal stenosis is such that it
would severely compromise delivery of gases beyond 
the obstruction allowing adequate emptying of the lungs
as well. Other obstructive upper airway anomalies 
(e.g., subglottis stenosis) could be overcome by the use 
of tracheostomy, but in more distal lesions of the trachea,
ventilatory management is more challenging. With 
conventional ventilator settings in a patient with severe tra-
cheal stenosis, there would be inadequate delivery of gases
beyond the site of obstruction, with build-up of proximal
pressure resulting in progressive CO2 retention and inade-
quate lung expansion. Because of inadequate emptying of
the lungs during expiration, air trapping occurs, along with
a subsequent decrease in cardiac output. In order to ensure
adequate delivery of gases beyond the obstruction, it is
necessary to prolong the inspiratory time so that adequate
lung expansion can be achieved. In view of the markedly
increased resistance, the time constant will also be
increased, justifying the need for high inspiratory time. For
this, the frequency of breaths would have to be kept at a
low value in order to allow adequate time for expiration
and at the same time avoid progressive air trapping. For
patients undergoing surgical repair of the tracheal lesions,
ECMO has also been used.78–81
CONGENITAL ALVEOLAR 
CAPILLARY DYSPLASIA
Congenital alveolar capillary dysplasia (ACD), with or
without misalignment of the pulmonary veins, is a rare
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cause of PPHN.82 This malformation represents a failure
of capillaries to extend into alveolar tissue of the lung and
is an unusual cause of pulmonary hypertension, persistent
fetal circulation, and respiratory distress in the newborn.
Histology shows increased septal connective tissue and
pulmonary veins accompanying small arteries in the cen-
ters of the acini, rather than occupying their normal posi-
tion in the interlobular septa. The number of pulmonary
arteries is decreased, and they show increased muscular-
ization. Pulmonary lobules are small, and radial alveolar
counts may be decreased. Alveoli are decreased in com-
plexity, their walls contain few capillaries, and there is
poor contact of capillaries with alveolar epithelium. The
primary defect is poorly understood. ACD causes severe
and irreversible PPHN with a uniformly fatal outcome.
Although most cases are sporadic, a familial predisposi-
tion has been reported, and a number of studies have sug-
gested that ACD be considered in any infant with severe
respiratory acidosis and PPHN who fails to improve after
the application of routine treatment modalities. As
Michalsky et al. reported,83 the usual presentation is that
of a term neonate, appropriate for gestational age, who
appears to be normal at the time of delivery. Most infants
develop progressive respiratory distress and cyanosis with
hypoxia, respiratory acidosis, and hypotension within 
48 hours of birth. The rapidly progressive nature of this
process results in the need for full ventilatory support soon
after the onset of symptoms. Associated anomalies have
been noted in approximately 50% of infants with ACD.
Initial chest radiographs are often reported to be
unremarkable or to show a mild hazy pattern. Radiographic
changes associated with barotraumas may develop later
in the course of treatment. Because of its lethal outcome,
ACD should be diagnosed as early as possible.
Clinicans should have a high suspicion for ACD in a
term infant with good Apgar scores who goes on to expe-
rience respiratory deterioration within a few hours of age.
The patient may have transient response to NO, minimal
response to HFOV, and variable response to prostacyclin.
Although ECMO is typically used as rescue therapy, result-
ing in rapid hemodynamic stabilization, open lung biopsy
should be considered before initiation of ECMO to prevent
the institution of futile and expensive treatment modalities.83
PULMONARY ALVEOLAR PROTEINOSIS 
AND INTERSTITIAL LUNG DISEASES
A number of genetic and environmental factors have
been clearly identified as affecting the severity of neona-
tal respiratory distress syndromes.84 Congenital alveolar
proteinosis syndromes are characterized by the accumu-
lation of surfactant material in the alveolar space.85 SP-B
deficiency leads to alveolar proteinosis, but it is likely
that many other causes may lead to similar pulmonary
pathology. Interstitial lung diseases (ILDs) in childhood
are a diverse group of conditions primarily involving the
alveoli and perialveolar tissues and leading to derange-
ment of gas exchange, restrictive lung physiology, and
diffuse infiltrates on radiographs.86 Childhood ILD is
not a disease entity but rather a group of disorders.
However, most ILDs share a common pathophysiologic
feature: namely, structural remodeling of the distal air-
spaces, leading to impaired gas exchange. In general, this
remodeling has been believed to be the sequela of per-
sistent inflammation; however, more recently the para-
digm has shifted away from inflammation to one of
tissue injury with aberrant wound healing resulting in
collagenous fibrosis.85 The multiple possible diagnostic
entities and lack of RCTs make specific recommenda-
tions regarding treatment of childhood ILD impossible.
If the process is secondary to an underlying condition,
patients should be treated for the underlying disease.
The appropriate management depends on the patient’s
age at presentation, the severity of symptoms, and the
anticipated course of the disease. Mechanical ventilation
is necessary in children with congenital alvelveolar pro-
teonisis and in some case of interstitial lung diseases. No
reports show any benefit from the use of HFO or other
unconventional forms of mechanical ventilation.
CONCLUSIONS
VILI is one of the major contributors to mortality and
morbidity in patients with congenital lung anomalies.
The clinical picture has changed following the applica-
tion of a lung protective strategy consisting of preserva-
tion of spontaneous ventilation, permissive levels of
hypercapnia (PaCO2, 60 to 65 mmHg or 9 kPa), and
avoidance of high inspiratory airway pressure (25 to 28
cmH2O), increasingly known as the gentle ventilation
concept. More newborns with severe respiratory insuffi-
ciency are saved and the amount of pulmonary sequalae
(BPD, chronic infections, progressive pulmonary vascu-
lar disease) diminished. There is a continuing need for
RCTs with enough power to determine the role of HFO
compared with conventional ventilation, as new modali-
ties such as liquid ventilation are still experimental at this
stage.
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TGF- Signaling Is Dynamically Regulated
During the Alveolarization of Rodent and
Human Lungs
Miguel A. Alejandre-Alca´zar,1 Matthias Michiels-Corsten,1 Alfin G. Vicencio,2 Irwin Reiss,3
Julie Ryu,4 Ronald R. de Krijger,5 Gabriel G. Haddad,4 Dick Tibboel,3 Werner Seeger,1
Oliver Eickelberg,1 and Rory E. Morty1*
Although transforming growth factor-beta (TGF-) signaling negatively regulates branching
morphogenesis in early lung development, few studies to date have addressed the role of this family of
growth factors during late lung development. We describe here that the expression, tissue localization, and
activity of components of the TGF- signaling machinery are dynamically regulated during late lung
development in the mouse and human. Pronounced changes in the expression and localization of the TGF-
receptors Acvrl1, Tgfbr1, Tgfbr2, Tgfbr3, and endoglin, and the intracellular messengers Smad2, Smad3,
Smad4, Smad6, and Smad7 were noted as mouse and human lungs progressed through the canalicular,
saccular, and alveolar stages of development. TGF- signaling, assessed by phosphorylation of Smad2, was
detected in the vascular and airway smooth muscle, as well as the alveolar and airway epithelium
throughout late lung development. These data suggest that active TGF- signaling is required for normal
late lung development. Developmental Dynamics 237:259–269, 2008. © 2007 Wiley-Liss, Inc.
Key words: development; alveolarization; septation; TGF-, transforming growth factor; mouse; rat; human
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INTRODUCTION
The process of lung development
strives to maximize the gas exchange
surface area, while minimizing the
blood–air barrier (Roth-Kleiner and
Post, 2003; Copland and Post, 2004).
This is achieved by branching of de-
veloping airways in early lung devel-
opment and progressive subdivision of
developing airspaces into alveoli in
late lung development by a process of
alveolarization (Roth-Kleiner and
Post, 2003; Copland and Post, 2004).
Alveolarization begins with branching
of distal airway saccules into imma-
ture alveoli, in the canalicular phase
of lung development, and continues
through the saccular phase, into the
alveolar phase, where alveolar septae,
supported by the extracellular matrix
(ECM), divide the terminal respira-
tory saccules, increasing the number
of alveoli. Alveolarization is driven by
growth factor-mediated communica-
tion between the different cell types of
the developing lung (Warburton et al.,
2000;Cardoso, 2001; JankovandTans-
well, 2004). The pleiotropic roles
played by the transforming growth
factor-beta (TGF-) family in control-
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ling cell proliferation, transformation
and apoptosis, as well as ECM depo-
sition and remodeling, have led to
TGF- being accredited with a key
role in lung development (Jankov and
Tanswell, 2004; Roth-Kleiner and
Post, 2005).
TGF- signaling is initiated by
binding of TGF- ligands to the type II
TGF- receptor (Tgfbr2, also called
TRII), which then complexes with a
type I TGF- receptor (either Tgfbr1,
also called activin-like kinase [ALK]-
5; or Acvrl1, also called ALK-1). The
type I receptor transmits signals
within the cell by means of second-
messenger Smad proteins, namely
Smad2, Smad3, and Smad4, or by
Smad-independent pathways. TGF-
signaling is potentiated by two acces-
sory type III TGF- receptors: Tgfbr3
(also called betaglycan), and endoglin
(CD105, the eng gene-product). TGF-
signaling is also regulated by Smad6
and Smad7, inhibitory Smads that an-
tagonize TGF- signaling. Activated
(phosphorylated) Smads are translo-
cated into the nucleus, where they
regulate gene transcription and,
hence, cell function (Massague´, 1998).
Several studies have implicated
TGF- signaling in early lung devel-
opment. All three TGF- isoforms
(Pelton et al., 1991) and type I (Zhao
et al., 2000b) and type II (Zhao and
Young, 1995) TGF- receptors are ex-
pressed in the embryonic rodent lung.
Exogenous addition of TGF- ligands
inhibited airway branching in vitro
(Sakurai and Nigam, 1997; Liu et al.,
2000), and down-regulation either of
Tgfbr2 (Zhao et al., 1996), or of
Smad2, Smad3, or Smad4 (Zhao et al.,
1998), which would block TGF- sig-
naling, enhanced lung branching in
vitro. In line with these findings, over-
expression of the inhibitory Smad,
Smad7, which antagonizes TGF- sig-
naling, promoted lung branching in
vitro (Zhao et al., 2000a).
TGF- signaling has received much
less attention in the context of late
lung development. Adenoviral-medi-
ated transfer of TGF-1 to the neona-
tal rat lung (Gauldie et al., 2003) and
overexpression of TGF-1 between
postnatal day (P) 7 and P14 in the
mouse lung (Vicencio et al., 2004) both
disrupted alveolar development, pro-
viding indirect evidence that TGF-
was a negative regulator of alveolar-
ization. However, blockade of TGF-
signaling by ablation of Smad3 be-
tween days P7 and P28 generated a
similar phenotype in mice, indicating
that TGF- can also act as a positive
regulator of alveolarization (Chen et
al., 2005). Similarly, Smad3 deficiency
in mice resulted in progressive air-
space enlargement with age, implicat-
ing TGF- in the maintenance of alve-
olar integrity in the developed lung
(Bonniaud et al., 2004). Together,
these data suggest that TGF- plays a
finely tuned and key role in the alveo-
larization process, as well as in the
maintenance of alveolar structure. No
study to date, however, has assessed
the expression of the TGF- signaling
system over the course of late lung
development. We describe here that
the expression, localization, and activ-
ity of components of the TGF- signal-
ing machinery are dynamically regu-
lated over the course of late lung
development in rodents and humans.
RESULTS
Early lung development encompasses
the embryonic stage (4–7 weeks after
conception in humans, embryonic
days [E] 9.5–12 in mice), and contin-
ues through the pseudoglandular
(5–17 weeks in humans, E12–E16.5 in
mice) and canalicular (16–26 weeks in
humans, E16.5–E17.5 in mice) stages
(Copland and Post, 2004). The alveo-
larization process begins at the end of
the canalicular stage. As late lung de-
velopment proceeds, distal airways
form saccular units in the saccular
stage (24–38 weeks in humans,
E17.5–P4), and secondary septae then
divide these units (septation) during
the alveolar stage (36 weeks preterm
to 36 months postnatal in humans,
P4–P28 in mice; Copland and Post,
2004). A progressive decrease in the
size of the alveolar air spaces, to-
gether with a concomitant increase in
the total number of alveoli, occurs
during this critical period of late
lung development (Copland and
Post, 2004).
The progress of late lung develop-
ment in themousewas characterized by
dramatic, dynamic changes in the
abundance of mRNA encoding compo-
nents of the TGF- signalingmachinery
(Fig. 1) as assessed by semiquantitative
and real-time reverse transcriptase-
polymerase chain reaction (RT-PCR).
In particular, the two type I TGF-
receptors exhibited opposite patterns
in mRNA abundance, where acvrl1
mRNA abundance significantly in-
creased over time (compare stages
E15 and P21; Fig. 1B,F), whereas tg-
fbr1 mRNA abundance significantly
decreased over time (compare stages
E15 and P21; Fig. 1C,F). A biphasic
pattern was observed for tgfbr3
mRNA abundance (Fig. 1A,F), while
eng mRNA abundance significantly
increased during late lung develop-
ment (compare stages E15 and P21;
Fig. 1F). Due to large variations
within each group, changes in the
abundance of tgfbr2 mRNA were not
detected (Fig. 1A,D). The abundance
of mRNA encoding Smad proteins was
also regulated during late lung devel-
opment in the mouse. The mRNA lev-
els of smad2, smad3, and smad4 were
significantly decreased by day P28
compared with stage E15 (Fig. 1A,G).
In the case of smad2, mRNA abun-
dance was significantly reduced as
early as day P3 compared with stage
E15 (Fig. 1A,G). In contrast, the
smad6 and smad7 mRNA levels sig-
nificantly increased during late lung
development in the mouse (compare
stages E15 and P21; Fig. 1A,G).
Immunoblot analysis of TGF- re-
ceptors and Smad proteins in extracts
from mouse lungs at different stages
of development (Fig. 2) revealed com-
parable patterns to those observed in
the mRNA profiles (Fig. 1). Expres-
sion levels of Acvrl progressively in-
creased while those of Tgfbr1 pro-
gressively decreased (compare the ex-
pression levels of both molecules at
stages E15 and P28 in Fig. 2B). Two
splice-isoforms of the tgfbr2 gene have
been described (Hirai and Fijita, 1996;
Krishnaveni et al., 2006), which en-
code high and low molecular mass Tg-
fbr2 protein isoforms. Both the higher
molecular mass Tgfbr2 isoform 1 (also
called TRII-B) and the lower molec-
ular mass Tgfbr2 isoform 2 were de-
tected in mouse lung extracts (Fig.
2A,B). Expression levels of Tgfbr2 also
exhibited dynamic regulation during
late lung development, peaking at the
late saccular stage (Fig. 2A,B). Consis-
tent with the mRNA abundance pat-
terns, all three Smad proteins investi-
gated, Smad2, Smad3, and Smad4,
initially exhibited stable expression
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Fig. 1. Expression of the transforming growth factor-beta (TGF-) signaling machinery during the late lung development in mice. A: Changes in the
expression of genes, assessed by semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR), encoding TGF- signaling machinery
during late lung development. Amplicons are illustrated from two different mouse lungs per developmental stage, representative of the patterns
observed in six other mouse lungs at the same developmental stage. B–E: Changes in mRNA expression were also confirmed by real-time RT-PCR
for the classic TGF- receptors acvrl1 (B), tgfbr1 (C), tgfbr2 (D), and tgfbr3 (E). F,G: Changes in mRNA expression of genes encoding TGF- receptors
(F) and TGF- Smads (G) assessed by semiquantitative RT-PCR (for which representative examples are illustrated in A) were quantified by
densitometric analysis of amplicons from six to eight different mouse lungs per developmental stage. Band intensities (described by pixel density, PD)
from samples were normalized for loading using the hspa8 amplicon from the same sample. Data reflect the mean normalized PD  SD (n  6–8).
*P  0.05 vs. embryonic day (E) 15. Pseud, pseudoglandular; can, canalicular.
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over the course of late lung develop-
ment; however, the expression of all
three Smads was significantly reduced
at day P28 compared with stage E15
(Fig. 2A,B). Taking the RT-PCR and im-
munoblot data together, these data sug-
gest that Tgfbr1/Tgfbr2/Smad2,3,4-
mediated signaling is dampened while
Acvrl1/Eng/Smad6/Smad7-mediated
signaling is potentiated, as normal late
lung development in the mouse pro-
ceeds. Interestingly, in a hyperoxia
model of bronchopulmonary dysplasia,
a disorder characterized by arrested al-
veolar development, the opposite trend
is noted, where Tgfbr2 and Smad4 lev-
els are dramatically up-regulated (Ale-
jandre-Alca´zar et al., 2007a).
In addition to changes in total ex-
pression levels in the lungs of healthy
mice, both TGF- receptors and Smad
proteins exhibited different localiza-
tion during late lung development.
Antibodies directed against Acvrl1
were not suitable for immunohisto-
chemical assessment of Acvrl localiza-
tion in the mouse (data not shown),
however, both Tgfbr1 (Fig. 3A) and
Tgfbr2 (Fig. 3C) exhibited staining in
the vessel walls of the developing lung
at postnatal day P7, and in the case of
Tgfbr1, some staining in the intersti-
tium was also observed. In contrast,
no staining was observed in the epi-
thelial lining of the airways (insets to
Fig. 3A,C). Toward the end of alveo-
larization (stage P28), staining in ves-
sel walls for Tgfbr1 (Fig. 3B) and Tg-
fbr2 (Fig. 3D) was lost, although
staining was now evident in the epi-
thelial lining of the airways.
Smad protein localization was also
different during late lung develop-
ment (Fig. 3E,F). Staining for Smad3
was evident in the vessel walls, in-
cluding the endothelium, as well as in
the interstitium and in the subepithe-
lial layer of the airways in the lungs of
mice at day P7 (Fig. 3E). An abun-
dance of nuclear-localized staining for
Smad3 was observed in this tissue,
indicating that TGF- signaling was
active. Little or no staining for Smad3
was observed in the in the airway ep-
ithelium (Fig. 3E). By day P28, much
of the interstitial staining for Smad3
was lost, although staining, including
nuclear staining, for Smad3 was still
observed in the vessel walls (Fig. 3F).
Additionally, an abundance of cytoso-
lic and nuclear staining was now ob-
served in the epithelial lining of the
airways (Fig. 3F).
To localize activated TGF- Smads,
mouse lung sections were stained for
phospho-Smad2 (Fig. 4A,B). Nuclear-
localized phospho-Smad2 was evident
in the interstitium, airway epithe-
lium, and in the vessel walls of mouse
lungs at day P7 (Fig. 4A). By day P28,
the interstitial staining was lost; how-
ever, staining was still detected in the
airway epithelium and in the vessel
walls (Fig. 4B), indicating that TGF-
signaling was broadly active at the
start of alveolarization (day P7), but
was confined to the epithelial lining of
airways toward the end of alveolariza-
tion (day P28).
Smad activation was assessed di-
rectly by immunoblot for phospho-
Smad2 in whole-lung extracts from
mice over the course of late lung de-
velopment (representative blots are il-
lustrated in Fig. 4C; and multiple
blots are quantified in Fig. 4E,F). A
robust phospho-Smad2 signal was ob-
tained at the early alveolarization
stages (days P3 and P7 in Fig. 4C, F),
which is consistent with the im-
munohistochemical data presented in
Figure 4A. By day P28, the phospho-
Smad2 signal was significantly re-
duced (day P28 in Fig. 4C,F). How-
ever, normalization of the phospho-
Smad2 signal for total Smad2 (Fig.
4F) clearly illustrates that, while the
abundance of phospho-Smad2 at day
P28 is significantly less than that at
day P3 (Fig. 4E), the proportion of the
total Smad2 pool that is activated
(phosphorylated) is significantly in-
creased at day P28 compared with day
P7 (Fig. 4F). These data suggest that
TGF- signaling remains active into
late lung development and, together
with the histochemical data for phos-
pho-Smad2 (Fig. 4A,B), suggest that
Fig. 2. Changes in protein expression of the transforming growth factor-beta (TGF-) signaling
machinery, assessed by immunoblot, during late lung development in the mouse. A: Blots illustrate
10-g samples from two different mouse lungs per developmental stage, which are representative
of the patterns observed in at least six other mouse lungs at the same developmental stage. B:
Bands derived from six different mouse lungs were quantified by densitometric analysis. Band
intensities (described by the pixel density, PD) from samples were normalized for loading using the
-tubulin band from the same sample. In the case of Tgfbr2, the lower (more heavily expressed)
isoform 2 was analyzed. Data reflect the mean normalized PD  SD (n  8). *P  0.05 vs.
embryonic day (E) 15. Pseud, pseudoglandular; can, canalicular.
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the bulk of this signaling at day P28
occurs in the airway epithelium.
TGF- signaling was also assessed
indirectly, in whole-lung extracts from
mice over the course of late lung de-
velopment using two TGF-/Smad2,3
target genes: ctgf (encoding connective
tissue growth factor) and serpine1 (en-
coding plasminogen activator inhibi-
tor-1; Wu et al., 2007; Zakrzewicz et
al., 2007). Whereas both genes were
expressed throughout late lung devel-
opment (Fig. 4D), their expression
was significantly increased at day P28
compared with stage E15 (Fig. 4G).
These data are consistent with the in-
creased proportion of phospho-Smad2
seen at day P28 (Fig. 4F). However,
they are not consistent with the in-
creased overall abundance of phospho-
Smad2 between days P3 and P14. It
may well be that these genes are in-
duced by TGF- in specific cell types
(for example the airway epithelium)
where TGF-/Smad2,3 signaling is ac-
tive only later in lung development (as
suggested by the immunohistochemi-
cal analysis for Smad3 and phospho-
Smad2 in Figs. 3 and 4). Alterna-
tively, the expression of ctgf and
serpine1 may also be positively and
negatively regulated by other factors
active during lung development,
hence, the lack of correlation with the
overall abundance of phospho-Smad2
between days P3 and P14. Indeed, ctgf
can also be induced by, for example,
angiotensin II (Iwanciw et al., 2003)
and serpine1 can be induced by me-
chanical stimulation of the airways
(Chu et al., 2006). Because all of these
factors do impact late lung develop-
ment, ctgf and serpine1 expression
may not represent ideal indirect read-
outs of TGF-/Smad2,3 signaling in
this context.
To assess the extent to which these
patterns were comparable to human
lung development, sections of healthy
human lungs in the canalicular, sac-
cular, and alveolar stages of develop-
ment were screened by immunohisto-
chemical analysis for the expression
and localization of components of the
TGF- signaling machinery (Figs. 5,
6). In whole-lung extracts from mice,
one of the type I TGF- receptors,
Acvrl1, exhibited a progressive in-
crease in expression as late lung de-
velopment proceeded, as assessed by
RT-PCR (Fig. 1A,B,F) and immuno-
blot (Fig. 2A,B). A similar trend was
observed in human lungs, where pro-
gressively more Acvrl1 staining was
observed in the canalicular (Fig.
5A,E), saccular (Fig. 5B, F), and the
alveolar (Fig. 5C,G) stages. Diffuse
staining was observed in the intersti-
tium throughout these stages. Stain-
ing was most evident in the bronchial
epithelium, and increased in intensity
in the vascular smooth muscle (Fig.
5C,G; thick arrows) in the alveolar
stage. The anti-Acvrl1 antibody did
not stain mouse tissue (data not
shown); therefore, comparisons with
Acvrl1 localization in rodents could
not be made. In the case of the second
type I TGF- receptor, Tgfbr1, no
staining was evident in the pseu-
doglandular stages (not shown); how-
Fig. 3. Changes in localization of components of the transforming growth factor-beta (TGF-)
signaling machinery during late lung development in the mouse. A–F: Type I TGF- receptor
(Tgfbr1; A,B), type II TGF- receptor (Tgfbr2; C,D) and Smad3 (Smad3; E,F), expression was
localized in the lungs of mice at postnatal day (P) 7 (A,C,E) and P28 (B,D,F) by immunohistochem-
istry. Insets in A and C, which are not taken from areas in the larger panels, illustrate airway staining.
Images represented for P7 and P28 tissues are derived from the same tissue block; however, the
panels are representative of staining patterns observed in three animals per developmental stage.
G–I: Staining of sections after preadsorption of antibodies with competing peptides for Tgfbr1 (G)
and Tgfbr2 (H), or replacing the antibody with a species-matched isotype control, in the case of
Smad3 (I). Arrows indicate examples of stained cells. Arrowheads in E and F indicate nuclear-
localized Smad3 in the lung vasculature. Asterisk, alveolus; aw, airway; v, vessel.
Chapter 3
42
Dynamic regulation of TGF-E signaling during alveolarization
43
ever, staining of uniform intensity
was observed diffusely in the intersti-
tium and was pronounced in the air-
way epithelium in the canalicular,
saccular, and alveolar stages of hu-
man development (Fig. 5A–C,E–G).
Additionally, pronounced staining
was observed in the vascular smooth
muscle in the saccular and alveolar
stages (Fig. 5B,C,F,G). A similar
staining pattern was observed for Tg-
fbr2 in human lungs (Fig. 6A–C,E–G),
where diffuse staining was evident in
the interstitium, as well as in the ep-
ithelial lining of the developing air-
ways. This staining increased in in-
tensity between the canalicular and
alveolar stages, becoming most in-
tense in the alveolar stage (Fig. 6C,G).
Staining for Tgfbr2 was also evident
in the vessel walls in the saccular (Fig.
6B,F) and alveolar (Fig. 6C,G) stages.
Active TGF- signaling was demon-
strated throughout human lung devel-
opment by the presence of nuclear-
Fig. 4.
Fig. 5.
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localized phospho-Smad2 in the
developing lungs, in the canalicular
(Fig. 6H,L), saccular (Fig. 6I,M), and
alveolar (Fig. 6J,N) stages. Staining
was observed in the interstitium, in
the vessel walls and was pronounced
in the epithelial lining of the develop-
ing airways (Fig. 6). Additionally, nu-
clear phospho-Smad2 staining was
also observed in the airway smooth
muscle in the alveolar stage of human
lung development (Fig. 6J,N). To-
gether, these data indicate that com-
ponents of the TGF- signaling ma-
chinery are expressed during late lung
development in humans and that the
expression of various components of
this machinery are differentially reg-
ulated as late lung development pro-
ceeds. Additionally, TGF- signaling
per se was active during human late
lung development. The alveolar phase
of lung development in humans spans
the period from 36 weeks gestation to
2.5 years postnatal. The tissue sec-
tions illustrated here are derived from
neonatal patients who died preterm in
utero, or in the first 3 weeks after
delivery. Therefore, all sections illus-
trated here are in the very early alve-
olar stage of lung development, prob-
ably equivalent to between days P3
and P7 in neonatal mouse lungs. With
this in mind, the expression patterns
observed for Acvrl1, Tgfbr1, Tgfbr2,
and phospho-Smad2 appear to be con-
sistent between mouse and human
over the course of late lung develop-
ment.
DISCUSSION
Our data suggest that TGF- signal-
ing may be required for normal late
lung development in mammals. Some
notable patterns in TGF- receptor
expression were observed. Two type I
TGF- receptors exist: Acvrl1 and Tg-
fbr1. The expression of these two re-
ceptors was differently regulated in
the mouse, with a progressive in-
crease in Acvrl1 expression and a pro-
gressive decrease in Tgfbr1 expression
during late lung development. Acvrl is
believed to play a role in the endothe-
lium in the maturation phase of angio-
genesis (Lamouille et al., 2002), while
the more ubiquitously expressed Tg-
fbr1 mediates ECM deposition and re-
modeling (Massague´, 1998). The pat-
terns in Acvrl vs. Tgfbr1 expression
that we observed over late lung devel-
opment suggest that endothelial mat-
uration is favored, while ECM produc-
tion is gradually down-regulated.
However, pronounced staining for
Acvrl1 was also noted in the vascular
smooth muscle and the airway epithe-
lium, for which no function has yet
been ascribed. To our knowledge, this
is the first report of Acvrl1 expression
in either cell type.
What other roles may TGF- play
during late lung development? Dy-
namic changes in the expression of com-
ponents of the TGF- signaling system
were observed in several compartments
of the developing lung. Diffuse staining
in the interstitium was observed
throughout late lung development.
Type II pneumocytes serve as progeni-
tor cells for the alveolar epithelium and
are an important component of the in-
terstitium. The differentiation of type II
pneumocytes is regulated, at least par-
tially, by a balance between glucocorti-
coid and TGF- signaling (McDevitt et
al., 2007). Furthermore, transdifferen-
tiation of type II pneumocytes into type
I pneumocytes is an important feature
of the alveolarization process (Copland
and Post, 2004). TGF-/Smad2,3,4 sig-
naling plays a key role in this type II to
type I pneumocyte transdifferentiation
(Bhaskaran et al., 2007), which may ex-
plain the active TGF- signaling ob-
served in the interstitium during the
alveolar phase of late lung develop-
ment, where type II to type I pneumo-
cyte transdifferentiation would occur.
The most pronounced staining for
TGF- signaling components in mouse
and human tissue was observed in the
airway epithelium. Furthermore, pro-
nounced staining for nuclear-localized
Smad3, and nuclear-localized phospho-
Smad2 was observed in the airway
epithelium as late lung development
proceeded. TGF- is a key growth factor
driving terminal squamous differentia-
tion of cultured bronchial epithelial
cells in vitro, as well as changes in air-
way epithelial cell shape, surface area,
and adhesion properties (Masui et al.,
1986). Those data suggest that TGF- is
Fig. 4. The transforming growth factor-beta (TGF-)/Smad signaling axis is active during late lung
development in the mouse. A,B: Localization of phospho-Smad2 in the lungs of mice at postnatal
day (P) 7 (A) and P28 (B). Panels are representative of staining patterns observed in three animals
per developmental stage. Arrows indicate examples of nuclear-localized phospho-Smad2. aw,
airway; v, vessel. The inset in B illustrates staining of a section after preadsorption of antibodies
with a competing peptide for phospho-Smad2/3. C: Direct assessment of Smad2 activation during
late lung development. Smad2 phosphorylation, total Smad2 levels, and -tubulin were assessed
by immunoblot in protein extracts of lungs from mice during the saccular (P3) and alveolar (P7–P28)
stages of late lung development. Blots illustrate 25-g samples from two different mouse lungs per
developmental stage that are representative of the patterns observed in six other mouse lungs at
the same developmental stage. D: Indirect assessment of TGF-/Smad signaling by mRNA
abundance of the TGF-/Smad2,3-responsive genes ctgf and serpine1, determined by semiquan-
titative reverse transcriptase-polymerase chain reaction (RT-PCR). Amplicons are illustrated from
two different mouse lungs per developmental stage, representative of patterns observed in six
other mouse lungs at the same developmental stage. E,F: Changes in the levels of phospho-Smad2
(normalized for -tubulin; E) or the proportion of phospho-Smad2 (normalized for total Smad2; F)
were quantified by densitometric analysis of immunoblot bands from six mouse lungs per devel-
opmental stage. Band intensities (described by the pixel density, PD) for phospho-Smad2 were
normalized for -tubulin or Smad2 using the respective band from the same sample. Data reflect
the mean normalized phospho-Smad2 PD  SD (n  6). *P  0.05 vs. E15. G: Changes in ctgf and
serpine1mRNA levels were quantified by densitometric analysis of amplicon bands from six mouse
lungs per developmental stage. Band intensities (described by the pixel density, PD) from samples
were normalized for loading using the hspa8 amplicon from the same sample. Data reflect the mean
PD normalized for the hspa8 PD  SD (n  6). *P  0.05 vs. embryonic day (E) 15. Pseud,
pseudoglandular; can, canalicular.
Fig. 5. Changes in the expression levels and localization of type I transforming growth factor-beta
(TGF-) receptors occur during human late lung development. A–N: The type I TGF- receptors
Acvrl1 (A–G) and Tgfbr1 (H–N) were localized in the developing lungs of patients at the canalicular,
saccular, and alveolar stages, by immunohistochemistry. The areas illustrated are representative of
staining patterns observed in three to five different patients per developmental stage. D and K
illustrate staining of sections where the immune antibody was replaced with a species-matched
isotype control, in the case of Acvrl1 (D), or after preadsorption of antibodies with a competing
peptide, in the case of Tgfbr1 (K). Where high-magnification images (lower row) are derived from the
low-magnification image (upper row), the magnified area is demarcated with a solid-lined box. Thin
arrows indicate examples of staining in the cells lining the conducting airways and in the intersti-
tium. Thick arrows indicate examples of staining in vessel walls. aw, airway; v, vessel.
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critically involved in airway develop-
ment, which is consistent with the
staining patterns that we observed in
the airway epithelium during late lung
development. In support of this idea, a
significant reduction in the abundance
of tgfb1 (encoding the TGF-1 ligand)
and tgfbr1 mRNA, as well as a signifi-
cant reduction in the protein expression
of TGF-1 and TGF-2 ligands, and Tg-
fbr1 and Tgfbr2, have been reported in
the bronchial epithelium and smooth
muscle of a patient with pulmonary aci-
nar aplasia, a severe form of pulmonary
hypoplasia (Chen et al., 1999).
Detection of phospho-Smad2 in
airway smooth muscle indicated that
TGF- signaling was also active in
this tissue. TGF- exhibits pro-pro-
liferative effects on airway smooth
muscle cells (Xie et al., 2007), and
active TGF- signaling in the airway
smooth muscle in the developing
lung may contribute to the muscu-
larization of the developing airways
during late lung development. This
idea is supported by studies in
asthma, where overactive TGF- sig-
naling is believed to underlie the air-
way smooth muscle cell hyperplasia
observed in asthmatic patients (Xie
et al., 2007).
While TGF- signaling is required
for normal late lung development, this
requirement is clearly finely tuned,
because too much TGF- signaling
can negatively impact alveolarization.
Neonatal rodents chronically exposed
to normobaric hypoxia (Vicencio et al.,
2002) or hyperoxia (Alejandre-Alca´zar
et al., 2007a) exhibited arrested alveo-
larization and developed bronchopul-
monary dysplasia. In the case of hy-
peroxia, this occurred concomitantly
with up-regulated Tgfbr2 and Smad4
expression, and increased TGF-/
Smad2,3 signaling in the developing
lung (Alejandre-Alca´zar et al., 2007a).
Dampening of TGF- signaling in this
model by administration of a neutral-
izing anti–TGF- antibody largely re-
stored normal alveolar architecture
(Nakanishi et al., 2007), validating a
pathological role for TGF- in hyper-
Fig. 6. Changes in the expression levels and localization of the type II transforming growth factor-beta (TGF-) receptor and phospho-Smad2 during
human late lung development. A–N: The type II TGF- receptor Tgfbr2 (A–G) and phospho-Smad2 (H–N) were localized in the developing lungs of
patients at the canalicular, saccular and alveolar stages, by immunohistochemistry. D and K illustrate staining of sections where the immune antibody
was preadsorbed with competing peptides for Tgfbr2 (D) or phospho-Smad2/3 (K). The areas illustrated are representative of staining patterns
observed in three to five different patients per developmental stage. Where high-magnification images (lower row) are derived from the low-
magnification image (upper row), the magnified area is demarcated with a solid-lined box. Thin arrows indicate examples of staining in cells lining
conducting airways and in the interstitium. Thick arrows indicate examples of staining in vessel walls. aw, airway; v, vessel.
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oxia-induced arrest of alveolar devel-
opment. At the same time, complete
blockade of TGF- signaling by abla-
tion of Smad3 in neonatal mice also
arrested alveolarization (Chen et al.,
2005). Combining the ideas in those
reports with data presented here, it is
emerging that, although TGF- is a
negative regulator of airway branch-
ing in early lung development, we
demonstrate here that TGF- signal-
ing is active in multiple tissue types in
the lung during normal late lung de-
velopment. The degree of TGF- sig-
naling must, however, be precisely
controlled, because both up- and
down-regulation of TGF- signaling
impairs the alveolarization process.
EXPERIMENTAL
PROCEDURES
Animals and Tissue
Treatment
The animal ethics authority of the
government of the State of Hessen
approved all animal procedures.
C57BL/6J mice were housed in hu-
midity- and temperature-controlled
rooms on a 12:12-hr light–dark cycle
and were allowed food and water ad
libitum. Mice at stages E15, E17,
E19, P1, P3, P5, P7, P14, P21, and
P28 were killed by intraperitoneal
injection of sodium pentobarbital.
Lungs were excised, flushed free of
blood with phosphate-buffered sa-
line (PBS), and processed immedi-
ately for RNA or protein extraction.
For histology, the heart and lungs
from mice at days P7 and P28 were
excised en bloc, and the lungs were
pressure fixed overnight at 20 cm
H2O with 4% (m/v) paraformalde-
hyde in PBS (20 mM Tris-Cl, 137
mM NaCl, pH 7.6), as described pre-
viously (Alejandre-Alca´zar et al.,
2007a). Paraffin sections (3 m)
were mounted on poly-L-lysine–
coated glass slides, dewaxed with xy-
lene (3  5 min), and rehydrated in a
graduated series of ethanol solutions
(100%, 95%, 70% [v/v], and PBS).
Human Tissue
Fetal and neonatal human lung tissue
was retrieved from archived autopsy
material at the Erasmus University
Medical Centre and the University of
Giessen Lung Center. Lung samples
were normal for their gestational age.
All human material was used with the
approval of the Human Subjects Re-
view Committees of the Erasmus Uni-
versity Medical Centre and the Uni-
versity of Giessen Lung Center.
Autopsy material was derived from fe-
tuses from induced or spontaneous
abortions, stillbirth, or neonates that
died from nonpulmonary causes
within 3 weeks after delivery. None of
these infants had infections at the
time of death. Tissue was fixed in 4%
(m/v) paraformaldehyde in PBS, be-
tween 1 and 12 hr after death. Before
fixation, tissue was stored at 4°C.
Immunohistochemistry
Hematoxylin staining, and expression
of TGF- receptors, Smads, and
smooth muscle actin (SMA) was as-
sessed on 3 m tissue sections as de-
scribed previously (Morty et al., 2007),
with anti-SMA (1:850; clone 1A4;
Sigma, Taufkirchen, Germany); goat
anti-Acvrl1 (catalog no. AF370; R&D
Systems, Wiesbaden, Germany), rab-
bit anti-Tgfbr1 (designated R-20, cat-
alog no. SC-399; Santa Cruz, San
Fransisco, CA; 1:50; used with block-
ing peptide SC-399P), rabbit anti-Tg-
fbr2 (designated C-16, catalog no. SC-
220; Santa Cruz, San Fransisco, CA;
1:50; used with blocking peptide
SC-220P), rabbit anti-phospho-Smad2
(Ser465/467) (catalog no. 05-953), and
mouse anti-Smad3 (clone 2C12; catalog
no. MAB10075) were both fromUpstate
(Charlottesville, VA; both used at 1:50).
The anti–phospho-Smad2(Ser465/467)
antibody was preadsorbed with a phos-
pho-Smad2/3 competing peptide from
Santa Cruz (catalog no. SC-11769P;
San Fransisco, CA). For competing pep-
tides, antibodies were preadsorbed for
30 min at a ratio of 1:5 (antibody:pep-
tide; mol:mol) before use. No competing
peptides were available for the anti-
Acvrl1 and anti-Smad3 antibodies.
Therefore, in the case of these two anti-
bodies, species-matched isotype control
antibodies (available with the His-
tostain Plus Kit from Zymed, San
Fransisco, CA) replaced the primary
antibodies. Immune complexes were
visualized with a Histostain Plus Kit
(Zymed, San Fransisco, CA). Al-
though the specificity of all antibod-
ies used for immunohistochemistry
has been validated (Zakrzewicz et
al., 2007), additional data are in-
cluded in the relevant panels using
antibodies preadsorbed with a com-
peting peptide, or where primary an-
tibodies were replaced with a spe-
cies-matched isotype control
antibody at the same concentration.
For mouse and human tissue, all
panels illustrated at a particular de-
velopmental stage are derived from
the same tissue block. The staining
patterns depicted are representative
for three mice at the same develop-
mental stage, or for between three
and five patients at the same devel-
opmental stage.
RNA Isolation,
Semiquantitative RT-PCR
and Quantitative Real-Time
RT-PCR
Total RNA was isolated from fresh
lung tissue using a Qiagen RNeasy kit
(Qiagen, Hilden, Germany). One mi-
crogram of total RNA was reverse-
transcribed using the ImProm-II Re-
verse Transcription System (Promega,
Mannheim, Germany). One microliter
of the RT reaction served as a tem-
plate in a PCR reaction using Plati-
num Taq (Invitrogen, Karlsruhe, Ger-
many). Total RNA was screened by
semiquantitative RT-PCR using the
following forward (for) and reverse
(rev) primers at the stated cycle num-
ber: acvrl1 (29 cycles): 5-AGG GCC
GAT ATG GTG AGG TGT GG-3 (for),
5-GCC GGT TAG GGA TGG TGG
GTG TC-3 (rev); ctgf (29 cycles): 5-
CCC GCC AAC CGC AAG ATT-3
(for), 5;-AGG CGG CTC TGC TTC
TCC A-3; (rev); eng (22 cycles): 5-
GAG TCG GCT GTG ATC TAC AGC
CTG TGG-3 (for), 5-CTG ATG ATC
ACC TCA TTG CTG ACC-3 (rev);
hspa8 (24 cycles): 5-CAA GCG AAA
GCA CAA GAA AGA CAT-3 (for), 5-
ATA CCA AGC GAA AGA GGA GTG
ACA TC-3 (rev); serpine1 (26 cycles):
5-TCA TCA ATG ACT GGG TGG
AA-3 (for), 5-GCC AGG GTT GCA
CTA AAC AT-3 (rev); smad2 (24 cy-
cles): 5-CTC CGG CTG AAC TGT
CTC CTA CT-3, (for), 5-TTA CAG
CCT GGT GGG ATC TTA CA-3 (rev);
smad3 (24 cycles): 5-AGA ACG GGC
AGG AGG AGA AGT GGT-3 (for), 5-
GGA TTC GGG GAG AGG TTT GGA
GA-3 (rev); smad4 (25 cycles): 5-ACA
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GAG AAC ATT GGA TGG AC-3 (for),
5-AGT AGC TGG CTG AGC AGT
AA-3 (rev); smad6 (24 cycles): 5-GAG
CAC CCC CAT CTT CGT CAA-3
(for), 5-AAC AGG GGC AGG AGG
TGA TG-3 (rev); smad7 (25 cycles):
5;-CCT CCT CCT TAC TCC AGA
TA-3 (for), 5-ACG CAC CAG TGT
GAC CGA TC-3 (rev); tgfbr1 (27 cy-
cles): 5-AGA GCG TTC ATG GTT
CCG AGA G-3 (for), 5-GGG GCC
ATG TAC CTT TTA GTG C-3 (rev);
tgfbr2 (25 cycles): 5-GAG AGG GCG
AGG GCG AGG AGT AAA GG-3
(for),. 5-GTG GTA GGT GAG CTT
GGG GT-3 (rev); and tgfbr3 (27 cy-
cles): 5-CCC TGT GTT TGT CCT
GAT GAG CGC CTG CC-3 (for), 5-
CCT ATG TCT AGT ACC ACA GCC
ATT C-3 (rev). Amplicons were sepa-
rated on a 1% (m/v) agarose gel and
visualized by ethidium bromide stain-
ing. Amplicons generated with these
primer pairs have been validated by
sequencing, and the stated cycle num-
bers lie in the logarithmic phase for
each PCR (Alejandre-Alca´zar et al.,
2007a,b; Zakrzewicz et al., 2007). For
quantification of changes in mRNA ex-
pression, band intensities from spe-
cific samples were normalized for
loading using the constitutively ex-
pressed hspa8 band from the same
sample. Densitometric analysis of am-
plicon bands was performed using a
GS-800 model calibrated densitome-
ter with Quantity One software (both
from Bio-Rad Laboratories, Munich,
Germany). Pixel densities were cor-
rected for background staining in the
same gel. When the band intensity ex-
ceeded the maximum detection limit
for the software, that band was ex-
cluded from the analyses.
Total RNA was also screened by
quantitative real-time RT-PCR ex-
actly as described previously (Alejan-
dre-Alca´zar et al., 2007a; Morty et al.,
2007; Zakrzewicz et al., 2007) using
the following intron-spanning forward
(for) and reverse (rev) primers: acvrl1:
5-CAG TCC ACC TGA TTC AGC
TTT-3 (for), 5-GGC AAC AGG AAT
CAA GAT TGT-3 (rev); hmbs: 5-ATG
TCC GGT AAC GGC GGC-3; (for), 5-
GGT ACA AGG CTT TCA GCA
TCG-3 (rev); tgfbr1: 5-GGG ATT
GCC ATA GC-3 (for), 5-TCC CTG
TTG TGG TGA TGT T-3 (rev); tgfbr2:
5-CAG AGG GCA CCA CCT TAA
AA-3 (for), 5-AAT GGT CCT GGC
AAT TGT TC-3 (rev); and tgfbr3: 5-
GGG CAT TGC GTT TGC AGC AT-3
(for), 5-CTG AGT GCT CCC TAT
GCT GT-3 (rev). Quantitative
changes in gene expression were ana-
lyzed by comparing the Ct values of
the genes of interest (using RNA sam-
ples from three different animals per
developmental stage, each sample as-
sessed in duplicate), normalized for
the ubiquitously expressed pseudo-
gene-free hydroxymethylbilane syn-
thase (hmbs) gene.
Protein Isolation and
Immunoblotting
Protein extraction from mouse lungs,
gel electrophoresis, and immunoblot-
ting were performed as described previ-
ously (Alejandre-Alca´zar et al., 2007a).
Lung protein extracts (10–25 g) were
resolved on 12% polyacrylamide gels
and transferred to nitrocellulose mem-
branes for immunoblotting. Blots were
probed with goat anti-Acvrl1 (catalog
no. AF370; R&D Systems, Wiesbaden,
Germany; 1:1,000), mouse anti-Tgfbr1
(designated R-20, catalog no. SC-399;
Santa Cruz, San Fransisco, CA; 1:1,500
for mouse), mouse anti-Tgfbr2 (desig-
nated C-16, catalog no. SC-220; Santa
Cruz, San Fransisco, CA;), rabbit anti-
phospho-Smad2(Ser465/467) (catalog
no. 05-953), and mouse anti-Smad3
(clone 2C12; catalog no. MAB10075)
were both from Upstate (Charlottes-
ville, VA; both used at 1:1,000), rabbit
anti-Smad4 (catalog no. H-552; Santa
Cruz, San Fransisco, CA; 1:1,000),
and rabbit anti-Smad2 (catalog no. 51-
1300; Zymed, San Fransisco, CA;
1:1,000), while mouse anti–-tubulin
(designated B-7, catalog no. SC-5286;
Santa Cruz, San Fransisco, CA;
1:2,500) served as a loading control.
Peroxidase-conjugated anti-mouse (1:
1,000–1:2,000) and anti-rabbit (1:
2,000–1:2,500) secondary antibodies
were from R&D Systems (Wiesbaden,
Germany). The specificity of all anti-
bodies used for immunoblotting has
been validated (Alejandre-Alca´zar et
al., 2007a). Densitometric analysis of
bands was performed as described for
PCR amplicons, above.
Statistical Treatment of Data
Data are presented as mean  SD.
Differences between groups were ana-
lyzed by analysis of variance and the
Student-Newman-Keul post hoc test
for multiple comparisons, with a P
value  0.05 regarded as significant.
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S, Hesse M, Schermuly RT, Seeger W, Eickelberg O, Morty
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model of bronchopulmonary dysplasia. Am J Physiol Lung Cell
Mol Physiol 292: L537–L549, 2007. First published October 27,
2006; doi:10.1152/ajplung.00050.2006.—Prematurely born infants
who require oxygen therapy often develop bronchopulmonary dyspla-
sia (BPD), a debilitating disorder characterized by pronounced alve-
olar hypoplasia. Hyperoxic injury is believed to disrupt critical sig-
naling pathways that direct lung development, causing BPD. We
investigated the effects of normobaric hyperoxia on transforming
growth factor (TGF)-� and bone morphogenetic protein (BMP) sig-
naling in neonatal C57BL/6J mice exposed to 21% or 85% O2
between postnatal days P1 and P28. Growth and respiratory compli-
ance were significantly impaired in pups exposed to 85% O2, and
these pups also exhibited a pronounced arrest of alveolarization,
accompanied by dysregulated expression and localization of both
receptor (ALK-1, ALK-3, ALK-6, and the TGF-� type II receptor)
and Smad (Smads 1, 3, and 4) proteins. TGF-� signaling was
potentiated, whereas BMP signaling was impaired both in the lungs of
pups exposed to 85% O2 as well as in MLE-12 mouse lung epithelial
cells and NIH/3T3 and primary lung fibroblasts cultured in 85% O2.
After exposure to 85% O2, primary alveolar type II cells were more
susceptible to TGF-�-induced apoptosis, whereas primary pulmonary
artery smooth muscle cells were unaffected. Exposure of primary lung
fibroblasts to 85% O2 significantly enhanced the TGF-�-stimulated
production of the �1 subunit of type I collagen (I�1), tissue inhibitor
of metalloproteinase-1, tropoelastin, and tenascin-C. These data dem-
onstrated that hyperoxia significantly affects TGF-�/BMP signaling in
the lung, including processes central to septation and, hence, alveo-
larization. The amenability of these pathways to genetic and pharma-
cological manipulation may provide alternative avenues for the man-
agement of BPD.
lung development; transforming growth factor-�; bone morphoge-
netic protein; neonatal chronic lung disease; alveolarization
BRONCHOPULMONARY DYSPLASIA (BPD) was first described by
Northway et al. (35) as a disease of preterm infants that
received prolonged mechanical ventilation and oxygen supple-
mentation for acute respiratory distress. The impact of oxygen
toxicity, barotrauma, volutrauma, and infection on the developing
lung resulted in “classic BPD,” histopathologically characterized
by airway epithelial metaplasia, peribronchial fibrosis, and vascu-
lar smooth muscle hypertrophy (36). Advances in surfactant and
steroid therapy and ventilation strategies have changed the patho-
logical picture from “classic BPD” to “new BPD,” also called
chronic lung disease of early infancy (CLD), which is charac-
terized more by alveolar and capillary hypoplasia and less by
fibroproliferative airway damage and parenchymal fibrosis (2).
Impaired alveolus formation is observed in both forms of BPD
and leads to a long-term reduction in total number of alveoli,
and hence reduces the surface area available for gas exchange
(3, 18, 19).
Whereas the pathogenesis of new BPD is largely unknown
(3), hyperoxic injury is thought to disrupt critical signaling
pathways that direct lung development, including branching
and septation (46, 56). Many signaling pathways critical to
these processes have been described (41, 46), notable among
them, signaling by the transforming growth factor (TGF)-�
superfamily, encompassing the TGF-� and bone morphoge-
netic protein (BMP) families (17, 41, 53–55).
TGF-� signaling is initiated by binding of TGF-� to the type
II TGF-� receptor (T�RII), which subsequently complexes
with the type I receptor (ALK-1 or ALK-5). The type I receptor
transmits signals within the cell via second-messenger Smad
proteins, namely Smads 1–4, or by Smad-independent path-
ways (27). TGF-� signaling can negatively regulate the
branching (17, 41, 54) and septation (15, 52) phases of lung
development. In the case of the latter, adenoviral-mediated
transfer of TGF-�1 to the neonatal rat lung (15) or overexpres-
sion of TGF-�1 between postnatal days P7 and P14 in the
mouse (52) both induced histological changes analogous to
those seen in BPD. Surprisingly, however, Smad3 knockout
mice exhibited retarded alveolarization between days P7 and
P28 (6), suggesting that TGF-� also acts as a positive regulator
of septation. This apparent paradox indicates that TGF-�
signaling plays a critical and finely tuned role in alveolariza-
tion. Consistent with these data, Smad3 deficiency in adult
mice caused air space enlargement and centrilobar emphysema
in late life (4, 6, 33), suggesting a key role for TGF-� signaling
in both the formation of alveoli and the maintenance of
alveolar structure.
In contrast to TGF-�, BMP ligands bind their type I recep-
tors ALK-3 (BMPRIa) or ALK-6 (BMPRIb), which activate
the type II receptor (BMPRII), thereby initiating a signaling
cascade primarily via Smads 1 and 4 (31). BMPs have been
accredited with key roles in early lung development, particu-
larly lung branching (9, 17, 53, 54). However, BMP-4 expres-
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sion declines prior to the saccular stage, suggesting that BMP-4
is not required for septation (41).
Signaling by the TGF-�/BMP superfamily clearly plays a
key role in lung development. It has also been reported that
chronic hypoxia can influence TGF-� ligand and receptor
expression (51), and that very low birth weight infants receiving
oxygen therapy exhibit elevated TGF-� levels in endotracheal
aspirates (24). Thus we suspected that oxygen supplementation
may influence TGF-�/BMP signaling in the neonatal lung.
Such perturbations could underlie the arrested alveolar devel-
opment associated with BPD. Indeed, the identification of
differential gene expression in lungs that develop BPD has
been identified as a “research priority” in BPD by a recent
National Institute of Child Health and Human Development/
National Heart, Lung, and Blood Institute and Office of Rare
Diseases joint workshop (18). Therefore, the object of this
study was to investigate the effects of hyperoxia on TGF-�/
BMP superfamily signaling in the lung.
MATERIALS AND METHODS
Chronic exposure to hyperoxia. The government of the State of
Hessen approved all animal procedures [Regierungspra¨sidium
Giessen II25.3–19c20–15(1) GI20/10-Nr.22/2000]. Adult and neo-
natal C57BL/6J mice were housed in humidity- and temperature-
controlled rooms on a 12:12-h light-dark cycle and were allowed food
and water ad libitum. On day P1, pups from four to eight litters (born
within 3 h of each other) were pooled and randomized to newly
delivered dams. Pups from one half of the combined litters were
maintained in 85% (vol/vol) O2, whereas pups from the other half
remained in room air [21% (vol/vol) O2]. Nursing dams were rotated
between hyperoxia and room-air litters every 24 h to prevent oxygen
toxicity in the dams. Hyperoxia exposures were done in 90 � 42 �
38-cm Plexiglas chambers, continuously ventilated at a rate of 3.5
l/min. Oxygen levels were monitored with a Miniox II monitor
(Catalyst Research, Owing Mills, MD). Dynamic compliance was
assessed by the volume-pressure compliance method in anesthetized
mice (26), where mice were mechanically ventilated with a tidal
volume of 6 ml/kg.
Lung processing and morphometric analysis. Mice were killed by
intraperitoneal injection of sodium pentobarbital and were exsangui-
nated by aortic transection. The heart and lungs were excised en bloc,
and the lungs were pressure-fixed overnight at 20 cmH2O with 4%
(mass/vol) paraformaldehyde in phosphate-buffered saline (PBS; 20
mM Tris�HCl, 137 mM NaCl, pH 7.6), as described previously (51).
Paraffin sections (3 �m) were mounted on poly-L-lysine-coated glass
slides, dewaxed with xylene (3 � 5 min), and rehydrated in a
graduated series of ethanol solutions [100% (vol/vol), 95% (vol/vol),
70% (vol/vol), and finally PBS]. The mean linear intercept (MLI) and
septal thickness were determined on sections stained for smooth
muscle actin and counter-stained with hematoxylin and eosin, as
described previously (51, 52).
Primary cell isolation and cell culture. Primary mouse alveolar
type II (ATII) cells were isolated and passaged exactly as described
previously (49). Primary human lung fibroblasts and primary human
pulmonary artery smooth muscle cells (PASMC) were isolated from
human donor lungs that had been rejected for transplantation, exactly
as we have described previously (14, 37). The fibroblast-derived cell
line NIH/3T3 and the mouse distal alveolar epithelial cell-derived
MLE-12 cell line were maintained and passaged according to the
recommendations of the American Type Culture Collection (ATCC,
http://www.atcc.org). To investigate the effects of 85% O2 on the
induction of apoptosis, proliferation, or synthesis of extracellular
matrix components by TGF-� or BMP, cells were maintained under
21% O2 or 85% O2 for 24 h, prior to stimulation with TGF-�1
(2 ng/ml) or BMP-2, BMP-4, or BMP-7 (each at 100 ng/ml) for a
further 48 h. Samples were analyzed at 24 and 48 h after application
of TGF-� or BMP ligand.
Protein detection by immunoblot. Frozen, unfixed lung tissue was
homogenized with a tissue grinder in lysis buffer [20 mM Tris�HCl,
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% (vol/vol) Triton
X-100] supplemented with Complete proteinase inhibitor cocktail
(Merck Biosciences, Bad Soden, Germany). Lysates from cultured
cells were similarly prepared using a cell scraper. Homogenates were
clarified by centrifugation (10,000 g, 4°C, 10 min). Protein concen-
tration was quantified with a Bio-Rad DC protein assay (Bio-Rad,
Hercules, CA). Cell extracts (10 �g) resolved on a 10% reducing
SDS-PAGE gel were transferred to a nitrocellulose membrane. Blots
were probed with the following antibodies: rabbit anti-ALK-3 or
anti-ALK-6 (1:2,000; R&D Systems, Wiesbaden, Germany); mouse
anti-ALK-5 (1:1,500; Santa Cruz, San Francisco, CA); mouse anti-
T�RII (1:1,000; Santa Cruz); rabbit anti-Smad1; rabbit anti-phospho-
Smad1 (Ser463/465); mouse anti-phospho-Smad2 (Ser465/467) and
mouse anti-Smad3 (both at 1:1,000; Upstate, Charlottesville, VA);
rabbit anti-Smad4 (1:1,000; Santa Cruz); and rabbit anti-Smad2
(Zymed, San Francisco, CA); whereas mouse �-tubulin (1:1,000;
Santa Cruz) served as a loading control. Peroxidase-conjugated anti-
mouse (1:1,000 to 1:2,000) and anti-rabbit (1:2,000 to 1:2,500)
secondary antibodies were from R&D Systems. Densitometric anal-
ysis of protein bands was performed using a GS-800 model calibrated
densitometer with Quantity One software (both from Bio-Rad Labo-
ratories, Munich, Germany). Band intensities from samples were
normalized for loading using the �-tubulin band from the same
sample. Expression ratios for immunoblot data reflect values normal-
ized for tubulin: [band pixel density (PD) (85% O2)/tubulin PD (85%
O2)]/[band PD (21% O2)/tubulin PD (21% O2)].
Total RNA isolation and semiquantitative and real-time RT-PCR.
Total RNA was isolated from unfixed lung tissue or from cultured
primary human lung fibroblasts using a Qiagen RNeasy kit (Qiagen,
Hilden, Germany), followed by DNase treatment to remove any
contaminating genomic DNA. Total RNA was screened for mRNA
encoding ALK-1, BMPRII, connective tissue growth factor (CTGF),
inhibitor of differentiation (Id) 1, Id2, Id3, and plasminogen activator
inhibitor-1 (PAI-1) using the primers indicated in Table 1 and the
hspa8 or gapdh genes to demonstrate RNA equivalence in the RT
reactions. One microgram of total RNA was reverse-transcribed using
the ImProm-II Reverse Transcription System (Promega, Mannheim,
Germany). One microliter of the RT reaction served as a template in
a PCR reaction using Platinum Taq (Invitrogen, Karlsruhe, Germany).
Amplicons were generated by an initial denaturation (5 min, 96°C),
followed by 25 cycles of denaturation (1 min, 96°C), annealing (1 min
at the annealing temperature described in Table 1), and primer
extension (3 min, 72°C). The PCR reactions were terminated with a
10-min primer extension step at 72°C. Amplicons were separated on
a 1% (mass/vol) agarose gel and visualized by ethidium bromide
staining. Band intensities from specific samples were normalized for
loading using the hspa8 band from the same sample. Expression ratios
for RT-PCR data reflect values normalized for the hspa8 band: [band
PD (85% O2)/hspa8 PD (85% O2)]/[band PD (21% O2)/hspa8 PD
(21% O2)].
Quantitative changes in mRNA expression of genes encoding ECM
and ECM-remodeling components were assessed by quantitative real-
time PCR exactly as described previously (22), using a Sequence
Detection System 7700 (Applied Biosystems, Foster City, CA) and
the intron-spanning primer pairs indicated in Table 1. The ubiqui-
tously expressed, pseudogene-free hydroxymethylbilane synthase
(hmbg) gene was used as reference. Cycling conditions were 95°C for
6 min, followed by 45 cycles of 95°C for 20 s, 62°C for 30 s, and 73°C
for 30 s. The exclusive amplification of the expected PCR product was
confirmed by melting curve analysis and gel electrophoresis. Changes
are expressed as: [ligand-induced fold change in cycle threshold (�Ct)
under 85% O2]/(ligand-induced fold change in �Ct under 21% O2).
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Immunostaining of lung tissue sections. Expression of TGF-�/BMP
receptors and Smad molecules was assessed on 3-�m tissue sections,
prepared as described above for lung morphometric analysis. After
antigen retrieval (performed in a pressure cooker using 6.5 mM
sodium citrate, pH 6.0) and quenching of endogenous peroxidase
activity with 3% (vol/vol) H2O2 for 20 min, sections were incubated
with the relevant primary antibody: mouse anti-SMA (1:450; Sigma,
Taufkirchen, Germany), rabbit anti-ALK-3 (1:400; R&D Systems),
rabbit anti-ALK-6 (1:350; R&D Systems), rabbit anti-T�RII (H-567,
1:100; Santa Cruz), and rabbit anti-Smad1, anti-Smad3, and anti-
Smad4 (all at 1:50; Upstate). Immune complexes were visualized with
the relevant peroxidase-coupled secondary antibody, provided in the
Histostain Plus Kit (Zymed).
Assessment of TGF-� or BMP signaling by luciferase transcrip-
tional reporter assay. Cells (either MLE-12 or NIH/3T3) were seeded
in 24-well plates and maintained under 21% O2 until 70% confluent.
Cells were transiently transfected with LipofectAMINE (Invitrogen)
according to the manufacturer’s recommendations, either with
p(CAGA)12 (Ref. 11) or with pID120 (Ref. 25), which contain a
TGF-�-responsive and a BMP-responsive promoter, respectively,
placed immediately upstream of a firefly luciferase gene. Alterna-
tively, cells were transfected with pGL3-basic (containing a promot-
erless luciferase gene) or pGL3-control (containing a constitutively
expressed luciferase gene) both from Promega (Mannheim, Germany)
as negative and positive controls, respectively. Cells were incubated
for a further 6 h in 21% O2 and then placed in either 21% O2 or 85%
O2 for 24 or 48 h, after which cells were stimulated with TGF-�1 (2
ng/ml) or BMP-2 (20 ng/ml) for 12 h. Cells were lysed and processed
for determination of firefly luciferase activity exactly as recommended
by the manufacturer. To cater for the effects of ligand stimulation and
hyperoxia on the baseline transcriptional activity of the cells, values were
normalized for the transcriptional activity of the pGL3-control vector.
Assessment of apoptosis and cell-cycle progression by flow cytom-
etry. Identificationofapoptoticcellswasperformedusingallophycocyanin-
conjugated annexin V (Invitrogen), following the recommendations of
the manufacturer, as described previously (45). Necrotic cells were
excluded by counter-staining with 2 �g/ml propidium iodide. Cell
cycle analysis was performed as described previously (45); briefly,
cells were harvested by trypsinization, fixed overnight at 4°C with
75% (vol/vol) ethanol, washed, and incubated in PBS containing 10
�g/ml propidium iodide and 100 �g/ml RNase (Merck Biosciences)
for 1 h at 37°C. Data were collected using a FACSCanto flow
cytometer and analyzed using a FACSDiva software package (both
from BD Biosciences, Heidelberg, Germany). A minimum of 10,000
cells were analyzed per sample. Gates based on forward and side
scatter were set to eliminate cellular debris and cell clusters.
Statistical analysis. Values are expressed as means � SD. Differ-
ences between the groups were assessed by one-way ANOVA and a
Student-Newman-Keuls test for multiple comparisons, with a P value
�0.05 considered significant.
RESULTS
Survival, growth, and respiration of neonatal mice exposed
to chronic hyperoxia. For chronic hyperoxia exposure, one group
of pups was exposed to 85%O2 starting at day P1 and terminating
at day P28. A second group was exposed to 21%O2 over the same
time period. A 100% survival was recorded for both groups of
pups. This high survival contrasts with the poorer survival (60%)
observed for FVB/N mice exposed to 85% O2 between days P0.5
and P28 (56), probably reflecting the well-described variability in
mouse strain sensitivity to hyperoxia (20).
A marked effect of hyperoxia on growth, as assessed by
trends in body mass changes, was observed (Table 2). On day
Table 1. Primers employed for RT-PCR
Gene Forward Primer Reverse Primer
Amplicon
Size, bp
Cycle
Number
Annealing
Temperature,
°C
Semiquantitative PCR
ALK-I 5�-AGGGCCGATATGGTGAGGTGTGG-3� 5�-GCCGGTTAGGGATGGTGGGTGTC-3� 735 29 58
BMPRII 5�-GGGGAAGAAGATAATGCG-3� 5�-GGACATCGAATGCTCAGAGG-3� 601 32 55
CTGF 5�-CCCGCCAACCGCAAGATT-3� 5�-AGGCGGCTCTGCTTCTCCA-3� 449 29 60
gapdh 5�-ACCCAGAAGACTGTGGATGG-3� 5�-TGTGAGGGAGATGCTCAGTG-3� 548 24 60
hspa8 5�-CAAGCGAAAGCACAAGAAAGACAT-3� 5�-ATACCAAGCGAAAGAGGAGTGACATC-3� 474 24 60
Id1 5�-GCCCCAGAACCGCAAAGTGA-3� 5�-AACCCCCTCCCCAAAGTCTCTG-3� 409 25 65
Id2 5�-AAAGCCTTCAGTCCGGTGAG-3� 5�-AGCCACAGAGTACTTTGCTATCAT-3� 400 25 60
Id3 5�-CGCGAGGCCGCGGTAAG-3� 5�-GTTCCGGAGTGAGCTCAGCTGTCT-3� 249 25 65
PAI-1 5�-TCATCAATGACTGGGTGGAA-3� 5�-GCCAGGGTTGCACTAAACAT-3� 508 26 60
Real-time PCR
Collagen 1 5�-CAAGAGGAAGGCCAAGTCGAG-3� 5�-TTGTCGCAGACGCAGATCC-3� 128 NA 59
Collagen 3 5�-CTGTGAATCATGCCCTACTGGTC-3� 5�-TAGCCTGCGAGTCCTCCTACTG-3� 96 NA 59
Elastin 5�-GGGTTGTGTCACCAGAAGCA-3� 5�-CCCGTAAGTAGGAATGCCTCC-3� 99 NA 59
MMP-1 5�-ACCCCAAAAGCGTGTGACAG-3� 5�-AGAAGGGATTTGTGCGCATG-3� 106 NA 59
MMP-2 5�-CCGCAGTGACGGAAAGATGT-3� 5�-GCCACGAGGAACAGGCTGTA-3� 102 NA 59
hmbg 5�-CCCACGCGAATCACTCTCAT-3� 5�-TGTCTGGTAACGGCAATGCG-3� 70 NA 59
Tenascin-C 5�-CCATCTATGGGGTGATCCGG-3� 5�-TCGGTAGCCATCCAGGAGAG-3� 139 NA 59
TIMP-1 5�-CGCAGCGAGGAGTTTCTCA-3� 5�-AGCTCAGGCTGTTCCAGGG-3� 94 NA 59
TIMP-3 5�-GGACCGACATGCTCTCAAT-3� 5�-CGGTACCAGCTGCAGTAGCC-3� 94 NA 59
BMPRII, BMP type II receptor; CTGF, connective tissue growth factor; Id, inhibitor of differentiation; PAI-1, plasminogen activator inhibitor-1; MMP, matrix
metalloproteinase; hmbg, hydroxymethylbilane synthase gene; TIMP, tissue inhibitor of metalloproteinase; NA, not applicable.
Table 2. Physiological parameters
Parameter 21% O2 85% O2 P Value
Body mass, g
day P14 7.2�1.1 6.0�0.9 �0.05
day P28 15.2�0.4 10.2�0.9 �0.01
Dynamic compliance, ml/kPa 5.2�0.3 4.4�0.4 �0.05
Mean linear intercept, �m 20.1�0.6 35.2�3.2 �0.01
Septal thickness, �m 4.4�0.3 5.3�0.2 �0.01
Physiological parameters of mice maintained under 21% O2 or 85% O2
assessed at postnatal day P28 (n � 18 for 21% O2 and n � 22 for 85% O2 for
all measurements with the exception of dynamic compliance measurements
where n � 8 for both groups).
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P14, pups exposed to 85% O2 exhibited a comparable body
mass to age-matched pups exposed to 21% O2 over the same
time period (Table 2). However, by day P28, pups exposed to
85% O2 exhibited an average body mass that was 33% lower
than that of age-matched pups exposed to 21% O2 (Table 2).
A marked effect of hyperoxia on dynamic respiratory com-
pliance (Cdyn) was also observed, since pups exposed to 85%
O2 between days P1 and P28 exhibited a Cdyn 25% lower than
that observed for age-matched pups exposed to 21% O2 (Table
2) at day P28. Thus, while without effect on survival, exposure
to chronic hyperoxia significantly impaired growth and respi-
ratory compliance of neonatal C57BL/6J mice.
Lung morphometry of neonatal mice after exposure to
chronic hyperoxia. Alveolar development was impaired in
pups exposed to 85% O2, evident by the enlarged and saccular
appearance of air spaces and the reduced number of secondary
crests (Fig. 1, A and B), compared with pups exposed to 21%
O2 (Fig. 1, C and D). Quantification of these parameters
supported our observations. The MLI is inversely proportional
to the alveolar surface area. By day P28, pups exposed to 85%
O2 exhibited a MLI approximately double that of pups exposed
to 21% O2 (Table 2), indicating a dramatic reduction in
alveolar surface area of pups exposed to 85% O2.
Similarly, mice exposed to 85% O2 exhibited a significant
increase in septal thickness (Table 2), which is typically
attributed to the accumulation of extracellular matrix compo-
nents, namely collagen and elastin fibers, in the interstitium
(2). These data indicate that exposure of C57BL/6J neonates to
chronic hyperoxia severely impaired alveolarization. This pa-
thology is consistent with morphometric changes observed in
FVB/N mice exposed to 85% O2 (56), as well as in preterm
baboon (7) and sheep (1) models of BPD.
Effect of chronic hyperoxia on abundance of TGF-�/BMP
signaling molecules in neonatal mouse lungs. Where antibod-
ies were available, lung samples were probed by immunoblot-
ting to investigate whether exposure to 85% O2 resulted in
changes in protein expression between the 85% and 21% O2
groups. Indeed, pronounced changes were observed for some
TGF-�/BMP superfamily receptors (Fig. 2A). The abundance
of the type I BMP receptors ALK-3 and ALK-6 was reduced
(twofold; Fig. 2, A and B) and increased (fourfold; Fig. 2, A and
D), respectively, particularly at days P21 and P28. The abun-
dance of the type I TGF-� receptor ALK-5 was reduced
(fourfold) in the 85% O2 group (Fig. 2, A and C), whereas
abundance of T�RII, particularly the short isoform (42), was
increased (fourfold; Fig. 2, A and E).
Temporal changes in the abundance of intracellular signal-
ing components of the TGF-�/BMP system were also observed
(Fig. 3A). The abundance of Smad1, the key transducer of
BMP signals, was increased in the 85% O2 group. This effect
peaked at day P14 (Fig. 3, A and B) and remained evident at
day P21. In contrast, the abundance of Smad3, a transducer of
TGF-� signals, was reduced between days P7 and P28 (Fig. 3,
A and C). Protein levels of the co-Smad, Smad4, which
transduces both TGF-� and BMP signals, were dramatically
(sixfold) increased at days P21 and P28 (Fig. 3, A and D). Thus
chronic hyperoxia markedly changed the abundance of TGF-
�/BMP superfamily proteins in the lungs of neonatal mice.
Protein expression of ALK-1 and BMPRII could not be
evaluated by immunoblot, since there are no commercial anti-
bodies available against ALK-1 and a commercial antibody
against BMPRII did not work in our hands (data not shown).
Therefore, gene expression in the lungs of neonatal mice
exposed to 85% or 21% O2 between days P1 and P28 was
assessed by semiquantitative RT-PCR (Fig. 2F). Levels of
mRNA encoding ALK-1 were upregulated in the 85% O2
group, evident at days P7, P21, and P28 (Fig. 2, F and G). In
contrast, with the exception of day P7, levels of BMPRII
mRNA were unchanged under hyperoxic conditions (Fig. 2, F
and H). Thus, in addition to the changes in TGF-�/BMP
superfamily expression observed by immunoblot (Figs. 2A and
3), chronic hyperoxia can also alter ALK-1 gene expression in
the lungs of neonatal mice. It is important to note, however,
that in the hyperoxia-injured lung, mRNA levels do not nec-
essarily correlate with protein abundance. Indeed, for some
proteins, such as surfactant protein D, mRNA levels and
protein abundance are inversely correlated (57). Therefore,
these RT-PCR data should be interpreted with caution.
Effect of chronic hyperoxia on localization of TGF-�/BMP
superfamily proteins in neonatal mice. In pups exposed to both
85% O2 and 21% O2, ALK-3 staining was evident in both the
airway epithelium and septae (Fig. 4A). The ALK-6 staining,
which was evident in the septae as well as in the airway
epithelium of pups exposed to 21% O2, was more intense in
lungs of pups exposed to 85% O2 (Fig. 4A). Similarly, whereas
little or no staining for T�RII was evident in lungs exposed to
21% O2, staining (particularly in the airway subepithelial
layer) was evident after exposure to 85% O2 (Fig. 4A). These
trends are consistent with a fourfold elevation in ALK-6 (Fig.
2, A and D) and T�RII (Fig. 2, A and E) protein abundance in
hypoxia-exposed lungs assessed by immunoblot.
Protein abundance of Smad1 in the lungs of pups at day P28
was similar in the 21% and 85% O2 groups (although it was
significantly elevated at days P14 and P21; Fig. 3, A and B).
Consistent with these data, Smad1 staining, evident in the
endothelial layer, as well as in the airway epithelium, was of a
similar intensity in lung sections from pups exposed to 21%
and 85% O2 (Fig. 4B). In contrast, strong Smad3 staining was
Fig. 1. Chronic hyperoxia impairs alveolarization in neonatal mice. Architec-
tural changes to lung structure were evident in hematoxylin- and eosin-stained
lung sections from mice at postnatal day P28, after exposure to 21% O2 (A–B)
or 85% O2 (C–D).
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evident in the airway epithelium and the septae in the lungs of
pups exposed to 21% O2 (Fig. 4B), although this staining was
less intense in the lungs of 85% O2-exposed pups (Fig. 4B),
reflecting the twofold decrease in Smad3 protein abundance
evident in immunoblots (Fig. 3, A and C). A similar correlation
was observed in the case of Smad4, which exhibits a dramatic
sixfold increase in protein abundance in the lungs of 85%
O2-exposed pups (Fig. 3, A and D). Smad4 staining was
localized primarily to the endothelium in the lungs of pups
exposed to 21% O2 (Fig. 4B). After exposure to 85% O2,
staining was more intense and was now also evident in the
airway epithelium and the alveolar septae (Fig. 4B). Together,
these data indicate that chronic exposure changes both the
protein abundance and localization of components of the
TGF-�/BMP superfamily.
Effect of chronic hyperoxia on TGF-�/BMP signaling in
neonatal mouse lungs. To address whether the dramatic alter-
ations in the expression of TGF-� and BMP signaling mole-
cules we observe actually translate to altered TGF-� and BMP
signaling in the neonatal mouse lung in response to high
oxygen concentrations, we assessed the expression of two
TGF-� responsive genes, PAI-1 and CTGF, as well as three
BMP-responsive genes, encoding Id1, Id2, and Id3. The PAI-1
mRNA expression was consistently upregulated in lungs of
pups exposed to 85% O2, in which CTGF mRNA levels were
also prominently upregulated, particularly at days P14 and P21
(Fig. 5A). Whereas no quantitative statement could be made
regarding Id1 mRNA levels, the mRNA levels of Id2 and Id3
were decreased, notably at days P14 and P21, in lungs of pups
exposed to 85% O2 (Fig. 5A). These data suggested that TGF-�
signaling was enhanced, whereas BMP signaling was damp-
ened in lungs of pups exposed to 85% O2. In further support of
this idea, we assessed the degree of phosphorylation of Smad1
and Smad2, which are specific transducers of BMP and TGF-�
signals, respectively. Indeed, at day P14, exposure to 85% O2
promoted both a significant decrease in Smad1 phosphoryla-
tion and a significant increase in Smad2 phosphorylation (Fig.
5, B and C). By day P28, Smad1 phosphorylation was restored
Fig. 2. Chronic hyperoxia alters expression of transforming growth factor-� (TGF-�) and bone morphogenetic protein (BMP) superfamily receptors in neonatal
mice. A: representative immunoblots illustrating expression of the TGF-�/BMP superfamily receptors ALK-3, ALK-5, ALK-6, and type II TGF-� receptor
(T�RII) in lungs extracted at days P7, P14, P21, and P28 from neonatal mice exposed to 21% O2 or 85% O2 from day P1. The �-tubulin served as a loading
control. Immunoblot data were quantified for ALK-3 (B), ALK-5 (C), ALK-6 (D), and T�RII (E); n � 3–6 for each bar. *P � 0.05. Changes in expression of
ALK-1 and BMP type II receptor (BMPRII) were assessed at the mRNA level because appropriate antibodies were not available. Total lung RNA was extracted,
and RT-PCR analysis was performed as described in MATERIALS AND METHODS, to detect genes encoding ALK-5 and BMPRII. A representative ethidium
bromide-stained agarose gel is illustrated in F, showing PCR amplicons obtained from RNA extracted at days P7, P14, P21, and P28 from neonatal mice exposed
to 21% O2 or 85% O2 from day P1. The hspa8 gene was used to demonstrate RNA equivalence in the RT reactions. Quantification of RT-PCR data is illustrated
for ALK-1 (G) and BMPRII (H); n � 4–6 for each bar. *P � 0.05.
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to levels observed; however, Smad2 phosphorylation remained
elevated in the 85% O2 group (Fig. 5, B and C). Together, these
data indicate that TGF-� signaling is most likely enhanced,
whereas BMP signaling is decreased, in lungs from pups
exposed to 85% O2.
Effect of hyperoxia on TGF-�/BMP signaling in epithelial
and fibroblast cell-lines. Since the impaired TGF-�/BMP sig-
naling we observed in the lungs of pups may have been
attributable to the undernourishment (clearly evident by re-
duced body mass) of pups exposed to 85% O2, we sought to
validate our observations in vitro in cell culture. Therefore,
TGF-� and BMP signaling was assessed in NIH/3T3 (fibro-
blast) and MLE-12 (epithelial) cells, using a luciferase-based
transcriptional reporter assay, employing the TGF-�-respon-
sive reporter p(CAGA)12 or the BMP-responsive reporter
pId120. Baseline transcriptional activity of the cells was al-
Fig. 3. Chronic hyperoxia alters expression of Smad
proteins in neonatal mice. A: representative immuno-
blots illustrating the expression of BMP-specific
Smad1, TGF-�-specific Smad3, and the co-Smad,
Smad4, in lungs extracted at days P7, P14, P21, and
P28, from neonatal mice exposed to 21% O2 or 85% O2
from day P1. The �-tubulin served as a loading control.
Immunoblot data were quantified for Smad1 (B),
Smad3 (C), and Smad4 (D); n � 4–6 for each bar.
*P � 0.05.
Fig. 4. Immunohistochemical localization of TGF-�/BMP superfamily receptor and Smad proteins in the lungs of neonatal mice chronically exposed to
hyperoxia. A: representative fields illustrating the expression patterns of TGF-�/BMP system receptors ALK-3, ALK-6, and T�RII in lungs extracted on day P28
from neonatal mice exposed to 21% O2 (left column) or 85% O2 (right column) from day P1. B: representative fields illustrate the expression patterns of
BMP-specific Smad1, TGF-�-specific Smad3, and the co-Smad, Smad4, in lungs extracted on day P28 from neonatal mice exposed to 21% O2 (left column) or
85% O2 (right column) from day P1.
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tered by hyperoxia (�11% reduced) and TGF-�1 (reduced by
as much as 17%), although not by BMP-2, as assessed by
changes in the expression of the constitutively active pGL3-
control construct (data not shown). Therefore, induction of
transcription was normalized for pGL3-control transcriptional
activity. Exposure of both MLE-12 and NIH/3T3 cells to 85%
O2 for 24 or 48 h dramatically (3- to 4-fold) increased their
sensitivity to TGF-�1 stimulation (Fig. 6, A and B). In contrast,
MLE-12 cells were poorly responsive to BMP-2 stimulation,
and MLE-12 responsiveness to BMP-2 was not affected by
elevated oxygen concentrations (Fig. 6C). NIH/3T3 cells were
responsive to BMP-2 stimulation, and after 48 h of exposure to
85% O2, the responsiveness of NIH/3T3 cells to BMP-2 was
significantly decreased (Fig. 6D). These data nicely support our
contention that hyperoxia has opposing effects on TGF-� and
BMP signaling, where TGF-� signaling is enhanced and BMP
signaling is dampened.
Effect of hyperoxia on TGF-�- and BMP-induced apoptosis
of ATII and PASMC. The hyperoxia-induced apoptosis of ATII
cells is believed to be an important factor in oxygen toxicity
Fig. 5. Induction of TGF-�/BMP signaling in the lungs
of neonatal mice chronically exposed to hyperoxia. A:
expression of mRNA of the TGF-�-inducible genes
encoding plasminogen activator inhibitor-1 (PAI-1) and
connective tissue growth factor (CTGF), and the BMP-
inducible genes encoding inhibitor of differentiation 1
(Id1), Id2, and Id3, in lungs extracted at days P7, P14,
P21, and P28 from neonatal mice exposed to 21% O2 or
85% O2 from day P1. The mRNA expression was
assessed by semiquantitative RT-PCR. The gapdh gene
was used to demonstrate RNA equivalence in the RT
reactions. Baseline phosphorylation of Smad proteins
was also assessed in lungs extracted at days P14 and P28
from neonatal mice exposed to 21% O2 or 85% O2 from
day P1 (B). Data were quantified by densitometry, by
comparing the ratio of phospho-Smad (pSmad) to
total Smad in hyperoxic vs. normoxic lungs (C). The
fold change in Smad phosphorylation was calculated
by [pSmad/total Smad (85% O2)]/[pSmad/total Smad
(21% O2)]; n � 3–4 for each bar. *P � 0.05.
Fig. 6. Effect of hyperoxia on TGF-� and BMP
signaling assessed by a luciferase reporter assay.
Mouse lung epithelial-12 (MLE-12) (A and C) or
NIH/3T3 (B and D) cells were transfected with
the TGF-�-responsive reporter p(CAGA)12 (A
and B) or the BMP-responsive reporter
pID120 (C and D) and maintained in 21% O2
(black bars) or 85% O2 (gray bars) for 24 or
48 h prior to stimulation with TGF-� (2 ng/ml)
or BMP-2 (20 ng/ml) for 12 h. Ligand-induc-
ible luciferase activity was normalized for lu-
ciferase activity of the constitutively active
pGL3-control vector to account for effects of
hyperoxia or TGF-�/BMP ligands on baseline
transcriptional activity. Determinations were
made for 3 separate experiments, each in qua-
druplicate. *P � 0.05; **P � 0.01.
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and the development of BPD (10). Since TGF-� (27) and BMP
ligands (31) have both been ascribed with proapoptotic activ-
ity, we sought to determine whether exposure of ATII cells and
PASMC altered their sensitivity to TGF-�- or BMP-induced
apoptosis. Primary ATII cells and primary PASMCwere exposed
to 21% O2 or 85% O2 for 24 h prior to stimulation with TGF-�1
or BMP-2, or addition of vehicle alone in the case of control
experiments, after which cells were assessed for apoptosis after an
additional 24 or 48 h. No significant differences in the percentage
of apoptotic cells were observed between control and BMP-2-
stimulated groups. However, both 24 and 48 h after TGF-�1
stimulation, the percentage of apoptotic cells in the 85% O2 group
was significantly increased compared with the 21% O2 group
(Fig. 7, A and C). In contrast, neither TGF-�1 nor BMP-2 induced
apoptosis in PASMC, irrespective of the oxygen concentration.
These data indicated that exposure of ATII cells to 85% O2 for as
little as 24 h could abnormally increase the sensitivity of ATII
cells to TGF-�-induced apoptosis.
Fig. 7. Effect of hyperoxia on TGF-�- and BMP-induced
apoptosis of primary alveolar type II (ATII) cells and primary
pulmonary artery smooth muscle cells (PASMC). Primary ATII
cells (A) and primary PASMC (B) were maintained under 21%
O2 or 85% O2 for 24 h prior to stimulation with vehicle [0.8%
(mass/vol) NaCl] alone (F), TGF-� (2 ng/ml; �), or BMP-2
(100 ng/ml; E). Cells were examined for induction of apoptosis
by flow cytometry 24 and 48 h after ligand stimulation. Data
represent the mean fold change in the percentage of apoptotic
cells in the 85% O2 group vs. the percentage of apoptotic cells
in the 21% O2 group at the time points indicated� SD (n� 3).
*P � 0.05. Staurosporine (Stauro; 100 nM, 24 h) was em-
ployed as a positive control for induction of apoptosis in both
cells types in 21% O2 (insets). C: original flow cytometry
scattergrams from a 72-h time point of an arbitrarily selected
representative experiment with ATII cells.
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Effect of hyperoxia on TGF-�- and BMP-induced prolifer-
ation of ATII and PASMC. Since both TGF-� and BMP ligands
can have pro- and antiproliferation activity in variety of cell
types (27, 31), we assessed the effects of TGF-�1 and BMP-2
on the proliferation of ATII cells and PASMC after exposure to
85% O2. Primary ATII cells and primary PASMC were ex-
posed to 21% O2 or 85% O2 for 24 h prior to stimulation with
TGF-�1 or BMP-2, or addition of vehicle alone in the case of
control experiments, after which cells were assessed for apop-
tosis after an additional 48 h (Fig. 8). No significant changes in
cell proliferation were observed, for ATII cells or for PASMC,
for either ligand.
Effect of hyperoxia on TGF-�- and BMP-induced extracel-
lular matrix proteins by lung fibroblasts. The production of
ECM and ECM-remodeling enzymes (and their inhibitors) by
interstitial fibroblasts is a key step in the alveolarization pro-
cess, and expression of many of these proteins may be stimu-
lated by TGF-�. Exposure of primary lung fibroblasts to 85%
O2 increased the basal expression of both Smad4 and T�RII
and increased the basal phosphorylation of Smad2, as assessed
by immunoblot (Fig. 9A). These data are consistent with our
observations made in whole lung extracts from pups chroni-
cally exposed to 85% O2.
Exposure of fibroblasts to 85% O2 also significantly altered
the basal mRNA levels of several important ECM or ECM-
remodeling proteins: mRNA levels for the �1 chains of colla-
gens I and III as well as tropoelastin and tenascin-C were
reduced, whereas tissue inhibitor of metalloproteinase-1
(TIMP-1) mRNA levels were increased, and matrix metallo-
proteinase (MMP)-1, MMP-2, and TIMP-3 mRNA levels were
unchanged (Fig. 9B).
We then assessed whether exposure to 85% O2 could alter
the induction of these genes by TGF-�1 (2 ng/ml) or BMP-2,
BMP-4, or BMP-7 (all at 100 ng/ml). The �1 chains of
collagens I and III, and MMP-1, MMP-2, and TIMP-3 were not
TGF-�-inducible in 21% O2, which is consistent with other
reports (21) illustrating that none of these genes are normally
TGF-� inducible in fibroblasts, in contrast, for example, to
collagens IV, VIII, and XV. However, levels of mRNA encod-
ing TIMP-1 (Fig. 9G), tropoelastin (Fig. 9I), and tenascin-C
(Fig. 9J) were significantly increased in the presence of TGF-�
in 21% O2. Of particular interest to our study, the ability of
TGF-� to increase mRNA levels of TIMP-1 and tropoelastin
was significantly enhanced after 24 h of exposure to 85% O2
(Fig. 9, G and J). Of further interest, collagen I mRNA levels
were increased by TGF-� in 85% O2 but not 21% O2 (Fig. 9C).
Levels of tenascin-C mRNA were also increased by TGF-� in
85% O2 (Fig. 9J); however, this increase was not significantly
different with respect to that observed in 21% O2. With the
exception of a small (but significant) decrease in collagen I
mRNA levels in response to BMP-7 (Fig. 9C), none of the
genes we investigated were regulated by BMP (Fig. 9, C–J). In
sum, our data indicate that exposure of primary lung fibroblasts
to 85% O2 significantly increases the capacity of TGF-� to
upregulate levels of mRNA encoding extracellular matrix com-
ponents.
DISCUSSION
Alveolarization begins with branching of distal airway sac-
cules into immature alveoli, in the canalicular phase of lung
development, beginning on embryonic day E16 in mice, and
continues through the saccular phase and into the alveolar
phase, occurring between days P5 and P21 (9). During this
time, ATII cells proliferate and differentiate into type I cells.
Alveolar septae divide the terminal respiratory saccules, in-
creasing the number of alveoli (9). The septae are supported by
Fig. 8. Effect of hyperoxia on TGF-�- and BMP-induced proliferation of
primary ATII cells and primary PASMC. A: primary ATII cells and primary
PASMC were maintained under 21% O2 (black bars) or 85% O2 (gray bars) for
24 h prior to stimulation with vehicle [Veh; 0.8% (mass/vol) NaCl] alone,
TGF-� (2 ng/ml), or BMP-2 (100 ng/ml). Cell-cycle analysis of the cell
populations was undertaken by flow cytometry 48 h after ligand stimulation.
The proportion of cells in S phase was taken as a measure of cell proliferation.
Data represent the mean fold change in the percentage of cells in S phase in the
85% O2 group vs. the percentage of cells in S phase in the 21% O2 group �
SD (n � 3). *P � 0.05. In the case of PASMC, analyses were made in the
presence of 0.5% (vol/vol) serum, whereas 5% (vol/vol) serum was employed
as a positive control for the induction of proliferation in 21% O2. B: original
flow cytometry histograms from an arbitrarily selected representative experi-
ment with ATII cells.
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the ECM, composed of a collagen scaffold, to which glyco-
proteins (like tenascin) and fibrinous proteins (like elastin) are
interwoven (41). The ECM is deposited by fibroblasts and is
continuously remodeled by matrix remodeling proteases (41).
Epithelial growth occurs concomitantly with that of lung capillar-
ies (46). This alveolarization process is mediated by paracrine,
autocrine, and juxtacrine communication between the epithelium
and endothelium, and their associated fibroblasts, undertaken by
signaling molecules including TGF-� and BMP (17).
Injury to the developing lung, like oxygen toxicity, may
disrupt critical signaling pathways that regulate lung develop-
ment, leading to developmental arrest. In the case of premature
infants, who usually present during the canalicular stage, a
pronounced arrest of alveolarization is observed culminating in
a pathology typical of BPD (2). In this study, we investigated
whether exposure of neonatal mice to hyperoxia during the
critical alveolarization period had any effect on the expression
and function of the TGF-�/BMP system, a key signaling
pathway in lung development. Elevated levels of TGF-� li-
gands have been detected in neonates with BPD undergoing
oxygen therapy (24) and in animal models of BPD (5). Fur-
thermore, exposure of ATII cells to 95% O2 promotes associ-
ation of Smad2/3/4 complexes with DNA (34), indicating that
hyperoxia upregulated TGF-� signaling. However, no study to
date has addressed the effect of hyperoxia on the expression of
nonligand components of the TGF-�/BMP signaling pathways.
The results that we present in the current study indicate that
temporal changes in the expression and localization of key
signaling components of the TGF-�/BMP system do occur
under hyperoxic conditions. Our data clearly indicate that
hyperoxia can “tweak” TGF-�/BMP signaling, and that TGF-
�-mediated effects are generally potentiated by hyperoxia,
whereas BMP signaling is generally dampened.
How could dysregulated TGF-�/BMP signaling arrest alveo-
larization? TGF-� has potent antiproliferative properties on
epithelial cells (43, 58) and some types of smooth muscle cells
Fig. 9. Effect of hyperoxia on TGF-�- and BMP-induced expression of extracellular matrix components by primary lung fibroblasts. A: basal expression of
components of the TGF-�/BMP signaling machinery in primary lung fibroblasts cultured for 48 h in 21% O2 and 85% O2. B: fold change induced by 85% O2
after 72 h in the basal mRNA levels of genes encoding collagen I�1-chain (Col1), collagen III �1-chain (Col3), matrix metalloproteinase-1 (MMP-1), MMP-2,
tissue inhibitor of metalloproteinase-1 (TIMP-1), TIMP-3, tropoelastin (Eln), and tenascin-C (TenC) in primary lung fibroblasts are illustrated. Data represent
the mean fold change in cycle threshold (�Ct) assessed by real-time RT-PCR in fibroblasts cultured in 85% O2 for 72 h vs. fibroblasts cultured in 21% O2 for
72 h � SD (n � 3). *P � 0.05. C: the induction of these 8 genes by TGF-�1 (2 ng/ml) or BMP-2 (B2), BMP-4 (B4), or BMP-7 (B7) (all at 100 ng/ml), in
fibroblasts cultured in 21% O2 (black bars) or 85% O2 (gray bars) for 24 h prior to a 48-h stimulation, are illustrated in C–J. Fold changes were calculated by:
[(�CtHYX,stim/�CtHYX,unstim)/(�CtNOX,stim/�CtNOX,unstim)], where HYX denotes hyperoxia (85% O2); NOX, normoxia (21% O2); stim, ligand-stimulated; and
unstim, unstimulated. Data represent the mean fold change � SD (n � 3). *P � 0.05, 21% O2 vs. 85% O2 groups; ¶P � 0.05, induced vs. noninduced groups
at the same O2 concentration.
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(45). The proliferation and differentiation of ATII cells are key
steps in the alveolarization process. It is known that TGF-� can
arrest proliferation of ATII cells (43) and prevent keratinocyte
growth factor-stimulated ATII cell proliferation (58). We dem-
onstrated in our study that after exposure to 85% O2 for as little
as 24 h, primary mouse ATII cells are significantly more
sensitive to the proapoptotic effects of TGF-�, although pri-
mary smooth muscle cells derived from the pulmonary artery
remained unaffected. Considering these data, it may well be
that enhanced TGF-� signaling in the alveolar epithelium after
exposure to hyperoxia promotes apoptosis (and thus prevents
proliferation and differentiation) of ATII cells, thereby con-
tributing to the hypoplasia associated with BPD (2).
We report in our study that neither TGF-� nor BMP-2
promoted the proliferation of ATII cells or PASMC. Although
BMPs are accredited with pro-proliferative properties (31), it is
noteworthy that we observe a downregulation of ALK-3 and an
upregulation of ALK-6 at the protein levels in pups exposed to
hyperoxia, since these two receptors have opposing functions:
ALK-3 promotes proliferation, whereas ALK-6 is antiprolif-
erative, promoting mitotic arrest and apoptosis (38). These data
would suggest that hyperoxia promotes a shift away from
ALK-3-mediated proliferation, in favor of ALK-6-mediated
growth arrest. Indeed, we did observe increased ATII cell
apoptosis in the presence of BMP-2, although the extent was
not statistically significant with respect to vehicle controls.
In the context of cell proliferation, the abnormally enhanced
TGF-� signaling during exposure to hyperoxia together with
the elevated ALK-1 levels we have observed are noteworthy,
since ALK-1 is primarily expressed in the endothelium, and
ALK-1 activity inhibits proliferation of endothelial cells by
inducing G0/G1 arrest (23). These two phenomena could, in
part, underlie the capillary hypoplasia observed in animal
models of BPD (8). However, since we have not focused on
endothelial cells in this study, this idea remains entirely spec-
ulative.
In addition to a direct effect on cell proliferation and apop-
tosis, dysregulation of TGF-� signaling would also impact
ECM deposition and remodeling, another key step in the
alveolarization process (41). TGF-� regulates the secretion of
some matrix-metabolizing enzymes: the MMPs and their cog-
nate inhibitors, TIMPs. Throughout the canalicular, saccular,
and alveolar phases of normal lung development, MMP-1,
MMP-2, MMP-9, and TIMP-2 are strongly expressed in hu-
mans (29) and mice (44), and during normal development,
MMP-9 expression peaks during alveolarization (5), indicating
the importance of matrix remodeling in this process. In our
study, we have illustrated that TGF-� stimulation dramatically
elevates levels of mRNA encoding TIMP-1 in fibroblasts
cultured in 85% O2, compared with fibroblasts cultured in 21%
O2, whereas mRNA levels of MMP-1 and MMP-2 were either
unaffected or decreased. These data are consistent with reports
that TIMP-1 protein expression is increased in rat (16) and
mouse (5) models of hyperoxia-induced arrest of alveolariza-
tion, although no changes in MMP-2 levels were observed.
These data are also consistent with reports of elevated TIMP-1
levels in BPD (12).
TGF-� regulates secretion of some components of the ECM,
including collagens, elastin, and tenascin-C (41), and their
deposition plays a key role in alveolarization. TGF-� can
stimulate collagen secretion by primary lung fibroblasts (13)
and upregulates expression of collagen (27), elastin (30), and
tenascin and fibronectin (59) in lung tissue. In our study, we
have illustrated that when fibroblasts are cultured in 85% O2,
levels of mRNA encoding collagen I�1, tropoelastin, and
tenascin-C in the primary lung fibroblasts are abnormally
increased in response to TGF-� stimulation. Taken together,
our data collectively suggest that abnormal upregulation of the
TGF-� system in the lung upon exposure to hyperoxia would
swing the balance in favor of interstitial ECM deposition and
would prevent turnover or breakdown of ECM components.
This is consistent with the increased thickening of alveolar
septa observed in this and other studies (1, 7), as well as the
detection of increased amounts of ECM components in the
interstitium in BPD (35, 48) and in several animal models of
BPD (1, 7, 39).
In sum, we illustrate in our study that hyperoxia dysregulates
both the expression of components of the TGF-�/BMP signal-
ing machinery and TGF-� and BMP signaling per se. We have
further demonstrated that this dysregulated signaling has at
least two functional consequences relevant to hyperoxia-in-
duced arrest of alveolarization and BPD: 1) hyperoxia in-
creases the sensitivity of ATII cells to TGF-�-induced apop-
tosis, and 2) hyperoxia modulates the expression of ECM and
ECM-remodeling components induced by TGF-� in fibro-
blasts.
The ability of all-trans retinoic acid (RA) to rescue failed
septation (28) and attenuate oxygen-induced inhibition of lung
septation (50) lends credence to our hypothesis. RA is a TGF-�
antagonist, since RA prevented TGF-�-stimulated ECM pro-
duction by lung fibroblasts (40), downregulates TGF-� recep-
tor expression (32), and reverses hyperoxia-induced cell-cycle
arrest (34). It may well be that RA exerts its protective effects
by downregulating TGF-� signaling, which we illustrate in our
study is abnormally upregulated by hyperoxia.
BPD is a significant complication of premature birth, affect-
ing up to 10,000 newborns annually, and has long-term respi-
ratory consequences that reach beyond childhood (47). Inten-
sive research is currently encouraged to delineate signaling
pathways that underlie the alveolar and capillary hypoplasia
that are the hallmarks of “new BPD” (18). Such research has
recently paid off, with the discovery that lung-specific vascular
endothelial growth factor gene transfer restored alveolar de-
velopment in a hyperoxia model of BPD (47). The data we
present in the current study implicate a second growth factor
signaling pathway, that of the TGF-�/BMP superfamily, in the
pathogenesis of BPD. It should be emphasized that our data do
not unequivocally demonstrate a causal effect between dys-
regulated TGF-� signaling and BPD. However, the elevated
TGF-� signaling observed in the lungs of neonates exposed to
hyperoxia, together with the increased sensitivity of lung
fibroblasts and epithelial cells to TGF-� after hyperoxic expo-
sure, are consistent with the increased epithelial cell apoptosis
and elevated ECM deposition observed in BPD. Given that the
TGF-�/BMP pathways are also amenable to pharmacological and
genetic manipulation in the lung, they may provide alternative
avenues for the management of this debilitating disorder.
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Abstract
Bronchopulmonary dysplasia (BPD) is a chronic lung disease of early infancy caused by oxidative
damage and/or mechanical ventilation that is characterized by impaired pulmonary and vascular
development. Angiogenic factors, inflammatory cytokines and the nitric oxide (NO) system have
been implicated in the pathogenesis of BPD. All of these factors play important and interrelated
roles in normal late lung development. However, little is known about their interactions in BPD.
Using a rodent model of hyperoxia-induced BPD, we demonstrated a pronounced dysregulation of
expression of a number of these factors during the period of alveolarization and vascularization.
Significantly altered expression at different postnatal ages was shown for a selected number of
oxygen-regulated factors (up-regulation of hypoxia-inducible factor (HIF)-1Į and down-regulation
of HIF-2Į), angiogenic factors (downregulation of vascular endothelial growth factor (VEGF) and
its receptor Flt-1), and components of the NO biosynthetic pathway (up-regulation of nitric oxide
synthase (NOS)-2, downregulation of NOS-3 and dimethylarginine dimethylaminohydrolase
(DDAH)). Expression of the pro-inflammatory cytokines tumor necrosis factor-Į (TNF-Į) and
interleukin (IL)-6 was up-regulated, and surfactant proteins (SP)-B and -C were down-regulated.
The altered expression of these molecules and their interactions may contribute to our knowledge
of the pathogenesis of BPD and identify potential therapeutic targets. Also, it may help define the
optimal time point for intervention.
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INTRODUCTION
Postnatal lung growth and development are dependent upon angiogenesis and
alveolarization, two integrated processes which continue over the first two years of
post natal life in humans, and three to four weeks post natal in mice.1,2 Preterm
birth interrupts normal pulmonary alveolar and vascular development, and leads to
long-term abnormalities in pulmonary growth and function. Prematurely born
neonates often require oxygen therapy and/or mechanical ventilation due to
respiratory insufficiency and hypoxemia. However, both oxygen therapy and
mechanical ventilation contribute to lung injury through the release of toxic free
radicals, inflammatory cytokines, and by disrupting the production of critical growth
factors and other signalling molecules in the lung.3
Given that embryonic lung development occurs in a relatively hypoxic environment,
HIF, which mediate cellular responses to oxygen levels, have been accredited with
key roles in lung development.4,5 This idea was confirmed by the observation that
activation of HIF through inhibition of prolyl hydroxylases restored normal lung
development. The function of HIF has been tightly coupled to NOS activity. NOS is
responsible for NO production, and is abundant in epithelial and endothelial cells
during fetal development. Indeed, abrogation of NO signalling causes alveolar
simplification and impaired pulmonary vascular growth. Other factors also impact
NO synthesis, and hence, HIF function, in the developing lung.6 For example, TNF-Į
is reported to decrease the expression of endothelial NOS (eNOS, NOS-3), but
increases expression of inducible NOS (iNOS, NOS-2) in cultured endothelial cells.7
Hypoxia-inducible factors also form an important link between NOS activity and that
of angiogenic growth factors, such as VEGF and its receptors VEGFR1 (Flt-1) and
VEGFR2 (Flk-1). The VEGF family of growth factors is believed to have a key role in
late lung development with NO expression up-regulating VEGF by stabilizing HIF-1Į
mRNA and protein.8,9 Thus, HIF, NOS, and VEGF signalling networks appear to be
intimately coupled in driving alveolar and pulmonary vascular development.10
Various attempts to prevent hyperoxic lung injury have revealed that restoration of
any one of the HIF, NOS or VEGF systems can partially ameliorate the deleterious
effects of hyperoxia on late lung development.11 However, no intervention to date
has been able to fully abrogate the development of BPD. Therefore, we have
compared the expression of essential components of all three systems (HIF, NOS
and VEGF), as well as two pro-inflammatory cytokines (TNF-Į and IL-6), as an
effort to understand how dysregulated expression of individual components may
perturb inter-pathway cross-talk in hyperoxia-induced arrest of alveolar
development in mice.
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MATERIAL AND METHODS
Animals
Mice (C57BL/6) were housed in humidity- and temperature-controlled facilities in 12
h light-dark cycle and were allowed food and water ad libitum. On the first day after
birth (P1), pups and nursing dams were either maintained under constant hyperoxic
conditions (85% O2) or kept in room air (normoxia; 21% O2) starting at postnatal
day 1 (P1) up to P7, P14, P21 or P28. Oxygen levels were monitored using a Miniox
II monitor (Catalyst Research, Owing Mills, MD). Dams were exchanged between
hyperoxic and normoxic litters every 24 h, to prevent an effect of oxygen in the
nursing dams.
Histomorphometry
Mice were sacrificed at day P7, P14, P21 or P28 by intraperitoneal injection of
pentobarbital. Lungs were excised, fixed overnight using 4% paraformaldehyde in
phosphate-buffered saline and embedded in paraffin. Sections (3 µm) were
mounted on glass slides, deparaffinized in xylene and rehydrated in a series of
ethanol dilutions. Mean linear intercept and septal thickness were determined on
sections stained for smooth muscle actin and counter-stained using hematoxylin
and eosin as has been described previously.
mRNA expression
Real-time PCR was pereformed with a TaqMan ABI PRISM 7700 SDS system
(Applied Biosystems, Foster City, CA). Primers and probes were designed using the
Primer Express software (Applied Biosystems, Foster City, CA, U.S.A.). Primers
were obtained from Roth (Karlsruhe, Germany) and MWG (Ebersberg, Germany);
probes were synthesized by Eurogentec (Seraing, Belgium). Sequences are given in
table 1.
Pulmonary tissue from five animals per treatment group (hyperoxia and normoxia
at P7, P14, P21 and P28) was snap frozen in liquid nitrogen immediately after
sacrificing the animals. Lung lobes were homogenized in liquid nitrogen. Total RNA
isolation was performed by using the guanidinium-thiocyanate-phenol chloroform
method (Trizol, Invitrogen, Karlsruhe, Germany). Reverse transcription was
performed using the SuperScript II First-Strand Synthesis System for RT-PCR Kit
(Invitrogen, Karlsruhe, Germany).
Real-time analysis was performed as previously described.12 Briefly, a cycler
programme of: 2 min at 50° C and 10 min at 95° C followed by 45 cycles of 15 s at
95° C and 1 min at 60° C. For relative quantification, we applied the ¨¨&7
method13 where mRNA expression of a target gene was normalized for expression
of an internal control gene, in this case ǃ-actin.
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Immunohistochemistry
Serial sections (3 µm) of paraffin-embedded lung tissue were prepared as described
for histomorphometry. Staining was performed according to standard protocols
(Histostain Kit, Zymed Laboratories, San Francisco, CA, U.S.A.). Briefly,
deparaffinized and rehydrated tissue sections were blocked with normal serum
(goat or rabbit, depending on the species of primary antibody). Antigen retrieval
was performed in a pressure cooker using sodium citrate (6.5 mM, pH 6.0).
Sections were incubated with primary antibodies directed against NOS-2 and -3,
DDAH-2, VEGF, VEGFR1 and VEGFR2, (Santa Cruz Biotechnology, Santa Cruz, CA)
at dilutions of 1:200. Biotinylated secondary antibodies were employed as part of
the immunodetection kits (Histostain Kit; or Vectastain Elite ABC kit (Vector
Laboratories, Burlingame, CA) in the case of DDAH-2). Immune reactions were
detected after binding of horse radish peroxidise (HRP)-labelled streptavidin to the
secondary antibody and incubation with a HRP-substrate/chromogen mixture
(Zymed Laboratories). Counter-staining was performed using Mayer's hematoxylin
(Zymed Laboratories).
Statistics
Data are given as mean and standard deviation. The mRNA expression was
analyzed using the Mann-Whitney U test and GraphPad Prism version 4 (GraphPad
Software Inc., San Diego, CA, U.S.A.). Differences at P < 0.05 were considered to
be statistically significant.
RESULTS
Growth and lung development in mouse pups exposed to chronic hyperoxia
The exposure to chronic hyperoxia (FiO2 = 0.85) was initiated on postnatal day P1
and was terminated on day P7, P14, P21 or P28. Each group contained time-
matched normoxic (FiO2 = 0.21) controls. Although the survival rate was 100% in
all treatment groups, chronic hyperoxia significantly compromised growth after 14
days, resulting in an average body mass that was a third lower than that of age-
matched controls, which is consistent with our findings in this model.14 Alveolar
development was impaired in neonatal mice when exposed to chronic hyperoxia. By
day P28, air spaces were dramatically enlarged, suggesting a reduction in alveolar
surface area (Figures 1-3).
Proinflammatory cytokines
Expression of TNF-Į and IL-6 were determined to explore acute effects in
pulmonary tissue due to hyperoxic exposure (Table 2 and Figure 4). Both, TNF-Į
and IL-6 mRNA expression was up-regulated, starting at day P7 (P < 0.01 and
P < 0.02, respectively; Table 2). Differences remained significant only for IL-6 by
day P14 (P < 0.05) and day P21 (P < 0.01).
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Figure 1 DDAH-2 and NOS-3 expression in lung sections from mouse pups after chronic
hyperoxia until day P14 compared to control animals maintained under normoxic conditions. The
upper panel illustrates mRNA expression assessed by real time RT-PCR as a dot-plot, each dot
representing the median mRNA expression for a single animal (n = 5, per group). Gene
expression was significantly down-regulated in hyperoxic animals compared to controls. The lower
panel illustrates immunohistochemical staining for DDAH-2 (A, control; B, hyperoxia) and NOS-3
(C, control; D, hyperoxia) in tissue sections (magnification 20×). In lung sections from hyperoxic
mice air spaces were enlarged (as is evident in panels B and D, compared with panels A and C).
The DDAH-2 protein expression (red-brownish staining) is evident in lung sections from control
animals (A), although not in lung sections from hyperoxic pups (B). Faint differences in NOS-3
protein expression are also visible.
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Expression of enzymes in the NO system
To investigate the induction of NOS genes in lung tissue, mRNA expression of NOS-
1 (nNOS), NOS-2 (iNOS) and NOS-3 (eNOS) was assessed by real-time RT-PCR.
Expression of NOS-1 mRNA was very low and did not change with time post partum
(Table 2). Expression of NOS-2, however, was up-regulated in mouse pups exposed
to hyperoxia for more than 21 days; this difference was significant for the groups at
P21 (P < 0.01; Table 2). In contrast, NOS-3 was down-regulated in the first 14
days after exposure to hyperoxia compared to control animals (P < 0.01 at day
P14), but not thereafter (Table 2).
The decrease in NOS-3 mRNA expression was observed along with a down-
regulation of DDAH-2 in hyperoxic pups at day P14 and day P21 (P < 0.01 and
P < 0.05, respectively; Table 2). Expression of DDAH-1 remained at a similar level
in both treatment groups over the time-course of the study.
Figure 2 Expression of NOS-2 (inducible NOS) in mouse lungs at day P21. NOS-2 expression
was up-regulated in pulmonary tissue from hyperoxic animals compared to controls. The upper
panel illustrates mRNA expression assessed by real time RT-PCR as a dot-plot, each dot
representing the median mRNA expression for a single animal (n = 5, per group). The lower panel
illustrates immunohistochemical staining for NOS-2 in tissue sections of (A) a control animal and (B)
an animal maintained under hyperoxic conditions (magnification 20×), which confirm the increased
NOS-2 expression at the protein level (red-brownish staining). Again, dramatically enlarged air
spaces can be seen in lung tissue from animals maintained under hyperoxic conditions (panel B),
compared with lung sections from animals maintained under normoxic conditions (panel A).
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Figure 1 DDAH-2 and NOS-3 expression in lung sections from mouse pups after chronic
hyperoxia until day P14 compared to control animals maintained under normoxic conditions. The
upper panel illustrates mRNA expression assessed by real time RT-PCR as a dot-plot, each dot
representing the median mRNA expression for a single animal (n = 5, per group). Gene
expression was significantly down-regulated in hyperoxic animals compared to controls. The lower
panel illustrates immunohistochemical staining for DDAH-2 (A, control; B, hyperoxia) and NOS-3
(C, control; D, hyperoxia) in tissue sections (magnification 20×). In lung sections from hyperoxic
mice air spaces were enlarged (as is evident in panels B and D, compared with panels A and C).
The DDAH-2 protein expression (red-brownish staining) is evident in lung sections from control
animals (A), although not in lung sections from hyperoxic pups (B). Faint differences in NOS-3
protein expression are also visible.
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Expression of enzymes in the NO system
To investigate the induction of NOS genes in lung tissue, mRNA expression of NOS-
1 (nNOS), NOS-2 (iNOS) and NOS-3 (eNOS) was assessed by real-time RT-PCR.
Expression of NOS-1 mRNA was very low and did not change with time post partum
(Table 2). Expression of NOS-2, however, was up-regulated in mouse pups exposed
to hyperoxia for more than 21 days; this difference was significant for the groups at
P21 (P < 0.01; Table 2). In contrast, NOS-3 was down-regulated in the first 14
days after exposure to hyperoxia compared to control animals (P < 0.01 at day
P14), but not thereafter (Table 2).
The decrease in NOS-3 mRNA expression was observed along with a down-
regulation of DDAH-2 in hyperoxic pups at day P14 and day P21 (P < 0.01 and
P < 0.05, respectively; Table 2). Expression of DDAH-1 remained at a similar level
in both treatment groups over the time-course of the study.
Figure 2 Expression of NOS-2 (inducible NOS) in mouse lungs at day P21. NOS-2 expression
was up-regulated in pulmonary tissue from hyperoxic animals compared to controls. The upper
panel illustrates mRNA expression assessed by real time RT-PCR as a dot-plot, each dot
representing the median mRNA expression for a single animal (n = 5, per group). The lower panel
illustrates immunohistochemical staining for NOS-2 in tissue sections of (A) a control animal and (B)
an animal maintained under hyperoxic conditions (magnification 20×), which confirm the increased
NOS-2 expression at the protein level (red-brownish staining). Again, dramatically enlarged air
spaces can be seen in lung tissue from animals maintained under hyperoxic conditions (panel B),
compared with lung sections from animals maintained under normoxic conditions (panel A).
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Table 2 The mRNA expression in mouse lungs after exposure to chronic hyperoxia compared
to controls (normoxia). Values given are mean r SD (95% CI of mean) after real time
RT-PCR as 2-''ct normalized for the ǃ-actin as house-keeping gene
Parameter Control Hyperoxia
TNF-Į P7
P14
P21
P28
1.29 r 0.19 (1.05 - 1.52)
2.24 r 1.08 (0.89 - 3.58)
1.11 r 0.18 (0.88 - 1.34)
2.25 r 1.52 (0.36 - 4.13)
12.79 r 22.13 (0.00 - 40.27)
2.94 r 2.48 (0.00 - 6.02)
1.99 r 0.34 (1.57 - 2.42)
3.60 r 0.76 (2.65 - 4.55)
P < 0.01
ns
ns
ns
IL-6 P7
P14
P21
P28
1.12 r 0.46 (0.54 - 1.69)
7.25 r 5.14 (0.87 - 13.64)
1.12 r 0.54 (0.45 - 1.79)
6.16 r 6.29 (0.00 - 13.97)
13.92 r 22.60 (0.00 - 41.97)
20.33 r 8.67 (9.57 - 31.09)
22.37 r 12.50 (6.86 - 37.89)
40.44 r 48.00 (0.00 - 100.00)
P < 0.02
P < 0.05
P < 0.01
ns
NOS-1 P7
P14
P21
P28
0.10 r 0.05 (0.03 - 0.16)
0.35 r 0.55 (0.00 - 1.03)
0.08 r 0.03 (0.04 - 0.11)
0.11 r 0.10 (0.00 - 0.23)
0.10 r 0.05 (0.04 - 0.16)
0.08 r 0.09 (0.00 - 0.20)
0.07 r 0.04 (0.03 - 0.12)
0.10 r 0.10 (0.00 - 0.18)
ns
ns
ns
ns
NOS-2 P7
P14
P21
P28
0.50 r 0.11 (0.36 - 0.64)
1.16 r 0.36 (0.72 - 1.60)
0.47 r 0.13 (0.31 - 0.62)
0.62 r 0.19 (0.39 - 0.85)
0.58 r 0.14 (0.41 - 0.75)
1.08 r 0.16 (0.88 - 1.29)
1.18 r 0.25 (0.87 - 1.49)
0.90 r 0.20 (0.66 - 1.15)
ns
ns
P < 0.01
ns
NOS-3 P7
P14
P21
P28
1.62 r 0.58 (0.91 - 2.34)
4.94 r 0.94 (3.77 - 6.11)
1.43 r 0.40 (0.94 - 1.93)
1.43 r 0.35 (1.00 - 1.85)
0.99 r 0.39 (0.50 - 1.47)
1.30 r 0.32 (0.90 - 1.69)
1,29 r 0.51 (0.65 - 1.93)
1.77 r 0.53 (1.11 - 2.43)
ns
P < 0.01
ns
ns
DDAH-1 P7
P14
P21
P28
1.91 r 0.68 (1.07 - 2.75)
2.08 r 1.00 (0.83 - 3.32)
0.94 r 0.27 (0.61 - 1.28)
1.45 r 0.48 (0.85 - 2.05)
2.59 r 1.62 (0.57 - 4.61)
1.43 r 0.39 (0.95 - 1.92)
2.31 r 1.53 (0.41 - 4.20)
2.57 r 0.96 (1.38 - 3.77)
ns
ns
ns
ns
DDAH-2 P7
P14
P21
P28
2.31 r 1.53 (0.41 - 4.20)
10.63 r 3.38 (6.43 -14.82)
0.51 r 0.12 (0.37 - 0.66)
0.72 r 0.63 (0.00 - 1.51)
0.65 r 0.30 (0.28 - 1.01)
1.07 r 0.93 (0.00 - 2.22)
0.25 r 0.10 (0.13 - 0.38)
0.45 r 0.21 (0.19 - 0.71)
ns
P < 0.01
P < 0.02
ns
HIF-1Į P7
P14
P21
P28
0.74 r 0.12 (0.59 - 0.89)
0.95 r 0.53 (0.30 - 1.61)
0.51 r 0.06 (0.44 - 0.59)
0.63 r 0.16 (0.43 - 0.84)
0.91 r 0.25 (0.61 - 1.22)
1.00 r 0.12 (0.86 - 1.15)
1.20 r 0.14 (1.03 - 1.37)
1.27 r 0.25 (0.95 - 1.58)
ns
ns
P < 0.01
P < 0.01
HIF-2Į P7
P14
P21
P28
3.68 r 0.71 (2.80 - 4.57)
5.87 r 4.35 (0.46 -11.28)
8.25 r 1.09 (6.90 - 9.60)
6.98 r 3.32 (2.85 - 11.10)
3.90 r 0.35 (3.47 - 4.33)
3.57 r 0.44 (3.02 - 4.12)
3.51 r 0.88 (2.41 - 4.61)
5.89 r 3.82 (1.15 - 10.64)
ns
ns
P < 0.01
ns
VEGF P7
P14
P21
P28
1.20 r 0.34 (0.77 - 1.62)
5.23 r 1.60 (3.24 - 7.21)
1.85 r 0.42 (1.33 - 2.37)
1.82 r 0.88 (0.73 - 2.19)
1.12 r 0.27 (0.78 - 1.46)
1.38 r 0.31 (0.99 - 1.76)
0.92 r 0.15 (0.73 - 1.11)
1.76 r 1.27 (0.19 - 3.34)
ns
P < 0.01
P < 0.01
ns
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Parameter Control Hyperoxia
VEGFR1 P7
P14
P21
P28
1.79 r 0.45 (1.23 - 2.35)
3.40 r 0.67 (2.56 - 4.23)
3.62 r 0.79 (2.63 - 4.61)
3.38 r 1.34 (1.73 - 5.04)
1.66 r 0.25 (1.35 - 1.97)
2.04 r 0.43 (1.51 - 2.58)
2.31 r 0.59 (1.57 - 3.05)
2.87 r 1.61 (0.87 - 4.87)
ns
P < 0.05
P < 0.05
ns
VEGFR2 P7
P14
P21
P28
1.38 r 0.37 (0.92 - 1.84)
2.48 r 0.75 (1.54 - 3.41)
1.97 r 0.28 (1.63 - 2.32)
1.89 r 0.57 (1.18 - 2.59)
1.59 r 0.48 (1.00 - 2.19)
1.93 r 0.36 (1.48 - 2.38)
1.92 r 0.46 (1.35 - 2.48)
1.84 r 0.32 (1.44 - 2.24)
ns
ns
ns
ns
PHD-1 P7
P14
P21
P28
1.75 r 1.06 (0.43 - 3.06)
2.77 r 0.91 (0.40 - 5.15)
1.13 r 0.25 (0.82 - 1.44)
1.25 r 0.70 (0.39 - 2.12)
2.05 r 1.80 (0.00 - 4.29)
1.40 r 0.63 (0.62 - 2.17)
0.85 r 0.07 (0.76 - 0.95)
1.37 r 0.48 (0.78 - 1.96)
ns
ns
ns
ns
PHD-3 P7
P14
P21
P28
0.44 r 0.28 (0.09 - 0.79)
0.23 r 0.22 (0.00 - 0.51)
0.04 r 0.02 (0.02 - 0.06)
0.06 r 0.04 (0.01 - 0.11)
0.36 r 0.25 (0.06 - 0.67)
0.11 r 0.06 (0.04 - 0.19)
0.04 r 0.01 (0.02 - 0.06)
0.06 r 0.01 (0.05 - 0.07)
ns
ns
ns
ns
PHD4 P7
P14
P21
P28
1.29 r 0.57 (0.57 - 2.00)
3.82 r 2.63 (0.02 - 6.54)
0.95 r 0.21 (0.69 - 1.20)
1.17 r 0.92 (0.02 - 2.31)
1.13 r 0.40 (0.64 - 1.62)
0.98 r 0.71 (0.09 - 1.86)
0.49 r 0.08 (0.39 - 0.58)
1.10 r 0.67 (0.26 - 1.93)
ns
ns
P < 0.01
ns
SP-B P7
P14
P21
P28
1.41 r 0.28 (1.06 - 1.76)
2.55 r 1.07 (1.22 - 3.88)
1.97 r 0.38 (1.49 - 2.45)
2.07 r 0.49 (1.46 - 2.68)
1.78 r 0.25 (1.48 - 2.09)
1.09 r 0.22 (0.81 - 1.36)
1.36 r 0.24 (1.06 - 1.66)
2.27 r 0.33 (1.86 - 2.68)
ns
P < 0.02
P < 0.02
ns
SP-C P7
P14
P21
P28
2.85 r 0.73 (1.94 - 3.75)
4.45 r 2.76 (1.02 - 7.88)
1.59 r 0.39 (1.11 - 2.08)
1.42 r 0.66 (0.59 - 2.24)
2.21 r 0.72 (1.32 - 3.11)
0.86 r 0.24 (0.56 - 1.15)
0.60 r 0.05 (0.53 - 0.66)
1.09 r 0.44 (0.54 - 1.63)
ns
P < 0.01
P < 0.01
ns
Angiogenic factors
The expression of HIF, prolyl hydroxylase domain-containing enzymes (PHD) that
regulate HIF stability, as well as that of VEGF and its receptors VEGFR1 (Flt-1) and
VEGFR2 (Flk-1) were determined, since dysregulated expression of these factors
may be responsible for impaired lung development. Expression of HIF-1Į was up-
regulated in hyperoxic animals at day P21 and day P28 (P < 0.01), while HIF-2Į
expression, was significantly down-regulated at day P21 compared to normoxic
animals (Table 2, P < 0.01). The mRNA expression of VEGF was decreased in
mouse pups exposed to hyperoxia for up to three weeks (P < 0.01), while VEGFR1
mRNA expression was reduced (P < 0.05) in hyperoxic mice at day P14 and day
P21. The expression of VEGFR2 remained unchanged in both groups (Table 2).
Expression of PHD mRNA levels decreased within the study period of four weeks;
however, PHD-2 mRNA was not detected. No significant differences were observed
Chapter 5
72
Table 2 The mRNA expression in mouse lungs after exposure to chronic hyperoxia compared
to controls (normoxia). Values given are mean r SD (95% CI of mean) after real time
RT-PCR as 2-''ct normalized for the ǃ-actin as house-keeping gene
Parameter Control Hyperoxia
TNF-Į P7
P14
P21
P28
1.29 r 0.19 (1.05 - 1.52)
2.24 r 1.08 (0.89 - 3.58)
1.11 r 0.18 (0.88 - 1.34)
2.25 r 1.52 (0.36 - 4.13)
12.79 r 22.13 (0.00 - 40.27)
2.94 r 2.48 (0.00 - 6.02)
1.99 r 0.34 (1.57 - 2.42)
3.60 r 0.76 (2.65 - 4.55)
P < 0.01
ns
ns
ns
IL-6 P7
P14
P21
P28
1.12 r 0.46 (0.54 - 1.69)
7.25 r 5.14 (0.87 - 13.64)
1.12 r 0.54 (0.45 - 1.79)
6.16 r 6.29 (0.00 - 13.97)
13.92 r 22.60 (0.00 - 41.97)
20.33 r 8.67 (9.57 - 31.09)
22.37 r 12.50 (6.86 - 37.89)
40.44 r 48.00 (0.00 - 100.00)
P < 0.02
P < 0.05
P < 0.01
ns
NOS-1 P7
P14
P21
P28
0.10 r 0.05 (0.03 - 0.16)
0.35 r 0.55 (0.00 - 1.03)
0.08 r 0.03 (0.04 - 0.11)
0.11 r 0.10 (0.00 - 0.23)
0.10 r 0.05 (0.04 - 0.16)
0.08 r 0.09 (0.00 - 0.20)
0.07 r 0.04 (0.03 - 0.12)
0.10 r 0.10 (0.00 - 0.18)
ns
ns
ns
ns
NOS-2 P7
P14
P21
P28
0.50 r 0.11 (0.36 - 0.64)
1.16 r 0.36 (0.72 - 1.60)
0.47 r 0.13 (0.31 - 0.62)
0.62 r 0.19 (0.39 - 0.85)
0.58 r 0.14 (0.41 - 0.75)
1.08 r 0.16 (0.88 - 1.29)
1.18 r 0.25 (0.87 - 1.49)
0.90 r 0.20 (0.66 - 1.15)
ns
ns
P < 0.01
ns
NOS-3 P7
P14
P21
P28
1.62 r 0.58 (0.91 - 2.34)
4.94 r 0.94 (3.77 - 6.11)
1.43 r 0.40 (0.94 - 1.93)
1.43 r 0.35 (1.00 - 1.85)
0.99 r 0.39 (0.50 - 1.47)
1.30 r 0.32 (0.90 - 1.69)
1,29 r 0.51 (0.65 - 1.93)
1.77 r 0.53 (1.11 - 2.43)
ns
P < 0.01
ns
ns
DDAH-1 P7
P14
P21
P28
1.91 r 0.68 (1.07 - 2.75)
2.08 r 1.00 (0.83 - 3.32)
0.94 r 0.27 (0.61 - 1.28)
1.45 r 0.48 (0.85 - 2.05)
2.59 r 1.62 (0.57 - 4.61)
1.43 r 0.39 (0.95 - 1.92)
2.31 r 1.53 (0.41 - 4.20)
2.57 r 0.96 (1.38 - 3.77)
ns
ns
ns
ns
DDAH-2 P7
P14
P21
P28
2.31 r 1.53 (0.41 - 4.20)
10.63 r 3.38 (6.43 -14.82)
0.51 r 0.12 (0.37 - 0.66)
0.72 r 0.63 (0.00 - 1.51)
0.65 r 0.30 (0.28 - 1.01)
1.07 r 0.93 (0.00 - 2.22)
0.25 r 0.10 (0.13 - 0.38)
0.45 r 0.21 (0.19 - 0.71)
ns
P < 0.01
P < 0.02
ns
HIF-1Į P7
P14
P21
P28
0.74 r 0.12 (0.59 - 0.89)
0.95 r 0.53 (0.30 - 1.61)
0.51 r 0.06 (0.44 - 0.59)
0.63 r 0.16 (0.43 - 0.84)
0.91 r 0.25 (0.61 - 1.22)
1.00 r 0.12 (0.86 - 1.15)
1.20 r 0.14 (1.03 - 1.37)
1.27 r 0.25 (0.95 - 1.58)
ns
ns
P < 0.01
P < 0.01
HIF-2Į P7
P14
P21
P28
3.68 r 0.71 (2.80 - 4.57)
5.87 r 4.35 (0.46 -11.28)
8.25 r 1.09 (6.90 - 9.60)
6.98 r 3.32 (2.85 - 11.10)
3.90 r 0.35 (3.47 - 4.33)
3.57 r 0.44 (3.02 - 4.12)
3.51 r 0.88 (2.41 - 4.61)
5.89 r 3.82 (1.15 - 10.64)
ns
ns
P < 0.01
ns
VEGF P7
P14
P21
P28
1.20 r 0.34 (0.77 - 1.62)
5.23 r 1.60 (3.24 - 7.21)
1.85 r 0.42 (1.33 - 2.37)
1.82 r 0.88 (0.73 - 2.19)
1.12 r 0.27 (0.78 - 1.46)
1.38 r 0.31 (0.99 - 1.76)
0.92 r 0.15 (0.73 - 1.11)
1.76 r 1.27 (0.19 - 3.34)
ns
P < 0.01
P < 0.01
ns
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Parameter Control Hyperoxia
VEGFR1 P7
P14
P21
P28
1.79 r 0.45 (1.23 - 2.35)
3.40 r 0.67 (2.56 - 4.23)
3.62 r 0.79 (2.63 - 4.61)
3.38 r 1.34 (1.73 - 5.04)
1.66 r 0.25 (1.35 - 1.97)
2.04 r 0.43 (1.51 - 2.58)
2.31 r 0.59 (1.57 - 3.05)
2.87 r 1.61 (0.87 - 4.87)
ns
P < 0.05
P < 0.05
ns
VEGFR2 P7
P14
P21
P28
1.38 r 0.37 (0.92 - 1.84)
2.48 r 0.75 (1.54 - 3.41)
1.97 r 0.28 (1.63 - 2.32)
1.89 r 0.57 (1.18 - 2.59)
1.59 r 0.48 (1.00 - 2.19)
1.93 r 0.36 (1.48 - 2.38)
1.92 r 0.46 (1.35 - 2.48)
1.84 r 0.32 (1.44 - 2.24)
ns
ns
ns
ns
PHD-1 P7
P14
P21
P28
1.75 r 1.06 (0.43 - 3.06)
2.77 r 0.91 (0.40 - 5.15)
1.13 r 0.25 (0.82 - 1.44)
1.25 r 0.70 (0.39 - 2.12)
2.05 r 1.80 (0.00 - 4.29)
1.40 r 0.63 (0.62 - 2.17)
0.85 r 0.07 (0.76 - 0.95)
1.37 r 0.48 (0.78 - 1.96)
ns
ns
ns
ns
PHD-3 P7
P14
P21
P28
0.44 r 0.28 (0.09 - 0.79)
0.23 r 0.22 (0.00 - 0.51)
0.04 r 0.02 (0.02 - 0.06)
0.06 r 0.04 (0.01 - 0.11)
0.36 r 0.25 (0.06 - 0.67)
0.11 r 0.06 (0.04 - 0.19)
0.04 r 0.01 (0.02 - 0.06)
0.06 r 0.01 (0.05 - 0.07)
ns
ns
ns
ns
PHD4 P7
P14
P21
P28
1.29 r 0.57 (0.57 - 2.00)
3.82 r 2.63 (0.02 - 6.54)
0.95 r 0.21 (0.69 - 1.20)
1.17 r 0.92 (0.02 - 2.31)
1.13 r 0.40 (0.64 - 1.62)
0.98 r 0.71 (0.09 - 1.86)
0.49 r 0.08 (0.39 - 0.58)
1.10 r 0.67 (0.26 - 1.93)
ns
ns
P < 0.01
ns
SP-B P7
P14
P21
P28
1.41 r 0.28 (1.06 - 1.76)
2.55 r 1.07 (1.22 - 3.88)
1.97 r 0.38 (1.49 - 2.45)
2.07 r 0.49 (1.46 - 2.68)
1.78 r 0.25 (1.48 - 2.09)
1.09 r 0.22 (0.81 - 1.36)
1.36 r 0.24 (1.06 - 1.66)
2.27 r 0.33 (1.86 - 2.68)
ns
P < 0.02
P < 0.02
ns
SP-C P7
P14
P21
P28
2.85 r 0.73 (1.94 - 3.75)
4.45 r 2.76 (1.02 - 7.88)
1.59 r 0.39 (1.11 - 2.08)
1.42 r 0.66 (0.59 - 2.24)
2.21 r 0.72 (1.32 - 3.11)
0.86 r 0.24 (0.56 - 1.15)
0.60 r 0.05 (0.53 - 0.66)
1.09 r 0.44 (0.54 - 1.63)
ns
P < 0.01
P < 0.01
ns
Angiogenic factors
The expression of HIF, prolyl hydroxylase domain-containing enzymes (PHD) that
regulate HIF stability, as well as that of VEGF and its receptors VEGFR1 (Flt-1) and
VEGFR2 (Flk-1) were determined, since dysregulated expression of these factors
may be responsible for impaired lung development. Expression of HIF-1Į was up-
regulated in hyperoxic animals at day P21 and day P28 (P < 0.01), while HIF-2Į
expression, was significantly down-regulated at day P21 compared to normoxic
animals (Table 2, P < 0.01). The mRNA expression of VEGF was decreased in
mouse pups exposed to hyperoxia for up to three weeks (P < 0.01), while VEGFR1
mRNA expression was reduced (P < 0.05) in hyperoxic mice at day P14 and day
P21. The expression of VEGFR2 remained unchanged in both groups (Table 2).
Expression of PHD mRNA levels decreased within the study period of four weeks;
however, PHD-2 mRNA was not detected. No significant differences were observed
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between mRNA expression in control animals and those maintained under hyperoxic
conditions, with the single exception of PHD-4 expression being significantly higher
in control animals compared to hyperoxic mouse pups at day P21 (Table 2).
Expression of surfactant associated proteins SP-B and SP-C
The mRNA expression of surfactant associated proteins SP-B and SP-C, employed
as a measure of lung development and function of surfactant-producing type II
cells, was decreased under chronic hyperoxia reaching significance at day P14 and
day P21 (P < 0.05 for SP-B and P < 0.01 for SP-C; Table 2).
Figure 3 Serial immunhistological staining for VEGF (A, D), VEGFR1 (B, E) and VEGFR2 (C, F)
in normoxic (left panel, A-C) and hyperoxic (right panel, D-F) lung tissue at day P21
(magnification 40×). Decreased expression of VEGF in hyperoxic mouse lungs (D) compared to
normoxic controls (A) confirmed the mRNA data, VEGFR1 expression (B vs. E) tended to be lower
at the protein level whereas VEGFR2 protein expression appeared to be higher in hyperoxic lung
tissue (F) compared to controls (C), but mRNA expression for VEGFR2 was similar in both groups
(Table 1).
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Protein expression
Comparing levels of protein expression with that of gene expression, we semi-
quantitatively inspected all tissue sections. At day P14, immunhistological staining
confirmed the reduced expression of DDAH-2 and NOS-3 found on mRNA level in
hyperoxic lung tissue although differences for NOS-3 were weak with regards to
immunostaining (Figure 1). At day P21, gene expression for NOS-2, the inducible
form of NOS was up-regulated not only as mRNA, but also on the protein level as is
shown in figure 2. At the same time, the expression of VEGF and its receptor Flt-1
was reduced in pulmonary tissue from mouse pups kept under hyperoxic conditions
compared to normoxic controls (Table 2); however, on the protein level, only VEGF
staining revealed corresponding differences; tissue slices treated with Flt-1
antibodies were found to be similar in hyperoxic versus normoxic animals. VEGF
receptor Flk-1 seemed to be slightly increased after chronic hyperoxia (Figure 3),
although no significant differences were observed on the mRNA level (Table 2).
DISCUSSION
Bronchopulmonary dysplasia develops in the early post-natal phase of late lung
development, as a result of hyperoxic injury and/or long term mechanical
ventilation and is characterized by impaired alveolar and vascular growth as well as
various degrees of inflammatory tissue damage.15 Several signalling pathways,
including those induced or regulated by the NOS, HIF and VEGF systems, have been
implicated in the development of BPD.6 These signalling pathways also interact with
one another. The aim of this study therefore was, to compare the expression of
essential components of all three systems, as an effort to understand how
dysregulated expression of individual components may perturb inter-pathway cross-
talk in hyperoxia-induced arrest of alveolar development in mice.
In our study, we have employed a model of chronic hyperoxia (FiO2 = 0.85) in
mouse pups for 28 days, which we have previously described in detail14 and in
which lung development was impaired with significantly enlarged air spaces
concomitant with a reduction of alveolar surface area. This morphological picture is
also found in human BPD, and other animal models of BPD.16-20
An early effect of exposure to a hyperoxic environment is the triggering of an
inflammatory cascade in the lung.21 In humans, the presence of some cytokines, for
example, IL-6, in tracheal aspirates at birth is an independent risk factor for the
development of BPD in preterm infants.22 In our study, we observed an initial up-
regulation of TNF-Į expression in the first week of hyperoxic exposure, and IL-6
mRNA expression was increased several-fold throughout the study period (Figure
4). Interestingly, TNF-Į not only triggers leukocyte recruitment, but also affects
other factors, such as endothelial NOS expression by decreasing NOS-3 promoter
activity.23
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Figure 4 mRNA expression levels of selected molecules, over the period day P7 to day P28.
Only molecules that significantly changed in expression levels (Table 1) are included. The relative
mRNA expression was calculated as group means htperoxia (HYX)/normoxia (NOX) over time (P7,
P14, P21, P28). Values are presented as a percentage of the normoxia values, and error bars
have been omitted for clarity.
Indeed, we observed that NOS-3 mRNA expression was significantly down-regulated
at day P14. Thus, these changes in NOS-3 expression may in part be mediated by
an increased expression of pro-inflammatory cytokines.24 In addition to the
decreased NOS-3 expression that we observed, NOS-3 activity may be further
reduced indirectly by the down-regulated expression of DDAH-2 we reported here.
Nitric oxide synthase is inhibited by endogenous arginine metabolites such as
asymmetric dimethylarginine which is degraded by DDAH known to be differentially
regulated during lung development.25 The reduced expression of DDAH might lead
to enhanced levels of asymmetric dimethylarginine (ADMA), an inhibitor of NOS-3
activity which then most likely affects HIF function. Of particular interest in our
study is the interaction between NOS-3, HIF-2Į and VEGF, since HIF stabilization
with chemical inhibitors of PHD increases VEGF expression, and hence, lung
vascularisation and alveolarization.9 The reduced NOS-3 activity we report here
lowers HIF-2Į expression levels, and this in turn, would decrease levels of
angiogenic factors such as VEGF.26
The altered expression of angiogenic factors plays an important role in the
development of BPD resulting in microvascular damage, diminished epithelial cell
proliferation, and arrest of alveolarization.18 Hosford and Olson18 speculated that
hyperoxia-induced changes in VEGF may be an important element in the etiology of
BPD. In support of this, Maniscalco et al.27 has shown that neonatal rabbits exposed
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to 100% O2 for nine days exhibited decreased VEGF mRNA levels and decreased
alveolar epithelial cell VEGF expression. Bhatt et al.28 reported that preterm human
neonates with RDS or BPD were deficient in VEGF and Flt-1, both on mRNA and
protein level. We demonstrated here that VEGF and its receptor Flt-1 were both
down-regulated in our hyperoxia model of BPD, and we propose that reduced NOS-
3 activity may, at least in part, mediate this effect. In addition to this impact on
vascular development, VEGF also affects surfactant production, i.e. the expression
of SP-B. Consequently, VEGF down-regulation would lead to a reduced expression
of SP.5 Since SP-B and SP-C are critically important for surface tension properties in
the alveolar compartment, they play a crucial role in directing late lung
development.
Returning to the NOS family of enzymes, in contrast to the down-regulated
expression of NOS-3, we observed up-regulated expression of NOS-2 after 21 days
of hyperoxic exposure. Interestingly, NOS-2 is known to down-regulate SP
expression, and these elevated NOS-2 levels would most likely further reduce SP
production, which would be additive to the deleterious effects of dysregulated VEGF
signalling on surfactant production.29
In summary, this paper describes a number of factors involved in the pathogenesis
of BPD. Although their roles in lung development and lung injury were described
previously, we are the first to report changes in their expression over time,
especially during alveolarization and vascularisation. It is during this time, that a
disturbance of lung development leads to BPD. Our results show differences in
expression of oxygen-regulated factors, angiogenic factors and components of the
NO biosynthetic pathway, as well as of pro-inflammatory cytokines and SP over
time. In addition, we present a model incorporating all these factors (Figure 5).
In conclusion, hyperoxia affects a variety of factors that impact lung development,
including an inflammatory response and disruption of endothelial and epithelial cell
function. Therefore, a single preventative measure or therapeutic treatment
targeting only one of these factors at a specific point in time may exhibit beneficial
effects on that particular parameter, but may not improve the overall clinical
outcome. Thus, it is likely that a combination of interventions, such as the
application of an inhibitor of NOS-2 as has recently been suggested by Yuba et al.30
together with high doses of antioxidants for neonates who require hyperoxic
treatment, may be more appropriate. Along these lines, the application of NO or the
administration of retinoic acid, which has been found to reduce ADMA levels and
increase NO synthesis in vitro needs to be further investigated. In addition, the
changes in expression of these factors were found to be time-dependent.31
Therefore, in clinical practice, it is not only important to know which pathway(s) to
therapeutically target, but also to define the optimal time point for such an
intervention.
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Figure 5 Hypothesis for the interaction of effects induced by chronic hyperoxia on pulmonary
gene expression regulating vascular and alveolar development.
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17.5 vs. 20.2 mm in controls; p  ! 0.001) and fronto-oc-
cipital diameters (median: 9.4 vs. 10.1 mm in controls; 
p  ! 0.001) compared to controls. Histomorphometric 
analyses were found to be without signifi cant differences 
between both groups. On the transcriptional level, how-
ever, mRNA expression of SP-A, -B and -C but not SP-D 
could be shown to be signifi cantly reduced in hypoxic 
fetuses compared to normoxic controls.  Conclusions: In 
conclusion, hypoxic conditions from day 14 to 17.5 led 
to IUGR in preterm mice and to signifi cant alterations of 
the developing surfactant system. We speculate restrict-
ed development of SP gene expression to be a causal 
factor for the increased risk of acute and chronic pulmo-
nary disorders in preterm infants with IUGR. 
 Copyright © 2005 S. Karger AG, Basel 
 Introduction 
 Research on intrauterine growth restriction (IUGR) 
has gained increasing interest secondary to its life-lasting 
consequences  [1] . Although the so-called ‘Barker hypoth-
esis’ is still controversially discussed  [2] , the main inter-
pretations of long-term consequences of IUGR are wide-
ly accepted including an increased risk for the develop-
ment of the metabolic syndrome and cardiovascular 
diseases  [3] . 
 Key Words 
 Intrauterine hypoxia  � Intrauterine growth retardation  � 
Lung development  � Surfactant proteins 
 Abstract 
 Background and Objectives: Preterm infants with intra-
uterine growth retardation (IUGR) reveal an increased 
risk for the development of acute and chronic pulmonary 
disorders, i.e. bronchopulmonary dysplasia (BPD). In or-
der to investigate the effect of IUGR on pulmonary de-
velopment, an easily reproducible animal model for fetal 
growth restriction has been established using hypoxia 
as a sole intervention in the last third of pregnancy. 
 Methods: Date-mated mice were randomly assigned to 
either being kept at a fraction of inspired oxygen (FiO 2 ) 
of 0.10 (hypoxic group) starting at day 14 or under 
 normoxic conditions until day 17.5 of gestation (control 
group). Variables of somatic growth were assessed and 
standardized histomorphometric analyses of pulmonary 
tissue were performed. Expression of surfactant proteins 
(SP)-A, -B, -C and -D was determined by quantitative rt-
PCR as biochemical indicators for lung development and 
maturation.  Results: Fetuses were delivered preterm at 
0.87 of gestation. Those grown under hypoxic conditions 
revealed signifi cantly lower birth weights (median: 0.69 
vs. 0.97 g in controls; p  ! 0.001), body lengths (median: 
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 A specifi c risk group for devastating consequences of 
IUGR is represented by preterm infants below 30 weeks 
of gestational age not only suffering from immaturity but 
also from direct consequences of IUGR including an in-
creased risk of neonatal mortality and morbidity. With 
regard to long-term consequences, the clinical outcome 
in these patients is mainly determined by the increased 
risk for the development of chronic lung diseases, i.e. 
bronchopulmonary dysplasia compared to age-matched 
controls  [4, 5] . 
 The ‘classical’ hypothesis during the 1980s, suggesting 
preterm infants to be protected from pulmonary compli-
cations in case of IUGR  [6] refl ects neonatal characteris-
tics of infants studied at that time, i.e. mean gestational 
age  ! 30 weeks. Currently, even more immature infants 
are representing the high-risk group for perinatal mortal-
ity and severe neonatal morbidity including pulmonary 
complications like the development of acute and espe-
cially chronic lung disease (bronchopulmonary dysplasia, 
BPD). Thus, IUGR has been described to be associated 
with a higher prevalence of the respiratory distress syn-
drome (RDS) in preterm infants, and furthermore, pul-
monary function later in life has been found to be com-
promised by fetal growth restriction  [7, 8] . 
 In previous studies a complex model was used induc-
ing IUGR by umbilico-placental embolization and thus 
studying the effects of several variables such as hypox-
emia, nutrient defi ciency and stress-related hormonal 
counter-regulation  [7, 9, 10] . 
 The aim of the present study therefore was to establish 
an easily reproducible animal model to investigate the 
consequences of IUGR on lung development. The focus 
was placed on the induction of fetal growth restriction by 
hypoxia still mimicking pathophysiological conditions 
relevant for human neonates. 
 Materials and Methods 
 Animals 
 Date-mated pregnant mice (C57BL/6, Charles River, Sulzfeld, 
Germany) were kept under constant conditions with respect to fl u-
id and nutritional supply until day 14 (embryonic day 14; E14). 
Thereafter, they were randomly assigned to either being kept at a 
fraction of inspired oxygen (FiO 2 ) of 0.10 (hypoxic group; n = 5) or 
under normoxic conditions until day 17.5 of gestation (FiO 2  0.21; 
control group; n = 5). Normobaric hypoxia was created by means 
of a ventilated chamber. FiO 2  was held constant by an autoregula-
tory control unit (model 4010, O 2  controller; Labotect, Göttingen, 
Germany). Excess humidity in the recirculating system was pre-
vented by condensation in a cooling unit. Carbon dioxide was con-
tinuously removed by soda lime. Cages were opened once a day for 
cleaning as well as for food and water supply. At day 17.5 of gesta-
tion, pregnant dams were anesthetized using ketamine/xylamine 
(40 and 4  � g/g body weight, respectively). Preterm delivery of 
mouse fetuses was carried out by Cesarean section (normal dura-
tion of gestation for mice: 19–21 days). 
 The study was approved by the Institution for Animal Protec-
tion and carried out in compliance with the guide for care and use 
of laboratory animals published in the National Institutes of Health 
[NIH publication 85-92, revised 1985]. 
 Auxological Measurements 
 We obtained auxological data from preterm mice with respect 
to birth weight, body length and fronto-occipital length by means 
of a precision scale (Mettler-Toledo, Wiesbaden, Germany) and a 
digital caliper (Mitutoyo, Neuss, Germany), respectively. For fur-
ther evaluation of lung development, lungs were excised and kept 
at –80  °  C either for molecular analyses and paraffi nated for histo-
logical investigation. 
 Lung Histology 
 Lungs were removed before the fi rst breath fi lled with fetal lung 
fl uid to standardize histologic evaluation. Tissue slices from paraf-
fi n-embedded fetal lungs were obtained from controls (n = 15) and 
hypoxic animals (n = 14), stained with hematoxylin/eosin, and eval-
uated by a pathologist (M.E.). Both fetal lungs and the heart were 
found in the paraffi n sections. Random fi elds from each ventral and 
dorsal part of the left and right lung were studied. An adequate 
number of 5 fi elds were evaluated referring to the limited size of 
the organ. 
 Septal thickness was measured after photodocumentation of the 
lung tissue using Axiovision 3.0 for AxioCam MRc (Zeiss, Ger-
many). Alveolar septa were measured at their thinnest point and 
averaged over ten measurements per lung. No tangential truncated 
septa were chosen for measurements. 
 Analysis of Surfactant Protein mRNA Expression 
 Messenger RNA expression of surfactant protein (SP)- A, -B, -C 
and -D was measured in tissue of the whole lung using the real-time 
RT-PCR technique (TaqMan ® ). Real-time PCR has been proven 
to be a sensitive and precise tool for the quantifi cation of mRNA 
and thus for gene expression studies  [11] . Primers and probes for 
SP-A, SP-B, SP-C, SP-D,  � -actin, 18S and porphobilinogen deam-
inase (PBGD;  table 1 ) were designed using the software Primer 
Express (Applied Biosystems, Foster City, Calif., USA) following a 
fi xed set of recommendations to allow the application of standard-
ized cycling conditions (2 min at 50  °  C, 10 min at 95  °  C, followed 
by 45 cycles for 15 s at 95  °  C and 1 min at 60  °  C). Control PCRs 
showed no signal for genomic DNA, proving mRNA specifi city. 
Primers were purchased from Roth (Roth, Karlsruhe, Germany), 
probes from Applied Biosystems. Lung tissue homogenization was 
performed in liquid nitrogen and total RNA was then extracted us-
ing the acid guanidinium-thiocyanate-phenolchloroform method 
(Trizol, Invitrogen GmbH, Karlsruhe, Germany). Total RNA isola-
tion, random primed reverse transcription and real-time PCR was 
performed following a standardized protocol as described previ-
ously  [12] . Primer and TaqMan probe sequences are depicted be-
low. Relative quantifi cation was performed using the  �� Ct meth-
od, which results in a ratio of target gene expression and the expres-
sion of a housekeeping or reference gene. As the validity of this 
method depends on the constant expression of the housekeeping 
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gene throughout the set of samples studied, we analyzed gene ex-
pression ratios of housekeeper  � -actin, 18S or PBGD and the total 
cDNA content of each sample, that was measured using a method 
based on the fl uorescent stain OliGreen. As  � -actin showed both, 
no differences between different experimental groups and the low-
est variation in all samples, it was chosen as reference gene for fur-
ther analysis. 
 Statistics 
 Data are given as mean  8 SD or median and range, respec-
tively. Auxological, histological and molecular biological variables 
were analyzed by Mann-Whitney U tests using SPSS for Windows 
version 6.1.3. Differences at p  ! 0.05 were considered to be statis-
tically signifi cant. 
 Results 
 Macroscopically, animals from the hypoxic group (n = 
31) were smaller and less developed compared to controls 
(n = 31;  fi g. 1 ). Auxologic measurements revealed signifi -
cantly lower birth weights (median: 0.69 vs. 0.97 g in 
controls; p  ! 0.001), body lengths (median: 17.5 vs. 
20.2 mm in controls; p  ! 0.001) and fronto-occipital di-
ameter (median: 9.4 vs. 10.1 mm in controls; p  ! 0.001) 
in these fetuses ( fi g. 2 ). 
 Using histomorphometry to investigate lung develop-
ment, there was no signifi cant difference with regard to 
number of saccular air spaces (60  8 7 vs. 61  8 6 per 
magnifi cation fi eld in hypoxic and control animals, re-
spectively) and septal thickness (12.1  8 1.3 vs. 11.5  8 
1.8  � m in hypoxic and control animals, respectively) in 
lung tissue from both groups. 
 On the transcriptional level, however, functional bio-
chemical variables such as the expression of SP were 
found to be different between the groups. Thus, pulmo-
nary SP-A mRNA expression was found to be signifi cant-
ly reduced in hypoxic fetuses compared to controls (p  ! 
0.001) whereas SP-D mRNA expression was not signifi -
cantly altered ( fi g. 3 ). 
 With regard to the hydrophobic SP, SP-B and SP-C, 
mRNA expression was signifi cantly lower (p  ! 0.05 and 
p  ! 0.01, respectively) in experimentally induced IUGR 
compared to normoxic fetuses ( fi g. 4 ). 
�-Actin (A)
Forward primer (FP): 5�-AGGTCATCACTATTGGCAACGA-3�
Reverse primer (RP): 5�-CAACGTCACACTTCATGATGGA-3�
Probe: 5�(FAM)-AGCCTTCCTTCTTGGGTATGGAATCCTGT-(TAMRA)3�
18S (S)
FP: 5�-TGCGAATGGCTCATTAAATCAG-3�
RP: 5�-TAGCTCTAGAATCACCACAGTTATCCA-3�
Probe: 5�(FAM)-ATGGTTCCTTTGGTCGCTCGCTCCT-(TAMRA)3�
Porphobilinogen deaminase (PBGD)
FP: 5�-GCGGAGTCATGTCCGGTAAC-3�
RP: 5�-ACTCGAATCACCCTCATCTTTGA-3�
Probe: 5�(FAM)-CCACAACCGCGGAAGAAAACGG-(TAMRA)3�
Surfactant protein A (SP-A) 
FP: 5�-AGTTGACTGACTGCCCATTGGT-3�
RP: 5�-ACTCTACGAGATCAAACATCAGATTCTG-3�
Probe: 5�(FAM)-TGCAAGCTGAGGACTCCCATTGTTTGC-(TAMRA)3�
Surfactant protein B (SP-B) 
FP: 5�-ATGGCCAAGTCGCACCTACT-3�
RP: 5�-CCAGAATTGAGGGCCTTGTG-3�
Probe: 5�(FAM)-CCCAGGTGCAGCTATCACGTCGG-(TAMRA)3�
Surfactant protein C (SP-C) 
FP: 5�-CCACTGGCATCGTTGTGTATG-3�
RP: 5�-GTAGGTTCCTGGAGCTGGCTTA-3�
Probe: 5�(FAM)-CTACCAGCGGCTCCTGACGGCC-(TAMRA)3�
Surfactant protein D (SP-D) 
FP: 5�-GGCCTCCATCTGCTGCCT-3�
RP: 5�-GGAGACAGAGGAATCAAAGGTGAA-3�
Probe: 5�(FAM)-AGCAGCACTGTCTGGAAGCCCGC-(TAMRA)3�
 Table 1. Primer and TaqMan ®  probes for 
quantitative RT-PCR 
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 Discussion 
 Different animal models of IUGR have been estab-
lished in the past (for review see  [13] ). Induction of IUGR 
in sheep by umbilical placental embolization revealed 
marked effects on lung development in the offspring  [7, 
9, 10] . The lungs of these lambs showed thickened alveo-
lar septa and a smaller number of alveoli, with these 
changes still being present at 8 weeks postnatal age  [14, 
15] . The aforementioned changes were induced in fetal 
sheep during a period of lung development changing from 
the saccular to the alveolar period  [16] . Whether these 
restrictions exert effects on lung function in adulthood, 
remains unclear, however epidemiological studies are 
suggestive  [8, 17] . 
 The main focus of the present study was therefore to 
develop a reliable animal model of IUGR, in which ana-
tomical, histological, and molecular changes of pulmo-
nary development can be assessed. As our group as well 
as others had demonstrated IUGR to increase the risk for 
the development of acute and chronic pulmonary disor-
ders in preterm infants compared to age-matched appro-
priately grown controls  [5, 8] , we specifi cally focused on 
pulmonary changes secondary to chronic intrauterine 
 hypoxia during the pseudoglandular to the terminal-sac-
cular stage of lung maturation. Thus, the present model 
is close to the stage of lung development in very preterm 
infants and mimics in utero conditions observed in IUGR 
secondary to placental insuffi ciency leading to hypoxic 
conditions for the fetus. Therefore, the present model par-
tially differs from previously introduced animal models 
using umbilico-placental embolization provoking not 
only severe hypoxemia but also affecting placental blood 
supply. 
 As shown here, a period of 3.5 days of intrauterine 
 hypoxia is suffi cient to induce a signifi cant growth restric-
tion with respect to body weight, length and fronto-oc-
cipital diameter in mice. Although lung weights have not 
been determined, previous studies, exposing pregnant 
rats to a longer time period of hypoxia (14–21 days of 
gestation), have shown lung volumes and weights to be 
signifi cantly different in fetuses from hypoxic and pair-
fed mothers compared to controls fed ad libitum. In rela-
tion to the body weight, however, lungs were of propor-
tional size. Furthermore, morphometric analysis of lung 
tissue also showed no difference between the groups with 
regard to the volume of saccular air spaces and saccular/
alveolar wall thickness  [18, 19] . This is in agreement with 
our data on lung histology where the number of saccular 
air spaces and septal thickness were not found to be sig-
nifi cantly different. Nevertheless, apart from auxological 
and pulmonary morphometric data, this report is the fi rst 
to describe signifi cant effects of solely hypoxia induced 
IUGR on the expression of genes encoding for SP-A, -B, 
-C, and -D. 
 As SP are known to reveal distinct developmental pat-
terns observed in fetal lung tissue of human and rodents 
 [20] , down-regulation of SP-A, -B and -C mRNA expres-
sion potentially refl ects hypoxia-induced delay in lung 
maturation. Clinically, a reduced synthesis of SP may 
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have potential implications for postnatal pulmonary ad-
aptation and the risk for the development of chronic lung 
disease (BPD) in preterm neonates. 
 Tokieda et al.  [21] observed that a complete deletion 
of the SP-B gene led to lethal respiratory failure shortly 
after birth in an animal model which is in line with fi nd-
ings in human neonates. Thus, a signifi cant reduction in 
SP-B mRNA expression in lung tissue from fetuses sub-
jected to intrauterine hypoxia may imply severe restric-
tions on postnatal pulmonary adaptation. In addition, it 
has recently been demonstrated that the absence of SP-C 
or structural effective forms could cause chronic intersti-
tial pneumonitis or even postnatal respiratory failure due 
to impaired intracellular processing of other SP (for re-
view see  [22, 23] ). Thus, a reduced synthesis of SP-C ob-
served in preterm mice may lead to postnatal pulmonary 
disorders. 
 Regarding the hydrophilic SP-A and -D, these are de-
scribed to be major factors of the innate pulmonary host 
defense  [24] . Experimental deletion of the SP-A gene does 
not affect postnatal pulmonary adaptation, but neverthe-
less, it leads to an increased susceptibility for bacterial 
infections and the development of pulmonary emphyse-
ma  [24, 25] . As pulmonary SP-A mRNA expression in 
preterm mice was signifi cantly reduced, this reveals a po-
tential role for hypoxia-induced IUGR on the pulmonary 
innate immune response and the development of chronic 
pulmonary disorders in premature infants. 
 The observation that IUGR was associated with a 
down-regulation of SP gene expression seems to be in 
contrast to previous studies in fetal sheep  [7, 10, 26] . 
However, the stage of lung development investigated dif-
fers between the animal models. In the present study, 
mice delivered at day 17.5 of gestation (term 19–21 days; 
0.87 of gestation) were found to be in the saccular stage 
of lung development and not yet in the transition to al-
veolarization  [27] . Our model therefore corresponds to 
human fetuses of about 25 weeks gestational age. This 
difference also affects the stage of type II cell differentia-
tion and thus surfactant production. 
 Confi rming the important impact of hypoxia on fetal 
development previous studies have shown profound al-
terations of the hypothalamic-pituitary-adrenal axis as 
well as lung maturation processes (for review see  [28] ). 
These effects have been shown to partially depend on the 
stage of fetal or neonatal development. This underlines 
the importance of assessing the effects of intrauterine 
 hypoxia on developmental processes in relation to the 
gestational age of the fetus. 
 As another important variable infl uencing lung devel-
opmental processes and overall outcome in premature 
infants, the effect of intrauterine endotoxin exposure (i.e. 
chorioamnionitis) has been demonstrated to be depen-
dent on the stage of lung maturation  [29–31] . Thus, a 
signifi cant interaction between delayed lung maturation 
due to IUGR and the impact of other perinatal factors as 
chorioamnionitis on pulmonary development can be pre-
sumed in the immature preterm infant. Furthermore, the 
indicated effects have to be discussed against the back-
ground of the complex interaction in the fetal-maternal 
unit, considering a potential affection of other growth fac-
tors by hypoxia-induced IUGR. There are different es-
sential loci where oxygen signalling pathways may cue the 
development of respiratory structures like mitochondrial 
biogenesis coupled with muted oxidative function depen-
dent on the hypoxia-sustained production of nitric oxide 
as well as the proliferation and epithelial/endothelial dif-
ferentiation of mesenchyme during the initiation of lung 
morphogenesis (for review see  [32] ). 
 In conclusion, intrauterine hypoxia-induced growth 
restriction in preterm mice led to signifi cant alterations 
of the pulmonary surfactant system during fetal develop-
ment suggesting consequences for postnatal lung adapta-
tion and differentiation. Potential mediators of the indi-
cated effects need to be further investigated. 
 Acknowledgement 
 The authors would like to thank A.-S. Seliger for her technical 
assistance. This work was supported by grants from the Bundes-
ministerium für Bildung und Forschung, Germany (NGFN 01 
GS0401). 
Chapter 6
88
PART
III
CLINICAL ASPECTS OF
BRONCHOPULMONARY DYSPLASIA
 References 
 1 Barker DJ: In utero programming of chronic 
disease. Clin Sci (Colch) 1998; 95: 115–128. 
 2 Hattersley AT, Tooke JE: The fetal insulin hy-
pothesis: an alternative explanation of the as-
sociation of low birthweight with diabetes and 
vascular disease. Lancet 1999; 353: 1789–
1792. 
 3 Plagemann A, Harder T, Rake A, Voits M, 
Fink H, Rohde W, et al: Perinatal elevation of 
hypothalamic insulin, acquired malformation 
of hypothalamic galaninergic neurons, and 
syndrome x-like alterations in adulthood of 
neonatally overfed rats. Brain Res 1999; 836: 
146–155. 
 4 Regev RH, Lusky A, Dolfi n T, Litmanovitz I, 
Arnon S, Reichman B: Excess mortality and 
morbidity among small-for-gestational-age 
premature infants: A population-based study. 
J Pediatr 2003; 143: 186–191. 
 5 Reiss I, Landmann E, Heckmann M, Missel-
witz B, Stillger R, Gortner L: Increased risk of 
bronchopulmonary dysplasia in very preterm 
infants being born small for gestational age. 
Arch Obstet Gynecol 2003;269:40–44. 
 6 Procianoy RS, Garcia-Prats JA, Adams JM, 
Silvers A, Rudolph AJ: Hyaline membrane dis-
ease and intraventricular haemorrhage in 
small for gestational age infants. Arch Dis 
Child 1980; 55: 502–505. 
 7 Harding R, Cock ML, Louey S, Joyce BJ, Da-
vey MG, Albuquerque CA, et al: The compro-
mised intra-uterine environment: Implications 
for future lung health. Clin Exp Pharmacol 
Physiol 2000; 27: 965–974. 
 8 Tyson JE, Kennedy K, Broyles S, Rosenfeld 
CR: The small for gestational age infant: ac-
celerated or delayed pulmonary maturation? 
Increased or decreased survival? Pediatrics 
1995; 95: 534–538. 
 9 Cock ML, Albuquerque CA, Joyce BJ, Hooper 
SB, Harding R: Effects of intrauterine growth 
restriction on lung liquid dynamics and lung 
development in fetal sheep. Am J Obstet Gy-
necol 2001; 184: 209–216. 
 10 Gagnon R, Langridge J, Inchley K, Murotsuki 
J, Possmayer F: Changes in surfactant-associ-
ated protein mRNA profi le in growth-restrict-
ed fetal sheep. Am J Physiol 1999; 276:L459–
L465. 
 11 Heid CA, Stevens J, Livak KJ, Williams PM: 
Real time quantitative PCR. Genome Res 
1996; 6: 986–994. 
 12 Hilgendorff A, Rawer D, Doerner M, Tutdibi 
E, Ebsen M, Schmidt R, et al: Synthetic and 
natural surfactant differentially modulate in-
fl ammation after meconium aspiration. Intens 
Care Med 2003; 3: 3. 
 13 Vuguin P: Animal models for assessing the 
consequences of intrauterine growth restric-
tion on subsequent glucose metabolism of the 
offspring: a review. J Matern Fetal Neonatal 
Med 2002; 11: 254–257. 
 14 Maritz GS, Cock ML, Louey S, Suzuki K, Har-
ding R: Fetal growth restriction has long-term 
effects on postnatal lung structure in sheep. Pe-
diatr Res 2004; 55: 287–295. 
 15 Maritz GS, Cock ML, Louey S, Joyce BJ, Al-
buquerque CA, Harding R: Effects of fetal 
growth restriction on lung development before 
and after birth: A morphometric analysis. Pe-
diatr Pulmonol 2001; 32: 201–210. 
 16 Lipsett J, Cool JC, Runciman SC, Kennedy 
JD, Martin AJ, Byard RW, et al: Morphomet-
ric analysis of pulmonary development in the 
sheep following creation of fetal diaphragmat-
ic hernia. Pediatr Pathol Lab Med 1997; 17: 
789–807. 
 17 Barker DJ, Godfrey KM, Fall C, Osmond C, 
Winter PD, Shaheen SO: Relation of birth 
weight and childhood respiratory infection to 
adult lung function and death from chronic ob-
structive airways disease. BMJ 1991; 303: 671–
675. 
 18 Larson JE, Thurlbeck WM: The effect of ex-
perimental maternal hypoxia on fetal lung 
growth. Pediatr Res 1988; 24: 156–159. 
 19 Schwartz JE, Kovach A, Meyer J, McConnell 
C, Iwamoto HS: Brief, intermittent hypoxia re-
stricts fetal growth in Sprague-Dawley rats. 
Biol Neonate 1998; 73: 313–319. 
 20 Durham PL, Nanthakumar EJ, Snyder JM: 
Developmental regulation of surfactant-asso-
ciated proteins in rabbit fetal lung in vivo. Exp 
Lung Res 1992; 18: 775–793. 
 21 Tokieda K, Whitsett JA, Clark JC, Weaver TE, 
Ikeda K, McConnell KB, et al: Pulmonary dys-
function in neonatal SP-B-defi cient mice. Am 
J Physiol 1997; 273:L875–L882. 
 22 Nogee LM: Alterations in SP-B and SP-C ex-
pression in neonatal lung disease. Annu Rev 
Physiol 2004; 66: 601–623. 
 23 Nogee LM, Dunbar AEr, Wert SE, Askin F, 
Hamvas A, Whitsett JA: A mutation in the sur-
factant protein C gene associated with familial 
interstitial lung disease. N Engl J Med 2002; 
344: 573–579. 
 24 Crouch E, Hartshorn K, Ofek I: Collectins and 
pulmonary innate immunity. Immunol Rev 
2000; 173: 52–65. 
 25 Hawgood S, Ochs M, Jung A, Akiyama J, Allen 
L, Brown C, et al: Sequential targeted defi cien-
cy of SP-A and -D leads to progressive alveolar 
lipoproteinosis and emphysema. Am J Physiol 
2002; 283:L1002–L1010. 
 26 Joyce BJ, Louey S, Davey MG, Cock ML, 
Hooper SB, Harding R: Compromised respira-
tory function in postnatal lambs after placental 
insuffi ciency and intrauterine growth restric-
tion. Pediatr Res 2001; 50: 641–649. 
 27 Cardoso WV: Lung morphogenesis revisited: 
old facts, current ideas. Dev Dyn 2000; 219: 
121–130. 
 28 Braems G: Fetal hypoxemia on a molecular 
level: Adaptive changes in the hypothalamic-
pituitary-adrenal (HPA) axis and the lungs. 
Eur J Obstet Gynecol Reprod Biol 2003; 
110(suppl 1):S63–S69. 
 29 Vayrynen O, Glumoff V, Hallman M: Infl am-
matory and anti-infl ammatory responsiveness 
of surfactant proteins in fetal and neonatal rab-
bit lung. Pediatr Res 2004; 55: 55–60. 
 30 Vayrynen O, Glumoff V, Hallman M: Regula-
tion of surfactant proteins by LPS and proin-
fl ammatory cytokines in fetal and newborn 
lung. Am J Physiol 2002; 282:L803–L810. 
 31 Jobe AH, Newnham JP, Willet KE, Sly P, Er-
vin MG, Bachurski C, et al: Effects of antenatal 
endotoxin and glucocorticoids on the lungs of 
preterm lambs. Am J Obstet Gynecol 2000; 
182: 401–408. 
 32 Land SC: Oxygen-sensing pathways and the 
development of mammalian gas exchange. Re-
dox Rep 2003; 8: 325–340. 
Chapter 6
88
PART
III
CLINICAL ASPECTS OF
BRONCHOPULMONARY DYSPLASIA
I.K.M. Reiss, E. Landmann, M. Heckmann, B. Misselwitz, L. Gortner
Arch Gynecol Obstet. 2003;269:40-44
Increased risk of bronchopulmonary dysplasia
and increased mortality in very preterm infants
being small for gestational age
chapter
7
I.K.M. Reiss, E. Landmann, M. Heckmann, B. Misselwitz, L. Gortner
Arch Gynecol Obstet. 2003;269:40-44
Increased risk of bronchopulmonary dysplasia
and increased mortality in very preterm infants
being small for gestational age
chapter
7
Chapter 7
92
Increased risk of bronchopulmonary dysplasia and increased mortality in very preterm infants
93
Irwin Reiss · Eva Landmann · Matthias Heckmann ·
Bj�rn Misselwitz · Ludwig Gortner
Increased risk of bronchopulmonary dysplasia and increased mortality
in very preterm infants being small for gestational age
Received: 17 September 2002 / Accepted: 21 February 2003 / Published online: 8 April 2003
� Springer-Verlag 2003
Abstract Objective: The objective was to evaluate the
impact of being born small for gestational age (SGA) on
neonatal mortality and neonatal pulmonary morbidity in
preterm infants <32 weeks of gestation. Methods: We
reviewed the data reported prospectively to the quality
assurance program of the Federal State of Hesse,
Germany, from 1990 to 1996 of infants <32 weeks of
gestation. SGA was defined as birth weight below the
10th percentile. Mann Whitney U tests were used to
compare continuous variables and Fisher’s exact tests to
analyze differences in dichotomous variables between
preterm SGA neonates and preterms born appropriate for
gestational age (AGA). The effect of SGA and other
potential risk factors for neonatal death and bronchopul-
monary dysplasia, i.e., requiring a fraction of inspired
oxygen >0.21 at day 28, was tested by multivariable
analyses. Results: Data from 1,365 infants were analyzed.
One hundred and eighty-three neonates were SGA (mean
[SD] birth weight 789 [179] g; mean [SD] gestational age
28.9 [1.7] weeks) and 1,182 were AGA (mean [SD] birth
weight 1,260 [348] g; mean [SD] gestational age 28.8
[2.1] weeks). Neonatal mortality and the rate of broncho-
pulmonary dysplasia were significantly higher in SGA
neonates (23 vs. 11% and 28 vs. 14%, respectively).
There was a statistically significant association of SGA
with neonatal death (odds ratio [OR] = 4.54, 95%
confidence interval [CI] 2.56, 8.04) and bronchopulmo-
nary dysplasia (OR=3.80, 95% CI 2.11, 6.84). Conclu-
sion: SGA neonates below 32 weeks gestation are a high-
risk group regarding neonatal mortality and neonatal
pulmonary morbidity.
Keywords Intrauterine growth restriction · Small for
gestational age · Respiratory distress syndrome ·
Bronchopulmonary dysplasia · Prematurity
Introduction
Neonates born with a birth weight below the 10th
percentile generally are classified as small for gestational
age (SGA) infants. In most cases this condition is
attributed to an intrauterine growth restriction. SGA
infants represent a significant percentage of infants
admitted to neonatal intensive care units. This especially
holds true for SGA infants <32 weeks gestational age in
whom an increased incidence of neonatal complications
was reported recently [4, 8]. However, studies focusing on
the influence of SGA on neonatal morbidity associated
with prematurity showed controversial results.
With regard to neonatal pulmonary morbidity, data
from the 1970s and 1980s suggested lower rates of
respiratory distress syndrome (RDS) in very preterm SGA
neonates [13]. In contrast, several recent studies revealed
no increased risk of RDS [2, 8, 14] or even a significantly
increased risk of RDS [4] in very preterm SGA neonates.
Up to now, only two studies focusing on the risk of
developing bronchopulmonary dysplasia have been pub-
lished. Both demonstrate an increased risk of broncho-
pulmonary dysplasia in very preterm SGA infants
compared with preterm neonates being born appropriate
for gestational age (AGA) [2, 8]. Recently, Egreteau et al.
[6] showed being born SGA to be one of the major risk
factors for chronic oxygen dependency in infants born
before 32 weeks gestation.
Therefore, our aim was to evaluate neonatal mortality
and pulmonary morbidity in very preterm neonates being
born SGA compared with AGA preterms obtained from a
large representative study sample.
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Materials and methods
We examined the morbidity and mortality in SGA neonates
compared with AGA neonates both being born after <32 weeks of
gestation using the perinatal and neonatal databases recorded by the
quality assurance system of the Federal State of Hesse, Germany,
from January 1990 to December 1996. All Hessian hospitals are
obliged to report perinatal data to the Hessian quality assurance
system center. Obstetrical data, e.g., prenatal corticosteroid
administration, preterm premature rupture of membranes (PROM),
Apgar score, and umbilical artery pH, have to be reported by the
institution where the child was born. If a newborn has to be
transferred to a pediatric hospital for further neonatal care, neonatal
data have to be reported by the institution the child was transferred
to, using an additional questionnaire. Thus for each child two
datasets are recorded independently. Trained physicians fill out
independently from each other the perinatal, as well as the neonatal
datasets. Both, the neonatal and the perinatal datasets have to be
sent to the Hessian quality assurance system center. We connected
both different datasets. All variables that had to be recorded in the
neonatal as well as in the perinatal questionnaire, i.e., date and time
of birth, calculated time of birth, gestational age, single or multiple
gestation, zip code, gender, and birth weight, had to coincide
completely. The sets of data, which did not completely coincide in
all these variables, were excluded from the study. Also, we
excluded all datasets that were filled out incompletely. We
expected a relatively high “drop-out” rate due to incomplete data
in either the perinatal or the neonatal dataset. Thus, in a second
step, we compared the variables gestational age, being SGA, RDS,
bronchopulmonary dysplasia, and mortality between all infants
born below 32 weeks of gestation and the infants born below
32 weeks of gestation whose perinatal and neonatal datasets could
be connected. Moreover, we compared the variables gestational
age, RDS, bronchopulmonary dysplasia, and mortality between all
SGA infants below 32 weeks gestation and the SGA infants below
32 weeks gestation whose perinatal and neonatal datasets could be
connected.
Infants with lethal malformations and chromosomal aberrations
were excluded from the study. Multiple gestations were not
excluded from the study, but the variables “twin” and “multiple
pregnancy �3” were included in the multivariable analyses
identifying risk factors for being born SGA, for neonatal mortality,
and for bronchopulmonary dysplasia.
Perinatal variables were defined as follows: The calculation of
gestational age was based on maternal menstrual history or early
prenatal ultrasound. SGA was defined as birth weight below the
10th percentile according to the percentiles published by Voigt et
al. [17] for German newborns. Preterm PROM was diagnosed when
the membranes had ruptured more than 12 h before birth.
Preeclampsia was diagnosed according to the criteria established
by the American College of Obstetricians and Gynecologists [1]. A
complete course of prenatal corticosteroids (two doses of beta-
methasone) was assumed if the first dose was administered �24 h
before birth and less than one week from birth. Pregnancy induced
hypertension was diagnosed when an arterial blood pressure >140/
90 Torr was measured repeatedly. The mode of delivery, insuffi-
ciency of the placenta, preterm labor, and a pathological car-
diotocogram were additionally recorded. Insufficiency of the
placenta was detected by pathological flow velocity waveforms
in the umbilical artery. Pathological cardiotocogram was observed
and described by deceleration, lack of acceleration, and increased
baseline fetal heart rate over 170 bpm.
Neonatal characteristics of study infants included the following
variables: Apgar score below 7 after 5 min, umbilical artery pH
below 7.1, need for intubation and days on mechanical ventilation
(including continuous positive airway pressure), intratracheal
surfactant administration, RDS (based on radiographic criteria
[5]), duration of oxygen dependency (days), oxygen requirements
or mechanical ventilation for pulmonary reasons on day 28 (i.e.,
bronchopulmonary dysplasia), duration of mechanical ventilation
(<3 days, 3–7 days, and >7 days), intraventricular hemorrhage
grades III and IV (according to the criteria of Papile et al. [11]),
periventricular leukomalacia [9], necrotizing enterocolitis [3],
retinopathy of prematurity diagnosed according to the criteria of
the International Committee [10], and patent ductus arteriosus [7].
Probable sepsis was defined as the presence of characteristic
clinical signs and typical laboratory data (positive blood culture,
abnormal differential blood count or increased C-reactive protein).
This definition did not allow us to distinguish between neonatal
sepsis with or without positive blood culture. Furthermore, the
neonatal mortality, i.e., death until day 28, and the total number of
hospital days until discharge were compared between both groups.
We used the SPSS statistical program (version 8.0) for
statistical analyses. To compare differences between groups, t-tests
were used for continuous variables when normally distributed;
otherwise the Mann-Whitney U-test was used. Dichotomous
variables were analyzed by c2-test. The level of significance was
set at p<0.05. The effect of the variables preterm labor, preterm
PROM, placental insufficiency, pregnancy induced hypertension,
maternal age, multiple pregnancy, and chorioamnionitis on the risk
of delivering an SGA neonate were investigated by multiple logistic
regression analyses. The effect of birth weight below the 10th
percentile and other possible risk factors on bronchopulmonary
dysplasia or death was investigated by multiple logistic regression
analyses as well. The level of significance was set at p<0.05.
Results of the multivariable analyses were expressed as odds ratios
(ORs) with 95% confidence intervals (CIs).
The present study was approved by the review board of the
Institute of Quality Assurance of the Federal State of Hesse,
Germany.
Results
A total of 37,393 neonates were reported by Hessian
pediatric hospitals between January 1990 and December
1996 to the Hessian neonatal database and 2,341 (6.3%)
out of these were born before 32 weeks of gestation.
Variables obtained within the perinatal as well as within
the neonatal datasets coincided in 1,365 (58.3%) infants
out of these 2,341. Thus, a total of 1,365 infants were
included in this analysis. There were no statistically
significant differences in the variables gestational age,
birth weight, being born SGA, RDS, bronchopulmonary
dysplasia, and mortality between all 2,341 infants born
below 32 weeks of gestation and the preterm infants
whose perinatal and neonatal datasets could be connected
(data not shown). There were also no statistically
significant differences between all SGA infants below
32 weeks gestation and those with combined peri- and
neonatal datasets with respect to basic neonatal and
outcome variables (mean [SD] gestational age: 28.8 [1.8]
vs. 28.9 [1.7] weeks; neonatal mortality: 24.2 vs. 23%;
RDS: 57.3 vs. 53.9%; bronchopulmonary dysplasia: 21.8
vs. 28.4%). Out of the total of 1,365 infants born before
32 weeks of gestation, 183 (13.4%) neonates were SGA.
The basic perinatal characteristics of SGA infants and
AGA infants are given in Table 1. The neonatal mortality
was significantly higher in SGA infants.
Among all variables included in the multivariable
analysis identifying risk factors for delivering an SGA
neonate, only the variable placental insufficiency was
associated with an increased risk for delivering an SGA
neonate (OR 6.6, CI 4.2, 10.2).
The neonatal morbidity of the surviving infants is
shown in Table 2. The mean duration of mechanical
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Table 1 Basic perinatal vari-
ables in small for gestational
age (SGA) infants and appro-
priate for gestational age
(AGA) infants
SGA infants (n=183) AGA infants (n=1,182) p
Gestational age (weeks) 28.9 (1.7)a 28.8 (2.1)a 0.731
Birth weight (g) 788.7 (178.7)a (380–1,230)b 1,259.5 (348.1)a (440–2,445)b <0.001
Gender (male/female); n (%) 107/76 (59/41) 640/542 (54/46) 0.300
Maternal age (years) 28.7 (5.0)a 29.1 (5.7)a 0.889
Prenatal corticosteroids; n (%) 105 (57) 669 (57) 0.873
Placental insufficiency; n (%) 85 (46) 103 (9) <0.001
Pregnancy induced hypertension;
n (%)
43 (24) 85 (7) <0.001
Preeclampsia; n (%) 54 (30) 128 (11) <0.001
Preterm PROM; n (%) 17 (9) 279 (24) <0.01
Pathological cardiotocogram;
n (%)
110 (60) 330 (28) <0.001
Preterm labor; n (%) 84 (46) 696 (59) <0.01
Cesarean section; n (%) 171 (93) 928 (79) <0.001
Apgar (5 min <7); n (%) 37 (23) 217 (20) 0.162
Umbilical artery pH <7.1; n (%) 8 (4) 34 (3) 0.253
Neonatal mortality; n (%) 42 (23) 128 (11) <0.001
a Mean (SD)
b Ranges
Table 2 Neonatal morbidity in
surviving SGA infants and
AGA infants
SGA (n=141) AGA (n=1,054) p
Respiratory distress syndrome; n (%) 76 (54) 583 (55) 0.735
Surfactant therapy; n (%) 56 (44) 359 (38) 0.858
Need for mechanical ventilationa; n (%) 112 (79) 764 (73) 0.303
Days on the ventilatora 16.4 (14.9)b 13 (14.5)b <0.05
Bronchopulmonary dysplasia; n (%) 40 (28) 145 (14) <0.001
Hospitalization (days) 93.3 (60.9)b 64.7 (32.9)b <0.001
Periventricular leukomalacia; n (%) 1 (1) 29 (3) 1.0
Intraventricular hemorrhage grades III and IV; n (%) 4 (3) 54 (5) 1.0
Retinopathy of prematurity; n (%) 26 (18) 134 (13) 0.385
Patent ductus arteriosus; n (%) 24 (17) 140 (13) 0.367
Necrotizing enterocolitis; n (%) 12 (9) 53 (5) 0.232
a Includes days on continuous positive airway pressure
b Mean (SD)
Table 3 Multivariable analysis predicting mortality for entire
cohort (n=1,365)
Risk factor Odds ratio 95% CI
Birth weight <10th percentile 4.54 2.56, 8.04
Gestational age 0.56 0.50, 0.62
Multiple pregnancy (twin) 1.27 0.74, 2.20
Multiple pregnancy (�3) 1.19 0.41, 3.41
Need for mechanical ventilationa 1.64 0.67, 4.00
Intraventricular hemorrhage grade III
and IV
3.36 1.80, 6.30
Sex female 0.64 0.42, 0.98
Prenatal corticosteroid administration 0.94 0.75, 1.18
Pregnancy induced hypertension 0.77 0.40, 1.47
Placental insufficiency 0.89 0.40, 1.96
Preterm rupture of membrane 0.82 0.51, 1.33
Preterm labor 1.03 0.67, 1.61
Cesarean section 0.90 0.52, 1.56
Probable sepsis 1.67 1.10, 2.59
Periventricular leukomalacia 0.74 0.41, 1.35
Patent ductus arteriosus 0.30 0.16, 0.57
Surfactant therapy 2.76 1.66, 4.59
a Includes continuous positive airway pressure
Table 4 Multivariable analysis predicting bronchopulmonary dys-
plasia for survivors (n=1,195)
Risk factor Odds ratio 95% CI
Birth weight <10th percentile 3.80 2.11, 6.84
Increasing gestational age (weeks) 0.67 0.60, 0.76
Gender female 0.63 0.41, 0.95
Prenatal corticosteroid administration 0.89 0.72, 1.11
Preterm premature rupture of membrane 1.16 0.74, 1.82
Preterm labor 0.93 0.61, 1.42
Cesarean section 0.83 0.48, 1.44
Days on the ventilator <3 days 7.79 0.89, 68.06
Days on the ventilator 3–7 days 15.16 1.96, 117.16
Days on the ventilator >7 days 63.88 8.51, 479.39
Probable sepsis 1.56 1.02, 2.38
Patent ductus arteriosus 1.49 0.92, 2.43
Surfactant therapy 1.57 1.01, 2.43
Multiple pregnancy (twin) 1.08 0.62, 1.87
Multiple pregnancy (�3) 0.37 0.10, 1.43
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ventilation as well as the incidence of bronchopulmonary
dysplasia was significantly higher, and the mean duration
of hospitalization was significantly longer in SGA infants
compared with AGA infants.
By multivariable analyses, birth weight below the 10th
percentile, low gestational age, need for ventilation
including continuous positive airway pressure, and intra-
ventricular hemorrhage grades 3 and 4 were identified
as risk factors for an increased neonatal mortality
(Table 3).
Birth weight below the 10th percentile, low gestational
age, male gender, and duration of ventilation were shown
to increase the risk of developing bronchopulmonary
dysplasia (Table 4).
Discussion
Intrauterine growth restriction implicates an intrauterine
growth pattern that deviates from the genetically deter-
mined growth percentile. Measuring intrauterine growth
repeatedly by ultrasonography is the only way to prove a
pathologic intrauterine growth pattern. Therefore, one has
to consider that in our study as well as in other studies,
neonates are defined as “SGA”, although their birth
weight is below the 10th percentile due to genetic reasons
rather than due to a pathologic pregnancy. On the other
hand, neonates with a pathologic intrauterine growth
pattern not resulting in a birth weight below the 10th
percentile are not defined as “SGA”.
Only complete datasets from both, the perinatal and
the neonatal survey have been taken in account in our
final analysis. Considering this criterion, 58.3% of all
datasets could be connected. We aimed to exclude the
possibility that our results are biased by the high loss
rate, by demonstrating that there were no statistically
significant differences in main perinatal and neonatal
characteristics and outcome variables between all 2,341
neonates and the 1,365 neonates, whose datasets could
be connected. We further showed that there are no
statistically significant differences in main perinatal
and neonatal characteristics and outcome variables
between all SGA neonates below 32 weeks of gesta-
tion and SGA neonates below 32 weeks of gestation
whose perinatal and neonatal datasets could be con-
nected.
The present study indicates being born SGA to result
in an increased neonatal mortality in preterm infants. This
finding is in accordance with several other studies [2, 4, 8,
12, 15, 16]. Our analyses showed birth weight below the
10th percentile to be associated with an about five-fold
increased risk of death during the neonatal period.
Few studies investigate the impact of SGA on
developing bronchopulmonary dysplasia. We therefore
aimed to obtain further data focusing on pulmonary
neonatal morbidity in SGA infants <32 weeks based on
data derived from a large representative population-based
study. The incidence of RDS and need for surfactant
administration did not differ between SGA infants and
AGA infants. Thus, we provide further evidence that
being SGA does not protect against RDS. However, our
data did show an increased pulmonary morbidity in SGA
neonates below 32 weeks gestation. In addition to a
significantly longer duration of ventilation, 28% within
the SGA group compared with 14% within the AGA
group developed bronchopulmonary dysplasia. By multi-
variable analyses, we identified the variable “being born
SGA” to increase the risk of developing bronchopulmo-
nary dysplasia 4-fold. This result is in accordance with a
recently published study which shows intrauterine growth
restriction to be one of the most important risk factors for
prolonged oxygen requirements in infants born at less
than 32 weeks gestation [6].
In conclusion, our data showed no differences between
SGA infants and AGA infants in variables describing the
early course of neonatal lung disease, i.e., RDS and need
for surfactant therapy, whereas the incidence of broncho-
pulmonary dysplasia was significantly higher in the SGA
group. SGA neonates below 32 weeks gestation thus
represent a high-risk group regarding neonatal mortality
and neonatal pulmonary morbidity.
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Bronchopulmonary 
dysplasia and 
intrauterine growth 
restriction
The pathogenesis of broncho pul-
monary dysplasia (BPD) is known to 
be multifactorial. We would like to 
add a further factor, not mentioned 
in the Seminar by John Kinsella and 
colleagues (April 29, p 1421),1 that 
modulates the risk and pathogenesis 
of BPD.
Intrauterine growth restriction 
increases the risk of BPD and prolongs 
the duration of mechanical ventilation 
in preterm infants younger than 
32 weeks of gestation.2 These fi ndings 
have been confi rmed in population-
based studies.3,4 Preterm infants 
younger than 28 weeks and born 
small for gestational age are known 
to be at especially high risk compared 
with age-matched infants without 
obvious signs of impaired intrauterine 
growth.3,4
The main mechanisms to explain 
how intrauterine growth restriction 
modulates the risk of a BPD have 
been described in animals. For 
example, in experi mentally growth-
restricted preterm lambs, impaired 
growth of terminal airways and gas 
exchange units has been shown. 
Furthermore, growth restriction 
leads to reduced expression of 
surfactant protein mRNA and could 
induce increased inflammatory 
activation.5
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Abstract
Lung inflammation plays an important role in the patho-
genesis of chronic lung disease in preterm infants. To
test the hypothesis that prolonged mechanical ventila-
tion induces pulmonary inflammation, we analyzed pro-
and anti-inflammatory mediators in bronchoalveolar la-
vage fluid obtained from ventilated preterm infants hav-
ing respiratory distress syndrome. Our results show a
strong correlation between the duration of mechanical
ventilation and the amount of proinflammatory media-
tors. However, the anti-inflammatory cytokine interleu-
kin 10 remained stable during the whole period of me-
chanical ventilation. These data support the hypothesis
that prolonged mechanical ventilation contributes to the
development of chronic lung disease by the induction of
lung inflammation without adequate stimulation of the
counterregulatory cytokine interleukin 10 in preterm in-
fants with respiratory distress syndrome.
Copyright © 2003 S. Karger AG, Basel
Introduction
A significant proportion of preterm infants less than 28
weeks of gestational age require mechanical ventilation
due to respiratory distress syndrome (RDS). Approxi-
mately 20% of the preterm infants !1,000 g birth weight
develop chronic lung disease (CLD) which contributes
profoundly to mortality and morbidity of preterm infants.
Factors such as barotrauma, oxygen toxicity, and imma-
turity of lung anatomy have been implicated in the devel-
opment of CLD [1]. However, there is growing evidence
that inflammatory lung injury may play a key role in its
pathogenesis. It has been demonstrated that elevated lev-
els of proinflammatory cytokines in bronchoalveolar la-
vage (BAL) fluid (BALF) can predict the development of
CLD [2, 3]. Several studies have shown that RDS and
mechanical ventilation were associated with increased
recruitment of inflammatory cells within the airways [4].
In adult patients with acute RDS, mechanical ventilation
can induce a systemic and local inflammatory response,
as demonstrated by an increase of cytokine levels in
serum and BALF under the influence of injurious ventila-
tory strategies [5, 6].
Patients and Methods
To test the hypothesis that prolonged mechanical ventilation
induces pulmonary inflammation in preterm infants, we analyzed
the proinflammatory mediators interleukin (IL) 8, elastase, and epi-
thelial neutrophil-activating peptide 78 (ENA-78) as well as the anti-
inflammatory cytokine IL-10 in BALF by enzyme-linked immunoas-
say during the first 2 weeks of life in conventional mechanically ven-
tilated preterm infants. Due to the fact that most infants could alrea-
dy be extubated after a few days of ventilation we recruited only 20
preterm infants for this study (median and range: gestational age 27
and 23–31 weeks, birth weight 980 and 460–1,570 g). Respiratory
failure was caused by RDS in all infants investigated. Premature rup-
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Fig. 1. Pro- and anti-inflammatory media-
tors in BALF during mechanical ventilation
of preterm infants. The amounts of IL-8 (a),
ENA-78 (b), and elastase (c) in BALF ob-
tained from preterm infants steadily in-
creased during mechanical ventilation. In
contrast, the amount of IL-10 (d) in BALF
remained stable during the whole period of
mechanical ventilation. The numbers of pre-
term infants investigated were 18 at 0–1
days, 20 at 2–4 days, and 19 at 5–12 days.
Data are presented as a vertical point plot on
a logarithmic scale; the median is indicated
by a line. * p ! 0.05 and ** p ! 0.001 as com-
pared with ventilation on days 0–1 using the
Wilcoxon signed-rank test.
ture of membranes was found in 7 out of 20 cases, an elevated C-
reactive protein concentration in 9 out of 20 cases. Exclusion criteri-
on was a ventilation period !5 days. For ethical reasons, a control
group of healthy preterm or term infants could not be recruited. The
BALF was obtained according to the guidelines on BAL in neonates
[7]. An aliquot of 1 ml/kg of normal saline was instilled using an
end-hole catheter into the right lower lobe. The fluid recovered was
immediately placed on ice and processed within a few hours after
collection. Supernatants were stored at –70 °C until analysis. Se-
creted components in BALF were standardized to secretory immu-
noglobulin A which is not affected by gestational age, lung injury, or
permeability [8]. A BAL was done only if indicated either before sur-
factant application or if pulmonary secretions made ventilation diffi-
cult. Consequently, most BALs were done during the first days of
ventilation with greater intervals later on. Furthermore, we expected
from our own in vitro data an early increase of proinflammatory
mediators already after a few hours [9]. Therefore, data obtained
from preterm infants were grouped into 0–1, 2–4, and 5–12 days of
ventilation (fig. 1). Statistical differences were tested by the nonpara-
metric Wilcoxon test for paired data and by the Mann-Whitney U
test for unpaired data. Correlation analysis was done with a Spear-
man rank test. p ! 0.05 was considered statistically significant. Statis-
tical analyses were performed using SPSS version 9.0 (SPSS, Chica-
go, Ill., USA). The study has been approved by the institutional ethics
committee.
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Results and Discussion
All proinflammatory mediators increased significantly
in BALF during mechanical ventilation in preterm in-
fants (fig. 1a–c). Furthermore, there was a strong correla-
tion between IL-8 (r = 0.67, p ! 0.0001), elastase (r = 0.58,
p ! 0.0001), as well as ENA-78 (r = 0.49, p ! 0.0001) and
the duration of ventilation in preterm infants without
infection, indicating a direct relationship between me-
chanical ventilation and inflammation. This is of special
concern because proinflammatory cytokines were related
to the pathogenesis of diverse neonatal diseases such as
CLD, intraventricular hemorrhage, periventricular leuko-
malacia, and necrotizing enterocolitis [10, 11]. Therefore,
mechanical ventilation may contribute significantly to the
induction of these diseases in preterm infants. Surprising-
ly, there was no correlation between severity of RDS as
defined by Giedion et al. [12], elevation of C-reactive pro-
tein, and the level of proinflammatory mediators in BALF
during prolonged ventilation (data not shown). This ob-
servation supports the role of mechanical ventilation in
the induction of pulmonary inflammation independent
of RDS or infection. However, a multivariance analysis
could not be done due to the low number of preterm
infants investigated. In contrast, the anti-inflammatory
cytokine IL-10 remained stable during the whole period
of mechanical ventilation in preterm infants (fig. 1d). It
has been demonstrated by others that neonates have a
reduced capacity to produce this anti-inflammatory cyto-
kine in RDS [2] and after endotoxin challenge [13].
Decreased or absent IL-10 production offers a theoretical
basis for dysregulated and persistent inflammation in the
lungs of preterm infants with RDS and predisposes these
infants toward the development of CLD.
In conclusion, we show an association between pro-
longed mechanical ventilation and pulmonary inflamma-
tion in ventilated preterm infants with RDS. Because a
direct relationship between injurious ventilatory strate-
gies and pulmonary inflammation has already been dem-
onstrated in adults [5, 6] we hypothesize from our data
that prolonged mechanical ventilation induces pulmo-
nary inflammation in preterm infants as well, but fails to
stimulate the anti-inflammatory cytokine IL-10 adequate-
ly. The susceptibility of the immature lung to CLD could
thus be a consequence of a developmentally regulated
imbalance between pro- and anti-inflammatory media-
tors in favor of the proinflammatory cascade with its
potential to induce tissue injury.
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Abstract
The aim of this prospective study was to determine
whether preterm infants with bronchopulmonary dys-
plasia (BPD) and signs of increased pulmonary artery
pressure have a deficiency of plasma arginine (ARG) and
systemic nitric oxide (NO) synthesis. Plasma amino acid
concentrations, Doppler pulmonary systolic time inter-
vals (ratio of acceleration time and ejection time cor-
rected for heart rate: AT/ETC) and urinary nitrate and
nitrite concentrations were determined at the 28th day
postnatal age and at 36 weeks postmenstrual age in 73
preterm infants less than 30 weeks gestational age. The
AT/ETC ratios were significantly lower in infants with BPD
(n = 32) compared to controls. However, total amino acid
concentrations, ARG intake as well as plasma ARG con-
centrations were not different between groups (median
(interquartile-range) Ìmol/l): control: 58 (42.5–75.5) and
54.5 (42–71) at day 28 and 36 weeks; BPD: 54.5 (31.5–
70.5) and 43 (35–62), respectively. Urinary nitrate and
nitrite concentrations, were not different between
groups at day 28, but significantly higher in infants with
BPD at 36 weeks (p = 0.014). In conclusion, plasma ARG
concentrations and systemic NO synthesis were not defi-
cient in preterm infants with BPD and signs of elevated
pulmonary artery pressure. 
Copyright © 2004 S. Karger AG, Basel
Introduction
L-Arginine (ARG) is the physiological substrate of the
enzyme-catalyzed synthesis of nitric oxide (NO) by var-
ious NO synthase isoforms. NO-related functions include
regulation of vascular tone and hemodynamics. NO-inde-
pendent effects of ARG include synthesis of creatine, pro-
line and polyamines, secretion of insulin, growth hor-
mones, glucagon and prolactin, as well as effects on coagu-
lation and immune function [1].
Low plasma ARG concentrations have been reported
in acute neonatal diseases such as persistent pulmonary
hypertension, respiratory distress syndrome and necrotiz-
ing enterocolitis [2–6]. Dietary ARG supplementation
may represent a novel nutritional strategy for preventing
and treating cardiovascular diseases of adults [7]. New
insights into the pathogenesis of bronchopulmonary dys-
plasia (BPD), the most frequent chronic neonatal disease,
indicate that BPD in preterm infants is characterized by
early endothelial cell damage and impaired vascular
growth, and thus, may be regarded as a vascular disease
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[8]. Infants with BPD are at risk to develop pulmonary
hypertension. In chronic lung disease, the increase in pul-
monary artery pressure could be explained partly by a loss
of the ability of the pulmonary endothelium to maintain
the production of vasodilating substances [9].
The aim of this prospective study was to investigate
whether plasma concentrations of ARG (as the only phys-
iological precursor of NO) are lower in preterm infants
with BPD and signs of elevated pulmonary artery pres-
sure compared to unaffected infants. Furthermore, the
renally excreted end-products of the oxidative metabolic
pathway of NO, nitrate and nitrite were determined as a
measure of whole-body NO synthesis.
Patients and Methods
The study was approved by the Ethics Committee of the Univer-
sity of Giessen and written informed parental consent was obtained.
Patients 
Preterm infants with a gestational age of less than 30 weeks (as-
sessed by obstetrical dating and/or a scoring system) were eligible for
the study. Exclusion criteria were major congenital anomalies, con-
genital heart disease, except patent ductus arteriosus or persistent
foramen ovale, inborn errors of metabolism, evidence of liver dys-
function (alanine aminotransferase greater than three times the
upper limit of normal or direct hyperbilirubinemia) and exchange
transfusion during the study period.
BPD was defined as the need for supplemental oxygen at the age of
28 days to reach a capillary oxygen saturation greater than 86% (Hew-
lett Packard CMS-Monitor with Oxisensor IITM, Nellcor Incorpo-
rated; Hewlett Packard GmbH, Böblingen, Germany) and characteris-
tic radiographic appearance of chronic lung disease [10]. The scoring
system by Palta et al. [11] was used to assess the severity of BPD.
For the first time, infants were studied on postnatal day 28 to
detect plasma ARG concentrations early. Again, infants were studied
subsequently at 36 weeks postmenstrual age to take the sequel of
BPD into account.
Echocardiography 
The Doppler and echocardiographic examinations were per-
formed using either a Hewlett Packard Sonos 2500 or Sonos 5000
ultrasound system and a 12-MHz multifrequency imaging transducer.
Pulmonary artery pressure was assessed non-invasively using Doppler
echocardiography. After a preliminary cross-sectional echocardio-
graphic examination to exclude structural defects, a two dimensional
image of the main pulmonary artery and pulmonary valve leaflets was
obtained from a modified parasternal short axis view. A Doppler sig-
nal was recorded from the center of the main pulmonary artery imme-
diately distal to the valve leaflets. Determinations of acceleration time
(AT, time interval between the systolic Doppler waveform leaving the
zero flow baseline and reaching its peak velocity) and ejection time
(ET, time interval between the systolic Doppler waveform leaving and
returning to the zero flow baseline) were obtained from at least five
consecutive Doppler velocity waveforms [12]. The mean AT/ET ratio
was calculated. The AT/ET ratio was divided by the square root of the
R-R interval from the simultaneously recorded ECG (AT/ETC) to
reveal a value corrected for heart rate. Doppler examinations were
performed by a single observer (M.H.) and infants were studied while
asleep or during a period of quiet wakefulness.
Laboratory Analyses 
Blood samples were immediately centrifuged and plasma was
stored at –70°C until plasma amino acid analysis by ion-exchange
column liquid chromatography (Biotronik LC 3000, Eppendorf,
Hamburg Germany, with automatised data analysis by EZ Chrom
Chromatography Data System).
The renally excreted end-products of the oxidative metabolic
pathway of NO, nitrate and nitrite were determined as a measure of
whole-body NO synthesis [13]. Spot urine specimens were collected
using sterile plastic bags. After centrifugation urinary nitrite and
nitrate concentrations were determined by Gas chromatography-
mass spectrometry (GC-MS) as described previously [14]. The most
frequently applied Griess assay may lead to an underestimation of
urinary nitrate concentrations, unlike the GC-MS method, which is
accurate and free of interferences [14]. Urine study samples were
analyzed in three runs, concomitantly with each of three quality con-
trol (QC1, QC2, QC3) samples, which were analyzed in duplicate.
QC1 sample was analyzed without external addition of nitrite and
nitrate, QC2 sample was spiked with 4 ÌM of nitrite and 400 ÌM of
nitrate; QC3 sample was spiked with 8 ÌM of nitrite and 800 ÌM of
nitrate. The concentrations of the internal standards [15N]nitrite and
[15N]nitrate were 8 and 800 ÌM in all samples. Mean recovery (accu-
racy) of the method for urinary nitrite and nitrate was 90 and 99% in
the QC2 sample, and 89 and 101% in the QC3 sample. Method’s
precision (expressed in terms of relative standard deviation) was
below 10.2% for nitrite and below 1.3% for nitrate in the QC sam-
ples. Creatinine was measured by the Jaffé method. A urinary tract
infection was excluded by microbiological culture in infants with ele-
vated C-reactive protein at the time of urinary collection.
Nutrition 
Formula-fed infants received Humana O (Humana GmbH, Her-
ford, Germany) or Pre-Aptamil (Milupa GmbH, Friedrichsdorf, Ger-
many) containing 51.8 mg/100 ml (0.30 mmol/100 ml) or 50 mg/
100 ml (0.29 mmol/100 ml) of ARG, respectively. In breast-fed
infants arginine intake was calculated according to the arginine con-
tent of pooled breast milk from mothers with preterm infants (54 mg/
100 ml equivalent to 0.31 mmol/100 ml) [15]. Additionally, FM 85
was given as a protein supplement (5% solution containing 24.2 mg/
100 ml equivalent to 0.14 mmol/100 ml ARG; Nestle AG, Germany).
Parenteral nutrition contained AminopädP (Baxter GmbH, Untersch-
leissheim, Germany) administered as a 10% amino acids mixture con-
taining of 910 mg/100 ml (5.2 mmol/100 ml) of ARG. The study pro-
tocol did not regulate the nutritional management of the infants.
Statistics
All data were analyzed using the SAS V8 statistical package (SAS
Institute Inc., Cary, N.C., USA). Data are presented as median and
interquartile range, as they were not distributed normally. Amino
acid concentrations and Doppler-derived variables were compared
between groups by nonparametric analysis of variance (ANOVA)
[16]. Multiple comparisons were made, thus, isolated significant dif-
ferences should be taken as provisional. For explorative statistical
analyses of qualitative and quantitative data, the Fisher exact test
and the Mann-Whitney U test were used, respectively.
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Table 1. Distribution of population characteristics and frequency of common neonatal complications
Control group
(n = 41)
BPD group
(n = 32)
p
Gestational age, weeks 29 (28–29)# 26 (25–27) !0.0001*
Birth weight, g 1,055 (920–1,180)# 760 (655–935) !0.0001*
AGA/SGA 35/6 25/7 0.54**
Gender, F/M 22/19 12/20 0.24**
Prenatal steroids 22 (54%) 20 (65%) 0.47**
RDS treated with surfactant 17 (41%) 25 (78%) 0.004**
PDA requiring treatment 11 (27%) 23 (71%) !0.0001**
NEC 4 (10%) 2 (6%) 0.69**
Intraventricular hemorrhage 1 II° 0 4 (13%) 0.026**
Infection at birth 11 (27%) 17 (53%) 0.03**
Hospital infection 9 (22%) 19 (59%) 0.002**
#Values presented as median (interquartile range). * Mann-Whitney U test. ** Fisher’s exact test. AGA = Appro-
priate for gestational age; SGA = small for gestational age; RDS = respiratory distress syndrome; PDA = patent ductus
arteriosus; NEC = necrotizing enterocolitis.
Table 2. Distribution (median
(interquartile range)) of AT/ETc ratios
of BPD group versus control group
Control BPD p
28th day 0.65 (0.49–0.80); n = 39 0.60 (0.44–0.64); n = 29 0.0018#
36 weeks 0.65 (0.54–0.76); n = 32 0.52 (0.44–0.65); n = 30 0.0034*
Statistics: Non-parametric ANOVA with gestational age# or postnatal age* as co-vari-
ables.
Results
Patients
Eighty preterm infants with a gestational age of less
than 30 weeks were admitted between June 2000 and
December 2001. Seventy-three of them matched the
study criteria. Table 1 shows the patients’ characteristics
and frequency of common neonatal complications. Four-
teen of 30 infants of the BPD group required supplemen-
tal oxygen at 36 weeks postmenstrual age. The Palta score
was 41 (19–50) at the 28th day of life and 17 (16–20) at 36
weeks postmenstrual age [11].
Echocardiography
At both time points, infants in the BPD group had sig-
nificantly lower AT/ET ratios compared to infants in the
control group (table 2).
Plasma Amino Acid Concentrations and Urinary
Nitrate and Nitrite Excretion
The severity of BPD, measured by the Palta score, did
not correlate significantly with plasma ARG concentra-
tions. However, there was a trend at day 28 (Spearman-
rank test; r = 0.32, p = 0.078 at day 28; r = 0.10, p = 0.71 at
36 weeks).
To compare plasma amino acid concentrations be-
tween groups, nonparametric ANOVA (see Patients and
Methods) with gestational age, arginine intake, total ami-
no acid intake and hospital infection as co-variables was
used at day 28 (table 3). There was a trend to slightly low-
er ARG concentrations in the BPD group, but the differ-
ence did not reach statistical significance (p = 0.089).
At 36 weeks, gestational age, postnatal age, arginine
intake and total amino acid intake were co-variables. Hos-
pital infection was no longer a co-variable due to its low
incidence (n = 2). No significant difference in plasma
ARG concentrations was found at 36 weeks.
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Table 3. Distribution (median (interquartile range)) of amino acid intake and plasma amino acid concentrations [Ìmol/l] of BPD group
versus control group
28th day
control (n = 40) BPD (n = 32) p
36 weeks
control (n = 32) BPD (n=32) p
Total caloric intake, kcal/kg 99 (88–114) 103 (91–111) 0.01* 108 (102–119) 109 (94–118) 0.32*
Total AA intake, g/kg/d 2.2 (2.0–2.7) 2.6 (2.1–3.2) 0.85* 2.4 (2.2–2.8) 2.6 (2.2–2.7) 0.55*
ARG intake, mmol/kg/d 0.45 (0.39–0.61) 0.55 (0.48–0.67) 0.68* 0.51 (0.44–0.57) 0.52 (0.44–0.61) 0.76*
Arginine 58 (42.5–75.5) 54.5 (31.5–70.5) 0.089# 54.5 (42–71) 43 (35–62) 0.96##
Citrulline 18.5 (12–22) 18.5 (16–26) 0.77*** 22.5 (17–31) 19.5 (16–28.5) 0.65**
Glutamine 428 (340–502) 376 (286–424) 0.77*** 492 (346–686) 476 (386–626) 0.20**
Ornithine 64 (43–82) 93 (56.5–106) 0.01*** 70 (59–83.5) 74.5 (56.5–103.5) 0.04**
Ornithine/citrulline 3.6 (2.8–4.6) 4.1 (3.2–5.5) 0.38### 3.1 (2.5–3.8) 3.8 (2.9 – 5.2) 0.06###
Nonessential amino acids 1,425 (1,129–1,692) 1,383 (1,137–1,728) 0.103*** 1,419 (1,209–1,723) 1,480 (1,220–1,885) 0.05**
Essential amino acids 918 (798–1,080) 1,057 (884–1,259) 0.55*** 961 (864–1,084) 1,028 (820–1,177) 0.22**
Plasma urea, mmol/l 6.1 (4.9–8.5) 9.2 (6.1–25.0) 0.01### 5.5 (4.3–6.1) 5.5 (4.3–7.6) 0.28###
Nonparametric ANOVA with co-variables.
* Weight; ** weight, gestational age, total amino acid (AA) intake; *** weight, gestational age, total AA intake, hospital infection.
# Weight, gestational age, ARG intake, total AA intake, hospital infection; ## weight, gestational age, ARG intake, total AA intake;
### gestational age.
Table 4. Sum of nitrate and nitrite concentrations, normalized to
creatinine excretion [Ìmol/mmol], of BPD group versus control
group
Control BPD p
28th day 300 (171–441); n = 22 241 (182–533); n = 19 0.28
36 weeks 227 (197–317); n = 19 290 (173–372); n = 22 0.014
Values presented as median (interquartile range). Nonparametric
ANOVA with co-variables: weight, gestational age.
Plasma concentrations of amino acids involved in the
ARG pathway (i.e. citrulline, glutamine and ornithine)
did not differ between groups except for a higher concen-
tration of ornithine in the BPD group (table 3). There was
a trend to a higher ratio of ornithine to citrulline, a marker
of urea cycle function, at 36 weeks. The plasma level of
urea was significantly higher in the BPD group compared
to control infants (p = 0.01) at day 28, but not at 36 weeks
postmenstrual age (p = 0.28) (table 3).
Creatinine-corrected urinary nitrate plus nitrite con-
centrations were not statistically different between groups
at day 28, but significantly higher in the BPD group at 36
weeks (p = 0.014) (table 4). Urinary nitrite + nitrate excre-
tion in our infants are of the same order of that in new-
borns reported by Tsukahara et al. [17, 18].
Nutrition
Fifty percent of the control group at day 28 (50% at
36 weeks) and 56% (41% at 36 weeks) of the BPD group
(p = 0.48 and 0.80) were fed with mother’s milk. The
incidence of partial or total parental nutrition was low
(0–25%) without significant differences between groups.
Discussion
Preterm infants with BPD had Doppler-derived signs
of elevated pulmonary artery pressure, but no differences
in plasma ARG concentrations and urinary nitrate +
nitrite excretion rates were found compared to control
infants. This holds true for ARG even after statistical
adjustment for potential confounding variables like in-
take of ARG and total amino acids or acute disease like
infections. One possible explanation for the lack of differ-
ences might be the severity of BPD in our study popula-
tion, because only three (9%) infants in the BPD group
were still ventilated at day 28. Thus, we cannot exclude
that plasma ARG concentrations may have been altered,
if a higher number of infants with a more severe pulmo-
nary disease would have been investigated.
However, the infants in the BPD group appeared to
have vascular disease in terms of Doppler derived signs of
elevated pulmonary artery pressure. In our study, the
ratio AT/ET was measured, which correlates inversely
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with pulmonary artery pressure. This ratio showed the
best correlation to pulmonary artery pressure, as esti-
mated by tricuspid regurgitation compared to other vari-
ables (r = –0.84) [12]. Only one infant of the BPD group
had a significant tricuspid regurgitation, which is in accor-
dance with the recently reported low incidence of tricus-
pid regurgitation in preterm infants [19].
The plasma ARG concentrations of our infants were at
the lower reference range reported for term breast-fed
infants [20], although the ARG intake was 25–50% higher
than reported for term breast-fed infants [21]. One could
speculate that the lack of difference in plasma ARG con-
centrations in our study population reflects a metabolic
adaptation to a higher ARG demand in a chronic disease.
Endogenous ARG synthesis, which plays an important
role during the neonatal period [1], may be upregulated.
In adult vascular disease, plasma ARG concentrations do
also not appear to be altered, but oral administration of
ARG was nevertheless found to be beneficial in those
patients [7]. That elevation of plasma ARG concentra-
tions can enhance systemic and vascular NO production
and also repair NO-related endothelial dysfunction [22] is
a paradox, because ARG is found in the mammalian
organism at concentrations by far exceeding the half-satu-
rating ARG concentrations [1] for all known NO synthase
isoforms [22]. Thus, plasma ARG concentrations may
play an important role in regulating endothelial NO syn-
thesis, with plasma ARG concentrations exceeding the
physiological levels being beneficial.
Elevated ornithine and urea concentrations and trend
to a higher ratio of ornithine to citrulline in the BPD
group possibly indicates an increased metabolism of ARG
via the arginase I pathway [1]. Upregulation of this
enzyme could limit availability of ARG as a substrate for
NO synthetase without detectable changes in plasma
ARG concentrations. However, because ARG metabo-
lism involves multiple organs and complex compartmen-
talization [1], and since only a very small portion of ARG
is metabolized via the ARG/NO pathway [23], it is not
possible to determine the status of the ARG/NO pathway
by simply comparing plasma concentrations of other ami-
no acids involved in the multiple metabolism of ARG.
Systemic NO production can be assessed by measuring
the urinary excretion of nitrite + nitrate [13, 17, 18] or
measuring plasma cGMP, the second messenger of NO
[24], whereas analyzing exhaled NO represents NO pro-
duction from the upper and lower respiratory tract [25].
NO synthesis is differentially regulated in different tissues
by three isoforms of NO synthase. Measuring the urinary
excretion of nitrite + nitrate reflect whole body NO syn-
thesis but cannot represent certain tissues or isoforms of
NO synthase. A study by Castillo et al. [23] using stable
isotope-labelled amino acids (L-[15N2,2H2]arginine and L-
[2H3]leucine) in the neonate with persistent pulmonary
hypertension indicated that there was a decreased argi-
nine utilization for NO production and a decreased uri-
nary excretion of NO products during the acute vasocon-
strictive state. In contrast, urinary nitrate and nitrite
excretions were increased in preterm infants with respira-
tory distress syndrome [17]. In our study, no difference in
urinary excretion of these NO metabolites was found
between BPD and control infants at day 28. At 36 weeks,
urinary excretion of NO metabolites was significantly
higher in the BPD group, which may reflect persisting pul-
monary inflammation or may be indicative of an upregu-
lated compensatory mechanism. Finally, exposure to high
concentrations of inspired oxygen could also contribute to
an increase of endogenous NO synthesis.
In conclusion, we found similar plasma ARG concen-
trations and similar or even higher urinary nitrate +
nitrite excretion in preterm infants with BPD, who had
signs of elevated pulmonary artery pressure, as well as in
control infants, suggesting that NO synthesis was not
impaired in the preterm infants with BPD. Healthy and ill
infants received comparable amounts of ARG by food.
With respect to NO synthesis, this moderate ARG intake
could have been more beneficial in the preterm infants
with BPD than in the control group. With regard to the
low plasma ARG concentrations in preterm infants in
general and the promising findings of ARG supplementa-
tion [7, 26, 27], our findings do not exclude a potential
benefit from ARG supplementation in preterm infants
with BPD. Future studies should also take into account
indirect NO-dependent or NO-independent and hor-
mone-related effects of ARG supplementation on cardio-
vascular diseases in infants. They also should include
markers like nitrotyrosine and 8-hydroxy-2)-deoxyguano-
sine to elucidate the role of NOx as activated oxygen spe-
cies in the pathogenesis of BPD as well as asymmetric
dimethylarginine, the endogenous inhibitor of endothelial
nitric oxide synthase.
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Abstract Objective: To determine
whether bovine surfactant given in
cases of severe pediatric acute respi-
ratory distress syndrome (ARDS) im-
proves oxygenation. Design: Single-
center study with 19 patients, fol-
lowed by a multicenter randomized
comparison of surfactant with a stan-
dardized treatment algorithm. Prima-
ry endpoint PaO2/FIO2 at 48 h, sec-
ondary endpoints: PaO2/FIO2 at 2, 4,
12, and 24 h, survival, survival with-
out rescue, days on ventilator, sub-
groups analyzed by analysis of vari-
ance to identify patients who might
benefit from surfactant. Setting: Multi-
center study in 19 reference centers
for ARDS. Patients: Children after
the 44th postconceptional week and
under 14 years old, admitted for at
least 4 h, ventilated for 12–120 h,
and without heart failure or chronic
lung disease. In the multicenter study
35 patients were recruited; 20 were
randomized to the surfactant group
and 15 to the nonsurfactant group.
Decreasing recruitment of patients
led to a preliminary end of this study.
Interventions: Administration of
100 mg/kg bovine surfactant intra-
tracheally under continuous ventila-
tion and PEEP, as soon as the
PaO2/FIO2 ratio dropped to less than
100 for 2 h (in the pilot study incre-
ments of 50 mg/kg as long as the
PaO2/FIO2 did not increase by 20%).
A second equivalent dose within 48 h
was permitted. Results: In the pilot
study the PaO2/FIO2 increased by a
mean of 100 at 48 h (n=19). A higher
PaO2/FIO2 ratio was observed in the
surfactant group 2 h after the first
dose (58 from baseline vs. 9), at 48 h
there was a trend towards a higher 
ratio (38 from baseline vs. 22). The
rate of rescue therapy was signifi-
cantly lower in the surfactant group.
Outcome criteria were not affected
by a second surfactant dose (n=11).
A significant difference in PaO2/FIO2
in favor of surfactant at 48 h was
found in the subgroup with an initial
PaO2/FIO2 ratio higher than 65 and
in patients without pneumonia. 
Conclusions: Surfactant therapy in
severe ARDS improves oxygenation
immediately after administration.
This improvement is sustained only
in the subgroup of patients without
pneumonia and that with an initial
PaO2/FIO2 ratio higher than 65
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Introduction
Acute respiratory distress syndrome (ARDS) is defined
by radiographic diagnosis of diffuse bilateral alveolar in-
filtrates, the degree of hypoxemia, lung function, and
histopathology. It is the final generalized inflammatory
response of the lung to catastrophic events of various
pulmonary and nonpulmonary origins and occurs in all
age groups. The diagnostic criteria have been established
by an American-European Consensus Conference [1, 2,
3]. ARDS in children is still associated with a high mor-
tality. Mortality is correlated with the severity of the un-
derlying disease [4, 5]; however, it is still generally ac-
cepted that the degree of hypoxemia predicts outcome
[5, 6, 7, 8]. Mortality in children with a PaO2/FIO2 ratio
lower than 100 in central Europe is still greater than 50%
[5]. Another outcome criteria is the aggressiveness of
ventilatory support, reflected in the peak inspiratory
pressure (PIP), mean airway pressure, and ventilation in-
dex [9, 10]. The enforcement of standardized ventilation
protocols and the lower incidence of both multiple trau-
ma and sepsis in central Europe have caused a continu-
ous decrease in severe ARDS incidence in children [11,
12, 13].
As the mortality is still high in children with profound
hypoxemia and severe underlying conditions such as im-
munosuppression [4, 5, 8, 13], many other therapies in
addition to baro- and volutrauma preventing ventilation
strategies have been reported. Nevertheless, randomized
controlled studies evaluating new therapeutic strategies
for the treatment of severe hypoxemic ARDS as nitric
oxide, high-frequency oscillatory ventilation (HFOV),
extracorporeal membrane oxygenation (ECMO), and
surfactant treatment are lacking in the pediatric age
group [14, 15, 16, 17, 18]. Exogenous surfactant im-
proves oxygenation in neonates not only with respiratory
distress syndrome but also in other conditions with sec-
ondary surfactant deficit such as meconium aspiration
syndrome and congenital pneumonia, comparable with
ARDS [19]. Oxygenation improved after surfactant 
administration in several case reports on adult ARDS 
patients [11, 20] and in a controlled study in moderate
pediatric ARDS [10]. A retrospective and prospective
survey of pediatric ARDS in all major German pediatric
intensive care facilities demonstrated that the mortality
and chronic illness after ARDS in patients with PaO2/
FIO2 ratios above 150 is very rare, and that most patients
with a PaO2/FIO2 ratio around 200 are not even ventilat-
ed [5]. For this reason the German-Austrian working
group on ARDS performed a controlled, randomized
study in severe, hypoxemic ARDS in children, associat-
ed with a very high mortality, and no evidence-based
treatment options available.
Patients and methods
A single-center pilot study was carried out in 19 pediatric patients
with ARDS and PaO2/FIO2 ratio lower than 100, aimed at dose
finding and calculating the number of patients required. This pilot
study treated patients with ARDS defined by consensus confer-
ence criteria and aged between the 44th postconceptional week
and 14 years of age. They were included if their PaO2/FIO2 ratio
was below 100 for at least 2 h. Ventilation in the pilot study was in
accordance with the ventilation algorithm established by the Ger-
man Working Group on Pediatric ARDS (Fig. 1). A bovine surfac-
tant (Alveofact, Boehringer, Ingelheim, Germany) was adminis-
tered in 50 mg/kg increments (intratracheal bolus under continu-
ous ventilation and PEEP over maximally 5 min) as long as the
PaO2/FIO2 ratio did not increase by 20% or decrease by 10%. The
PaO2/FIO2 ratio was determined at 48 h The increase/decrease
from baseline was evaluated using the Mann-Whitney U test. No
other exclusion criteria were applicable [17, 19]. This pilot study
as the following mulitcenter study were approved by the ethics 
review board of the principal investigators’ institution (Medical
University of Lübeck).
The subsequent multicenter study was an open, randomized,
parallel group comparison performed at 19 German pediatric in-
tensive care units between May 1997 and November 1999. These
units were referral centers for children with severe respiratory fail-
ure. All children were randomized if they fulfilled the following
criteria: ARDS Consensus Conference criteria, lung injury score
[21] of at least 2, ventilation between 12 and 120 h, age between
44th postconceptional week and 14 years, admission for at least
4 h, no echocardiographically detectable left heart failure, and a
PaO2/FIO2 ratio lower than 100. Written informed consent was ob-
tained from the parents or legal guardians. Patients were excluded
if they were under other investigational or experimental therapies:
nitric oxide, high frequency ventilation with current disease, liquid
ventilation, prostaglandins, steroids for therapy of ARDS, ECMO;
chronic lung disease such as bronchopulmonary dysplasia or cys-
tic fibrosis, participation in other clinical studies except treatment
protocols and studies for oncological diseases. In addition, pa-
tients with severe hypoxemia, i.e., PaO2 lower than 50 after 4 h of
treatment in the referral center were excluded.
Thirty-eight patients were recruited over the 18-month period
(mean age 3.9 years), but three randomized patients were not in-
cluded in the study, as their PaO2/FIO2 ratio improved to 100 or
higher before the start of treatment. All patients in the participat-
ing centers with ARDS in the specified age group who were not
included as they did not fulfill all entry criteria were recorded and
evaluated as “intended to treat patients” if their PaO2/FIO2 ratio
was below 100. All patients in the participating centers were ven-
tilated according to a ventilation algorithm (Fig. 1) [4], blood
pressure was kept above the 50th percentile for age, fluid intake
between 90% and 100% maintenance [22], and hemoglobin levels
above 12 g/dl. As the PaO2/FIO2 ratio was less than 100, patients
were randomized either to receive 100 mg/kg bovine surfactant
(Alveofact, Boehringer-Ingelheim, Germany), administered under
continuous PEEP and ventilation as a bolus over not longer than
5 min to the distal tip of the endotracheal tube (n=20), or be con-
tinuously treated based on the ventilation algorithm and concomi-
tant therapy outlined above (n=15). In the surfactant group an ad-
ditional dose of 100-mg/kg surfactant during the 48-h observation
period was allowed if the PaO2 decreased by 20% from the maxi-
mum level reached. Diagnoses, age, weight and other demograph-
ic characteristics are depicted in Table 2, including the ratio of im-
munosuppressed patients (after bone marrow transplant or under
chemotherapy), PRISM III score, and pneumonia; there were no
significant differences between the two groups in regard to these
factors.
PaO2, FIO2, paCO2, pH, peak inspiratory pressure, PEEP, ven-
tilatory rate, tidal volume, blood pressure, heart rate, hemoglobin,
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all medications administered, fluid balance, and the derived vari-
ables (PaO2/FIO2, Hallman oxygenation index, ventilatory index,
mean airway pressure) were recorded 2, 4, 12, 24, and 48 h after
randomization. The patients were followed to day 30 or to dis-
charge/transfer from the referral center to document outcome data:
survival, rescue therapy, days on ventilator, days in the ICU, 
Pediatric Risk of Mortality (PRISM) III score [23], lung injury
(Murray score) [21], and days in hospital.
Random allocation was performed centrally by telephone (24 h
coverage). The randomization schedule was designed to achieve 
a 1:1 randomization at each participating center. If the PaO2 de-
creased to below 50 mmHg for at least 1 h in any patient, all res-
cue therapies considered appropriate by the principal investigator
of the center were allowed (e.g., NO, HFOV, additional surfactant,
ECMO, vasodilators). Rotational therapy or prone positioning was
obligatory.
Fig. 1 Algorithm for ventila-
tory management in the study
centers before and after ran-
domization
Table 1 Reasons for not randomizing patients with ARDS and
PaO2/FIO2 ratio less than 100 (“intended to treat”). The survival
rates were not compared statistically because of the small number
of patients in each section of the intended to treat patients; the
overall survival rate was 36%
n Age range Nonsurvivors
(months)
n %
Admission under resuscitation/death at arrival 6 8–152 6 100
On ventilator for longer than 120 h 6 3–152 5 80
Chronic lung or left heart disease 10 2.5–160 3 33
Under rescue therapy before study 11 3–156 8 72
No informed consent 6 3–145 3 50
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The study was conducted as a multicenter, open, randomized
parallel comparison. The primary variable was the change from
baseline in the PaO2/FIO2 ratio at 48 h after the first administra-
tion of surfactant or randomization to the control group. Second-
ary endpoints were: peak inspiratory pressure, positive end-expira-
tory pressure, mean airway pressure, in- and expiration time, res-
piratory rate, FIO2, PaO2, paCO2, SaO2, pH, heart rate, and blood
pressure 2, 4, 12, 24, 48, and 120 h after randomization. In addi-
tion Murray Score, PRISM III score at baseline, 48 and 120 h,
clinical status at 30 days after randomization, days on ventilator,
days in intensive care, days on supplemental oxygen, mortality at
day 30, ventilator-free days at day 30, and the necessity of rescue
therapy as ECMO, HFOV, NO, or rescue surfactant. The primary
hypothesis defined was tested by the Mann-Whitney U test at an
error level of α≤0.05. A secondary analysis was performed to 
detect changes from baseline for all other time points up to 48 h
by the same test procedure.
For all other variables the same procedures were performed.
The number of deaths was compared between groups by means of
Fisher’s exact test, as were patients who received rescue therapy
(each rescue therapy was summarized by frequencies). In a third
analysis the combined event death and/or rescue therapy was in-
vestigated. We performed multiple regression analyses for changes
in the oxygenation index at 2, 4, 12, 24, and 48 h to analyze differ-
ences between special subgroups. We used a linear model for re-
peated measurements. For this post hoc analysis the following
subgroups were evaluated: baseline PaO2/FIO2 less than vs. 65 or
higher, baseline PRISM III score less than vs. 12 or higher, age
under 1 year vs. 2 years or older, girls vs. boys, body weight less
than vs. 12 kg or higher, time since FIO2 being higher than 0.5 at
randomization shorter than 24 vs. 24 h or longer, time since PIP
being higher than 30 cmH2O shorter than 30 h or longer, pneumo-
nia vs. no pneumonia, sepsis vs. no sepsis, and immunosuppres-
sion vs. no immunosuppression.
Results
In the pilot study the average increase in PaO2/FIO2 was
54 at 4 h and 103 after 48 h (p<0.01). Seven patients
died despite improved oxygenation. The average dose of
surfactant given was 94 mg/kg (Table 3). This led to the
multicenter study dose of 100 mg/kg.
Regarding the primary variable, change in PaO2/FIO2
over the 48-h observation period, PaO2/FIO2 was signifi-
cantly higher in the surfactant group 2 h after the first
surfactant dose (p<0.003). Even after 48 h the surfactant
group patients still showed a greater, albeit not signifi-
cantly greater, increase in PaO2/FIO2 ratio (Fig. 2). Us-
ing the Hallman oxygenation index as oxygenation pa-
rameter produced similar results; oxygenation was sig-
nificantly improved after 2 and 4 h (p<0.00222 and
p<0.05). Considering secondary endpoints, mortality and
mortality and/or rescue therapy was lower in the surfac-
tant group, however not significantly so at all times dur-
ing the study period. Mortality in both groups was con-
siderably lower than that in the “intended to treat” pa-
tients (64%). Patients in the surfactant group received
significantly less rescue therapy than those in the non-
surfactant group (p<0.05).
There was a reduction in mean airway pressures used
in the surfactant group after 2 and 24 h (p<0.05,
p<0.007; (Fig. 3, Tables 4, 5) – there was no difference
Table 2 Patient characteristics in surfactant and nonsurfactant groups
Surfactant Controls Overall Comments
Randomized 22 16 38 −
Treated 20 15 35 −a
Age (range; years) 3.5 (0–13) 4.5 (0–12) 3.9 (0–13) n.s.
Female 7 (35%) 7 (46.7%) 14 (40%) −
Body weight (kg) 15.7±10.4 22.4±20.7 18.6±15.8 n.s.
Time since FIO2 >0.5 (h) 35.2±25.5 49.8±44.5 n.s.
Time since PIP >30 cmH2O (h) 24.9±21.8 34.1±32.9 n.s.
Causative diagnosis pneumonia 15 (68.2%) 11 (68.7%) n.s. 
Causative diagnosis sepsis 7 (31.8%) 5 (31.3%) n.s.
Under immunosuppression 9 7 n.s.
Rescue ECMO 0 2 −b
Rescue NO 4 4 −b
Rescue HFOV 2 3 −b
Rescue surfactant 0 4 −b
Rescue vasodilators 1 1 −b
Nonsurvivors/mortality 8 (44%) 9 (60%) p=0.29
Death and/or rescue 11 (56%) 12 (80%) p=0.13
Ventilator-free (alive and without ventilator) n.s.
0 days 12 (63.2%) 9 (64.3%)
10–20 days 3 (15.8%) 3 (21.4%)
>20 days 4 (21.1%) 2 (14.3%)
PRISM III at randomization, median 11.5 11 n.s.
Lung injury score (Murray) at randomization 3.0 3.3 n.s.
PaO2/FIO2 at baseline 71.3±13.7 64.3±16.2 n.s.
2nd surfactant dose 11 −
a Three patients improved within the 2 h between reaching a PaO2/FIO2 <100 and final randomization
b Rescue therapy after the study surfactant medication was given
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Table 3 Data of the pilot study in 19 patients, their diagnoses, age, body weight and PaO2/FIO2 ratio at baseline, 4 and 48 h (RSV respi-
ratory syncytial virus)
Patient Diagnosis Age Weight PaO2/FIO2 Outcome
no. (months) (kg)
0 h 4 h 48 ha
1 Meningococcemia 24 15 84 111 444 Survived
2 Pneumonia 26 10.3 31 109 160 Survived
3 Pneumonia 18 8 48 148 242 Survived
4 RSV bronchiolitis 13 8 38 115 151 Survived
5 Pertussis pneumonia 14 7.2 116 99 145 Died
6 Near drowning 38 12 43 174 240 Survived
7 Liver failure 9 4 65 96 108 Died
8 Sepsis 2 3 61 242 50 Died
9 Sepsis 7 8 32 57 − Died
10 Pneumonia 38 9 64 53 − Died
11 Burns 54 17 61 84 65 Died
12 RSV bronchiolitis 2 2.5 59 94 137 Died
13 Pneumonia 54 15 64 100 113 Died
14 Pneumonia 3 2.5 64 96 92 Survived
15 Near drowning 69 23 63 176 290 Survived
16 Aspiration 10 8 47 66 109 Survived
17 Aspiration 12 10 46 87 105 Survived
18 Pneumonia 3 3.2 60 128 122 Survived
19 Aspiration 6 6 63 88 160 Survived
Mean±SD 21±20 9±5 58±19 112±46 161±97 p<0.01
a n=17
Fig. 2 Medians and interquartile ranges (25–75 percentiles) of the
oxygenation index (PaO2/FIO2) in the 48-h observation period of
the surfactant group (group 1) and controls (group 2)
Fig. 3 Medians and interquartile ranges (25–75 percentiles) of
changes of peak inspiratory pressure in cmH2O (a) and positive
end-expiratory pressure (b) over the 48-h observation period in the
surfactant group (group 1) and controls (group 2)
�
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between paCO2 or pH in the two groups at any time of
the 48-h observation period. Tidal volumes were kept be-
low 10 ml/kg in all cases as specified in Fig. 1. Lung in-
jury and PRISM III scores decreased from 0 to 48 h;
however, only the decrease in PRISM III reached the
level of significance (p 0.05). No other significant dif-
ferences in secondary outcome criteria were detected.
Eleven patients in the surfactant group received the pos-
sible second dose of 100–mg/kg surfactant; no signifi-
cant increase in PaO2/FIO2 after this second dose was
observed at any time. No treatment associated adverse
events were observed in the surfactant group; however,
the expected risk of intermittent obstruction of the endo-
tracheal tube with a short time deterioration in oxygen-
ation was observed in three patients.
In a post hoc analysis of the PaO2/FIO2 changes from
baseline between 2 and 48 h considering various patient
characteristics as additional information no significant
differences were found regarding Murray Score PRISM
III score, age, sex, time with FIO2 longer than 0.5, PIP
higher than 30 cmH2O, sepsis vs. no sepsis, or immuno-
suppression vs. no immunosuppression (Table 6). How-
ever, a significant difference in PaO2/FIO2 increase was
found between those whose initial ratio was higher than
65 and those whose initial ratio was less and 65 and
group 2 patients (p<0.028, Fig. 4); patients with the low-
er ratio had a 100% mortality in both groups even when
rescue therapy was applied. In addition, surfactant pa-
tients without pneumonia had significantly better oxy-
genation after 48 h than nonsurfactant patients with
pneumonia (p<0.0017, Fig. 5). In addition, a trend to 
efficacy of surfactant was seen in patients weighing at
least 12 kg (p=0.055).
The study had to be stopped earlier than originally
planned due to increasing recruitment difficulty. To
demonstrate that the trial was not being stopped at aTa
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Fig. 4 Z statistic of the primary endpoint, change in PaO2/FIO2 
ratio at 48 h between the surfactant group (group 1) and controls
(group 2)
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prejudicial time point the primary comparison between
treatments was performed sequentially, post hoc begin-
ning with the first ten evaluable patients. The resulting
Z statistics, which are approximately normally distribut-
ed, are depicted graphically vs. the number of patients
(Fig. 4).
Discussion
In patients with ARDS less endogenous surfactant is pro-
duced, and this is inactivated, modified, and not reused,
thus causing an absolute and relative surfactant deficien-
cy [20, 24, 25, 26, 23]. As surfactant is a major biologi-
cal factor for alveolar recruitment, surfactant deficit is a
key problem in ARDS, and substitution of surfactant in
Table 5 PRISM III and 
Murray score at baseline, 
48, and 120 h (no significant 
differences)
Surfactant Controls
Baseline 48 h 120 h Baseline 48 h 120 h
PRISM III 11.5±6.5 11.55±6.5 11.0±6.7 11.0±4.5 11.0±7.0 11.0±4.0
Murray score 3.0±0.7 2.8±0.4 2.6±1.0 3.3±0.4 3.1±0.7 3.1±0.5
Table 6 p values in linear models for the change from baseline in
the PaO2/FIO2 ratio between 2 and 48 h including various addi-
tional factors of clinical concern. The significant interactions be-
tween treatment and morbidity characteristics (e.g., pneumonia,
PaO2/FIO2<65) indicate that the difference between treatment
groups depends on the baseline value of the oxygenation index
and on the presence of pneumonia as a causative diagnosis for
ARDS. These differences are clearly demonstrated by the median
profiles which are displayed separated for the respective sub-
groups
Factor of interest Surfactant Factor of interest Treatment 
treatment (morbidity characteristics) by factor
No 0.079 − –
Baseline PaO2/FIO2 (<65 vs. >65) 0.220 0.019 0.028
Baseline lung injury score (<3.1 vs. >3.1) 0.103 0.958. 0.426
Baseline PRISM III (<12 vs. >12) 0.069 0.232 0.786
Age (<1 vs. ≥2 years) 0.076 0.291 0.783
Sex 0.139 0.727 0.285
Body weight (≤12 vs. >12 kg) 0.059 0.570 0.055
Time since FIO2 >0.5 before randomization (<24 vs. >24 h) 0.122 0.617 01.77
Time since PIP >30 cmH2O before randomization (<30 vs. >30 h) 0.096 0.269 0.893
Pneumonia (primary pulmonary ARDS) 0.001 0.047 0.002
Sepsis 0.123 0.085 0.965
Under immunosuppression 0.135 0.135 0.743
Fig. 5 PaO2/FIO2 changes from baseline in the group of patients
with an initial PaO2/FIO2 ratio less than and greater than 65 (dotted
lines) in the surfactant group (group 1) and controls group (group 2)
Fig. 6 PaO2/FIO2 changes from baseline in the group of patients
with (dotted lines) and without pneumonia in the surfactant group
(group 1) and controls (group 2)
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ARDS could be an important therapeutic tool [19, 23,
26]. As early as 1989 it was hypothesized that surfactant
could be of therapeutic value not only in premature in-
fant’s respiratory distress syndrome but also in ARDS
[24]. In that year the first case report of a successfully
surfactant-treated child with severe hypoxemic ARDS
was published [27]. Surfactant therapy in preterm infants
is now based on sound data (e.g., [28, 29, 30]). In respi-
ratory failure of term infants, in some ways resembling
ARDS, a randomized study demonstrated a significant
reduction in the need for ECMO [31]. Several uncon-
trolled studies have been published on adult ARDS [32,
33]; a large controlled study using small doses of aero-
solized synthetic surfactant found no advantage of sur-
factant [33], and a smaller administering a bolus reported
improved oxygenation and slightly increased survival in
the treatment group [34]. In the pediatric population sur-
factant has been used in several case reports and in small
uncontrolled studies of near fatal ARDS [17, 19, 24, 35].
In mild to moderate ARDS (Hallman oxygenation index
less than 10) a randomized study demonstrated improved
oxygenation immediately after surfactant administration
and most ventilation-associated parameters [36]. In pa-
tients with severe hypoxemia we observed a short period
of improved oxygenation, as in the study by Willson et
al. [36] in patients with less severe hypoxemia.
The originally planned number of patients, however,
could not be recruited in the time period scheduled. This
might be due to the fact that the overall incidence of
ARDS in children decreased dramatically in central Eu-
rope during the study period [13, 37]. The study was
stopped as the recruitment dropped in this obviously
high mortality group. As a sequential analysis of the pri-
mary endpoint (normalized Z statistics) demonstrated,
the study was not stopped at a point at which there was a
significant difference in respect of the primary outcome
criteria; this would have been true at an earlier time
point.
The overall mortality rate in this study is comparable
to that of other studies carried out in severe hypoxemic
pediatric ARDS [4, 5, 13]. The trend towards a de-
creased mortality and need for rescue medication in such
a high mortality population might nevertheless be impor-
tant as no other evidence-based treatment option exists.
Surfactant may be only one factor in improving oxygen-
ation in severe ARDS; it enhances the benefits of the
“open lung concept,” prone positioning, and NO-induced
pulmonary vasodilatation [25, 38, 39]. The improvement
in oxygenation in the control group, which was managed
only on a strictly enforced ventilation algorithm and
blood pressure and fluid intake protocol, suggests that
standardized treatment alone using conventional meth-
ods leads to an overall improvement in patient outcome.
This is in line with similar findings by Steinhard et al.
[12] who reported improved patient outcome simply by
introducing enforced ventilatory management protocols.
Surfactant might also be directly involved in improving
the balance of pro- and anti-inflammatory mediators in
ARDS and therefore be a causative approach [39, 40,
41]. The design of modified surfactant solutions being
more prone against inactivation by different proteins in
the course of ARDS could enhance and prolong the 
effect of surfactant on oxygenation [42].
As patients without pneumonia showed a significant
improvement and patients weighing more than 12 kg had
a benefit from surfactant, it can be speculated that these
small infants, in whom pneumonia is the principal cause
of ARDS, would require much higher surfactant doses.
This would be in accordance with experimental results in
which in pneumonia surfactant inactivation was in-
creased, compared with other causes of ARDS [38].
Higher doses of the surfactant preparation used cannot
be applied as they would obstruct the major airways. A
second dose showed no benefit in our study, either in the
data analysis of primary and secondary endpoint criteria
or in the post hoc analysis of subgroups. If at all, higher
initial doses in selected patients could be considered if a
preparation were available with lower volume, lower vis-
cosity, and perhaps more prone to inactivation. Surfac-
tant treatment with a listed price of � 200–400/100 mg is
still very expensive.
Conclusions
This study reveals the difficulty in obtaining conclusive
results from randomized studies in an intensive care set-
ting and patients with a high mortality. Many “intended
to treat” patients could not be randomized as they had
underlying lung or heart disease, were dying at arrival in
the ICU, or had been ventilated for more than 5 days in
regional hospitals. An additional difficulty for such a
study is the decreasing incidence of ARDS in children.
Our study confirmed results of a previous randomized
study by Willson et al. [38] reporting improved oxygen-
ation in pediatric patients with mild to moderate ARDS.
The improvement in oxygenation was sustained for pa-
tients without pneumonia as underlying disease and with
a PaO2/FIO2 ratio greater than 65. The latter subgroup
does not seem to benefit from any other available rescue
tool at this moment. Ventilation variables could be re-
duced in the surfactant group. The devastating conse-
quences of aggressive ventilation in these children with
severe ARDS can probably be ameliorated with surfac-
tant treatment. We conclude that surfactant treatment in
severe pediatric ARDS might offer benefits to the pa-
tients.
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Abstract
Pulmonary surfactant given to infants and adults with respiratory failure is metabolized and recycled to a large
extent. A small proportion also enters the circulation in cases of increased permeability of the alveolar-capillary
membrane. We therefore investigated whether exogenous surfactants such as a natural bovine (natSF) or a synthetic
(synSF) preparation had an impact on inflammatory conditions involving the adhesion of neutrophils to endothelial
cells. Human umbilical cord vein endothelial cells (HUVEC) were plated on coverslips until confluence, activated by
tumor necrosis factor-alpha and incubated with or without surfactant in the media. Human neutrophils passed the
HUVEC layer in a flow chamber and interactions were visualized using a video microscope. To test if surfactant
affected the expression of cell adhesion molecules, RT-PCR analyses were performed for E-selectin, vascular cell
adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1). Using concentrations between 50
and 300 mg/ml of surfactant in the pre-incubation media the number of adherent neutrophils increased by 10–20% at
the higher concentration of the natSF (�Po 0:05) whereas the synSF had no effect. Increased neutrophil adhesion was
associated with a significant up-regulation of mRNA levels for E-selectin and VCAM-1; mRNA levels for ICAM-1,
however, were not affected by the presence of surfactant. These observations indicate that natSF but not synSF might
have pro-inflammatory effects when higher amounts of the exogenous dose reach the circulation. This might be
explained by different fatty acid profiles, e.g. the presence of arachidonic acid in the natSF or higher concentrations of
surfactant-associated protein-C in the synSF.
Keywords: Surfactant; Neutrophil; Adhesion
Abbreviations: dNTP, desoxynucleotide triphosphate; DTT, dithiothreitol; FAME, fatty acid methyl ester; GAP-DH, glyceraldehyde 3-phosphate
dehydrogenase; HUVEC, human umbilical cord vein endothelial cells; ICAM-1, intercellular adhesion molecule 1; natSF, natural surfactant; NF-kB,
nuclear factor kappa B; RDS, respiratory distress syndrome; SP, surfactant-associated proteins; synSF, synthetic surfactant; TNF-a, tumor necrosis
factor-alpha; VCAM-1, vascular cell adhesion molecule 1.
�Corresponding author. Center of Pediatrics, Feulgenstrasse 12, D-35392 Giessen, Germany. Tel.: +49-641-9939044; fax: +49-641-9939049.
E-mail address: silvia.rudloff@ernaehrung.uni-giessen.de (S. Rudloff).
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Introduction
Surfactants are routinely used to treat preterm infants
with respiratory distress syndrome (RDS), and are being
evaluated for the treatment of infants and adults with
acute respiratory distress syndrome (ARDS) (Jobe,
1993; Ware and Matthay, 2000). ARDS is characterized
by an impaired pulmonary gas exchange secondary to
atelectasis and disruption of the alveolar-capillary
membrane. In consequence, small amounts of exogen-
ous pulmonary surfactant may directly enter the
circulation (Hallman et al., 1994; Lachmann et al.,
1987). There is emerging evidence that natural and
synthetic surfactant preparations exert different effects
on immunological reactions such as the accumulation of
neutrophils in the lung alveoli (Kukkonen et al., 2000;
Speer and Groneck, 1998; Tegtmeyer et al., 1996).
Surfactant consists of a mixture of phospholipids, the
composition of which differs depending on its origin.
For example, fatty acid composition in natural surfac-
tant derived from bovine or porcine lung is more
heterogeneous than in synthetic preparations also
containing long chain omega-6 and omega-3 fatty acids.
It has also been shown that the presence of certain
surfactant-associated proteins (SP) especially SP-A has
immune modulating properties (Kramer et al., 2001;
LeVine et al., 1999; Rosseau et al., 1999). However, in
surfactant preparations for therapeutic use, SP-B and
SP-C, but not SP-A, are present in natural surfactants of
bovine or porcine origin, and their recombinant variants
in synthetic products. These natural surfactants but also
some protein-free synthetic surfactants have recently
been shown to inhibit intracellular signaling events in
leukocytes. As a consequence, they decrease the risk of
tissue destruction and chronic inflammation (Brenner et
al., 2000). However, other groups reported SP-B to
enhance the induction of immunoglobulin M immune
responses (Van Iwaarden et al., 2001). Most recently,
Augusto et al. (2003) observed that SP-C used CD14 on
macrophages as immunological targets.
Endothelial immune responses are triggered by
activation via cytokines leading to an increased expres-
sion of cell adhesion molecules such as selectins,
intercellular adhesion molecule 1 (ICAM-1) and vascu-
lar cell adhesion molecule 1 (VCAM-1) on the cell
surface. Interactions of these molecules with their
counterpart ligands on leukocytes mediates adhesion
and extravasation at the site of inflammation (Vestweber
and Blanks, 1999). These reactions are also major
contributors to the development of chronic lung disease
(Mulligan et al., 1991; Sarafidis et al., 2001).
We therefore investigated whether natural or syn-
thetic surfactant administered to patients with acute
lung injury has a direct effect on neutrophil adhesion to
tumor necrosis factor-alpha (TNF-a) activated and non-
activated endothelial cells. These experiments were
performed under flow conditions thus mimicking the
dynamic behavior of neutrophils on stimulated en-
dothelium. Furthermore, the influence of endothelial
cells with regard to the expression of adhesion molecules
was also included.
Methods
Surfactant preparations
In the present study, two surfactant preparations were
used one of which was a commercially available
phospholipid preparation from bovine lung (natSF)
purchased from Boehringer (Ingelheim, Germany). The
second surfactant was a synthetic product (synSF)
provided by Altana Pharma (Konstanz, Germany)
which has not been released for therapeutic use in
RDS yet. The protein fraction of natSF consisted of SP-
B and SP-C in a proportion of about 1% each (related
to dry weight). In synSF, however, recombinant SP-C
(2% of the dry weight) represents the only constituent of
the protein fraction. The lipid portion of the two
surfactants was individually analyzed as described in
the following section.
Determination of free and phospholipid-bound fatty
acids
Lipids were extracted using methanol/chloroform
according to the method of Bligh and Dyer (1959). Free
fatty acids were converted to fatty acid methyl ester
(FAME) using diazomethane and purified by means of
silica thin layer chromatography with toluol as devel-
oping solvent. FAMEs were identified using primuline
(Wright, 1971) and extracted using chloroform. Phos-
pholipids were separated from neutral lipids by thin
layer chromatography with chloroform/methanol/water
(65/25/4 v/v/v) as mobile phase and isolated with
chloroform/methanol (2/1 v/v). Phospholipid-bound
fatty esters were converted to FAME using 2mol/l
HCl/methanol and subjected to gas chromatography as
previously described (Schmidt et al., 2001). Briefly, gas
chromatographic separation was performed using a
silica capillary column (CP-Sil 88, 50mm� 0.25mm,
Chrompack, Frankfurt, Germany), with the detector
(FID) at 300 1C and hydrogen as carrier gas (flow rate
1.0ml/min). A linear gradient was used from 120 to
220 1C at 3 1C/min and 5min at 220 1C. FAMEs were
identified by comparison with the retention times of
commercial standards (Sigma, Deisenhofen, Germany).
The resulting peak areas were corrected against blanks
by means of the internal standard and treated with
empirically determined mass/response factors.
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Neutrophil isolation
Human neutrophils were isolated from 50ml hepar-
inized peripheral blood by agglutinating erythrocytes
using dextran (Sigma, St. Louis, USA) for 30min,
followed by density gradient centrifugation on a Ficoll
gradient. Neutrophils were treated with ammonium
chloride to remove remaining erythrocytes, washed
twice in PBS and suspended in RPMI medium
(Biochrom KG, Berlin, Germany) supplemented with
10% fetal calf serum (Gibco BRL, Karlsruhe, Germany)
and 1/100 (v/v) penicillin/streptomycin (Gibco BRL,
Karlsruhe, Germany). Cells were tested for purity
(above 90%) and viability (above 95% throughout the
study) by flow cytometry and trypan blue staining,
respectively.
Preparation of endothelial cells
Endothelial cells were obtained from human umbilical
veins according to a method described by Jaffe et al.
(1973). Human umbilical cord vein endothelial cells
(HUVEC) were used for further experiments after the
first passage when they had reached confluence on
fibronectin (Biochrom KG, Berlin, Germany) coated
coverslips. The purity and the characteristics of the
endothelial cell populations were determined by indirect
immunofluorescence using a monoclonal antibody for
van Willebrand factor (DAKO Diagnostica GmbH,
Hamburg, Germany).
Neutrophil adhesion assay
Neutrophil adhesion was determined as described
recently (Kru¨ll et al., 1999; Mayer et al., 2002).
Confluent HUVEC monolayers were stimulated with
10 ng TNF-a (RandD Systems, Minneapolis, MN,
USA) per milliliter of cell culture media for 4 h prior
to the experiments. One hour prior to the flow
experiment, HUVEC were incubated with the surfactant
preparations. It was assumed that secondary to a
severely disturbed integrity of the alveolar-capillary
membranes up to 10% or more of the surfactant applied
exogenously (100mg/kg body weight) may enter the
circulation (N. Lachmann, pers. comm.). Thus, concen-
trations of 50–300 mg surfactant per milliliter of media
were used to incubate the HUVEC layer prior to contact
with neutrophils.
HUVEC-coated coverslips were then set into a
parallel plate flow chamber (Keutz, Reiskirchen, Ger-
many). Neutrophils (2� 106 cells in 0.5ml) were allowed
to pass the HUVEC layer at a flow rate of 6.7ml/h
revealing a shear force of 1 dyne/cm2. Experiments were
evaluated using a phase contrast microscope (Type
DMJL from Leica, Wetzlar, Germany) and videotaped
over the entire time of neutrophil perfusion. After all
neutrophils had passed the flow chamber, cell adhesion
was determined by counting the number of adherent
neutrophils at eight randomized areas of the coverslip
(Mayer et al., 2002).
Expression of cell adhesion molecules
RNA from HUVEC was extracted by a guanidinium
thiocyanate method according to the method described
by Chomczynski and Sacchi (1987) with slight modifica-
tions followed by first-strand cDNA synthesis. For each
sample, 5 mg RNA was added to first-strand buffer
(50mmol/l Tris–HCl, 75mmol/l potassium chloride,
3mmol/l magnesium chloride, 20mmol/l dithiothreitol
(DTT)), 0.5mmol/l of each desoxynucleotide triphos-
phate (dNTP), 20U RNaseOUTTM ribonuclease inhi-
bitor, 100 ng oligo(dT)15-primer (MBI Fermentas, St.
Leon-Roth, Germany) and 200U SuperScript II RNase
H� Reverse Transcriptase (Invitrogen, Karlsruhe, Ger-
many). First-strand cDNA synthesis was carried out in a
total volume of 20 ml at 42 1C for 1 h and was inactivated
by heating at 70 1C for 15min.
PCR amplification of sequence specific fragments was
carried out with those amounts of cDNA derived from
the linear range of amplification in Taq buffer (20mmol/
l Tris–HCl, 50mmol/l potassium chloride), 1.5mmol/l
magnesium chloride, 0.2mmol/l of each dNTP,
7.5 mmol/l of each primer (see Table 1) and 0.4U Taq
DNA polymerase (Promega, Mannheim, Germany) in a
total volume of 50 ml. PCR was performed with cycle
conditions of 94 1C for 4min followed by 30 cycles of
denaturing at 94 1C for 45 s, annealing at 55 1C for 45 s,
primer extensions at 72 1C for 45 s and end synthesis at
72 1C for 10min. RT-PCR products were separated on a
2% agarose gel and visualized by ethidium bromide. A
yX174 DNA/HaeIII marker was used in all PCR
experiments as a size control of the amplified products.
No products were obtained for any genes without
reverse transcription indicating the specificity of mRNA
determination.
The amplified products were photographed, and the
intensity of the bands was analyzed by densitometry
(SigmaGel software). The area under the curve (AUC)
for E-selectin, ICAM-1 and VCAM-1 was set against
that for the standard gene glyceraldehyde 3-phosphate
dehydrogenase (GAP-DH).
Statistics
The effects of the different surfactant preparations
were determined by comparing the numbers of neutro-
phils that adhered to stimulated HUVEC with and
without surfactant incubation. The effects on cell
adhesion are given as mean7SD of at least three
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independent sets of experiments with five-fold determi-
nations for each surfactant preparation and concentra-
tion tested. For the effects on the molecular basis, at
least three independent experiments were carried out for
each type of cell adhesion molecule. Data are given as
mean7SD. For all experiments the results for the
treatment of TNF-a-activated HUVEC was set to 100%
in order to compare data within different experimental
days. The results were compared using Student’s t-test
for the evaluation of different treatments. Effects were
considered to be significant at �Po 0:05; ��Po 0:01 and
���Po 0:005:
Results
The composition of the surfactant preparations
investigated in the present study differed with regard
to lipids and proteins. The lipid fraction of both
surfactant preparations mostly consisted of dipalmitoyl-
phosphatidylcholine. NatSF and synSF contained
2.170.2% and 2.670.2% total free fatty acids (in
percent of total lipids, w/w), respectively. The pool of
free fatty acids in synSF consisted of palmitic and oleic
acid only, whereas the natSF contained a variety of fatty
acids including the omega-6-fatty acids linoleic and
arachidonic acid in relative amounts of 4.2% and 1.9%,
respectively (Fig. 1). Phospholipid fatty acids of synSF
also consisted exclusively of palmitic and oleic acid. The
main fatty acids of natSF were palmitic acid
(41.971.9% of all phospholipid fatty acids), oleic acid
(35.470.6%) and stearic acid (10.371.0%). The ome-
ga-6-fatty acids linoleic acid and arachidonic acid had a
relative distribution of 2.970.5% and 1.270.0%,
respectively (Fig. 1).
Endothelial cells were activated using TNF-a which
revealed a significant increase in the number of adherent
neutrophils to about 200–300 cells per high magnifica-
tion field compared to 20–30 cells per field on resting, i.e.
non-activated HUVEC (Fig. 2A and B). The incubation
Table 1. Primer specifications for the housekeeping gene GAP-DH and cell adhesion molecules
Name Position Size Orientation Sequence (50-30)
GAP-DH 558–1010 452 bp Sense GACCACAGTCCATGCCATCACT
Antisense TCCACCACCCTGTTGCTGTAG
ICAM-1 849–1087 237 bp Sense TATGGCAACGACTCCTTCT
Antisense CATTCAGCGTCACCTTGG
VCAM-1 — 513 bp — a
E-selectin — 485 bp — a
aSequence not published (primers were purchased from R&D Systems, Minneapolis, MN, USA).
Fig. 1. Gas chromatographic analyses of surfactant fatty acid
profiles: (A) natSF free fatty acids; (B) synSF free fatty acids
and (C) natSF phospholipid-bound fatty acids. Definitions of
abbreviations: 14:0=myristic acid; 16:0=palmitic acid;
18:0=stearic acid; 16:1=palmitoleic acid; 18:1=oleic acid;
18:2=linoleic acid; 18:3=linolenic acid; 20:3(6)=eicosatrie-
noic acid; 20:4=arachidonic acid; 20:5=eicosapentaenoic
acid, 22:6=docosahexaenoic acid; IST=internal standard.
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with 50 and 100 mg/ml natSF did not further increase
neutrophil adhesion. However, a concentration of 200
and 300 mg/ml natSF resulted in a significant enhance-
ment of neutrophil adhesion (�Po 0:05) by 20.070.5%
and 12.172.5%, respectively (Figs. 2C and 3). SynSF
had an only minor effect on neutrophil adhesion by
slightly reducing the number of adherent cells by
3.573.7% (Po 0:25; Fig. 3).
To test whether surfactant had a direct effect on
endothelial cells, mRNA levels of the most important
cell adhesion molecules E-selectin, VCAM-1 and
ICAM-1 were determined using semiquantitative RT-
PCR. Non-activated HUVEC expressed low mRNA
levels for ICAM-1, VCAM-1 and E-selectin with
5.171.8, 6.771.7 and 5.173.6% of the positive control,
respectively (Fig. 4, insert nc). After cytokine stimula-
tion, mRNA levels of all three cell adhesion molecules
increased significantly compared to non-stimulated
HUVEC. These values were subsequently used as
positive controls (Fig. 4, insert pc). No further effect
on gene expression was observed when only 50 and
100 mg/ml natSF were used in the pre-incubation media.
However, after additions of 200 and 300 mg/ml natSF,
VCAM-1 (118.973.9% and 122.775.1%, respectively)
and E-selectin mRNA levels (123.078.9% and
116.576.1%, respectively) increased significantly com-
pared to the positive control (Fig. 4D and F); only
ICAM-1 mRNA levels remained in the range observed
for the positive control (Fig. 4B). Incubating HUVEC
with the same concentration of synSF revealed the
Fig. 2. High magnification field (� 20) from videotape showing adherent neutrophils (light colored) on a HUVEC monolayer. A
total of 4� 106 neutrophils was injected into the flow system. (A) Control experiment using non-stimulated HUVEC. (B) HUVEC
were incubated with hrTNF-a (10 ng/ml) for 4 h prior to the flow experiment. (C) HUVEC were pre-incubated with, e.g. 200 mg/ml
surfactant for 1 h prior to the flow experiment.
Fig. 3. Effects of surfactant on neutrophil adhesion to TNF-a-stimulated cells: (A) synSF and (B) natSF. HUVEC were stimulated
with 10 ng/ml TNF-a for 4 h and co-incubated for 1 h prior to the flow experiment with 50–300 mg/ml of surfactant or unstimulated
(negative control, nc). Cell adhesion was determined by an analysis of eight random high magnification fields (� 20) from videotape.
Adhesion of neutrophils to TNF-a-activated HUVEC was set at 100% for each experiment (positive control, pc). Values given are
means7SD of three independent experiments each including 4–6 replications (�Po 0:05 and ���Po 0:005).
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opposite effect. A significant decrease of the mRNA
levels for VCAM-1 (90.372.3% and 85.774.3%
of the positive control, respectively) and E-selectin
(85.375.6% and 81.476.7%) was found compared to
the control (Fig. 4C and E) at 200 and 300 mg/ml
whereas at 50 and 100 mg/ml natSF, the expression levels
remained unchanged. Similar to natSF, synSF had no
influence on ICAM-1 mRNA levels and stayed in the
same range as the positive control (Fig. 4A).
The observed effects of synSF and natSF on
neutrophil adhesion and mRNA levels seemed to be
dependent on TNF-a stimulation because in both cases
the application of surfactant alone (300 mg/ml) failed to
affect neutrophil adhesion to endothelial cells (Fig. 5)
and mRNA expression levels of adhesion molecules in
unstimulated HUVEC (Fig. 6).
Discussion
Both, synthetic and natural surfactants have been well
documented to improve oxygenation in preterm infants
with RDS and experimental models of acute lung injury
(Spragg et al., 2000). Despite this treatment, a significant
number of non-responders to surfactant treatment is
explained by an influx of inflammatory cells into the
alveolar space due to an increased permeability of the
alveolar-capillary membrane (Ware and Matthay, 2000).
Fig. 4. Effect of natSF and synSF on TNF-a-stimulated expression of ICAM-1, VCAM-1 and E-selectin mRNA in HUVEC by
semiquantitative RT-PCR. HUVEC were pre-incubated with (positive control, pc) or without (negative control, nc) TNF-a (10 ng/
ml) for 4 h and co-incubated with the indicated concentrations of natSF and synSF for 1 h. RNA was extracted, reverse transcribed
and amplified by PCR using specific primers for GAP-DH (as a constitutively expressed standard gene), VCAM-1, ICAM-1 and E-
selectin. (Upper panel) Photographs of the UV-illuminated gel electrophoresis of amplified cDNA products from a representative
experiment. (Lower panel, A–F) Ratio of target gene to standard gene in treated cells. (Inserts) Ratio of target gene to standard gene
in controls (n ¼ 3; �Po 0:05 and ���Po 0:005).
Fig. 5. Effects of surfactant on neutrophil adhesion to
unstimulated cells. HUVEC were incubated for 1 h with
300 mg/ml surfactant prior to the flow experiment. Cell
adhesion was determined by an analysis of eight random high
magnification fields (� 20) from videotape. Adhesion of
neutrophils to TNF-a-activated HUVEC (pc) was set at
100% for each experiment. Values given are means7SD of
three independent experiments each including 4–6 replications
(���Po 0:005).
Fig. 6. Effect of natSF and synSF on the expression of ICAM-1, VCAM-1 and E-selectin mRNA in unstimulated HUVEC by
semiquantitative RT-PCR. HUVEC were incubated with 300 mg/ml natSF or synSF, whereas the negative control was only
supplemented with media and the positive control was activated by hrTNF-a (10 ng/ml). RNA was extracted, reverse transcribed
and amplified by PCR using specific primers for GAP-DH (as a constitutively expressed standard gene), VCAM-1, ICAM-1 and E-
selectin. Ratio of target gene to standard gene in controls and treated cells for (A) VCAM-1, (B) E-selectin and (C) ICAM-1 (n ¼ 3;
���Po 0:005). (Inserts) Photographs of the UV-illuminated gel electrophoresis of amplified cDNA products from a representative
experiment.
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Therefore, surfactants might influence different pro-
cesses with both positive as well as potentially negative
effects. Recent observations indicate that surfactants do
have an impact on cell–cell interactions or cell signaling
events (Vestweber and Blanks, 1999). We therefore
addressed the questions whether natural and synthetic
preparations have an influence (a) on the adhesion of
neutrophils to unstimulated and TNF-a-stimulated
endothelial cells, and (b) on the endothelial cells
themselves affecting the expression of various cell
adhesion molecules. In addition, the different fatty acid
compositions of natSF and synSF, e.g. palmitic and
oleic acid, or the presence of omega-3 (e.g. eicosapen-
taenoic acid and docosahexaenoic acid) and omega-6
fatty acids (e.g. linoleic acid and arachidonic acid) were
investigated since they may be involved in regulating
various transcription pathways.
Inflammatory processes in general are mediated by
leukocyte–endothelial cell interactions. An increased
neutrophil transmigration, however, is associated with
tissue damage and the development of chronic inflam-
mation.
The contribution of surfactant constituents (phos-
pholipids, free fatty acids and SP) with immune
modulating properties within the inflamed lung tissue
is not well understood. We therefore proposed that up
to 10% or more of the exogenously applied surfactant
dose (100mg/kg body weight) may enter the blood
circulation when the permeability is increased due to
edema associated with acute respiratory failure (Lach-
mann et al., 1987). In order to mimic the conditions of
leukocytes in the systemic blood circulation we used a
flow model where shear stress forces were set accord-
ingly. Under these conditions, a pre-incubation of TNF-
a-activated endothelial cells with natSF at concentra-
tions of 200 and 300 mg/ml lead to an increase in the
number of adherent neutrophils of about 12–20%
compared to the positive controls where HUVEC were
exposed to TNF-a only. The same concentrations of
synSF had a slightly reducing, but non-significant effect
on cell adhesion, lower concentrations had no impact.
Reports from other groups with respect to immune
modulating effects of a natural surfactant on human
monocytes may seem contradictory (Pinot et al., 2000;
Walti et al., 1997). However, both groups used a porcine
surfactant which might differ from the preparations
used in our study regarding its composition and the
concentrations they had applied. Furthermore, the
effects they had observed were limited to monocytes.
Van Iwaarden et al. (2001) showed that the administra-
tion of SP-B in combination with surfactant lipids
enhanced the immune responses in sera of mice whereas
SP-C had no effect. This is in accordance with our
findings for the synSF containing only SP-C as no
increase in neutrophil adhesion was observed. In
addition, it has been shown recently that SP-C itself
had an effect on the immune response, not by enhancing
leukocyte infiltration but through their affinity toward
bacterial endotoxins (Augusto et al., 2003).
A second set of experiments addressed the question
whether surfactant directly caused a stimulation of the
expression of cell adhesion molecules in endothelial
cells. In the present study, the addition of TNF-a to
human HUVEC led to an increased mRNA expression
for E-selectin, VCAM-1 and ICAM-1.
The application of natSF not only caused a rise in the
number of adherent neutrophils but also markedly
enhanced TNF-a-induced VCAM-1 mRNA and E-
selectin mRNA expression in a dose-dependent manner.
However, it needs to be emphasized that an effect was
only observed at high concentrations of natSF, i.e., 200
and 300 mg/ml whereas the lower concentrations had no
impact. The synSF preparation, on the other hand,
selectively decreased E-selectin and VCAM-1 mRNA
expression which was associated with a slight but not
significant reduction of the number of adherent neu-
trophils on endothelial cells. The data presented
demonstrated that surfactant plays a particular role in
the modulation of TNF-a-stimulated neutrophil adhe-
sion and expression of adhesion molecules because it did
not have an impact on neutrophil adhesion and
expression levels when applied to unstimulated HU-
VEC. Thus, both surfactant preparations only modu-
lated the TNF-a-stimulated cell adhesion and mRNA
expression.
One can speculate that polar lipid components which
were shown to activate endothelial cells might be the
factors for the increased expression of surface adhesion
molecules (Ochi et al., 1995; Subbanagounder et al.,
2002). Both, incorporation of the phospholipids into
cellular membranes and uptake of free fatty acids in the
cell affect physicochemical properties and activities of,
e.g., enzymes and receptors (Houliston et al., 2001;
Menendez et al., 2004). Because of the existence of
multiple cellular targets for TNF-a, it is difficult to
readily decipher the mechanisms involved in neutrophil
adhesion and adhesion molecule expression. The overall
effect could be a direct action on intracellular signaling
pathways which are induced by TNF-a (e.g. activation
of transcription factors such as nuclear factor kappa B
(NF-kB)) or an effect of TNF-a itself (e.g. activation on
receptor expression). It is most likely that our findings
may be explained by the different composition of both
surfactants with regard to the fatty acid profiles. In
synSF, the predominant fatty acids are palmitic acid and
oleic acid whereas the natSF contained a mixture of
fatty acids including arachidonic acid and linoleic acid.
Although the role of fatty acids in adhesion events is
controversial our data are in accordance with recently
published reports (Hii et al., 1999; Paine et al., 2000). In
both studies, it was clearly shown that, e.g. arachidonic
acid is able to serve as an intracellular second messenger
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and to induce adhesion processes by influencing
different signal transduction cascades resulting in a
modulation of the potency of the TNF-a signal pathway
with the consequence of changeable expression levels of
adhesion molecules. Recently, Moghaddami et al. (2003)
showed that arachidonic acid stimulates the expression
of receptors for TNF in different cell lines. Thus, an
increase in TNF-receptor expression could result in a
more pronounced effect of TNF-a with the consequence
of activating signal transduction pathways and up-
regulating the expression of adhesion molecules as we
have observed. In contrast to natSF, synSF selectively
attenuated TNF-a-stimulated VCAM-1 and E-selectin
expression and adhesion of neutrophils to HUVEC.
This effect could be explained by the fatty acid profile,
i.e. palmitic and oleic acid, the predominant fatty acids
in synSF. Oleate is known to decrease the adhesion of
monocytes to endothelial cells and is accompanied by a
decreased expression of adhesion molecules like VCAM-
1 and E-selectin (Carluccio et al., 1999; De Caterina and
Libby, 1996). A possible explanation of the pre-
translational effect of oleate to decrease adhesion
molecule expression could be the extent of NF-kB
activation after endothelial cell stimulation.
Interestingly, the incubation of HUVEC with natSF
or synSF had an impact on E-selectin and VCAM-1
expression, but no effect on the mRNA expression for
ICAM-1. An explanation might be that the VCAM-1
promoter consists of two NF-kB binding sites, whereas
that for E-selectin has three sites and that for ICAM-1
just one (Collins, 1993; Van de Stolpe and Van der Saag,
1996). Thus, distinct pathways may regulate the expres-
sion of these proteins and surfactant may affect only the
signaling pathways involved in VCAM-1 and E-selectin
regulation.
In conclusion, although the concentration of free fatty
acids (e.g. arachidonic acid) in the natSF was found to
be in a physiological range it may be high enough to
induce acute changes with regard to leukocyte–endothe-
lial cell interactions. It is further notable that natural
surfactants in general are not standardized with the
consequence that the concentrations of fatty acids and
other constituents may vary within batches. Therefore,
the effects seen in vitro should be further investigated
and may be taken into consideration when high risk
patients with apparent inflammatory symptoms are to
be treated with surfactant.
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Abstract Objective: Meconium as-
piration syndrome remains a relevant
cause of neonatal respiratory failure
and is associated with severe pulmo-
nary changes including surfactant in-
activation and pronounced inflam-
matory changes. The present study
investigated the effect of two differ-
ent surfactant preparations—recom-
binant surfactant protein C surfactant
(rSP-C Surf) and natural bovine sur-
factant—on pulmonary gas exchange
and inflammatory response. Design
and subjects: Twenty-three newborn
piglets were intubated, mechanically
ventilated, received 5 ml/kg 20%
sterile meconium for induction of
lung injury, and were randomized
thereafter for controls (n=7), rSP-C
Surf (n=8), or natural surfactant
(n=8). Surfactants were given as an
intratracheal bolus (75 mg/kg) and
animals were further ventilated.
Measurements and results: Lung
function variables, arterial blood gas
samples and lung tissues were ob-
tained. Histological evaluation was
performed in right lung tissue using
an established score. Cytokine
mRNA expression (left lung tissue)
was quantified using TaqMan real-
time PCR (∆∆CT method, normal-
ized to controls). In addition to sig-
nificant improvement in gas ex-
change and lung function, histologi-
cal evaluation showed significantly
lower sum scores in the rSP-C Surf
group than in controls). Cytokine
mRNA expression of IL-1β in whole
lung tissue was significantly lower
after administration of rSP-C Surf
than in natural surfactant and con-
trols whereas IL-10 mRNA expres-
sion was significantly induced in
both surfactant groups. Conclusions:
Surfactant administration improved
both gas exchange and pulmonary
inflammatory cytokine transcription.
Mechanisms underlying the differen-
tial inflammatory response in both
surfactant preparations need to be
further addressed.
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Introduction
Meconium aspiration syndrome (MAS) remains a rele-
vant cause of respiratory failure in term neonates, and
despite intensive perinatal treatment it is still associated
with high neonatal mortality and morbidity [1]. MAS-in-
duced pulmonary changes include typical histological
characteristics [2], inflammatory cell infiltration with re-
lease of vasoactive substances [3], airway obstruction,
and surfactant dysfunction and inactivation [4, 5]. Exper-
imental models of MAS have therefore been established
for studying the pathogenesis of respiratory failure in ne-
onates. A number of studies have been performed ad-
dressing the pulmonary response to surfactant in MAS
[6, 7]; however, results still remain controversial [8].
Type, dosage, and mode of surfactant administration are
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under investigation. Meconium constituents such as
lysophosphatidylcholine, bilirubin, bile salts, and proin-
flammatory agents and the presence of hemoglobin in
the lung are able to disrupt the surfactant monolayer for-
mation and stabilization thus interfering with surface
tension-lowering properties i.e., surfactant inactivation.
Therefore the need for repetitive administration of natu-
ral surfactant to overcome its inactivation has been re-
ported [9, 10], whereas recent studies revealed serious
precautions against the lavage technique [11].
In addition to the improvement in MAS-induced air-
way obstruction and atelectasis following exogenous sur-
factant, its potential in influencing the pulmonary in-
flammatory response is discussed. As increased levels of
tumor necrosis factor (TNF) α, interleukin (IL) 1β, 6,
and 8, and low levels of IL-10 are known to be present in
lung tissue after meconium aspiration [12, 13], and in
vitro studies demonstrating an altered inflammatory re-
sponse of polymorph nuclear leukocytes following sur-
factant incubation [14] seem to be of great potential.
Therefore the objective of the present study was to
evaluate the effect of bolus administration of two differ-
ent surfactant preparations-a natural bovine surfactant
containing surfactant protein B (SP-B) and surfactant
protein C (SP-C) and a synthetic surfactant containing
recombinant SP-C (rSP-C Surf) on (a) variables of lung
function and gas exchange, (b) lung histology, and (c) in-
flammatory cytokine transcription in a piglet model of
MAS.
Materials and Methods
Animals
Twenty-three newborn piglets of either sex and a median age of
6 days (range 1–11) and a median weight of 2200 g (range
1900–2500) were studied. Animal experiments were approved by
the State Ethics Committee for Animal Eexperiments of the state
of Hesse, Germany, and performed according to the Guidelines for
the Care and Use of Laboratory Animals of the National Institutes
of Health.
Protocol
Intravenous anesthesia was induced with ketamine (2 mg/kg body
weight, b.w.; Inresa, Freiburg, Germany) and midazolam
(0.2 mg/kg b.w., Roche, Grenzach-Wyhlen, Germany) after an in-
tramuscular bolus of 50 mg/kg b.w. ketamine. Following relax-
ation with vercuronium (0.2 mg/kg b.w.; Inresa), the piglets were
intubated with a cuffed endotracheal tube (3.0 mm outer diameter;
Rüsch, Kernen-Rommelshausen, Germany). Continuous infusion
with midazolam (1 mg/kg b.w. per hour), ketamine (2 mg/kg b.w.
per hour), and vecuronium (0.6 mg/kg b.w. per hour) provided se-
dation, analgesia and muscular relaxation. Ringer’s solution was
given intravenously at a rate of 5 ml/kg b.w. per hour. Animals
were ventilated using a pressure controlled mode (Servo 900, Sie-
mens, Germany), with a positive inspiratory pressure (PIP) of
15 cmH2O, a positive endexpiratory pressure (PEEP) of 2 cmH2O,
and a respiratory rate of 30 cycles/min (rate of inspiration to expi-
ration 30:70) at 100% oxygen (FIO2 1.0). Under these conditions
normocapnia was observed. Body temperature was maintained in
an art-specific range (38°–39°C) with radiant warmers and heating
pads. An arterial catheter (20 G; Arrow, Erding, Germany) was
placed into the right common carotid artery and a central venous
line (4.0 F; Arrow) in the right femoral vein. Arterial blood gases
(paO2, paCO2, and pH; ABL Radiometer 555, Diamond Diagnos-
tics, Mass., USA), heart rate, blood pressure, central venous pres-
sure, and electrocardiography (78354A Hewlett-Packard) were
monitored before and during induction of lung injury, immediately
before treatment and every 30 min thereafter. Tidal volumes were
detected by pneumotachograph (CO2SMO plus 8100, Novametrix
Medical Systems, USA) at the end of the endotracheal tube and
ventilation efficiency index (VEI) was further calculated as:
3,800/(δP×δR×PaCO2) [15]. After a stabilization period of 30 min
ventilation pressures were increased (PIP 25 cmH2O, PEEP
4 cmH2O) and remained unchanged during the residual ventilation
period. Lung injury was induced in all animals by a bolus admin-
istration of 5 ml/kg b.w. of 20% meconium given in aliquots of
2–4 ml via the endotracheal tube under ongoing ventilation ac-
cording to Soukka et al. [16]. Thirty minutes after induction of
lung injury piglets were prospectively randomized to one of the
following groups: group 1 (n=7) received intratracheal (i.t.) ad-
ministration of 1.5 ml/kg b.w. physiological saline (Braun, Mel-
sungen, Germany); group 2 (n=8) received 75 mg rSP-C Surf/kg
b.w. intrathecally (Altana Pharma, Constance, Germany); and
group 3 (n=8) received 75 mg bovine (SP-B and SP-C) surfac-
tant/kg b.w. intrathecally with 75 mg corresponding 1.5 ml each.
After another observation period of 330 min (360 min after induc-
tion of lung injury) piglets were killed using an overdose of potas-
sium chloride and phenobarbitone. All animals survived the whole
observation period with the exception of one control animal dying
from severe respiratory failure. Immediately after death the chest
was opened and a cannula was placed into the pulmonary artery,
and the left atrium was opened and the lung was perfused in situ
with Ringer’s lactate containing procaine (250 mg/l), eparine
(20 U/ml), and calcium chloride (2.2 mmol/l) for 10 min. PIP was
increased for 15 s to 25 cmH2O and thereafter reduced and left at
10 cmH2O. Thereafter tissue samples of the superior and inferior
lobe of the left lung were extracted and immediately snap-frozen
in liquid nitrogen for real time polymerase chain reaction (PCR)
analyses. Afterwards right lungs were perfused with 300 ml of a
formaldehyde (4.6%) and glutaraldehyde (0.5%) solution for ap-
prox. 10 min. Finally, the trachea was clamped at a PEEP of
10 cmH2O, and right lungs were removed and submersed in the
above solution for histomorphological analyses.
Preparation of pooled meconium
Meconium was collected from healthy full-term neonates with his-
tory of neither perinatal complications nor maternal drug adminis-
tration during pregnancy and delivery. Probes were tested for ste-
rility, pooled, and further lyophilized and diluted with sterile sa-
line to a 20% concentrated solution, equivalent to 65 mg/ml lyo-
philized meconium [16].
Therapeutic surfactants
Experiments were performed using a recombinant SP-C based sur-
factant (Altana) or a natural bovine surfactant. In the rSP-C Surf
phenylalanine replaces cystein in positions 4 and 5 and isoleucin
replaces methionin in position 32 within the recombinant human
34 amino acid SP-C sequence. The final surfactant contained 2%
rSP-C (wt:wt) in phospholipids (dipalmitoylphosphatidylcholine
and palmitoyloleoylphosphatidyl-glycerol at a 70:30 ratio (wt:wt),
50 mg/ml), plus 5% palmitic acid, which was added to facilitate
the preparation of this surfactant product. The rSP-C Surf surfac-
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tant was delivered as lyophilized powder and was suspended in
0.9% sterile saline (Braun) to a concentration of 50 mg/ml pho-
spholipids. The natural bovine surfactant, also provided as lyophi-
lized powder, was resuspended in sterile saline 0.9% (Braun) to a
final concentration of 50 mg/ml. Its composition has been de-
scribed previously [17].
Lung histology
Tissue slides were obtained from dependent and nondependent
parts of the right lung of each animal as described above and
stained with hematoxylin-eosin to perform histological analyses.
Lung histology was evaluated by a pathologist (M.E.), blinded to
the animal’s group assignment, according to a previously de-
scribed histological score [18]. Variables scored for histological
evaluation were atelectasis, alveolar and interstitial inflammation,
alveolar and interstitial hemorrhage, alveolar and interstitial ede-
ma, necrosis, and overdistension. The variables were scored using
a five-point scale with no injury corresponding to 0 points and 4
points indicating maximum injury.
Measurements of cytokine mRNA expression by real-time PCR
Cytokine mRNA expression of IL-1β, IL-6, IL-8, IL-10, and trans-
forming growth factor (TGF) β was measured in tissue of the left
lung lobe, obtained as described above and stored at −80°C, using
the real-time reverse-transcriptase PCR technique (TaqMan). To
normalize gene expression mRNA of the housekeeping genes β-ac-
tin (A) and hypoxanthine-guanine-phosphoribosyl-transferase (H)
was quantified. Cytokine mRNA expression was analyzed both for
whole left lung tissue and in each left lung lobe separately.
For this purpose lung-tissue was homogenized in liquid nitro-
gen and total RNA was then extracted using the acid guanidinium-
thiocyanate-phenolchloroform method (Roti Quick, Roth, Germa-
ny). The RNA concentration was measured spectrophotometrical-
ly and quality was estimated by agarose gel electrophoresis with
ethidium bromide staining; 0.5 µg RNA was reverse transcribed in
a volume of 100 µl at 42°C for 50 min after a denaturation step at
65°C with random hexamer primers and deoxyribonucleoside tri-
phosphates (all chemicals from Gibco BRL, Calif., USA).
TaqMan real-time PCR
Real-time PCR has been confirmed to be a sensitive and precise
tool for the quantification of nucleic acids and thus for gene ex-
pression studies [19]. Primers and probes for IL-1β, IL-6, IL-8,
IL-10, TGF-β, hypoxanthine phosphoribosyltransferase (HPRT)
and β-actin were designed using Primer Express software (Ap-
plied Biosystems) with reference to Hardt et al. [20] following a
fixed set of recommendations to allow the application of standard-
ized cycling conditions (2 min at 50°C, 10 min at 95°C, followed
by 45 cycles for 15 s at 95°C and 1 min at 60°C). Control PCRs
showed no signal for pure genomic DNA, confirming mRNA
specificity. Primers were purchased from Roth and probes from
Applied Biosystems. The reaction (total volume 25 µl) contained
approximately 5 ng cDNA, primers and probes in a final concen-
tration of 300 nM and 200 nM, respectively, as well as commer-
cial reagents (Universal Master Mix, Applied Biosystems). Rela-
tive quantification of gene expression was performed using the
∆∆Ct method, which results in a ratio of target gene expression to
equally expressed housekeeping genes. The ratio found in a cali-
bration sample that may be arbitrarily chosen serves as a reference
point and is set to be 1. In this study control samples were sub-
sumed for this purpose. HPRT and β-actin were chosen as house-
keeping genes. To fulfill the requirements for the ∆∆Ct method,
PCR efficiency was determined by running cDNA dilution series
(seven steps of 1:2 dilution performed in duplicate). PCR efficien-
cy varied between 95.7% (IL-6) and 105.4% (IL-10).
Primer and TaqMan probes
– Hypoxanthine-guanine-phosphoribosyl transferase:
– Forward: 5′-TGGAAAGAATGTCTTGATTGTTGAAG-3′
– Reverse: 5′-ATCTTTGGATTATGCTGCTTGACC-3′
– TaqMan probe: 5′(VIC)-ACACTGGCAAAAVAATGCAAAC-
CTTGCT-(TAMRA)3′
– β-Actin:
– Forward: 5′-TCATCACCATCGGCAACG-3′
– Reverse: 5′-TTCCTGATGTCCACGTCGC-3′
– TaqMan probe: 5′(VIC)-CCTTCCTGGGCATGGAGTCCTG-
C-(TAMRA)3′
– Interleukin 1β:
– Forward: 5′-GGTTTCTGAAGCAGCCATGG-3′
– Reverse: 5′-GATTTGCAGCTGGATGCTCC-3′
– TaqMan probe: 5′(FAM)-AAAGAGATGAAGTGCTGCACC-
CAAAACCTG-(TAMRA)3′
– Interleukin 6:
– Forward: 5′-GGGTAGGGAAGGCAGTAGCC-3′
– Reverse: 5′-GAATCCCTCTCCACAAGCG-3′
– TaqMan probe: 5′(FAM)-
CTTCAGTGGAGTCGCCTTCTCCCTAA-(TAMRA)3′
– Interleukin 8:
– Forward: 5′-TTCTGCAGCTCTCTGTGAGGC-3′
– Reverse: 5′-GGTGGAAAGGTGTGGAAGTC-3′
– TaqMan probe: 5′(FAM)-TTCTGGCAAGAGTAAGTGCAG-
AACTTCGATG-(TAMRA)3′
– Interleukin 10:
– Forward: 5′-TTGGAGCTTGCTAAAGGCACT-3′
– Reverse: 5′-CGGCGCTGTCATCAATTTCT-3′
– TaqMan probe: 5′(FAM)-CACCTCCTCCACGGCCTTGCTC-
TT-(TAMRA)3′
– Transforming growth factor β:
– Forward: 5′-TACGCCAAGGAGGTCACCC-3′
– Reverse: 5′-CAGCTCTGCCCGAGAGAGC-3′
– TaqMan probe:
5′(FAM)–CTAATGGTGGAAAGCGGCAACCAAATGTA-
(TAMRA)3′
Free fatty acid analysis of therapeutic surfactant preparations
Lipids in rSP-C Surf and natural bovine surfactant were extracted
using methanol/chloroform according to the method of Bligh and
Dyer [21]. Free fatty acids were converted to fatty acid methyl es-
ter using diazomethane and then purified by means of thin layer
chromatography (Silica 60 plates, Merck, Darmstadt, Germany),
with toluol as developing solvent. Fatty acid methyl ester was
identified using primuline [22] and subjected to gas chromatogra-
phy as previously described [23, 24].
Statistical analysis and data presentation
Histological results are given as geometric mean ±standard devia-
tion with 95% confidence intervals. Results of real-time PCR ana-
lyses are given as geometric mean and dispersion factor (lognor-
mal standard deviation). Data were normalized to the housekeep-
ing gene and further to the control values. Data analysis was per-
formed using SPSS for Windows. The t test or the Mann-Whitney
U test was used to compare two groups and analysis of variance or
the Kruskal-Wallis test to compare of more than three groups, as
appropriate. In the case of significance, Bonferroni’s and Dunn’s
posthoc tests were applied, respectively. Significance was consid-
ered with a p value less than 0.05.
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Results
Gas exchange and lung function
Prior to induction of acute respiratory failure by admin-
istration of meconium an adequate oxygenation was ob-
served in all groups. After administration of meconium
the arterial pO2, tidal volumes, and VEI were reduced
with high significance in all animals (see Table 1;
Fig. 1). After intratrached administration of either rSP-
C Surf or natural bovine surfactant (75 mg/kg b.w.) ar-
terial pO2, tidal volumes, and VEI significantly im-
proved in surfactant treated animals as compared to
controls. Initial effects were observed 30 min and maxi-
mum effects 330 min after bolus administration of rSP-
C Surf and natural bovine surfactant (p<0.0001 vs. con-
trol; Table 1).
Histology
Data from 22 piglets were available for histological eval-
uation of tissue samples from the superior and inferior
right lung lobes. Gross macroscopic examination of the
lungs revealed severe dystelectasis without differences
between left and right lungs. A differing degree of histo-
logical alterations was observed in each study group.
Sum scores, including atelectasis, alveolar and interstiti-
al inflammation, hemorrhage, edema, necrosis, and over-
distension were significantly lower in the rSP-C Surf
group (53±12; n=8) than controls (72±9; n=7; p<0.01;
Fig. 2). There also was a trend towards lower sum scores
in the natural bovine surfactant group (62±10; n=8) than
in controls.
Cytokine and growth factor expression
Lung tissue of 12 piglets (control n=3; rSP-C Surf n=5,
natural bovine surfactant n=4) was available for real
time PCR analyses; material of one piglet had to be ex-
cluded because of poor mRNA quality with degradation.
Tissue samples of the superior and inferior left lung lobe
showed significantly lower IL-1β mRNA expression in
the rSP-C Surf group than in controls [p<0.02, normal-
ized to HPRT (H) and β-actin (A)] and to natural bovine
surfactant treated animals (p<0.05, H, A; Table 2;
Fig. 3). IL-6, IL-8, and TGF-β mRNA expression tended
to be higher in natural bovine surfactant treated animals
than in rSP-C Surf and controls (Table 2). Cytokine
mRNA expression of IL-10 was significantly higher in
both surfactant groups than in controls in whole lung tis-
sue (p<0.05, H, A; Table 2; Fig. 4).
Table 1 Lung function variables in MAS before and after surfac-
tant administration
Control rSP-C Surf nat SF 
(n=6) (n=8) (n=8)
Tidal volume (min)
−30 23.4±4.2 21.5±4.8 20.8±4.9
0 13.5±4.1 13.7±4.5 12.4±8.1
30 14.9±3.02 17.98±4.7 16.3±6.8
330 13.5±1.2 22.3±3.9* 19.5±6.7*
VEI (min)
−30 1.17±0.25 1.03±0.2 1.05±0.46
0 0.55±0.17 0.46±0.2 0.46±0.29
30 0.56±0.13 0.67±0.29 0.58±0.31
330 0.44±0.08 0.89±0.15* 0.89±0.3*
Fig. 1 Levels of paO2 (kPa) before and after meconium and fol-
lowing surfactant administration (rSP-C or natural bovine surfac-
tant, nat SF) or physiological saline (controls). *p<0.02 vs. con-
trols, §p<0.05 vs. natural bovine surfactant
Fig. 2 Lung histology sum scores for alveolar and interstitial in-
flammation, alveolar and interstitial hemorrhage, atelectasis, alve-
olar edema, interstitial edema, overdistension, and necrosis in the
rSP-C Surf (75 mg/kg b.w.) and the natural surfactant group (nat
SF; 75 mg/kg b.w.) compared to controls. Data given as boxplots,
geometric mean, standard deviation, and 95% confidence interval.
*p<0.05 vs. controls
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Fig. 3 Pulmonary IL-1β
mRNA expression normalized
to HPRT (H, left panel) or β-
actin (A, right panel) in the su-
perior (SL) and inferior (IL)
lobe of the left lung in newborn
piglets with experimentally in-
duced MAS (5 ml/kg meconi-
um) after administration of
rSP-C Surf, natural bovine sur-
factant (nat SF), or physiologi-
cal saline. Results are normal-
ized to controls, logarithmic
scale. **p<0.02 vs. controls,
§p<0.05, §§p<0.02 vs. natural
bovine surfactant
Fig. 4 Pulmonary IL-10
mRNA expression normalized
to HPRT (H, left panel) or β-
actin (A, right panel) in the su-
perior (SL) and inferior (IL)
lobe of the left lung in newborn
piglets with experimentally in-
duced MAS (5 ml/kg meconi-
um) after administration of
rSP-C Surf, natural bovine sur-
factant (nat SF), or physiologi-
cal saline. Results are normal-
ized to controls, logarithmic
scale. *p<0.05, **p<0.02,
***p<0.01 vs. controls
Table 2 Cytokine mRNA ex-
pression in superior and inferi-
or left lung lobes and in inferi-
or left lung lobe; normalization
to HPRT (H) and β-actin (A)
and further to mRNA expres-
sion in control subjects. Data
given as geometric mean and
dispersion factor
Control (n=3) Superior, inferior Inferior
rSP-C Surf (n=5) nat SF (n=4) rSP-C Surf (n=5) nat SF (n=4)
IL-1β/H 1±0.19 0.17±0.30**,5* 0.77±0.05 0.17±0.30**,5* 0.77±0.05
IL-1β/A 1±0.33 0.19±0.27**,4* 0.63±0.1 0.19±0.27**,4* 0.63±0.1
IL-6/H 1±0.19 1.92±0.29 4.61±0.09 1.92±0.29 4.61±0.09
IL-6/A 1±0.33 2.11±0.38 3.78±0.2 2.11±0.38 3.78±0.2
IL-8/H 1±0.14 0.35±0.30 1.34±0.07 0.35±0.30 1.34±0.07
IL-8/A 1±0.22 0.38±0.16 1.1±0.11 0.38±0.16 1.1±0.11
IL-10/H 1±0.35 3.19±0.47* 3.61±0.28** 3.19±0.47* 3.61±0.28**
IL-10/A 1±0.56 3.5±0.54*** 2.96±0.8*** 3.5±0.54*** 2.96±0.8***
TGF-β/H 1±0.21 0.88±0.4 2.52±0.23 0.88±0.4 2.52±0.23
TGF-β/A 1±0.42 0.97±0.24 2.06±0.58 0.97±0.24 2.06±0.58
Analyzing cytokine mRNA expression in both lung
lobes separately, significantly lower levels of IL-1β and
IL-6 mRNA were observed in the lower lung lobe from
rSP-C Surf treated animals than in natural bovine surfac-
tant (p<0.05, H, A) and controls (IL-1β, p<0.05, H; Ta-
ble 2). Again in the natural bovine surfactant group a
tendency to higher IL-6 and TGF-β mRNA expression
levels was observed. IL-10 mRNA expression was sig-
nificantly increased in the rSP-C Surf group in the upper
and lower left lung lobe (p<0.05, A, vs. controls; Ta-
ble 2), a trend to higher expression levels was observed
for natural bovine surfactant.
Free fatty acid analysis
Chromatographic analyses revealed nearly 2% (w/w) ar-
achidonic acid referring to total free fatty acid concentra-
tions in the natural bovine surfactant samples. The frac-
tion of free fatty acids in natural bovine surfactant was
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nearly 3% (wt:wt) compared to total phospholipids and
significant amounts of ω-3 fatty acids eicosapentaenoic
acid (1%) and docosahexaenoic acid (0.6%) were found
in the analyzed natural bovine surfactant probes. The
profiles of the tested natural bovine surfactant charges
(n=3) were almost identical. In contrast the recombinant
SP-C surfactant contained no arachidonic acid, and free
fatty acids were composed mainly of palmitic acid (82%)
and oleic acid (12%). Again, the profiles of different
charges (n=3) were stable in the analyses.
Discussion
The present study investigated lung function and inflam-
matory pulmonary response in a well established piglet
model of MAS [16] after bolus administration of two
different surfactant preparations. Response to surfactant
administration was determined by monitoring pulmonary
gas exchange, tidal volumes, and pulmonary inflamma-
tory reaction. Following the early phase of MAS with
predominantly mechanically impaired gas exchange, ex-
pression of proinflammatory cytokines in meconium as-
piration is the second step of the pathophysiological cas-
cade leading to neonatal lung failure resembling acute
respiratory distress syndrome (ARDS) [12, 13, 16]. Sur-
factant administration is a therapeutic option previously
used in several studies on treatment strategies for ARDS-
like lung failure in neonates [6, 10, 18, 25]. Therefore
surfactant preparations with different protein contents
and different administration techniques gained increas-
ing interest [26, 27, 28, 29].
In the present study bolus administrations of two differ-
ent surfactant preparations—rSP-C Surf and natural bovine
surfactant—used in a piglet model of MAS showed an ade-
quate response with improved gas exchange and tidal vol-
umes. As recent studies revealed serious concerns against
surfactant lavage techniques, bolus treatment was chosen
for this experimental setting and confirmed for both surfac-
tant preparations as an efficient and safe intervention in
MAS. Apart from these “classical variables,” surfactant ef-
fects on the inflammatory response in MAS have not been
studied systemically yet. As cytokines themselves play a
crucial role in altering the surfactant system [30], interac-
tions between these two pathophysiologically important
opponents seem to be of considerable interest.
Because mRNA expression precedes protein forma-
tion, mRNA expression of early cytokines was quanti-
fied using TaqMan real-time PCR as a highly sensitive
approach. It is a well established fact, lung maturation to
show apicobasal pattern in the neonatal period. Further-
more initial distribution of meconium in MAS has been
described to differ vertically involving more severely the
lower lung areas [3, 31]. Therefore cytokine mRNA ex-
pression was analyzed both in whole lung tissue and for
upper and lower lung lobe separately.
Administration of rSP-C Surf led to significantly low-
er proinflammatory cytokine mRNA expression in whole
lung tissue than in natural bovine surfactant and controls.
With the natural bovine surfactant mRNA expression of
the proinflammatory cytokines even tended to be higher
than in controls. As an indicator of direct anti-inflamma-
tory properties of exogenous pulmonary surfactant prep-
arations IL-10 mRNA expression was found to be in-
duced after administration of both surfactant prepara-
tions. As IL-10 with its strong anti-inflammatory proper-
ties has been discussed as a potential therapeutic option
for treatment of chronic inflammatory pulmonary disor-
ders of the newborn [32, 33, 34], the present findings
might implicate important clinical potentials.
The differential modulation of the inflammatory re-
sponse was even more evident, when results were ana-
lyzed for upper and lower lung lobe separately, rSP-C
Surf revealing most pronounced anti-inflammatory prop-
erties. Differing results in pro- and anti-inflammatory
cytokines in the superior and inferior left lung lobe may
be due to the above differences in maturation and region-
al distribution of meconium as well as exogenous surfac-
tant. The trend towards a differential cytokine mRNA
expression concerning Il-1β and IL-6, more evident in
whole left lung tissue, may be due to time dependence in
cytokine activation and to their differential role in the in-
flammatory cascade. Analyses of dynamics in cytokine
expression could further explain the extent to which me-
conium and especially different surfactant preparations
affect the complex system of inflammatory pulmonary
response in the time course. Furthermore there is evi-
dence in pulmonary inflammatory response a hierarchic
regulation of cytokines to be apparent. Studies have
shown IL-1 β to induce IL-8 expression in human bron-
chial epithelial cells [35].
Although anti-inflammatory properties of rSP-C Surf
and natural bovine surfactant could be explained by a re-
duction in ventilator-associated lung injury, identical tid-
al volumes in both surfactant groups strongly contradict
this explanation. Therefore differing qualitative and
quantitative surfactant protein and phospholipid compo-
sitions must be considered as potential modifiers of the
inflammatory response. Therefore effects of the recombi-
nant surfactant might be due to its increased content of
SP-C, whose dysfunction was shown to cause severe in-
terstitial lung disease by dysregulation of intracellular
surfactant processing [36]. Furthermore, SP-C was
shown to interact with inflammation-stimulating agents
such as lipopolysaccharides [37] and may thus have im-
pact on pulmonary inflammatory processes. The above
properties of SP-C and differing phospholipid composi-
tions of surfactant preparations also may explain the re-
sults of other studies that have demonstrated different
biophysical interactions [24, 29], gas exchange, and lung
mechanics [28] after administration of various surfactant
preparations. In contrast, recent reports found no differ-
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ence in the inflammatory response after administration
of four different surfactant preparations in a model of
ventilator-associated lung injury [27].
Furthermore interactions between additional contents
of the surfactant preparations and meconium itself or
lung tissues must be considered. Phospholipase A2, pres-
ent in meconium [38], has been discussed as being re-
sponsible for morphological alterations in lung injury
[39] and additionally has been demonstrated to inactivate
natural surfactant. These interactions might be different
for various surfactant preparations, as it has been shown
recently that resistance towards inactivation mediated by
meconium of the rSP-C Surf is superior to animal lung’s
derived surfactant preparations [29]. Furthermore, the
rate of surfactant subtype conversion induced by meco-
nium [40] may be altered by differing protein and phos-
pholipid contents.
Another important property of phospholipase A2 is the
generation of arachidonic acid, known to be a major pre-
cursor of eicosanoids, which mediate various inflamma-
tory processes in both premature and adult lungs [41].
This precursor was found in the natural bovine surfactant
preparation in contrast to the studied recombinant prod-
uct as demonstrated chromatographically. This might ex-
plain previously reported activating properties of natural
surfactant preparations [42].
Having established gas exchange and tidal volumes to
be improved after bolus administration of both surfactant
preparations, differences between the rSP-C and the nat-
ural bovine surfactant were demonstrated with respect to
their immunomodulatory properties. Since there is evi-
dence that persistently high levels of inflammatory cyto-
kines are a pathophysiological mainstay for the develop-
ment of chronic lung disease in newborns [33, 34], the
evaluation of immunomodulatory surfactant properties
seems to be of considerable interest. As the exact se-
quence of the reduced inflammatory response following
surfactant in the present model of MAS is unclear, fur-
ther studies are mandatory to address potential underly-
ing mechanisms.
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Effects of a recombinant surfactant protein-C-based surfactant on
lung function and the pulmonary surfactant system in a model of
meconium aspiration syndrome*
Anne Hilgendorff, MD; Martin Doerner; Daniel Rawer; Jürgen Leick; Andreas Trotter, MD;
Michael Ebsen, MD; Clemens Ruppert, PhD; Andreas Günther, MD; Ludwig Gortner, MD; Irwin Reiss, MD
Meconium aspiration syn-drome (MAS) remains arelevant cause of respira-tory failure in term neo-
nates despite intensive perinatal treatment
(1). MAS-induced pulmonary changes in-
clude, among others, typical histologic find-
ings (2), inflammatory cell infiltration with
release of vasoactive substances (3), airway
obstruction, and surfactant dysfunction and
inactivation (4, 5).
Besides the evaluation of treatment
strategies such as anti-inflammatory
drugs, high-frequency ventilation, in-
haled nitric oxide, and liquid ventilation,
a number of clinical and animal studies
have been performed addressing the pul-
monary response to surfactant in MAS
(6–9). Nevertheless, despite remarkable
treatment effects, the type of surfactant
preparation, its dosage, and the mode of
administration are under current investi-
gation. Repetitive administration of nat-
ural surfactant seems needed to over-
come its inactivation induced by
meconium constituents such as lyso-
phosphatidylcholine, bilbirubin, bile
salts, and inflammatory processes (10,
11). Recent reports further suggested
synthetic recombinant surfactant protein
(rSP)-C-based surfactant preparations, a
safe and efficient therapy in acute lung
injury and acute respiratory distress syn-
drome (ARDS) (12–14), to be less suscep-
Objective:Meconium aspiration syndrome (MAS) remains a relevant
cause of neonatal respiratory failure and is characterized by severe
impairment of pulmonary gas exchange, surfactant inactivation, and
pronounced inflammatory changes. Surfactant administration has been
shown as an effective treatment strategy in MAS. The present study
aimed at investigating the impact of a recombinant surfactant protein
(SP)-C-based surfactant on pulmonary gas exchange and lung function
in this model of neonatal lung injury. Furthermore, SP-B and -C were
determined on the transcriptional and protein level.
Design: Laboratory experiment.
Setting: University laboratory.
Subjects: Twenty three newborn piglets (median age 6 days,
weight 1900–2500 g).
Interventions: Piglets were intubated and mechanically ventilated
and then received 20% sterile meconium (5 mL/kg) for induction of
lung injury. After 30 mins, animals were randomized for control (n�
7, MAS controls), recombinant SP-C surfactant (n � 8), or natural
surfactant (n� 8). Surfactant preparations were administered as an
intratracheal bolus (75 mg/kg), and animals were ventilated for
another 330 mins. Nonventilated newborn piglets at term (n � 28;
median weight 1484 g, range 720–1990 g) served as a healthy
reference group (healthy controls).
Measurements and Main Results: Lung function variables, arterial
blood gas samples, and lung tissues were obtained. Expression of
SP-B and -C messenger RNA was quantified in left lung lobe tissue
using real-time polymerase chain reaction. Protein concentrations
were determined by enzyme-linked immunosorbent assay. Scanning
electron microscopy and transmission electron microscopy were
performed in tissue samples of the right lung lobe. Compared with
healthy controls, SP-B messenger RNA expression was significantly
increased in MAS (p < .02), whereas SP-C messenger RNA expres-
sion was found to be significantly reduced (p < .001). SP concen-
trations, however, were not significantly different. Although a signif-
icant improvement of gas exchange and lung function was observed
after surfactant administration in both groups, surfactant messenger
RNA expression and protein concentrations were not significantly
altered. Scanning and transmission electron microscopy showed
severe pulmonary ultrastructural changes after meconium aspiration
improving after surfactant treatment.
Conclusions: Impairment of lung function in MAS, associated
with marked changes in SP messenger RNA expression, can be
sufficiently treated using recombinant SP-C-based or natural sur-
factant. Despite improved lung function and gas exchange as well
as pulmonary ultrastructure after treatment, pulmonary SP mes-
senger RNA expression and concentrations remained significantly
affected, giving important insight into the time course following
surfactant treatment in MAS. (Crit Care Med 2006; 34:203–210)
KEY WORDS: pulmonary surfactant; surfactant proteins; respira-
tory insufficiency; newborn; meconium aspiration
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tible to inactivation mediated by meco-
nium compared with natural surfactant
preparations (15). In contrast, synthetic
but apoprotein-free surfactant prepara-
tions such as Exosurf or Pumactant were
revealed to be much more sensitive to
inactivation by plasma proteins and
meconium constituents (16, 17). Thus,
the objective of the present study was to
evaluate whether bolus administration of
the rSP-C-based surfactant is capable of
reconstituting lung function in a piglet
model of MAS compared with a standard
treatment regime.
In addition, to investigate whether ex-
ogenous surfactant preparations display
an impact on the recovery of pulmonary
function by affecting pulmonary surfac-
tant protein expression, surfactant pro-
tein (SP)-B and -C were determined on
the transcriptional and protein level. To
visualize fundamental changes in lung
tissue at an ultrastructural level (e.g.,
morphologic features of alveolar epithe-
lial cells and alveolar septa), scanning
electron microscopy (SEM) and transmis-
sion electron microscopy (TEM) were
performed in pulmonary tissue.
MATERIALS AND METHODS
Animal. Twenty-three newborn piglets, at
a median age of 6 days (range 1–11 days) and
a median weight of 2200 g (range 1900–2500
g), were studied in a model of experimentally
induced MAS. Pulmonary healthy, nonventi-
lated newborn piglets at term (healthy con-
trols, n � 28, median weight 1484 g, range
720–1990 g) served as a control group to
define physiologic levels of SP messenger RNA
(mRNA) expression and pulmonary protein
concentrations. Animal experiments were ap-
proved by local authorities and performed ac-
cording to the Guidelines for the Care and Use
of Laboratory Animals of the National Insti-
tutes of Health.
Protocol. The experimental protocol has
been previously published (18). In brief, intra-
venous anesthesia was induced with ketamine
and midazolam after an intramuscular bolus
of ketamine. The piglets were intubated with a
cuffed endotracheal tube (3.0 mm outer diam-
eter; Rüsch, Kernen-Rommelshausen, Ger-
many), and continuous infusion with midazo-
lam (1 mg/kg of body weight per hour),
ketamine (2 mg/kg of body weight per hour),
and vecuronium (0.6 mg/kg of body weight
per hour) provided sedation, analgesia, and
muscular relaxation, respectively. Animals
were ventilated using a pressure-controlled
mode (Servo 900, Siemens, Germany), with a
positive inspiratory pressure of 15 cm H2O, a
positive end-expiratory pressure of 2 cm H2O,
and a respiratory rate of 30 cycles/min (rate of
inspiration to expiration 30–70) at 100% ox-
ygen (FIO2 1.0). Under these conditions, nor-
mocapnia was observed. An arterial catheter
(20-gauge, Arrow, Erding, Germany) was
placed into the right common carotid artery
and a central venous catheter (4.0-Fr, Arrow)
in the right femoral vein. Arterial blood gases
(PaO2, PaCO2, and pH; ABL Radiometer 555,
Diamond Diagnostics, Holliston, MA), heart
rate, blood pressure, central venous pressure,
and electrocardiogram (78354A Hewlett-
Packard) were monitored before and during
induction of lung injury, immediately before
treatment, and every 30 mins thereafter. Tidal
volumes were detected by pneumotachograph
(CO2SMO plus 8100, Novametrix Medical Sys-
tems) at the end of the endotracheal tube, and
ventilation efficiency index (VEI) was further
calculated (19) as well as dynamic compliance.
Lung function variables were related to body
weight. After a stabilization period of 30 mins,
ventilation pressures were increased (positive
inspiratory pressure 25 cm H2O, positive end-
expiratory pressure 4 cm H2O) and were left
unchanged during the remaining ventilation
period. Lung injury was induced in all animals
by a bolus administration of 5 mL/kg of body
weight of meconium 20% given in 2- to 4-mL
aliquots via the endotracheal tube under on-
going ventilation according to Soukka et al.
(20). Thirty minutes after induction of lung
injury, piglets were prospectively randomized
to one of the following groups: group 1 (MAS
control; n � 7) received intratracheal admin-
istration of 1.5 mL/kg of body weight physio-
logic saline (Braun, Melsungen, Germany);
group 2 (rSP-C SF; n � 8) received 75 mg of
rSP-C surfactant/kg of body weight intratra-
cheally (Venticute; ALTANA Pharma, Kon-
stanz, Germany); group 3 (natural SF, n � 8)
received 75 mg of bovine (SP-B and SP-C
containing) surfactant (Alveofact; Boehringer
Ingelheim, Ingelheim, Germany)/kg of body
weight intratracheally, at a concentration of
75 mg/1.5 mL.
After another observation period of 330
mins (360 mins after induction of lung in-
jury), piglets were killed. All animals survived
the whole observation period with the excep-
tion of one animal of the MAS control group
dying from severe respiratory failure. Imme-
diately after death, the chest was opened and a
cannula was placed into the pulmonary artery,
the left atrium was opened, and the lung was
perfused in situ with Ringer’s lactate contain-
ing procaine (250 mg/L), heparin (20 units/
mL), and calcium-chloride (2.2 mmol/L) for
10 mins. After perfusion of the lung, positive
inspiratory pressure was first increased for 15
secs to 25 cm H2O and then reduced to 10 cm
H2O. Thereafter, tissue samples of the supe-
rior and inferior lobe of the left lung were
extracted and immediately snap-frozen in liq-
uid nitrogen for real-time polymerase chain
reaction (PCR) and protein analyses. In the
next step, right lungs were perfused with 300
mL of a formaldehyde (4.6%)/glutaraldehyde
(0.5%) solution for approximately 10 mins.
Finally, the trachea was clamped at a positive
end-expiratory pressure of 10 cm H2O, and
right lungs were removed and submersed in
2.5% glutaraldehyde in phosphate buffer (pH
7.2) for TEM and SEM. To estimate physio-
logic pulmonary surfactant mRNA expression
levels and protein concentrations, 28 nonven-
tilated newborn piglets were killed according
to the standardized procedure described here
and served as a healthy control group. Tissue
samples of the left lung lobe were obtained for
mRNA and protein analyses.
Preparation of Pooled Meconium. Meco-
nium was collected from healthy full-term ne-
onates with neither history of perinatal com-
plications nor maternal drug administration
during pregnancy and delivery and prepared as
described previously (20).
Therapeutic Surfactant Preparations. Ex-
periments were performed using an rSP-C-
based surfactant (Venticute) or a natural bo-
vine surfactant extract (Alvofact). The rSP-C
surfactant contains 2% of a human recombi-
nant nonpalmitoylated SP-C in phospholipids
(dipalmitoylphosphatidylcholine and palmi-
toyloleoyl-phosphatidylglycerol in a 70:30 ra-
tio (weight/weight), 50 mg/mL, plus 5 %
palmitic acid). Alveofact® is an organic calf
lung lavage extract containing the hydropho-
bic apoproteins SP-B and SP-C (approximately
1.5%) as described previously (21). Both sur-
factant preparations were provided as lyophi-
lized powder and resuspended in sterile saline
0.9% (Braun) to a final concentration of 50
mg/mL.
Measurements of Surfactant Protein B
and C mRNA Expression by Real-Time PCR.
Expression of SP-B and -C mRNA was mea-
sured in tissue of the left upper and lower lung
lobe using the real-time reverse transcriptase
(RT)-PCR technique (TaqMan). Primers and
probes for SP-B, SP-C, 18-S, and �-actin were
designed using Primer Express software (Ap-
plied Biosystems, Foster City, CA) following a
fixed set of recommendations to allow the ap-
plication of standardized cycling conditions (2
mins at 50°C, 10 mins at 95°C, followed by 45
cycles for 15 secs at 95°C, and 1 min at 60°C).
Control PCRs showed no signal for genomic
DNA proving mRNA specificity. Primers were
purchased from Roth (Karlsruhe Germany)
and probes from Applied Biosystems. Lung
tissue homogenization was performed in liq-
uid nitrogen, and total RNA was then extracted
using the acid guanidinium-thiocyanate-
phenolchloroform method (Roti Quick, Roth).
Total RNA isolation, random primed reverse
transcription, and real-time PCR were per-
formed following a standardized protocol as
described previously (18). Primer and TaqMan
probe sequences are depicted next. Relative
quantification was performed using the ��Ct
method, which results in a ratio of target gene
expression and the expression of a housekeep-
ing or reference gene.
As the validity of this method depends on
the constant expression of the housekeeping
gene throughout the set of samples studied,
we analyzed gene expression ratios of 18S (S)
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and �-actin (A) as well as the total mRNA
content of each sample. As 18S showed both
no differences between different experimental
groups and the lowest variation in all samples,
it was chosen as reference gene for further
analysis.
Primer and TaqMan probes.
18S:
Forward primer (FP): 5'–GCC GCT AGA
GGT GAA ATT CTT G–3'
Reverse primer (RP): 5'–CAT TCT TGG CAA
ATG CTT TCG–3'
Probe: 5'(FAM)–CCG GCG CAA GAC GGA
CCA GA–(TAMRA)3'
�-Actin:
FP: 5'–TCA TCA CCA TCG GCA ACG–3'
RP: 5'–TTC CTG ATG TCC ACG TCG C–3'
Probe: 5'(FAM)–CCT TCC TGG GCA TGG
AGT CCT GC–(TAMRA)3'
Surfactant protein B (SP-B):
FP: 5'–TCC GCT GGT CGT TGA TCA C–3'
RP: 5'–GTT TGC ACA GGC CCA AGT G–3'
Probe: 5'(FAM)–CAG AGC CAA ATG AAC
CTG AAG GCC ATC–(TAMRA)3'
Surfactant protein C (SP-C):
FP: 5'–CAC CTT CTC CAT TGG CTC TAG
TG–3'
RP: 5'–ATA CTC TGC GGA GAC ATC TTC
ATG–3'
Probe: 5'(FAM)–TGA CTA CCA GCG GCT
CCT GAT TGC C–(TAMRA)3'
Quantification of Surfactant Proteins in
Lung Homogenate. SP-B and SP-C were quan-
tified in lung homogenates of the left upper
and lower lung lobe by enzyme-linked immu-
nosorbent methods as described earlier (22,
23) with slight modifications. In brief, for
quantification of SP-B, lung homogenate was
diluted 1:1000 with phosphate-buffered saline
(PBS)/1-propanol 1:1, pH 7.4 and for quanti-
fication of SP-C lung homogenate was diluted
1:500 with 80% 2-propanol, pH 3.5. Samples
were transferred to a microtiter plate and the
proteins were allowed to bind. After selective
removal of phospholipids (iisopropylether/
butanol [3:2, volume/volume] wash for SP-B,
methanol wash for SP-C) and saturation of
free binding sites, plates were incubated with
primary antibodies (anti-SP-B, 8B5E, raised
against porcine SP-B, 5 �g/mL in PBS/1%
bovine serum albumin; anti-SP-C, polyclonal
antiserum raised against human rSP-C and
cross-reacting with porcine SP-C, 1:2000 dilu-
tion [volume/volume] in PBS/1% bovine se-
rum albumin). Microtiter plate-bound anti-
bodies were detected using secondary species-
specific biotinylated antibodies (SP-B,
antimouse immunoglobulin G; SP-C, antirab-
bit immunoglobulin G [Amersham Bio-
sciences, Freiburg, Germany], each 1:1000 in
1% bovine serum albumin/PBS) with subse-
quent application of AB-complex and ABTS as
substrate. Absorbance was measured at 450
nm with an enzyme-linked immunosorbent
assay photometer (Tecan, Crailsheim, Ger-
many). SP content was calculated with respect
to the dry lung weight employing cubic-
spline-interpolated standard curves obtained
from isolated human SP-B and recombinant
human dipalmitoylated SP-C, respectively.
Scanning Electron Microscopy. Fixation
for SEM was carried out in formaldehyde
3.5%. Material was prepared out of the lung
tissue, dried using the critical point method,
Figure 1. Levels of PaO2 (kPa; left upper panel), PCO2 (kPa; right upper panel), dynamic compliance (Cdyn; mL/cm H2O; left lower panel), and ventilation
efficiency index (VEI; right lower panel) before and after meconium and following either surfactant administration (recombinant surfactant protein C
[rSP-C] or natural bovine surfactant [nat SF]) or physiologic saline (meconium aspiration syndrome [MAS] controls), respectively. Results are given as
mean and SEM; **p � .001 vs. MAS controls.
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and sputtered with gold after mounting. Mea-
surements were carried out using the scan-
ning electron microscope Zeiss DSM 950
(Zeiss, Jena, Germany) with the pathologist
blinded for the animals‘ group assignment.
Tissue samples for SEM were collected from
areas with macroscopic changes, as, for exam-
ple, atelectases, significant changes in consis-
tency, and/or conspicuous color of the lung
tissue. From lungs with no visible macro-
scopic alterations, specimens from peripheral
segments of the upper and lower lobes and
central parts of the lung tissue were selected
for analysis.
Transmission Electron Microscopy. For
TEM, tissue samples were fixed for 2 hrs in
2.5% glutaraldehyde in phosphate buffer (pH
7.2). After postfixation in osmiumtetroxide
and block contrast with uranyl acetate, they
were dehydrated in an increasing alcohol con-
centration and embedded in Epon 812 (Shell
Chemicals, Houston, TX). Thin sections were
cut using a Reichert Om U3 Ultramicrotome
(Vienna, Austria), stained with methylene blue
for 2 mins, and evaluated by light microscope.
Ultrathin sections of selected tissue areas were
stained with lead citrate and examined by TEM
(Zeiss EM 900, Jena, Germany). Tissue sam-
pling for TEM was performed as described for
SEM analysis.
Statistical Analyses and Data Presenta-
tion. Results of lung function testing are given
as mean and SEM. The effect of surfactant treat-
ment on lung function variables over the
study period was tested by a two-way analysis
of variance procedure with repeated measure-
ments as normal distribution could be as-
sumed.
Results of real-time PCR analyses (arbi-
trary units) and protein measurements are
given as median and range and are repre-
sented in the figures as box plots, as the data
are not normally distributed. Real-time PCR
results were normalized to two housekeeping
genes. For further statistical analysis and
comparison of groups, data were logarithmi-
cally transformed and one-way analysis of vari-
ance was performed with post hoc Scheffé.
Data analysis was performed using SPSS for
Windows, version 11.5. Calculated p values are
given in the Results section.
RESULTS
Gas Exchange and Lung Function. All
animals survived the whole observation
period with the exception of one animal
of the MAS control group dying from
severe respiratory failure. After induction
of acute respiratory failure by administra-
tion of meconium, PaO2, dynamic com-
pliance, and VEI were significantly re-
duced in all animals, whereas PaCO2
significantly increased up to two- to
three-fold (Fig. 1). Intratracheal admin-
istration of either rSP-C surfactant or
natural bovine surfactant (each 75 mg/kg
of body weight) significantly improved
PaO2, dynamic compliance, and VEI and
significantly decreased PaCO2 in surfac-
tant-treated animals compared with MAS
controls (p � .001, two-factor analysis of
variance; Fig. 1). There was a tendency
toward faster and more sustained effects
regarding PaO2, PaCO2, dynamic compli-
ance, and VEI in the rSP-C surfactant-
treated group after induction of lung fail-
ure compared with animals treated with
natural surfactant, although there was no
statistically significant difference (Fig. 1).
Scanning and Transmission Electron
Microscopy. Pulmonary ultrastructural
changes were screened using SEM and
TEM in right lung lobe tissue samples. In
lungs of newborn piglets following meco-
nium aspiration (MAS controls), significant
structural changes were found with intra-
alveolar granulocytes identified by typical
cytoplasmic patterns. In these sampled
lung areas, changing amounts of neutro-
phils could be found in the majority of
alveoli analyzed, and �50% of the alveolar
septa showed a marked thickening. About
30% of the thickened alveolar septa showed
fibrin deposition (Fig. 2). After rSP-C treat-
ment, no influx of inflammatory cells could
be detected, and alveolar structures were
intact with thin alveolar septa (Fig. 2).
TEM revealed that MAS controls had
structural changes in the cytoplasm of
alveolar epithelial cells as well as intra-
alveolar granulocytes with cell detritus
(Fig. 3). After surfactant treatment, intact
alveolar septa and capillaries as well as
alveolar epithelial cells could be shown
(Fig. 3).
SP-B and C mRNA Expression. Lung
tissue from 18 piglets was available for
real-time PCR analyses. Material of one
piglet in the saline and two piglets in the
natural surfactant group had to be fur-
ther excluded because of poor mRNA
quality due to degradation (MAS controls,
n � 5; rSP-C SF, n � 6; natural SF, n �
4). Control samples of the left lung lobe
from 28 healthy newborn piglets (healthy
controls) were available for examination.
There was no significant difference in
SP-B and -C mRNA expression when an-
alyzing SP mRNA expression in upper
and lower lung lobes separately. There-
fore, means were calculated and used for
further analysis. In the figures, results
are given normalized to 18S; normaliza-
tion to �-actin showed comparable re-
sults.
Tissue samples of the superior and inferior
left lung lobe showed a significantly increased
SP-B mRNA expression after induction of
lung injury with meconium and mechanical
ventilation (MAS controls) compared with
healthy controls (p � .001, Fig. 4). In con-
trast, SP-C mRNA expression was signifi-
cantly decreased after induction of lung in-
jury (MAS controls) compared with healthy
controls (p � .001; Fig. 5). After treatment
with either synthetic rSP-C or natural bovine
surfactant, SP-BmRNA expression was found
to remain significantly increased (p � .001
vs. healthy controls; Fig. 4), and SP-C mRNA
expression significantly decreased compared
with healthy controls (rSP-C vs. healthy con-
Figure 2. Scanning electron microscopy (SEM) before (A) and after administration of recombinant
surfactant protein C (rSP-C) surfactant in a piglet model of meconium aspiration syndrome (B; rSP-C
surfactant, 75 mg/kg body weight). A, lung tissue of a control animal. Thickened alveolar septa, fibrin
deposition, and numerous intra-alveolar granulocytes indicate lung injury (arrow, SEM, magnification
�500). B, lung tissue after therapy with rSP-C surfactant. The alveolar structure is intact and septa
are thin. No inflammatory cells could be shown (SEM, magnification �360).
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trols p� .001; natural SF vs. healthy controls
p � .02; Fig. 5). No significant differences
between SP-B or SP-C mRNA expression
were observed with regard to the different
treatment regimes, although there was a
trend toward elevated SP-BmRNA expression
in the surfactant-treated groups compared
with MAS controls.
SP-B and C Concentrations. Lung tis-
sue from 18 piglets was available for anal-
ysis; material of one piglet in the saline
and two piglets in the natural surfactant
group had to be further excluded because
of protein degradation (MAS controls, n
� 5; rSP-C SF, n� 6; natural SF, n� 4).
Control samples of the left lung lobe from
ten healthy newborn piglets (healthy con-
trols) were available for examination.
There was no significant difference in SP-B
and -C concentrations in lung homoge-
nates when analyzing SP concentrations in
upper and lower lung lobes separately.
Therefore, means were calculated and used
for further analysis. SP-B and -C were de-
tectable in homogenates of the left lung
and were related to lung dry weight for
comparison. Pulmonary SP-B and -C pro-
tein contents were not significantly altered
after induction of lung injury by meconium
(MAS controls) when compared with pul-
monary healthy controls. Nevertheless, a
trend toward decreased SP-B concentra-
tions could be observed in lung homoge-
nates after induction of lung injury (p �
.2). Surfactant treatment did not alter pul-
monary SP-B and -C concentrations signif-
icantly (Figs. 4 and 5).
DISCUSSION
This is the first report to describe the
response of exogenous surfactant admin-
istration on pulmonary gas exchange and
lung function variables as well as ultra-
structural changes to the alveolar-
capillary unit and effect on the pulmo-
nary surfactant system in an established
piglet model of MAS (20) after bolus ad-
ministration of either an rSP-C or a nat-
ural bovine SP-B- and SP-C-containing
surfactant.
Meconium aspiration leading to neo-
natal ARDS-like lung failure through me-
chanically impaired gas exchange and in-
duction of pronounced pulmonary
inflammatory changes (20, 24, 25) signif-
icantly responds to exogenous surfactant
administration (26). In the past decade,
different administration techniques and
alteration of protein contents in surfac-
tant preparations gained increasing inter-
est to improve the treatment response in
ARDS-like lung failures of the neonate
(15, 27–29).
As rSP-C surfactant revealed to be ef-
ficient in premature lambs and rabbits
suffering from respiratory distress syn-
drome (19) as well as in different models
of acute lung injury (13, 30), the present
model of MAS addressed its potencies in a
model of lung injury mainly character-
ized by severe inflammatory changes. Se-
rious concerns about the surfactant la-
vage techniques, which have been raised
from recent studies (31), formed the ra-
tionale for bolus treatment in this exper-
imental setting and confirmed both sur-
Figure 3. Transmission electron microscopy (TEM) before (A) and after administration of recombinant
surfactant protein C (rSP-C) surfactant in a piglet model of meconium aspiration syndrome (B; rSP-C
surfactant, 75 mg/kg body weight). A, lung tissue of a control animal. In the center, an alveolar septum
with an oval nucleus can be seen. The cytoplasm of the alveolar type I cells show severe edema and loss
of organelles (arrows, TEM, magnification �7000). B, lung tissue after therapy with rSP-C surfactant.
The alveolar septum shows two distinct nuclei. Cytoplasm of alveolar type I (stars) cells is regularly
arranged; furthermore, an intact capillary is seen (arrow, TEM, magnification �7000).
Figure 4. Pulmonary surfactant protein-B (SP-B) messenger RNA expression normalized to 18S (A)
and SP-B protein concentrations in lung homogenate (dry weight; B) in the left lung lobe of newborn
piglets with experimentally induced meconium aspiration syndrome (MAS; 5 mL/kg meconium)
following administration of physiologic saline, recombinant surfactant protein C (rSP-C), or natural
bovine surfactant (nat SF). Means were calculated from values of upper and lower lung lobe. Median,
interquartile range (box limits, 25th and 75th percentiles), and extreme values (error bars) are
indicated in the figure. **p � .001 vs. healthy controls.
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factant preparations as efficient and safe
treatment strategies in MAS.
For rSP-C surfactant, an adequate re-
sponse with significantly improved gas
exchange, dynamic compliance, and ven-
tilation efficiency index can be shown in
this piglet model of MAS. Time and ex-
tent of pulmonary recovery were at least
comparable to effects in the group treated
with natural surfactant, with a tendency
toward faster and more sustained effects
regarding PaO2, PaCO2, dynamic compli-
ance, and VEI in the rSP-C surfactant-
treated group. The effects of rSP-C treat-
ment in MAS, supporting findings of
other investigators mentioned previously
(13, 30), can be partially attributed to the
well-known properties of SP-C facilitat-
ing the adsorption of surfactant phospho-
lipids to an air-water interface and stabi-
lizing the interfacial lipid layer during
film compression (32, 33). Although SP-C
has fewer effects on the adsorption rate of
phospholipids than SP-B, there are im-
portant functions attributed to SP-C,
such as film stabilization and respreading
after film collapse (34). As there is no
consensus about the relative importance
of the specific SP for optimal function of
exogenous surfactant preparations, we
hypothesized that rSP-C surfactant would
affect the recovery of pulmonary function
by affecting the pulmonary surfactant
system and either stimulate endogenous
SP RNA expression or mobilize intracel-
lular surfactant protein pools as a poten-
tial mechanism for the recombinant SP-
C-based surfactant to compensate for its
lack in SP-B. The importance of the hy-
drophobic SP-C in normal lung function
is highlighted by the fact that dysfunction
of SP-C has been shown to cause severe
interstitial lung disease in newborns,
older children, and adults (35, 36). As
dysregulation of intracellular SP process-
ing is known to be causally related to the
pathophysiology of the disease and fur-
thermore in vitro studies showed SP-C
but not SP-B to enhance the uptake of
isopropylether liposomes by type II cells
(37), an important role of SP-C regarding
surfactant metabolism and function can
be assumed. Therefore, in the present
study SP-B and C were determined on the
transcriptional and protein level in lung
homogenates after exogenous surfactant
administration. For quantification of
mRNA expression in pulmonary tissue,
TaqMan real-time PCR was used as a
highly sensitive approach. Compared
with control animals, the induction of
lung injury by meconium resulted in a
significant reduction of SP-C mRNA ex-
pression when compared with pulmonary
healthy controls. This indicates severe
changes to alveolar type II cells, as SP-C
has so far been detected in alveolar type II
cells of the mature lung only (38). In-
deed, signs of an impaired structure of
alveolar epithelial cells in MAS controls
could be detected by using SEM and
TEM. In accordance to our findings, pre-
vious studies revealed reduced SP-C con-
centrations in bronchoalveolar lavage
specimens of patients suffering from
ARDS (22). SP-B mRNA expression could
be shown to be significantly up-regulated
and potentially represents compensatory
or repair mechanisms of type II cells in
the alveolar compartment. Vayrynen et
al. (39) found alterations of SP-B and -C
expression by lipopolysaccharide and cy-
tokines to be dependent on the degree of
lung maturation. Lungs of term neonates
revealed reduced SP-B and -C expression
in response to lipopolysaccharide,
whereas SP-B was shown to be induced
by inflammatory stimuli in the prema-
ture lung, indicating differential regula-
tion of surfactant protein expression. Di-
vergent effects observed in our study
regarding SP-B mRNA expression may be
due to the short observation period or
differences between in vitro and in vivo
conditions. Furthermore, corresponding
pulmonary protein concentrations were
determined and revealed no significant
differences in SP-B and-C concentrations
after induction of lung injury, although
SP-B levels showed a trend to lower levels
compared with pulmonary healthy con-
trols. This finding may indicate compen-
satory mechanisms in a formerly healthy
lung exposed to pronounced changes
leading to severe lung injury.
Regarding the effect of exogenous sur-
factant administration on the pulmonary
surfactant system, neither treatment re-
gime led to significant differences in pul-
monary SP-B and -C mRNA expression and
protein concentration when compared with
saline-treated controls after induction of
lung injury by meconium (MAS controls).
Nevertheless, SP-B mRNA expression
tended to be higher in surfactant-treated
animals, potentially indicating regenerat-
ing mechanisms in alveolar epithelial cells.
As results of TEM and SEM could demon-
strate structural reconstitution of the alve-
olar-capillary compartment following sur-
factant administration, these findings may
represent the time course of pulmonary
recovery following severe mechanical and
inflammation-induced lung injury. Thus,
improved gas exchange and lung function
were followed by structural reconstitution.
This leads to recovery of the surfactant sys-
tem, not entirely acquired in the study set-
ting. In accordance with these findings,
other studies have shown recovery of the
pulmonary surfactant system indicated by
SP-B and -C concentrations reaching base-
line levels not earlier than 4 hrs after in-
duction of lung injury (40). In animal mod-
Figure 5. Pulmonary surfactant protein-C (SP-C) messenger RNA expression normalized to 18S (A)
and SP-C protein concentrations in lung homogenate (dry weight; B) in the left lung lobe of newborn
piglets with experimentally induced meconium aspiration syndrome (MAS; 5 mL/kg meconium)
following administration of physiologic saline, recombinant surfactant protein C surfactant (rSP-C
SF), or natural bovine SF (nat SF). Means were calculated from values of upper and lower lung lobe.
Median, interquartile range (box limits, 25th and 75th percentiles), and extreme values (error bars) are
indicated in the figure. *p � .03; **p � .001 vs. healthy controls.
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els of ARDS, even up to 48 hrs have been
reported for an increase of surfactant pro-
teins after lung failure (41).
As recent studies revealed resistance
of synthetic rSP-C-based surfactant prep-
arations to inactivation by meconium
(15) as well as anti-inflammatory poten-
cies of rSP-C (18), a regulatory or protec-
tive effect of rSP-C on type II cells or
different parts of the alveolar-capillary
compartment has to be considered. Nev-
ertheless, the differing phospholipid con-
tent of both surfactant preparations also
has to be taken into account as a possible
additional mechanism influencing their
effects on lung function and surfactant
protein expression.
As there are limitations to the study re-
garding the number of subjects studied, re-
sults have to be interpreted on an explorative
level; further studies are needed addressing
the ability of different surfactant preparations
to interfere with alveolar type II cell metabo-
lism as a possible cause for individual effects
of surfactant preparations exceeding their
various biophysical properties.
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by real-time PCR.  Results: The PEEP level applied (0.3 vs. 
0 kPa) largely influenced dynamic compliance after admin-
istration of rSP-C surfactant (4.45 vs. 2.58 ml/kg), whereas 
natural surfactant improved compliance regardless of the 
PEEP applied (4.86 vs. 4.24 ml/kg) compared to controls (2.41 
vs. 1.55 ml/kg). Accordingly, administration of PEEP signifi-
cantly increased alveolar count in all groups as well as SP-C 
mRNA expression, whereas SP-B expression and protein 
content both remained unchanged.  Conclusion: Response 
to rSP-C surfactant depends on the PEEP level applied in our 
model of neonatal RDS. These findings should be consid-
ered for the conception of clinical trials regarding treatment 
strategies in neonatal RDS.  Copyright © 2006 S. Karger AG, Basel 
 Introduction 
 Natural surfactant therapy and administration of pos-
itive distending airway pressure both are standards in 
treatment regimes for neonatal respiratory distress syn-
drome (RDS) in preterm infants. 
 Introduced into clinical routine use as second genera-
tion surfactants in the beginning 90s, surfactant prepara-
 Key Words 
 Respiratory distress syndrome  � Rabbit  � Natural bovine 
surfactant  � Recombinant SP-C surfactant  � Positive
end-expiratory pressure 
 Abstract 
 Background and Objectives: Different types of surfactant 
preparations were shown not to exert uniform response in 
preterm infants suffering from respiratory distress syndrome 
(RDS). Therefore, the effects of a recombinant surfactant 
protein C (rSP-C) based preparation and a natural surfactant 
were compared applying different levels of positive end-ex-
piratory pressure (PEEP) in experimental RDS.  Methods: Pre-
term rabbits (n = 7–14 per group; 27 days gestation; term 30 
days) were randomized for receiving either 100 mg/kg rSP-C 
or natural bovine surfactant and were compared with saline 
treated controls. Animals were ventilated for 30 min with ei-
ther 0.3 or 0 kPa PEEP at standardized tidal volumes and lung 
mechanics were measured as well as lung histology and 
mRNA expression of surfactant associated proteins B and C 
 The results were presented in part at the meeting of the Society for 
Pediatric Research 2002 in Baltimore and 2003 in Seattle, USA. 
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tions are either organic lavage or minced lung extracts 
containing the hydrophobic surfactant proteins (SP) B 
and C. Both SP are known for their surface tension low-
ering property, essential for adequate postnatal pulmo-
nary adaptation and maintenance of lung physiology. 
Underscoring their important function, the complete ab-
sence of SP-B has been shown to lead to progressive lethal 
pulmonary failure during the neonatal period and is ad-
ditionally associated with a decreased concentration of 
mature SP-C pro-protein  [1–3] . SP-C, a highly active pep-
tide enhancing the movement of phospholipids to the 
air–water interface, inherits important functions as the 
facilitation of re-spreading after surface film collapse and 
maintenance of film stability  [3, 4] . 
 As third generation surfactants protein-free synthetic 
phospholipids and lipid mixtures containing recombi-
nant SP-C (rSP-C) or a synthetic SP-B mimetic peptide 
have been developed  [5] . Very recently, studies have been 
published, describing multicenter randomized clinical 
trials showing SP-B mimetic based third generation sur-
factant to be effective in prevention of acute and chronic 
pulmonary disorders in preterm infants  [6, 7] . Further-
more, experimental studies on a rSP-C based surfactant 
preparation demonstrated adequate biophysical proper-
ties and increasing lung volumes in preterm rabbits com-
parable to natural surfactant preparations  [8–10] . Ac-
cordingly, rSP-C based surfactant was effective in animal 
models of surfactant deficiency induced by saline lung 
lavage and in experimental meconium aspiration  [11, 12] . 
Nevertheless, there is up to now no consensus about the 
relative importance of the specific surfactant associated 
proteins for optimal function of exogenous surfactant 
preparations and the composition of an ‘ideal’ surfactant 
preparation for treatment of neonatal RDS. 
 With respect to ventilation strategies in neonatal RDS, 
the administration of continuous distending airway pres-
sure or positive end-expiratory positive airway pressure 
(PEEP) has been demonstrated to improve lung function 
and furthermore, has been described to strongly modify 
the effects of exogenously administered surfactant prepa-
rations in experimental settings  [13] . Although the ap-
plication of PEEP in ventilation strategies for preterm in-
fants is clinical routine, high-mean airway pressure re-
sulting from increasing PEEP can result in reduced 
cardiac output and therefore may predispose to various 
neonatal complications especially in the extremely pre-
term infant  [14, 15] . The approach of administering inad-
equately high levels of PEEP using either nasal continu-
ous positive airway pressure systems or a combination 
with mechanical ventilation strategies may thus expose 
infants to an increased risk of acute cerebral hemody-
namic compromise  [15–17] . 
 Therefore, the comparison of a second generation nat-
ural surfactant being in clinical use with a third genera-
tion preparation at different levels of PEEP in a neonatal 
model of RDS may provide further insights into differen-
tial surfactant properties and lead to implications for 
clinical practice. 
 Materials and Methods 
 The experiments were performed according to the Guidelines 
for the Care and Use of Laboratory Animals of the National In-
stitutes of Health and were approved by local authorities of the 
animal investigation committee. 
 Twelve pregnant New Zealand White Rabbits (Bauer, Neuen-
stein-Lohe, Germany) on day 27 of gestation (physiologic gesta-
tion 30 days) were anesthetized with ketamine (10 mg/kg) and 
xylazine (20 mg/kg), body temperature was kept within the phys-
iologic range by heating pads and tracheotomy was performed 
followed by mechanical ventilation. Preterm rabbits were sequen-
tially delivered by cesarian section and given ketamine (10 mg/
kg) and xylazine (20 mg/kg) by intraperitoneal injection to pro-
vide analgesia and sedation. After a tube made from an 18-gauge 
stainless-steel needle was secured into the trachea, the newborn 
rabbits (birth weight 27.4  8 3.6 g; mean  8 standard deviation) 
were randomized to receive either saline or surfactant prepara-
tions. Ventilated control animals received 2 ml/kg saline, where-
as animals of the surfactant groups obtained either bovine lung-
lavage derived surfactant Alveofact � (100 mg/kg) or rSP-C-based 
surfactant Venticute � (100 mg/kg) at volumes of 2 ml/kg each. 
The animals were then transferred to a 37  °  C temperature-con-
trolled ventilator-plethysmography system (Boehringer-Ingel-
heim, Biberach, Germany) using microprocessor-controlled 
magnet valves for in- and expiration. Constant inspiratory flow 
was adjusted using an air regulator attached before the inspira-
tion-valve. Volume-controlled, pressure-limited ventilation was 
adjusted to a tidal volume of 7–8 ml/kg, fraction of inspiratory 
oxygen (FiO 2 ) was 1.0 and air humidity 100%. After an initial 
positive inspiratory pressure (PIP) of 3.5 kPa,  � P (peak inspira-
tory pressure [PIP] – PEEP) was limited to 3 kPa for further ex-
perimental procedure. 
 Mechanical ventilation regimes were further stratified using 
0.3 kPa or zero PEEP (ZEEP; 0 kPa), respectively. Animals were 
ventilated at a rate of 30 breaths per minute and an inspiration to 
expiration rate (I:E) of 1: 2 according to Davis et al.  [18] for overall 
30 min after surfactant administration. 
 Time course of  � P, and tidal volumes (ml) were continuously 
monitored and documented every 5 min during the observation 
period. Dynamic compliance (C dyn ) was calculated per breath ac-
cording to the following formula: 
 
TV
P� ×kg
 (TV = tidal volume,  � P = peak inspiratory pressure [PIP] – PEEP). 
Animals were sacrificed at the end of the protocol with an over-
dose of ketamine and xylazine. After opening of the thorax at the 
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end of the experiment animals were included showing a heart rate 
within the physiologic range and no signs of pneumothorax. Ex-
clusion of animals with no adequate cardiac activity or pneumo-
thorax led to differences in the number of animals within the 
different study groups. One group of animals served as a non-ven-
tilated control group to define base-line levels of SP expression 
and animals were therefore sacrificed immediately after cesarean 
section as described above. 
 For further evaluation of lung histology and SP expression, 
lungs were either paraffin-embedded for histological investiga-
tion or kept at –80  °  C for molecular analyses. For histological 
analyses lungs were perfused with a formaldehyde (4.6%)-glutar-
aldehyde (0.5%) solution for approximately 10 min under applica-
tion of 2.0 kPa PIP in a standardized setting. After clamping of 
the trachea lungs were removed and submersed in the same solu-
tion. 
 Lung Histology 
 Lung tissue was embedded in paraffin and tissue slides were 
obtained from dependent and non-dependent parts of the left and 
right lung. The slides were stained with hematoxylin-eosin (slides 
of 0.5  � m thickness). Lung histology was evaluated by a patholo-
gist (M.E.), blinded to the animal group assignment. Lung tissue 
was screened in order to identify areas representative for the al-
veolar structure of the investigated lung tissue. These representa-
tive fields from each ventral and dorsal part of the lungs were 
studied morphometrically at a 400-fold magnification. Number 
of alveoli and terminal airways were counted in five representa-
tive fields. Septal thickness was measured after photodocumenta-
tion of the lung tissue using Axiovision 3.0 for AxioCam MRc 
(Zeiss, Wetzlar, Germany). Alveolar septa were measured at their 
narrowest diameter and mean values of ten measurements per 
lung were calculated excluding not exactly longitudinally trun-
cated septa. 
 Measurements of SP-B and -C mRNA Expression by 
Real-Time PCR 
 Total RNA isolation, random primed reverse transcription 
and real-time PCR were performed following a standardized pro-
tocol as described previously  [12] . Lung tissue homogenization 
was performed in liquid nitrogen and total RNA was then ex-
tracted using the aid guanidinium-thiocyanate-phenol-chloro-
form method (Roti Quick, Roth, Karlsruhe, Germany). Expres-
sion of SP-B and -C mRNA was measured in tissue of the left lung 
lobe using the real-time RT-PCR technique (TaqMan [TM]). 
Primers and probes for SP-B, SP-C, 18-S and  � -Actin were de-
signed using Primer Express software (Applied Biosystems, Fos-
ter City, USA) following a fixed set of recommendations to allow 
the application of standardized cycling conditions (2 min at 50  °  C, 
10 min at 95  °  C, followed by 45 cycles for 15 s at 95  °  C and 1 min 
at 60  °  C). Control PCRs showed no signal for pure genomic DNA, 
proving mRNA-specificity. Primers were purchased from Roth, 
probes from Applied Biosystems, respectively. Primer and Taq-
Man probe sequences are depicted below. Relative quantification 
was performed using the  �� Ct method, which results in a ratio of 
target gene expression and the expression of a housekeeping or 
reference gene. As the validity of this method depends on the con-
stant expression of the housekeeping gene throughout the set of 
samples studied, we analyzed gene expression ratios of 18S (S) and 
 � -actin (A) as well as the total mRNA content of each sample. 
Since  � -actin showed both no differences between different ex-
perimental groups and the lowest variation in all samples as rec-
ommended for housekeeping genes, it was chosen as reference 
gene for further analysis. 
 Primer and TaqMan TM  Probes 
 � -Actin 
 Forward primer (FP): 5 � -TCA TCA CCA TCG GCA ACG-3 � 
 Reverse primer (RP): 5 � -TTC CTG ATG TCC ACG TCG C-3 � 
 Probe: 5 � (VIC)-CCT TCC TGG GCA TGG AGT CCT GC-
(TAMRA)3 � 
 18S 
 FP: 5 � -GCC GCT AGA GGT GAA ATT CTT G-3 � 
 RP: 5 � -CAT TCT TGG CAA ATG CTT TCG-3 � 
 Probe: 5 � (VIC)-CCG GCG CAA GAC GGA CCA GA-(TAM-
RA)3 � 
 SP-B 
 FP: 5 � -TCC GCT GGT CGT TGA TCA C-3 � 
 RP: 5 � -GTT TGC ACA GGC CCA AGT G-3 � 
 Probe: 5 � (FAM)-CAG AGC CAA ATG AAC CTG AAG GCC 
ATC-(TAMRA)3 � 
 SP-C 
 FP: 5 � -CAC CTT CTC CAT TGG CTC TAG TG-3 � 
 RP: 5 � -ATA CTC TGC GGA GAC ATC TTC ATG-3 � 
 Probe: 5 � (FAM)-TGA CTA CCA GCG GCT CCT GAT TGC 
C-(TAMRA)3 � 
 Quantification of Surfactant Proteins in Lung Homogenates 
 SP-B was quantified by ELISA methods as described previ-
ously with slight modifications  [19] . For quantification of SP-B, 
lung homogenate was diluted 1: 1,000 with PBS/1-propanol 1: 1, 
pH 7.4 and transferred to the microtiter plate. Following selective 
removal of phospholipids by incubation with diisopropylether/
butanol, and saturation of free binding sites with BSA buffer (1% 
BSA in PBS) the plates were probed with a monoclonal anti-SP-B 
antibody (8B5E, raised against porcine SP-B, 5  � g/ml in BSA buf-
fer, 12 h incubation). Microtiter plate-bound antibody was de-
tected employing a monoclonal, biotinylated anti-mouse anti-
body (Amersham Biosciences, Freiburg, Germany, 1: 1,000 in BSA 
buffer; 2 h incubation) with subsequent application of AB-com-
plex (diluted in PBS, 2 h incubation) and using ABTS (2,2 � -azino-
bis-[3-ethylbenzthiazoline-6-sulfonic acid]) as substrate. Absor-
bance was measured at 450 nm and SP content was calculated 
with respect to the dry lung weight employing cubic-spline-inter-
polated standard curves obtained from isolated human SP-B. 
 Statistical Analyses and Data Presentation 
 Data are given as mean and standard deviation. Normal dis-
tribution can be assumed. Statistical analyses were performed us-
ing two-way ANOVA-test, determining the effects of surfactant 
administration and application of PEEP (SPSS for Windows ver-
sion 11.5). For distinct comparison of groups one-way ANOVA 
with posthoc Scheffé was chosen. SP-B and -C mRNA expression 
was analyzed for each lung lobe separately. Data of real-time PCR 
analyses are given as arbitrary units. The level of significance is 
given in the result section. 
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 Results 
 Lung Function Variables 
 The effect of the PEEP level applied varied between 
both surfactant preparations: In animals ventilated at 0 
kPa PEEP (ZEEP), natural surfactant showed a strong 
tendency towards increased tidal volumes and dynamic 
compliance; the PIP – PEEP difference ( � P) accordingly 
was significantly decreased (p  ! 0.001 vs. controls;  ta-
ble 1 ;  fig. 1 ). Contrary to this, administration of rSP-C 
surfactant resulted in less pronounced effects on tidal 
volumes, dynamic compliance and  � P compared with 
the natural surfactant group and controls. Mechanical 
ventilation at 0.3 kPa PEEP combined with either natural 
or recombinant surfactant administration both improved 
dynamic compliance and decreased  � P significantly 
Group n
(rabbits)
Tidal volume
ml/kg b.w.
Dynamic compliance
ml/kPa/kg b.w.
� P (PIP–PEEP)
kPa
Saline (ZEEP) 7 4.5783.00 1.5581.11 3.0480.21
Saline (PEEP 0.3) 6 7.5382.05 2.4181.40 2.4680.44
nat SF (ZEEP) 6 8.0080.35 4.2480.80 1.9580.36b
nat SF (PEEP 0.3) 11 7.2982.02 4.8681.96b 1.4980.75b, c, d
rSP-C SF (ZEEP) 7 5.4982.63 2.5881.75 2.4480.56
rSP-C SF (PEEP 0.3) 14 8.1881.16a 4.4580.93b 1.6580.53b
Mean 8 standard deviation; PEEP (positive end-expiratory pressure; kPa); ZEEP 
(0 kPa PEEP).
a p < 0.02; b p < 0.001 vs. saline ZEEP.
c p < 0.001 vs. saline PEEP 0.3.
d p < 0.001 vs. rSP-C PEEP 0.3.
 
 Table 1. Lung function variables after 
30 minutes of ventilation 
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compared to saline treated controls (p  ! 0.001 vs. con-
trols;  table 1 ;  fig. 1 ). Comparison of both surfactant prep-
arations at PEEP 0.3 revealed no statistically significant 
differences with respect to improved tidal volumes and 
dynamic compliance ( fig. 1 ;  table 1 ). 
 Two-way ANOVA analyses revealed no statistically 
significant interactions between PEEP strategies and sur-
factant preparations with respect to dynamic compliance 
and  � P (p = 0.4; C dyn  and p = 0.7;  � P). 
 Histology 
 Alveolar count was significantly influenced by appli-
cation of PEEP as the number of alveoli increased sig-
nificantly when PEEP at 0.3 kPa was applied (mean 43.8 
 8 7.4/field) compared to ZEEP ventilated animals (mean 
36.6  8 5.3/field; p  ! 0.02). This effect was comparable in 
both surfactant groups and controls, i.e., no statistical 
significant interaction (two-way ANOVA, p = 0.2). Ad-
ministration of either surfactant preparation had no sig-
nificant effect on alveolar count (i.e., number of alveoli 
and terminal airways). 
 Septal thickness did not differ significantly when com-
paring both levels of PEEP (0.3 kPa PEEP: mean 7.4  8 
2.6/field vs. ZEEP: mean 6.4  8 1.1/field) or surfactant 
and control groups. 
 SP-B and -C mRNA Expression 
 Material of two animals (saline, PEEP 0.3; rSP-C SF, 
ZEEP) had to be excluded because of poor mRNA qual-
ity with degradation. Focusing on the effects of different 
PEEP levels, SP-C expression was found to be significant-
ly up-regulated in upper and lower lung lobes when ani-
mals were ventilated with PEEP (0.3 kPa) compared to 
ZEEP (p  ! 0.02,  fig. 2 ). This effect could further be shown 
regardless of either surfactant administration, i.e., no sta-
tistically significant interaction (two-way ANOVA, p = 
0.5). SP-B and -C mRNA expression in upper and lower 
lung lobes was not significantly different between both 
surfactant groups when compared to each other as well 
as to ventilated and non-ventilated control animals ( ta-
ble 2 ). Normalization of mRNA expression to  � -Actin 
and 18S showed comparable results. 
 SP-B Protein Content in Lung Homogenates 
 SP-B concentrations in lung homogenates as deter-
mined by ELISA technique were not significantly altered 
by ventilation strategies (1.25  8 0.96 (saline; ZEEP); 
1.22  8 0.09 (saline; PEEP 0.3) or administration of dif-
ferent surfactant preparations (1.22  8 0.09 (saline; PEEP 
0.3); 2.72  8 2.23 (nat SF; PEEP 0.3); 1.07  8 0.60 (rSP-C 
SF; PEEP 0.3). 
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rabbits ventilated with PEEP (0.3 kPa) 
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(ZEEP). SP-C mRNA expression in the up-
per ( a ) and lower lung lobe ( b ) is given in 
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 Table 2. Pulmonary surfactant protein mRNA expression (upper 
and lower lung lobe) 
Group n (rabbits) SP-B/A SP-C/A
Control (non ventilated) 3 0.9280.40 0.7680.19
Saline (ZEEP) 3 0.9580.36 0.6680.19
Saline (PEEP 0.3) 2 1.5481.07 1.2180.36
nat SF (ZEEP) 3 1.0680.22 0.6180.08
nat SF (PEEP 0.3) 6 0.8780.45 0.9780.32
rSP-C SF (ZEEP) 2 1.0780.34 0.7480.06
rSP-C SF (PEEP 0.3) 7 1.2280.65 0.8580.24
Mean 8 standard deviation, 2��Ct; PEEP (positive end-expir-
atory pressure; kPa).
p values (two-way ANOVA) are given in the text.
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 Discussion 
 Administration of exogenous surfactant and various 
levels of PEEP have been established as standard treat-
ment regimes in neonatal RDS  [17] . In the present animal 
model of primary surfactant deficiency, administration 
of the rSP-C-based surfactant could be shown to be effec-
tive in improving pulmonary function and was further 
found to be equivalent to the natural surfactant prepara-
tion if PEEP was applied. There was, however, a strong 
tendency towards a superiority in terms of lung mechan-
ics in favor of the natural surfactant compared to the rSP-
C based preparation if low PEEP levels, i.e., 0 kPa were 
used. 
 Previous studies have confirmed the efficacy of rSP-C 
based surfactant preparations in preterm animal models 
compared to a natural sheep surfactant, although this 
specific natural surfactant preparation has not accessed 
clinical routine  [18] . We thus aimed at comparing the 
rSP-C surfactant with a natural surfactant preparation 
currently in clinical use, and were able to observe effects 
depending on the surfactant preparation and the level of 
PEEP applied. In clinical practice, surfactant administra-
tion in the preterm infant currently is combined with me-
chanical ventilation strategies applying different levels of 
PEEP and thus mean airway pressure, revealing relevant 
impact not only on pulmonary functions but also on oth-
er organ functions, as, among others, cerebral hemody-
namics  [15, 16] . For this purpose, surfactant prepara-
tions, which exert their effects on lung mechanics and 
oxygenation also at low PEEP levels seem to be qualified 
for clinical use in preterm neonates. 
 The present data on lung mechanics are in line with 
those, published for the effects of a third generation sur-
factant, containing a SP-B analog in a primate model of 
RDS  [20] . Thus, with respect to their effects on lung 
 mechanics and hemodynamics at different levels of 
PEEP further comparative studies of natural second and 
third generation surfactants are mandatory in order to 
optimize treatment strategies in preterm infants with 
RDS. 
 In order to delineate the effect of exogenous surfactant 
administration on surfactant homeostasis, SP-B and SP-
C mRNA expression as well as SP-B protein concentra-
tion were measured in lung homogenates. In the present 
model of primary surfactant deficiency neither the rSP-C 
based nor the bovine surfactant preparation significantly 
affected SP-B or -C mRNA expression or SP-B protein 
concentrations during the observation period. Our data 
are in line with studies, comparing a natural bovine and 
protein-free synthetic lung surfactant preparation with 
respect to maturation of surfactant synthesis. Whereas 
incorportation of 3H-choline and 14C-glycerol and over-
all disaturated phosphatidylcholine synthesis was influ-
enced differentially by natural surfactants compared to 
the protein-free preparation, pulmonary surfactant 
mRNA synthesis was not affected by neither surfactant 
preparation  [21] . Nevertheless, the time course of the 
present study setting has to be taken into account when 
interpreting the results. 
 As PEEP is routinely used in ventilation strategies for 
preterm infants suffering from RDS, its effect on pulmo-
nary histologic patterns and intrapulmonary distribu-
tion of exogenously administered surfactant containing 
a SP-B mimetic protein have been focused in previous 
studies. Maintaining PEEP during the administration 
procedure further improved gas exchange and surfac-
tant distribution patterns  [13] . In the present study, an 
increasing number of recruited primitive alveoli was ob-
served when PEEP was applied indicating alveolar re-
cruitment by the ventilation strategy. However, no ad-
ditional effects of surfactant administration could be 
found regarding histologic variables, although lung me-
chanics further improved. Histologic long-term effects 
potentially resulting from reduced  � P and improved 
compliance could not be addressed due to the time 
course of the present experimental setting. Further-
more, we could demonstrate alterations of SP-C mRNA 
expression following administration of PEEP at a level 
of 0.3 kPa regardless of the type of surfactant exogenous-
ly administered. Increased SP-C mRNA expression may 
reflect improved alveolar type II cell integrity, preserved 
by PEEP administration. In accordance with this, previ-
ous studies have found ventilation with PEEP to mini-
mize loss of total alveolar surfactant and large surfactant 
aggregates  [22] . Furthermore, stabilization of alveoli by 
PEEP has been found to reduce ventilator-induced lung 
injury, which is known to further affect surfactant func-
tion  [23] . As the effect of PEEP on SP-C mRNA expres-
sion could be shown to be most pronounced in controls, 
this finding may further reflect protective effects of 
PEEP ventilation on pulmonary epithelial structures. In 
accordance with this increasing alveolar counts follow-
ing the application of PEEP compared to ZEEP venti-
lated animals indicates recruitment of alveoli by unfold-
ing. Formation of new alveoli seems unlikely in the study 
period. 
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 Conclusions 
 In conclusion, we were able to demonstrate natural 
and recombinant surfactant preparations to exert differ-
ential effects on lung mechanics depending on the PEEP 
level applied in a neonatal model of RDS. As recently pub-
lished clinical trials failed to establish clear-cut superior-
ity of a third generation surfactant compared to standard 
natural surfactant preparations in terms of relevant neo-
natal outcome variables using conventional ventilation 
strategies  [6, 7] , the present data suggest further studies 
to be necessary in order to optimize surfactant replace-
ment strategies in preterms with neonatal RDS. Thus, 
special attention should be paid to the level of PEEP, ei-
ther by nasal CPAP or mechanical ventilation as this 
might be a critical modifier of the response to surfactant 
treatment as well as its complications in neonatal RDS in 
preterm neonates  [24] . 
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ABSTRACT
Objective
Several concepts of treatment in neonatal ARDS have been proposed in the last years. The
present study compared the effects of an open lung concept positive pressure ventilation
(PPVOLC) with a conventional ventilation strategy combined with administration of two different
surfactant preparations on lung function and surfactant homoeostasis.
Design and subjects
After repeated whole-lung saline lavage, 16 newborn piglets were assigned to either PPVOLC
(n = 5) or surfactant treatment under conventional PPV using a natural bovine (n = 5) or a
monomeric protein B based surfactant (n = 6).
Measurements and results
Comprehensive monitoring showed each treatment strategy to improve gas exchange and lung
function, although the effect on PaO2 and pulmonary compliance declined over the study period in
the surfactant groups. The overall improvement of the VEI was significantly greater in the PPVOLC
group. Phospholipid and protein analyses of the bronchoalveolar lavage fluid showed significant
alterations to surfactant homoeostasis in the PPVOLC group, whereas IL-10 and SP-C mRNA
expression was tendentially increased in the surfactant groups.
Conclusions
The different treatment strategies applied could be shown to improve gas exchange and lung
function in neonatal ARDS. To which extent differences in maintenance of lung function and
surfactant homeostasis may lead to long-term consequences needs to be studied further.
Open lung vs surfactant in neonatal ARDS
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INTRODUCTION
In neonatal acute respiratory distress syndrome (ARDS)-like lung disorders different
mechanical ventilation strategies as well as exogenous surfactant administration
have been suggested by various animal studies and introduced into clinical practice
although large clinical trials have not been performed yet.1,2 As shown in
experimental studies, the open lung concept (OLC) as an alternative ventilation
strategy, improves gas exchange and reduces ventilator-induced lung injury in
models of secondary surfactant deficiency.3,4 These effects were seen while applying
the OLC during high-frequency oscillatory ventilation or positive pressure
ventilation.3 Furthermore, histology and biochemical analyses of bronchoalveolar
lavage specimen showed reduced signs of lung injury and pulmonary inflammation
in OLC ventilated animals.4 However, respiratory failure in term neonates is often
accompanied by secondary surfactant deficiency, contributing to impairment of lung
function in these infants. Thus, exogenous surfactant administration in neonatal
ARDS-like lung injury is a clinically well established treatment option.1,5 Even in
meconium aspiration syndrome, leading to severe inflammatory-induced lung
failure, exogenous surfactant administration is part of therapeutic concepts.6
Experimentally, the restoration of pulmonary function and gas exchange as well as
the amelioration of pulmonary inflammatory processes has been shown.7
Nevertheless, it has not been extensively investigated whether surfactant therapy in
neonatal ARDS attains different effects on gas exchange, lung function, surfactant
homoeostasis or pulmonary inflammatory processes compared to the OLC without
surfactant replacement, although these effects may lead to differences in short and
long term pulmonary outcome following neonatal ARDS. Furthermore, there is still
no consensus on ventilation strategy in these infants in combination or without
surfactant administration until now.8
Concerning the choice of the surfactant preparation applied, surfactant preparations
with altered protein and phospholipid contents compared to natural surfactant
products have gained increasing interest in treatment of ARDS-like lung
disorders9,10 due to their potential resistance towards surfactant inactivation.11
Thus, two different surfactant preparations have been chosen for surfactant
replacement therapy in the present study: A natural bovine surfactant, frequently
used in clinical treatment regimes for neonatal ARDS12,13 and a modified monomeric
SP-B based bovine surfactant, that had recently been demonstrated to improve
biological activity of the surfactant preparation compared to standard preparations
in a neonatal lung lavage model.14
Aim of the present study was to compare a treatment strategy applying the OLC
without surfactant replacement with a treatment regime using exogenous surfactant
administration under conventional ventilation for their effects on gas exchange and
lung function variables in a piglet model of neonatal ARDS. Furthermore, different
variables of the surfactant system have been assessed using molecular and
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biochemical analyses of surfactant proteins (SP) and phospholipid composition in
order to obtain sensitive markers for lung injury processes. Regarding the impact of
different treatment strategies on pulmonary inflammatory processes secondary to
lavage-induced lung failure, histologic changes and pulmonary interleukin mRNA
expression have been analyzed.
MATERIALS AND METHODS
Animal preparation
The experiments were performed according to the Guidelines for the Care and Use
of Laboratory Animals of the National Institutes of Health and were approved by
local authorities of the animal investigation committee.
Anesthesia was performed in 16 newborn piglets, aged 6 r 5 days and at a weight
of 3.0 r 0.5 kg (mean r SD each) with ketamine and midazolam after an
intramuscular bolus of ketamine as published previously.7 The piglets were
tracheotomized, a cuffed endotracheal tube (3.0 mm outer diameter; Rüsch,
Kernen-Rommelshausen, Germany) was introduced into the trachea and connected
to the Evita XL (Dräger, Lübeck, Germany). Animals were ventilated using a
pressure-controlled mode with a peak inspiratory pressure (PIP) of 9 - 12 cm H2O, a
positive end-expiratory pressure (PEEP) of 2 cm H2O, and a respiratory rate of
25 - 30 cycles/min, a rate of inspiration to expiration of 1:2 at 100% oxygen (FiO2
1.0). Under these conditions, normocapnia was observed. A neuromuscular block
was induced with pancuromium bromide (0.5 mg/kg i.v.), followed by a continuous
infusion with fentanyl (20 µg/kg/h), midazolam (0.3 mg/kg/h) and pancuromium
bromide (0.3 mg/kg/h) to provide sedation, analgesia and muscular relaxation. The
right common carotid artery was cannulated (20 G, Arrow, Erding, Germany) for
continuous blood gas and blood pressure monitoring (Paratrend/Trendcare, Philips
Medical, Böblingen, Germany). A double-lumen central venous line (4.0 Fr, Arrow)
was placed in the right femoral vein for infusion of fluids and medication. A
continuous infusion of 5% dextrose was started (100 mL/kg/d) and all animals
received one dose of cefotaxime (100 mg/kg). Body temperature was measured
rectally and kept between 38 °C and 39 °C.
Lavage Procedure
Respiratory failure was induced by repeated saline lavage (50mL/kg; 37 °C) as
described previously.15 Lavage procedures were repeated at 3-min interval until
partial arterial oxygen pressure (PaO2) was below 10.7 kPa at the following
ventilator settings: PIP/PEEP 25/5 cm H2O; rate 40 breaths/min; I:E ratio 1:2 and
FiO2 1.0.
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Experimental Protocol
Within 10 min after the final lavage, animals were randomly allocated (T = 0 h) to
one of the three study groups and ventilated for a period of 5 h. FiO2 was kept at
1.0 during the whole experimental procedure. Animals that showed no recovery
from lung lavage procedures in the different treatment groups, indicated by a PaO2
< 60 kPa, were excluded from further analyses.
PPVOLC group
In this group (n = 5), animals with an PaO2 below 13.3 kPa one hour after the
whole-lung lavage procedure, were applied to pulmonary recruitment, that was
attained according to the protocol previously published by van Kaam et al.4 The
ventilatory rate was increased to 80 breaths per minute with an I:E ratio of 1:1.
These settings remained unchanged during the experiment. PEEP was increased up
to 15 cm H2O and PIP was stepwise increased (5 cm H2O each step) to open up the
lung. Recruitment of previously collapsed alveoli during this procedure decreased
intrapulmonary shunt and thus increase oxygenation.3 Optimal alveolar recruitment
was defined as PaO2 levels t 60 kPa.3 The level of PIP needed to recruit the lung was
accordingly defined the opening pressure (PIPO).
After this recruitment procedure, PIP and PEEP were simultaneously decreased in
equal steps every 2 to 3 min until PaO2 dropped below 60 kPa, indicating increased
intrapulmonary shunting. The level of PEEP at this stage of alveolar collapse was
called the closing pressure (PEEPC). PEEP was then raised to a level of 2 cm H2O
above PEEPC and PIP was momentarily raised to PIPO (about 19 s) to fully recruit
the lung. Thereafter, the pressure amplitude was set to keep the partial arterial
carbon dioxide pressure (PaCO2) within the target range (4 - 6 kPa). PEEP only was
decreased if there were signs of alveolar overdistension such as increasing PaCO2,
decreasing PaO2 or decreasing blood pressure.
Surfactant group
In this group, animals were ventilated in the pressure-controlled mode, applying a
conventional ventilation strategy, i.e. PIP/PEEP 25/5 cm H2O; rate 40 breaths/min;
I:E ratio 1:2 and FiO2 1.0.
Ten minutes after surfactant depletion with whole-lung lavage animals received
either natural bovine surfactant (SF-RI1; Alveofact®; n = 5) or a modified
surfactant with a monomeric protein B (mon SP-B; n = 6) at a dosage of 100 mg/kg
each. Details on surfactant preparations are given below. Surfactant preparations
were administered as an intratracheal bolus under continuous chest movements and
maintenance of PEEP. Again the pressure amplitude was set to keep the PaCO2
within the target range (4 - 6 kPa) and PEEP was only decreased if there were signs
of alveolar overdistension such as increasing PaCO2, decreasing PaO2 or decreasing
blood pressure.
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order to obtain sensitive markers for lung injury processes. Regarding the impact of
different treatment strategies on pulmonary inflammatory processes secondary to
lavage-induced lung failure, histologic changes and pulmonary interleukin mRNA
expression have been analyzed.
MATERIALS AND METHODS
Animal preparation
The experiments were performed according to the Guidelines for the Care and Use
of Laboratory Animals of the National Institutes of Health and were approved by
local authorities of the animal investigation committee.
Anesthesia was performed in 16 newborn piglets, aged 6 r 5 days and at a weight
of 3.0 r 0.5 kg (mean r SD each) with ketamine and midazolam after an
intramuscular bolus of ketamine as published previously.7 The piglets were
tracheotomized, a cuffed endotracheal tube (3.0 mm outer diameter; Rüsch,
Kernen-Rommelshausen, Germany) was introduced into the trachea and connected
to the Evita XL (Dräger, Lübeck, Germany). Animals were ventilated using a
pressure-controlled mode with a peak inspiratory pressure (PIP) of 9 - 12 cm H2O, a
positive end-expiratory pressure (PEEP) of 2 cm H2O, and a respiratory rate of
25 - 30 cycles/min, a rate of inspiration to expiration of 1:2 at 100% oxygen (FiO2
1.0). Under these conditions, normocapnia was observed. A neuromuscular block
was induced with pancuromium bromide (0.5 mg/kg i.v.), followed by a continuous
infusion with fentanyl (20 µg/kg/h), midazolam (0.3 mg/kg/h) and pancuromium
bromide (0.3 mg/kg/h) to provide sedation, analgesia and muscular relaxation. The
right common carotid artery was cannulated (20 G, Arrow, Erding, Germany) for
continuous blood gas and blood pressure monitoring (Paratrend/Trendcare, Philips
Medical, Böblingen, Germany). A double-lumen central venous line (4.0 Fr, Arrow)
was placed in the right femoral vein for infusion of fluids and medication. A
continuous infusion of 5% dextrose was started (100 mL/kg/d) and all animals
received one dose of cefotaxime (100 mg/kg). Body temperature was measured
rectally and kept between 38 °C and 39 °C.
Lavage Procedure
Respiratory failure was induced by repeated saline lavage (50mL/kg; 37 °C) as
described previously.15 Lavage procedures were repeated at 3-min interval until
partial arterial oxygen pressure (PaO2) was below 10.7 kPa at the following
ventilator settings: PIP/PEEP 25/5 cm H2O; rate 40 breaths/min; I:E ratio 1:2 and
FiO2 1.0.
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Experimental Protocol
Within 10 min after the final lavage, animals were randomly allocated (T = 0 h) to
one of the three study groups and ventilated for a period of 5 h. FiO2 was kept at
1.0 during the whole experimental procedure. Animals that showed no recovery
from lung lavage procedures in the different treatment groups, indicated by a PaO2
< 60 kPa, were excluded from further analyses.
PPVOLC group
In this group (n = 5), animals with an PaO2 below 13.3 kPa one hour after the
whole-lung lavage procedure, were applied to pulmonary recruitment, that was
attained according to the protocol previously published by van Kaam et al.4 The
ventilatory rate was increased to 80 breaths per minute with an I:E ratio of 1:1.
These settings remained unchanged during the experiment. PEEP was increased up
to 15 cm H2O and PIP was stepwise increased (5 cm H2O each step) to open up the
lung. Recruitment of previously collapsed alveoli during this procedure decreased
intrapulmonary shunt and thus increase oxygenation.3 Optimal alveolar recruitment
was defined as PaO2 levels t 60 kPa.3 The level of PIP needed to recruit the lung was
accordingly defined the opening pressure (PIPO).
After this recruitment procedure, PIP and PEEP were simultaneously decreased in
equal steps every 2 to 3 min until PaO2 dropped below 60 kPa, indicating increased
intrapulmonary shunting. The level of PEEP at this stage of alveolar collapse was
called the closing pressure (PEEPC). PEEP was then raised to a level of 2 cm H2O
above PEEPC and PIP was momentarily raised to PIPO (about 19 s) to fully recruit
the lung. Thereafter, the pressure amplitude was set to keep the partial arterial
carbon dioxide pressure (PaCO2) within the target range (4 - 6 kPa). PEEP only was
decreased if there were signs of alveolar overdistension such as increasing PaCO2,
decreasing PaO2 or decreasing blood pressure.
Surfactant group
In this group, animals were ventilated in the pressure-controlled mode, applying a
conventional ventilation strategy, i.e. PIP/PEEP 25/5 cm H2O; rate 40 breaths/min;
I:E ratio 1:2 and FiO2 1.0.
Ten minutes after surfactant depletion with whole-lung lavage animals received
either natural bovine surfactant (SF-RI1; Alveofact®; n = 5) or a modified
surfactant with a monomeric protein B (mon SP-B; n = 6) at a dosage of 100 mg/kg
each. Details on surfactant preparations are given below. Surfactant preparations
were administered as an intratracheal bolus under continuous chest movements and
maintenance of PEEP. Again the pressure amplitude was set to keep the PaCO2
within the target range (4 - 6 kPa) and PEEP was only decreased if there were signs
of alveolar overdistension such as increasing PaCO2, decreasing PaO2 or decreasing
blood pressure.
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Mean arterial blood pressure, heart rate, ventilator settings, and lung function
variables were recorded at the end of the instrumentation period, at the end of the
lavage procedure and every 30 minutes thereafter. Although blood gas monitoring
was available continuously to provide surveillance of ventilation, data were recorded
at these same time points.
Therapeutic surfactant preparations
Alveofact® (SF-RI1) is a chloroform/methanol extract of bovine lungs containing
phospholipids, neutral lipids and the hydrophobic surfactant apoproteins SP-B and
SP-C as described previously.16 The monomeric SP-B surfactant was prepared from
SF-RI1 by selective reduction of dimeric SP-B and -C by addition of
mercaptoethanol (ME; 50 mg per 2 mL vial) at room temperature for 12 hours and
subsequent removement of ME by vacuum extraction. Except for SP-B content
subsequent analyses of the obtained surfactant preparations showed no significant
differences regarding their phospholipid and apo-protein profile. Both surfactant
preparations were provided as lyophilized powder and resuspended in sterile saline
0.9% (Braun) to a final concentration of 60 mg/mL.
Lung function variables
Tidal volumes, resistance and dynamic compliance were measured by the Evita XL
(Dräger, Lübeck, Germany) and related to body weight in order to compensate for
different lung volumes. Ventilation efficiency index (VEI17) and PIP-PEEP difference
('P) were further calculated.
Bronchoalveolar lavage
At the end of the experiment (T = 5h) piglets were sacrificed by an overdose of
phenobarbitone and bronchoalveolar lavage (BAL) was performed with physiological
saline (3 x 50 mL/kg). The percentage of lung lavage fluid recovered was calculated
and recovery of BAL fluid was comparable in all animals studied. Samples were
centrifuged for 10 min at 300 x g at 5 °C to remove cells and membranous debris
and the supernatant was processed for analyses of surfactant protein and
phospholipid concentrations.
Surfactant protein and phospholipid analyses
Protein analysis
Total BAL proteins were calculated using a commercial assay (BCA assay, Pierce,
Rockford, IL, USA). SP-B and SP-C were analyzed using ELISA techniques as
described previously.18,19
Lipid analysis
Lipids were extracted from BALF with chloroform/methanol,20 and the phospholipid
content was determined by spectrophotometric measurement of phosphorus
according to the method of Rouser et al.21 Individual phospholipid classes were
separated by high performance thin-layer chromatography and quantified using
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scanning densitometry as previously described.22 Total fatty acids were analyzed by
gas-liquid chromatography (Chrompack CP 9001, Varian, Darmstadt, Germany)
following acid-catalyled transmethylation into fatty acid methyl ester (FAME) as
previously described.23 For characterization of relative content of large surfactant
aggregates (LSA), BALF was centrifuged at 48,000 x g (1 h, 4°C), the pellet was
resuspended in 0.9% NaCl and assessed for the PL-content. Recovery of PL in the
pellet was used to calculate relative LSA content.
Histologic processing
After the end of the experiment following the lung lavage procedure, the right lung
was perfused with 300 mL of a formaldehyd (4.6%)-glutaraldehyd (0.5%)-solution
for approximately 10 minutes. Finally, the trachea was clamped at a PEEP of 10
cmH2O, right lungs were removed under maintenance of PEEP and submersed in the
above mentioned solution for histomorphologic analyses. Tissue slides were
obtained from dependent and non-dependent parts of the right lung. Four tissue
slides were analysed from both the upper and lower lung lobe and two slides from
the middle lung lobe, respectively. The slides were stained with hematoxylin-eosin
(slides of 0.5 µm thickness). Lung histology was evaluated by a pathologist (M.E.),
blinded to the animal´s group assignment, according to a previously described
histologic score.24 Variables scored for histologic evaluation were atelectasis,
alveolar and interstitial inflammation, alveolar and interstitial hemorrhage, alveolar
and interstitial edema, necrosis and overdistension. The variables were scored using
a four-point scale with no injury corresponding to 0 points and 4 points indicating
maximum injury.
Measurements of interleukin and surfactant protein (SP) -B and -C mRNA
expression by realtime PCR
Messenger RNA (mRNA) expression of interleukin (IL) -1E, IL-6, IL-8, IL-10 and SP-
B and SP-C was measured in tissue of the left lung lobe using the real-time RT-PCR
technique (TaqMan). Samples were obtained from representative parts of the
upper and lower lung lobe.
Primers and probes were designed using Primer Express software (Applied
Biosystems, Foster City, USA) following a fixed set of recommendations as
described previously.7 Control PCRs showed no signal for genomic DNA, proving
mRNA-specifity. Primers were purchased from Roth (Roth, Karlsruhe Germany),
probes from Applied Biosystems, respectively. Lung tissue homogenization was
performed in liquid nitrogen and total RNA was then extracted using the acid
guanidinium thiocyanate-phenol-chloroform method (Roti Quick, Roth). Total RNA
isolation, random primed reverse transcription and real-time PCR was performed
following a standardized protocol as described previously.7 Primer and TaqMan
probe sequences are depicted in table 1. Relative quantification was performed
using the ''Ct method, which results in a ratio of target gene expression and the
expression of a housekeeping or reference gene.
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variables were recorded at the end of the instrumentation period, at the end of the
lavage procedure and every 30 minutes thereafter. Although blood gas monitoring
was available continuously to provide surveillance of ventilation, data were recorded
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('P) were further calculated.
Bronchoalveolar lavage
At the end of the experiment (T = 5h) piglets were sacrificed by an overdose of
phenobarbitone and bronchoalveolar lavage (BAL) was performed with physiological
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scanning densitometry as previously described.22 Total fatty acids were analyzed by
gas-liquid chromatography (Chrompack CP 9001, Varian, Darmstadt, Germany)
following acid-catalyled transmethylation into fatty acid methyl ester (FAME) as
previously described.23 For characterization of relative content of large surfactant
aggregates (LSA), BALF was centrifuged at 48,000 x g (1 h, 4°C), the pellet was
resuspended in 0.9% NaCl and assessed for the PL-content. Recovery of PL in the
pellet was used to calculate relative LSA content.
Histologic processing
After the end of the experiment following the lung lavage procedure, the right lung
was perfused with 300 mL of a formaldehyd (4.6%)-glutaraldehyd (0.5%)-solution
for approximately 10 minutes. Finally, the trachea was clamped at a PEEP of 10
cmH2O, right lungs were removed under maintenance of PEEP and submersed in the
above mentioned solution for histomorphologic analyses. Tissue slides were
obtained from dependent and non-dependent parts of the right lung. Four tissue
slides were analysed from both the upper and lower lung lobe and two slides from
the middle lung lobe, respectively. The slides were stained with hematoxylin-eosin
(slides of 0.5 µm thickness). Lung histology was evaluated by a pathologist (M.E.),
blinded to the animal´s group assignment, according to a previously described
histologic score.24 Variables scored for histologic evaluation were atelectasis,
alveolar and interstitial inflammation, alveolar and interstitial hemorrhage, alveolar
and interstitial edema, necrosis and overdistension. The variables were scored using
a four-point scale with no injury corresponding to 0 points and 4 points indicating
maximum injury.
Measurements of interleukin and surfactant protein (SP) -B and -C mRNA
expression by realtime PCR
Messenger RNA (mRNA) expression of interleukin (IL) -1E, IL-6, IL-8, IL-10 and SP-
B and SP-C was measured in tissue of the left lung lobe using the real-time RT-PCR
technique (TaqMan). Samples were obtained from representative parts of the
upper and lower lung lobe.
Primers and probes were designed using Primer Express software (Applied
Biosystems, Foster City, USA) following a fixed set of recommendations as
described previously.7 Control PCRs showed no signal for genomic DNA, proving
mRNA-specifity. Primers were purchased from Roth (Roth, Karlsruhe Germany),
probes from Applied Biosystems, respectively. Lung tissue homogenization was
performed in liquid nitrogen and total RNA was then extracted using the acid
guanidinium thiocyanate-phenol-chloroform method (Roti Quick, Roth). Total RNA
isolation, random primed reverse transcription and real-time PCR was performed
following a standardized protocol as described previously.7 Primer and TaqMan
probe sequences are depicted in table 1. Relative quantification was performed
using the ''Ct method, which results in a ratio of target gene expression and the
expression of a housekeeping or reference gene.
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For housekeeping genes E-Actin (A) and hypoxanthin-guanine-phosphoribosyl-
transferase (HPRT) were chosen and validated by variation analyses in all samples.
As E-actin showed both no differences between different experimental groups and
the lowest variation in all samples, it was chosen as reference gene for further
analysis.
Statistical analyses and data presentation
Results are given as mean and standard deviation (SD). Results of real-time PCR
analyses are given in arbitrary units and were normalized to housekeeping gene
expression. Data analysis was performed using SPSS for Windows Version 6.1.3. As
normal distribution has been shown, two-way ANOVA with repeated measurements
was performed for analysis of lung function variables over the time course. In order
to compare outcome levels between the groups differences from T = 5 – T = 0 were
calculated and one-way ANOVA was performed with posthoc Scheffé. Results of the
histologic evaluation as well as from determination of lavage specimen and real-
time PCR were analyzed using one-way ANOVA with posthoc Scheffé. Calculated
P-values are given in the result section.
RESULTS
All animals survived during the study period. There were no statistical significant
intergroup differences in age, weight or number of lavages needed to induce the
lung injury. No air leaks were observed within the study period. Blood gas values
and lung function variables before and immediately after lavage were comparable in
the three treatment groups (Table 2a). One animal of the natural surfactant group
and 2 animals of the mon SP-B surfactant group did not recover after surfactant
administration and required intensified ventilation (OLC) in order to reach PaO2
levels t 60 kPa. As this alteration in treatment strategy was not comparable with
the other study groups, these animals were therefore excluded from further
analysis. Thus, 13 animals were available for analyses.
No animal included for further analyses showed signs of hemodynamic compromise.
Data on hemodynamics were not significantly different between the groups.
Gas exchange and lung function
After induction of lung injury, PaO2, dynamic compliance and VEI were significantly
reduced in all animals (see figure 1), whereas the resistance increased significantly.
PaCO2 remained largely unchanged.
Mean opening pressure was 35 r 4 cm H2O, mean closing pressure 8 r 3 cm H2O in
the PPVOLC group.
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As E-actin showed both no differences between different experimental groups and
the lowest variation in all samples, it was chosen as reference gene for further
analysis.
Statistical analyses and data presentation
Results are given as mean and standard deviation (SD). Results of real-time PCR
analyses are given in arbitrary units and were normalized to housekeeping gene
expression. Data analysis was performed using SPSS for Windows Version 6.1.3. As
normal distribution has been shown, two-way ANOVA with repeated measurements
was performed for analysis of lung function variables over the time course. In order
to compare outcome levels between the groups differences from T = 5 – T = 0 were
calculated and one-way ANOVA was performed with posthoc Scheffé. Results of the
histologic evaluation as well as from determination of lavage specimen and real-
time PCR were analyzed using one-way ANOVA with posthoc Scheffé. Calculated
P-values are given in the result section.
RESULTS
All animals survived during the study period. There were no statistical significant
intergroup differences in age, weight or number of lavages needed to induce the
lung injury. No air leaks were observed within the study period. Blood gas values
and lung function variables before and immediately after lavage were comparable in
the three treatment groups (Table 2a). One animal of the natural surfactant group
and 2 animals of the mon SP-B surfactant group did not recover after surfactant
administration and required intensified ventilation (OLC) in order to reach PaO2
levels t 60 kPa. As this alteration in treatment strategy was not comparable with
the other study groups, these animals were therefore excluded from further
analysis. Thus, 13 animals were available for analyses.
No animal included for further analyses showed signs of hemodynamic compromise.
Data on hemodynamics were not significantly different between the groups.
Gas exchange and lung function
After induction of lung injury, PaO2, dynamic compliance and VEI were significantly
reduced in all animals (see figure 1), whereas the resistance increased significantly.
PaCO2 remained largely unchanged.
Mean opening pressure was 35 r 4 cm H2O, mean closing pressure 8 r 3 cm H2O in
the PPVOLC group.
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Figure 1 Gas exchange (Pao2) and lung function (Cdyn)
Time course of PaO2 (left panel) and dynamic compliance (Cdyn; right panel) over the observation
period. Induction of lung injury by repetitive lavage procedures (T = 0) is followed by open lung
concept positive pressure ventilation (PPVOLC; n = 5) or surfactant treatment under conventional
positive pressure ventilation with a modified monomeric surfactant protein B surfactant (mon SP-
B; n = 4) or a natural bovine surfactant (Alveofact®; nat SF; n = 4). Results are given as mean
and standard deviation.
After experimental intervention (OLC, surfactant administration), PaO2, tidal
volumes, difference of PIP-PEEP ('P), resistance, VEI (P < 0.001 each) and dynamic
compliance (P = 0.01) significantly improved over the time course in each
treatment group (Table 2a).
Regarding differences between the treatment groups, two-way ANOVA testing
revealed a significant difference with respect to PaO2 (P < 0.001; figure 1) and PaCO2
(P < 0.05) levels over the time course with declining effects in the nat SF group 3
hours after intervention. Comparing the relative change of the variables over the
study period (T = 5 – T = 0), gas exchange variables showed a response to each
experimental strategy and the overall change did not differ between the groups
(Table 2b).
Comparable results were found for the development of the dynamic compliance and
the 'P over the study period with a significant difference between the study groups:
Dynamic compliance could be shown to increase up to two-fold, with declining
effects in the surfactant groups after 3 hours (figure 1), whereas 'P could be
decreased in all experimental groups during the observation period with most
pronounced effects in the PPVOLC and the mon SP-B group (P = 0.001).
Nevertheless, changes in dynamic compliance or 'P over the study period (T = 5 –
T = 0) were not statistically significantly different between the groups. Mean airway
pressure was found to be significantly higher in the PPVOLC group compared to both
surfactant treated groups (P = 0.015; data not shown).
The tidal volumes achieved under different ventilation strategies were significantly
lower in the PPVOLC group over the whole study period compared to both surfactant
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Figure 1 Gas exchange (Pao2) and lung function (Cdyn)
Time course of PaO2 (left panel) and dynamic compliance (Cdyn; right panel) over the observation
period. Induction of lung injury by repetitive lavage procedures (T = 0) is followed by open lung
concept positive pressure ventilation (PPVOLC; n = 5) or surfactant treatment under conventional
positive pressure ventilation with a modified monomeric surfactant protein B surfactant (mon SP-
B; n = 4) or a natural bovine surfactant (Alveofact®; nat SF; n = 4). Results are given as mean
and standard deviation.
After experimental intervention (OLC, surfactant administration), PaO2, tidal
volumes, difference of PIP-PEEP ('P), resistance, VEI (P < 0.001 each) and dynamic
compliance (P = 0.01) significantly improved over the time course in each
treatment group (Table 2a).
Regarding differences between the treatment groups, two-way ANOVA testing
revealed a significant difference with respect to PaO2 (P < 0.001; figure 1) and PaCO2
(P < 0.05) levels over the time course with declining effects in the nat SF group 3
hours after intervention. Comparing the relative change of the variables over the
study period (T = 5 – T = 0), gas exchange variables showed a response to each
experimental strategy and the overall change did not differ between the groups
(Table 2b).
Comparable results were found for the development of the dynamic compliance and
the 'P over the study period with a significant difference between the study groups:
Dynamic compliance could be shown to increase up to two-fold, with declining
effects in the surfactant groups after 3 hours (figure 1), whereas 'P could be
decreased in all experimental groups during the observation period with most
pronounced effects in the PPVOLC and the mon SP-B group (P = 0.001).
Nevertheless, changes in dynamic compliance or 'P over the study period (T = 5 –
T = 0) were not statistically significantly different between the groups. Mean airway
pressure was found to be significantly higher in the PPVOLC group compared to both
surfactant treated groups (P = 0.015; data not shown).
The tidal volumes achieved under different ventilation strategies were significantly
lower in the PPVOLC group over the whole study period compared to both surfactant
Chapter 16
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groups (P = 0.002). Relative changes of tidal volumes (T = 5 – T = 0) showed a
significant decline in the mon SP-B group when compared to the nat SF group
(P < 0.05 vs nat SF).
Improved VEI were found in all treatment groups but differed in its time course
between the groups (P = 0.015; figure 2). Most pronounced effects were seen in
the PPVOLC and the mon SP-B group, although effects decreased in the mon SP-B
group towards the end of the observation period (figure 2). The relative change of
the VEI over the observation period (T = 5 – T = 0) was found to be significantly
greater in the PPVOLC group compared to the mon SP-B and nat SF treated group
(P < 0.05; figure 2).
Lung histology
Lung histology was examined in tissue slices of the right upper, middle and lower
lung lobes. All study groups revealed significantly higher histologic scores in the
upper and lower lung lobe compared to the middle lung lobe (P < 0.05, data not
given in detail). Figure 3 shows the histological sum score of the different treatment
groups. Although there was a tendency towards lower sum scores in the mon SP-B
group (27 r 20) compared to the PPVOLC group (46 r 17) and the nat SF group (41 r
23) there was no significant difference.
Surfactant protein (SP) and phospholipid analyses
Total phospholipid and total protein content, phospholipid class profiles, total lipids
fatty acid profiles, recovery of large surfactant aggregates and surfactant proteins
(SP)-B and –C, were determined in cell depleted BAL specimen and are displayed in
table 3. Total PL concentrations were elevated up to 3-fold in both surfactant groups
with significant differences between the nat SF group compared to the PPVOLC group
(P = 0.012; figure 4). Total protein content was not different between the study
groups, resulting in an increase of the phospholipid-protein ratio in both surfactant
groups compared to the PPVOLC group (nat SF P = 0.05; mon SP-B P = 0.09).
Regarding phospholipid composition, the relative content of phosphatidylcholine and
phosphatidylglycerol was found to be significantly increased in both surfactant
groups (P < 0.05 vs PPVOLC) and reached near normal levels. Accordingly, the
relative content of phosphatidylserine, phosphatidylinositol, phosphatidyl-
ethanolamine and sphingomyelin decreased in the mon SP-B and nat SF groups
with significant effects for phosphatidylserine (P < 0.001 vs PPVOLC). Analyses of the
total fatty acids revealed a significantly increased relative content of palmitic acid in
both surfactant groups (P < 0.01 vs PPVOLC; figure 4) whereas levels of
polyunsaturated fatty acids and all unsaturated fatty acids decreased significantly
(P < 0.01 vs PPVOLC). Levels of arachidonic acid decreased in both surfactant groups
compared to the PPVOLC group, eicospentaenoic acid increased in the nat SF treated
group (P < 0.01 vs PPVOLC).
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groups (P = 0.002). Relative changes of tidal volumes (T = 5 – T = 0) showed a
significant decline in the mon SP-B group when compared to the nat SF group
(P < 0.05 vs nat SF).
Improved VEI were found in all treatment groups but differed in its time course
between the groups (P = 0.015; figure 2). Most pronounced effects were seen in
the PPVOLC and the mon SP-B group, although effects decreased in the mon SP-B
group towards the end of the observation period (figure 2). The relative change of
the VEI over the observation period (T = 5 – T = 0) was found to be significantly
greater in the PPVOLC group compared to the mon SP-B and nat SF treated group
(P < 0.05; figure 2).
Lung histology
Lung histology was examined in tissue slices of the right upper, middle and lower
lung lobes. All study groups revealed significantly higher histologic scores in the
upper and lower lung lobe compared to the middle lung lobe (P < 0.05, data not
given in detail). Figure 3 shows the histological sum score of the different treatment
groups. Although there was a tendency towards lower sum scores in the mon SP-B
group (27 r 20) compared to the PPVOLC group (46 r 17) and the nat SF group (41 r
23) there was no significant difference.
Surfactant protein (SP) and phospholipid analyses
Total phospholipid and total protein content, phospholipid class profiles, total lipids
fatty acid profiles, recovery of large surfactant aggregates and surfactant proteins
(SP)-B and –C, were determined in cell depleted BAL specimen and are displayed in
table 3. Total PL concentrations were elevated up to 3-fold in both surfactant groups
with significant differences between the nat SF group compared to the PPVOLC group
(P = 0.012; figure 4). Total protein content was not different between the study
groups, resulting in an increase of the phospholipid-protein ratio in both surfactant
groups compared to the PPVOLC group (nat SF P = 0.05; mon SP-B P = 0.09).
Regarding phospholipid composition, the relative content of phosphatidylcholine and
phosphatidylglycerol was found to be significantly increased in both surfactant
groups (P < 0.05 vs PPVOLC) and reached near normal levels. Accordingly, the
relative content of phosphatidylserine, phosphatidylinositol, phosphatidyl-
ethanolamine and sphingomyelin decreased in the mon SP-B and nat SF groups
with significant effects for phosphatidylserine (P < 0.001 vs PPVOLC). Analyses of the
total fatty acids revealed a significantly increased relative content of palmitic acid in
both surfactant groups (P < 0.01 vs PPVOLC; figure 4) whereas levels of
polyunsaturated fatty acids and all unsaturated fatty acids decreased significantly
(P < 0.01 vs PPVOLC). Levels of arachidonic acid decreased in both surfactant groups
compared to the PPVOLC group, eicospentaenoic acid increased in the nat SF treated
group (P < 0.01 vs PPVOLC).
T
ab
le
2
b
O
ve
ra
ll
di
ff
er
en
ce
s
in
ga
s
ex
ch
an
ge
an
d
lu
ng
fu
nc
ti
on
va
ri
ab
le
s
(T
5
-
T0
)
P
a
o
2
P
a C
O
2
C
d
yn
/
kg
V
T
/k
g
R
es
V
E
I
'
P
T
5
–
T
0
PP
V
O
LC
64
.9
0
±
9.
22
-1
.7
1
±
2.
57
0.
42
±
0.
40
-2
.7
5
±
0.
96
-1
7.
2
±
5.
43
0.
19
±
0.
07
8
*
/
§
-7
.2
±
3.
27
m
on
S
P-
B
51
.1
4
±
33
.4
7
1.
63
±
1.
27
-0
.1
8
±
0.
42
-8
.0
±
4.
24
*
-1
1.
35
±
13
.1
0
0.
04
3
±
0.
07
-6
.0
±
4.
69
na
t
S
F
40
.7
8
±
20
.4
9
-0
.3
8
±
1.
71
0.
13
±
0.
27
-1
.2
5
±
3.
59
0.
3
±
5.
91
0.
02
±
0.
06
-3
±
0.
82
*
P
<
0.
05
vs
na
t
S
F,
§
P
<
0.
05
vs
m
on
S
P-
B
T
ab
le
3
Ph
os
ph
ol
ip
id
an
d
su
rf
ac
ta
nt
pr
ot
ei
n
an
al
ys
es
of
la
va
ge
sp
ec
im
en
g
ro
u
p
n
(p
ig
le
ts
)
P
L
[µ
g
/
m
l]
P
P
Q
LS
A
[%
P
L]
S
P
-B
/
P
L
[%
(w
/
w
)]
S
P
-C
/
P
L
[%
(w
/
w
)]
P
C
[%
]
P
G
[%
]
P
S
[%
]
P
I
[%
]
PP
V
O
LC
5
48
.6
5
±
7.
99
0.
08
±
0.
01
47
.7
±
4.
4
13
.7
1
±
3.
08
3.
06
±
0.
28
73
.8
4
±
5.
57
3.
59
±
1.
82
3.
97
±
2.
44
6.
87
±
2.
37
m
on
S
P-
B
4
13
1.
10
±
59
.6
9
0.
33
±
0.
16
62
.7
±
5.
3
4.
78
±
2.
01
**
1.
23
±
0.
45
**
81
.8
7
±
1.
38
*
7.
27
±
2.
25
*
0.
00
±
0.
00
**
3.
87
±
1.
94
na
t
S
F
4
17
6.
03
±
68
.9
1*
*
0.
37
±
0.
21
*
63
.6
±
6.
2*
6.
19
±
1.
73
**
1.
06
±
0.
62
**
*
81
.1
9
±
1.
43
*
8.
44
±
1.
10
**
0.
00
±
0.
00
**
3.
52
±
0.
79
g
ro
u
p
n
(p
ig
le
ts
)
P
E
[%
]
S
P
H
[%
]
P
U
FA
[%
]
U
sa
t
FA
[%
]
T
L
1
6
:0
[%
]
T
lf
a
2
0
:4
(A
A
)
[%
]
T
lf
a
2
0
:5
(E
P
A
)
[%
]
PP
V
O
LC
5
7.
94
±
3.
63
3.
80
±
1.
42
19
.9
4
±
1.
39
40
.3
4
±
1.
41
44
.7
8
±
1.
73
5.
54
±
0.
55
0.
16
±
0.
03
m
on
S
P-
B
4
4.
99
±
1.
21
2.
02
±
0.
85
12
.1
6
±
3.
76
*
*
33
.1
9
±
3.
27
*
*
52
.9
7
±
3.
78
*
*
3.
03
±
0.
71
*
*
0.
15
±
0.
02
na
t
S
F
4
0.
47
±
0.
18
2.
11
±
0.
81
11
.5
2
±
3.
09
*
*
35
.7
6
±
1.
78
*
50
.2
4
±
2.
17
*
*
2.
58
±
0.
82
*
*
*
0.
29
±
0.
06
*
*
PP
Q
(p
ho
sp
ho
lip
id
-t
o-
pr
ot
ei
n
ra
ti
o)
;
Ph
os
ph
ol
ip
id
cl
as
se
s
ar
e
gi
ve
n
as
pe
rc
en
t
(w
/w
)
of
al
lp
ho
sp
ho
lip
id
s.
LS
A
=
la
rg
e
su
rf
ac
ta
nt
ag
gr
eg
at
es
,
gi
ve
n
as
pe
rc
en
t
(w
/w
)
of
al
lB
A
LF
ph
os
ph
ol
ip
id
s.
PC
(p
ho
sp
ha
ti
dy
lc
ho
lin
e)
;
PG
(p
ho
sp
ha
ti
dy
lg
ly
ce
ro
l)
;
PS
(p
ho
sp
ha
ti
dy
ls
er
in
e)
;
PI
(p
ho
sp
ha
tid
yl
in
os
it
ol
);
PE
(p
ho
sp
ha
tid
yl
et
ha
no
la
m
in
e)
;
S
PH
(s
ph
in
go
m
ye
lin
);
Fa
tt
y
ac
id
s
w
er
e
de
rm
in
ed
in
th
e
B
A
L
to
ta
ll
ip
id
fr
ac
ti
on
an
d
ar
e
gi
ve
n
as
pe
rc
en
t
(w
/w
)
of
al
l
fa
tt
y
ac
id
s.
PU
FA
(p
ol
yu
ns
at
ur
at
ed
fa
tt
y
ac
id
s
in
th
e
to
ta
ll
ip
id
fr
ac
ti
on
)
;
TL
16
:0
(p
al
m
it
ic
ac
id
in
th
e
to
ta
ll
ip
id
fr
ac
ti
on
).
A
A
=
A
ra
ch
id
on
ic
ac
id
,
EP
A
=
Ei
co
sp
en
ta
en
oi
c
ac
id
*
P
<
0.
05
vs
PP
V
O
LC
;
**
P
<
0.
01
vs
PP
V
O
LC
;
**
*
P
<
0.
00
1
vs
PP
V
O
LC
§
P
<
0.
05
vs
m
on
S
P-
B
;
§§
P
<
0.
01
vs
m
on
S
P-
B
Chapter 16
180
0
0.1
0.2
0.3
0.4
0.5
H 0 1 2 3 4 5
PPVOLC (n=5)
mon SP-B (n=4)
nat SF (n=4)
VE
I
time (h)
0
0.1
0.2
0.3
PPVOLC
n=5
mon SP-B
n=4
nat. SF
n=4
VE
I(
T=
5
–
T=
0)
*
*
B
PPVOLC
C
mon SP-B
D
nat SF
Figure 2 Ventilation efficiency index (VEI)
Left panel: Time course of ventilation efficiency index (VEI) over the observation period. Induction
of lung injury by repetitive lavage procedures (T = 0) is followed by open lung concept positive
pressure ventilation (PPVOLC; n = 5) or surfactant treatment under conventional positive pressure
ventilation with a nat SF (n = 4) or a mon SP-B (n = 4). Right panel: Difference of VEI over the
study period (T5 - T0). Results are given as mean and standard deviation. * P < 0.05 vs PPVOLC.
Figure 3 Histological sum scores (upper, middle and lower right lung lobe)
Histologic sum scores (atelectasis, alveolar and interstitial inflammation, alveolar and interstitial
hemorrhage, alveolar and interstitial edema, necrosis and overdistension) of upper, middle and
lower right lung lobe using a four-point scale with no injury corresponding to 0 points and 4 points
indicating maximum injury (A). Hematoxylin-eosin staining of exemplary histologic slides showing
dystelectasis and neutrophiles in nearly all alveoli in the PPVOLC group (B), regularly ventilated
lung parenchyma in the monomeric SP-B group (C) and dystelectasis and neutrophiles in some of
the alveoli in the natural SF group (D; hematoxylin-eosin, magnification 100x). Study groups:
PPVOLC (n = 5); surfactant treatment under conventional PPV with mon SP-B (n = 4) or a nat SF
(n = 4). Results are given as mean and standard deviation.
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The relative content of large surfactant aggregates was increased in the surfactant-
treated groups compared to PPVOLC (nat SF P = 0.06; mon SP-B P = 0.048). Both,
total SP-B and SP-C concentrations were not statistically different between the
experimental groups. Nevertheless, levels were significantly lower in the surfactant
groups compared to the PPVOLC group (P < 0.001) when normalized to the total PL
content of each sample.
Interleukin and surfactant protein B and C mRNA expression analysis.
Interleukin and SF mRNA expression was determined in the upper and lower left
lung lobes. As there were no significant differences between the results obtained
from the upper and lower left lung lobes, means were calculated and used for
further analyses. Results normalized to E-Actin are represented in table 4 and in
figure 5. Normalization to the housekeeping gene HPRT confirmed the results.
Analyses of the pulmonary interleukin mRNA expression in the left lung revealed no
significant differences between the study groups. Nevertheless, there was a
tendency towards increased mRNA expression levels of the pro-inflammatory
cytokines IL-1E, IL-6 and IL-8 in the nat SF group compared to mon SP-B and the
PPVOLC group (P = 0.1; figure 5; table 4). Furthermore, mRNA expression of the
anti-inflammatory cytokine IL-10 showed a tendency towards increased levels in
both surfactant groups compared to the PPVOLC group (P = 0.1; figure 5).
Furthermore, SP-B and -C mRNA expression were found to be not significantly
different. However, SP-C mRNA expression was shown to be tendentially increased
in the mon SP-B and nat SF groups compared to the PPVOLC group (table 4).
Figure 4 Total Phospholipids and Palmitic Acid in BAL fluid
Total Phospholipids and palmitic acid (in percent (weight/weight; w/w) of all BAL fatty acids) in
cell depleted BALF in the three different study groups. Study groups: PPVOLC (n = 5); surfactant
treatment under conventional PPV with mon SP-B (n = 4) or a nat SF (n = 4). Median, 95%
confidence interval and range are indicated in the figure. ** P < 0.01 vs PPVOLC
Chapter 16
180
0
0.1
0.2
0.3
0.4
0.5
H 0 1 2 3 4 5
PPVOLC (n=5)
mon SP-B (n=4)
nat SF (n=4)
VE
I
time (h)
0
0.1
0.2
0.3
PPVOLC
n=5
mon SP-B
n=4
nat. SF
n=4
VE
I(
T=
5
–
T=
0)
*
*
B
PPVOLC
C
mon SP-B
D
nat SF
Figure 2 Ventilation efficiency index (VEI)
Left panel: Time course of ventilation efficiency index (VEI) over the observation period. Induction
of lung injury by repetitive lavage procedures (T = 0) is followed by open lung concept positive
pressure ventilation (PPVOLC; n = 5) or surfactant treatment under conventional positive pressure
ventilation with a nat SF (n = 4) or a mon SP-B (n = 4). Right panel: Difference of VEI over the
study period (T5 - T0). Results are given as mean and standard deviation. * P < 0.05 vs PPVOLC.
Figure 3 Histological sum scores (upper, middle and lower right lung lobe)
Histologic sum scores (atelectasis, alveolar and interstitial inflammation, alveolar and interstitial
hemorrhage, alveolar and interstitial edema, necrosis and overdistension) of upper, middle and
lower right lung lobe using a four-point scale with no injury corresponding to 0 points and 4 points
indicating maximum injury (A). Hematoxylin-eosin staining of exemplary histologic slides showing
dystelectasis and neutrophiles in nearly all alveoli in the PPVOLC group (B), regularly ventilated
lung parenchyma in the monomeric SP-B group (C) and dystelectasis and neutrophiles in some of
the alveoli in the natural SF group (D; hematoxylin-eosin, magnification 100x). Study groups:
PPVOLC (n = 5); surfactant treatment under conventional PPV with mon SP-B (n = 4) or a nat SF
(n = 4). Results are given as mean and standard deviation.
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The relative content of large surfactant aggregates was increased in the surfactant-
treated groups compared to PPVOLC (nat SF P = 0.06; mon SP-B P = 0.048). Both,
total SP-B and SP-C concentrations were not statistically different between the
experimental groups. Nevertheless, levels were significantly lower in the surfactant
groups compared to the PPVOLC group (P < 0.001) when normalized to the total PL
content of each sample.
Interleukin and surfactant protein B and C mRNA expression analysis.
Interleukin and SF mRNA expression was determined in the upper and lower left
lung lobes. As there were no significant differences between the results obtained
from the upper and lower left lung lobes, means were calculated and used for
further analyses. Results normalized to E-Actin are represented in table 4 and in
figure 5. Normalization to the housekeeping gene HPRT confirmed the results.
Analyses of the pulmonary interleukin mRNA expression in the left lung revealed no
significant differences between the study groups. Nevertheless, there was a
tendency towards increased mRNA expression levels of the pro-inflammatory
cytokines IL-1E, IL-6 and IL-8 in the nat SF group compared to mon SP-B and the
PPVOLC group (P = 0.1; figure 5; table 4). Furthermore, mRNA expression of the
anti-inflammatory cytokine IL-10 showed a tendency towards increased levels in
both surfactant groups compared to the PPVOLC group (P = 0.1; figure 5).
Furthermore, SP-B and -C mRNA expression were found to be not significantly
different. However, SP-C mRNA expression was shown to be tendentially increased
in the mon SP-B and nat SF groups compared to the PPVOLC group (table 4).
Figure 4 Total Phospholipids and Palmitic Acid in BAL fluid
Total Phospholipids and palmitic acid (in percent (weight/weight; w/w) of all BAL fatty acids) in
cell depleted BALF in the three different study groups. Study groups: PPVOLC (n = 5); surfactant
treatment under conventional PPV with mon SP-B (n = 4) or a nat SF (n = 4). Median, 95%
confidence interval and range are indicated in the figure. ** P < 0.01 vs PPVOLC
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Table 4 Pulmonary cytokine and surfactant protein mRNA expression (left lung lobe)
group n
(piglets)
IL-1ǃ/A IL-6/A IL-8/A IL-10/A SP-B/A SP-C/A
PPVOLC 5 0.73 ± 0.51 1.27 ± 1.21 0.10 ± 1.3 0.34 ± 0.16 2.84 ± 2.17 0.82 ± 0.65
mon SP-B 4 0.35 ± 0.38 0.59 ± 0.78 0.03 ± 0.04 0.62 ± 0.32 4.05 ± 2.31 1.67 ± 0.87
nat SF 4 2.10 ± 1.77 3.96 ± 3.82 0.23 ± 0.22 0.67 ± 0.2 2.95 ± 1.27 1.09 ± 0.35
Normalization to E-Actin (A). Values are given as fold change (2-''Ct). Means were calculated from
values of upper and lower lung lobe.
Figure 5 Pulmonary interleukin mRNA expression (upper and lower left lung lobe)
Pulmonary interleukin (IL) -1E (left panel) and IL-10 (right panel) mRNA expression normalized to
E-Actin in piglets with experimentally induced neonatal ARDS –like lung failure. Study groups:
PPVOLC (n = 5); surfactant treatment under conventional PPV with mon SP-B (n = 4) or a nat SF
(n = 4). Median, 95% confidence interval, range, and extreme values ({) are indicated in the
figure. Means were calculated from values of upper and lower lung lobe.
DISCUSSION
Respiratory failure often accompanies critical illness and determines morbidity in
term neonates. Thus, evaluation of therapeutic strategies in neonatal ARDS-like
lung disorders remains an important issue as demonstrated by a multitude of
experimental and clinical studies.13,25 Several concepts of treatment have been
established in the last years. Under these, surfactant treatment is an established
therapeutic option, as secondary surfactant deficiency may be causally related to
the clinical picture and a potential cause for the impairment in lung function.
Nevertheless, surfactant treatment is a very cost-intensive therapy and surely has
its limitations due to adverse effects or the need for repetitive doses. Thus,
conventional ventilation is often used as first-line management of the disease. If
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conventional ventilation strategies fail, further treatment regimes are searched for
in order to minimize ventilator-induced lung injury. Nevertheless, there is still no
consensus on ventilation strategy in these infants in combination or without
surfactant administration until now.8 Furthermore, different treatment regimes as
exogenous surfactant administration under conventional ventilation or application of
open lung ventilation strategies without surfactant replacement may result in
differing effects on gas exchange, lung function, surfactant homoeostasis or
pulmonary inflammatory processes and thus short and long term pulmonary
outcome following neonatal ARDS.
In the present study, both treatment strategies investigated, administration of
exogenous surfactant under conventional ventilation as well as application of the
OLC, were found to be efficient in improving gas exchange and lung function in
neonatal ARDS. The effects on lung function and gas exchange have been confirmed
for each treatment strategy in previous experimental studies.3,12,26
To experimentally assess the effects of exogenous surfactant administration in
neonatal ARDS compared to the OLC, a standard treatment regime using natural
bovine surfactant has been chosen. However, surfactant preparations with varying
protein and phospholipid contents have gained increasing interest in treatment of
ARDS-like lung failure.9,10 As native SP-B in humans is secreted in the alveoli
predominantly in its dimeric form, modification of the dimeric structure leads to
differences in the function of SP-B and is currently under further investigation.27,28
Recently, modification of a natural surfactant preparation (SF-RI1) into a
monomeric SP-B content has been demonstrated to improve biological activity
compared to standard preparations in vivo.14 Thus, the monomeric SP-B surfactant
has been chosen as an alternative surfactant treatment in the present model.
Regarding the effects of the different treatment regimes applied on lung function
and gas exchange in detail, the decrease of PaO2 levels in the natural surfactant
group at the end of the study period might reflect the need for repetitive doses of
surfactant to achieve sustained treatment effects and may be a consequence of
surfactant inactivation in the alveolar compartment.29 Furthermore, levels of
dynamic compliance did not reach initial values during the observation period and
treatment effects declined to the end of the study period in the surfactant treated
groups. In line with our findings, van Kaam and colleagues have shown a dose-
dependency of the surfactant effect whereas a time-dependency with declining
effects over time could be shown in the present study.30 Besides the the need for
repetitive or increased doses of exogenous surfactant the indicated effects may be
due to ventilator-induced lung injury under the conventional ventilation regime in
the surfactant treated animals. Improvement of VEI over the study period was
found to be most pronounced in the PPVOLC group, which may reflect the potential of
this ventilation strategy to more equal recruitment of different parts of the lung. In
contrast, surfactant is known to preferably reach lower lung lobes and its
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E-Actin in piglets with experimentally induced neonatal ARDS –like lung failure. Study groups:
PPVOLC (n = 5); surfactant treatment under conventional PPV with mon SP-B (n = 4) or a nat SF
(n = 4). Median, 95% confidence interval, range, and extreme values ({) are indicated in the
figure. Means were calculated from values of upper and lower lung lobe.
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term neonates. Thus, evaluation of therapeutic strategies in neonatal ARDS-like
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established in the last years. Under these, surfactant treatment is an established
therapeutic option, as secondary surfactant deficiency may be causally related to
the clinical picture and a potential cause for the impairment in lung function.
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its limitations due to adverse effects or the need for repetitive doses. Thus,
conventional ventilation is often used as first-line management of the disease. If
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conventional ventilation strategies fail, further treatment regimes are searched for
in order to minimize ventilator-induced lung injury. Nevertheless, there is still no
consensus on ventilation strategy in these infants in combination or without
surfactant administration until now.8 Furthermore, different treatment regimes as
exogenous surfactant administration under conventional ventilation or application of
open lung ventilation strategies without surfactant replacement may result in
differing effects on gas exchange, lung function, surfactant homoeostasis or
pulmonary inflammatory processes and thus short and long term pulmonary
outcome following neonatal ARDS.
In the present study, both treatment strategies investigated, administration of
exogenous surfactant under conventional ventilation as well as application of the
OLC, were found to be efficient in improving gas exchange and lung function in
neonatal ARDS. The effects on lung function and gas exchange have been confirmed
for each treatment strategy in previous experimental studies.3,12,26
To experimentally assess the effects of exogenous surfactant administration in
neonatal ARDS compared to the OLC, a standard treatment regime using natural
bovine surfactant has been chosen. However, surfactant preparations with varying
protein and phospholipid contents have gained increasing interest in treatment of
ARDS-like lung failure.9,10 As native SP-B in humans is secreted in the alveoli
predominantly in its dimeric form, modification of the dimeric structure leads to
differences in the function of SP-B and is currently under further investigation.27,28
Recently, modification of a natural surfactant preparation (SF-RI1) into a
monomeric SP-B content has been demonstrated to improve biological activity
compared to standard preparations in vivo.14 Thus, the monomeric SP-B surfactant
has been chosen as an alternative surfactant treatment in the present model.
Regarding the effects of the different treatment regimes applied on lung function
and gas exchange in detail, the decrease of PaO2 levels in the natural surfactant
group at the end of the study period might reflect the need for repetitive doses of
surfactant to achieve sustained treatment effects and may be a consequence of
surfactant inactivation in the alveolar compartment.29 Furthermore, levels of
dynamic compliance did not reach initial values during the observation period and
treatment effects declined to the end of the study period in the surfactant treated
groups. In line with our findings, van Kaam and colleagues have shown a dose-
dependency of the surfactant effect whereas a time-dependency with declining
effects over time could be shown in the present study.30 Besides the the need for
repetitive or increased doses of exogenous surfactant the indicated effects may be
due to ventilator-induced lung injury under the conventional ventilation regime in
the surfactant treated animals. Improvement of VEI over the study period was
found to be most pronounced in the PPVOLC group, which may reflect the potential of
this ventilation strategy to more equal recruitment of different parts of the lung. In
contrast, surfactant is known to preferably reach lower lung lobes and its
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administration therefore often leads to inhomogenous recruitment and holds the
risk of partial overdistension. However, 'P values could be reduced in all study
groups possibly leading to a reduction of shear stress and therefore traumatic
lesions in the lung in the experimental ventilatory setting.
In order to define the impact of the treatment strategies applied on lavage-induced
lung injury, surfactant homoeostasis and inflammatory processes, histologic
patterns, cytokine and surfactant mRNA expression as well as phosholipid profiles of
BALF were investigated.
Regarding histologic patterns, the evaluated score comprising different variables
indicating the degree of lung injury showed no significant differences between the
groups. Nevertheless, analyses showed alterations to pulmonary tissue, reflecting
the delay of structural recovery compared to reconstitution of lung function and gas
exchange after indcution of neontatal ARDS-like lung injury. Interestingly, the
monomeric SP-B preparation revealed distinct improvement in lung structure,
indicating the altered surfactant preparation to be effective in influencing surfactant
homeostasis and thus the recovery in physiologic lung function.
Alterations to the surfactant system have been shown to closely reflect lung injury
processes, especially alveolar type-II cell integrity and metabolism.19,22,31
Furthermore, reconstitution of the surfactant system has been discussed as an
important measure assessing different treatment regimes in ARDS-like lung
disorders in children and infants. As expected, the phospholipid profile in BAL
specimen showed a normalization of the phospholipid and fatty acid profile in both
surfactant groups with an increase in concentrations of phosphatidylcholine and
phosphatidylglycerol as well as the palmitic acid concentration in the total lipid
fraction. In contrast, the phospholipid analyses of the PPVOLC group showed the
typical profile for ARDS-like lung failure with a reduced recovery of
phosphatidylcholine and phosphatidylglycerol, an increased relative content of
polyunsaturated fatty acids, i.e. arachidonic acid and a decreased relative content of
palmitic acid.22,31 Furthermore, the relative content of large surfactant aggregates
and the phospholipid-to-protein ratio in the BALF were significantly reduced in the
PPVOLC group. These findings reflect a significantly reduced recovery of the
surfactant system in the PPVOLC ventilated animals compared to the surfactant
treated groups, potentially leading to short and long term consequences regarding
lung injury processes and pulmonary function. Regarding the surfactant protein
concentrations in the BALF, levels were comparabel in all study groups. In the case
of SP-C, this may suggest a stabilization of type-II cell integrity and surfactant
homeostasis under the indicated treatment regimes as previous studies showed
significantly reduced SP-C levels in BAL specimen from conventionally ventilated
ARDS patients.19 An early recovery of alveolar type-II cell integrity and metabolism
after lavage-induced lung injury may be further indicated by tendentially increased
SPC mRNA expression in the in the surfactant treated groups.
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Nevertheless, the combination of both treatment strategies will gain increasing
interest as shown by latest studies.2,32 Here, open lung ventilations strategies after
exogenous surfactant administrations allowed reduction of both the opening and the
closing pressures after some hours, which may be explained by a higher alveolar
stabilization after recruitment maneuvers in combination with the effect of
surfactant administration. Futhermore, the present study showed the relative SP-B
and SP-C concentration after normalization to the total PL content of each sample,
to be lower in the surfactant-treated groups. This may be assigned to a higher rate
of ventilator-induced lung injury in the conventionally ventilated, surfactant treated
animals, where higher 'P values and tidal volumes compared to the PPVOLC group
may led to an increased rate of shear stress to the lung. Furthermore, limits of
surfactant treatment in combination with a conventional ventilation strategy are
demonstrated by cases with an absent response to exogenous surfactant
administration as one animal in the natural surfactant and two animals in the
monomeric SP-B group did not recover from lung failure and required an intensified
ventilation regime.
In terms of pulmonary inflammatory processes, previous studies have been shown
for the OLC ventilation to reduce signs of inflammation in BALF when compared to
conventional ventilation strategies.3 In the present study analyses of pulmonary
pro-inflammatory cytokine mRNA expression showed no significant differences
between the OLC and the surfactant treated groups. However, mRNA expression of
the anti-inflammatory cytokine IL-10 showed a tendency towards increased levels in
the surfactant groups compared to the PPVOLC group, possibly indicating anti-
inflammatory or lung protective effects of exogenous surfactant. The tendency
towards increased IL-1E, IL-6 and IL-8 mRNA expression in the natural surfactant
group has also previously been shown in vivo for natural surfactant treated animals
in a model of experimental meconium aspiration syndrome7 and for endothelial cell
activation in vitro33 and may be explained by a higher concentration of arachidonic
acid in the natural surfactant preparation.
In conclusion, we could show in a descriptive manner both treatment strategies, the
administration of exogenous surfactant under conventional ventilation as well as the
application of an intensified mechanical ventilation concept following the OLC to be
efficient in improving lung function and gas exchange in neonatal ARDS.
Nevertheless, administration of surfactant led to a more pronounced effect on gas
exchange and compliance in the first hours, although improvement in oxygenation
declined after 3 hours in the natural surfactant group. In contrast, improvement in
VEI was found to be more evident in the PPVOLC group. Thus, differences between
the surfactant and the PPVOLC groups regarding maintenance of the effects on lung
function as well as surfactant homoeostasis and the pulmonary inflammatory
balance may lead to pulmonary long-term consequences which should be addressed
in further studies. Limitations of the study that need to be addressed are the
potential induction of lung injury processes by the initial conventional ventilation as
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well as the application of relatively high tidal volumes in the PPVOLC group compared
to previous OLC ventilation regimes. Changing ventilation strategies and modifying
existing concepts reflect everyday clinical practice, but further studies are needed to
address the impact of these variables on pulmonary outcome. As well clinical
studies are needed in order to verify findings from animal studies. As the results
indicate differing surfactant preparations to reveal distinct effects on lung function
variables, further studies are needed to define an optimized surfactant composition.
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SUPPLEMENTAL METHODS
Animal preparation
The piglets were tracheotomized, a cuffed endotracheal tube (3.0 mm outer
diameter; Rüsch, Kernen-Rommelshausen, Germany) was introduced into the
trachea and connected to the Evita XL (Dräger, Lübeck, Germany). Animals were
ventilated using a pressure-controlled mode with a peak inspiratory pressure (PIP)
of 9 - 12 cm H2O, a positive end-expiratory pressure (PEEP) of 2 cm H2O, and a
respiratory rate of 25 - 30 cycles/min, a rate of inspiration to expiration of 1:2 at
100 % oxygen (FiO2 1.0). Under these conditions, normocapnia was observed. A
neuromuscular block was induced with pancuromium bromide (0.5 mg/kg i.v.),
followed by a continuous infusion with fentanyl (20 µg/kg/h), midazolam (0.3
mg/kg/h) and pancuromium bromide (0.3 mg/kg/h) to provide sedation, analgesia
and muscular relaxation. The right common carotid artery was cannulated (20 G,
Arrow, Erding, Germany) for continuous blood gas and blood pressure monitoring
(Paratrend/Trendcare, Philips Medical, Böblingen, Germany). A double-lumen
central venous line (4.0 Fr, Arrow) was placed in the right femoral vein for infusion
of fluids and medication. A continuous infusion of 5% dextrose was started (100
mL/kg/d) and all animals received one dose of cefotaxime (100 mg/kg). Body
temperature was measured rectally and kept between 38 °C and 39 °C.
Experimental Protocol
PPVOLC group
The ventilatory rate was increased to 80 breaths per minute with an I:E ratio of
1:1. These settings remained unchanged during the experiment. PEEP was
increased up to 15 cm H2O and PIP was stepwise increased (5 cm H2O each step) to
open up the lung. Recruitment of previously collapsed alveoli during this procedure
decreased intrapulmonary shunt and thus increased oxygenation and optimal
alveolar recruitment was defined as PaO2 levels t 60 kPa.3 The level of PIP needed
to recruit the lung was accordingly defined the opening pressure (PIPO).
After this recruitment procedure, PIP and PEEP were simultaneously decreased in
equal steps every 2 to 3 min until PaO2 dropped below 60 kPa, indicating increased
intrapulmonary shunting. The level of PEEP at this stage of alveolar collapse was
called the closing pressure (PEEPC). PEEP was then raised to a level of 2 cm H2O
above PEEPC and PIP was momentarily raised to PIPO (about 19 s) to fully recruit
the lung. Thereafter, the pressure amplitude was set to keep the partial arterial
carbon dioxide pressure (PaCO2) within the target range (4 - 6 kPa). PEEP only was
decreased if there were signs of alveolar overdistension such as increasing PaCO2,
decreasing PaO2 or decreasing blood pressure.
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Many lung diseases in children - and even sometimes in adults too - are
characterized by failure of development and/or destruction of the alveoli. Maturation
of the human lung continues well after the newborn period through a spectrum of
lung developmental stages ranging from neonatal to infant and adult phases of lung
development.1,2 Infant and adult lungs is a differ importantly in alveolar structure,
matrix composition and angiogenesis, especially when new alveoli are formed and
septum differentiation takes place.3-5 Injury to the developing lung often leads to
impaired alveolarization and vascularization, and thus in poor lung function.6-11
Ventilator-induced lung injury (VILI) may be associated with alveolar structural
damage, pulmonary edema, inflammation and fibrosis.12 Oxygen toxicity and
barotraumas - but also volutrauma - induce an inflammatory response in the
developing lung, which persists in infants who develop bronchopulmonary dysplasia
(BPD).13 Disturbance of late lung development resulting from ventilation and
oxygen toxicity is not only found in premature lungs. Infants born with
compromised respiratory status, either due to immaturity or conditions such as
congenital lung hypoplasia, congenital diaphragmatic hernia (CDH) or space-
occupying processes including lobar emphysema, often require mechanical
ventilation and supplemental oxygen. Individually and in combination, these
measures will predispose the newborn to VILI. In CDH, BPD occurs in around 33%
of survivors.14
Septum differentiation and Extracellular matrix
Two developmental phases are to be distinguished in the formation of the
respiratory system: (1) the initial creation of an air-conducting system and (2) the
later development of the respiratory alveoli.15 Septum differentiation (secondary
crest outgrowth) is the achievement of the final mature morphology of the lung.
During this process, the airways grow into the surrounding mesenchyme while
alveolar septa undergo branching into 2nd and 3rd generations and invaginate
inwards into the airspace.15 Alveolar septation is a necessary step to increase the
blood-gas interface. Among the variety of factors that participate in the control of
budding of secondary septa, elastin deposition in the thickness of primary septa
appears to have a spatially instructive role.16,17 The specific sites of elastic fiber
formation correspond precisely to the location of future buds. During
alveolarization, alveolar type (ATII) cells proliferate and differentiate into type I
cells. Alveolar septa divide the terminal respiratory saccules, increasing the number
of alveoli.15 The septa are supported by the extracellular matrix (ECM), composed of
a collagen scaffold, in which glycoproteins and elastin are involved.17
The onset of septa formation is heralded by the initial deposition of elastin at
specific sites in the walls of the developing saccules. In the normal lung, deposition
and arrangement of elastin fibers is particularly important in the formation and
maintenance of alveolar structures. Various abnormalities of lung elastin have been
documented in infants with Bronchopulmonary Dysplasia (BPD).18 Bruce and
coworkers showed an increase of urinary desmosine excretion, which is a biomarker
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of elastin degradation in mechanically ventilated infants developing BPD during the
first week.19 Breakdown of lung elastin in BPD has been attributed to inflammatory
processes associated with infection and/or hyperoxia.20,21 Non-survivors of severe
BPD showed increased accumulation of distributed elastic fibers in the distal lung
parenchyma. This accumulation was associated with reduced septation and fewer
alveoli which are typical pathological feature of the "new-type" of BPD.22
In animal studies, Wendel et al. described the importance of elastin in the formation
of the alveoli.23 Deletion of the elastin gene in mice led to neonatal death from
respiratory failure associated with reduced terminal airway branching and defective
vasculogenesis in the lung. These mice showed loss of septa formation and
emphysema.
The mechanism by which abnormal elastin synthesis contributes to failed alveolar and
lung capillary formation in BPD is unclear. Several studies have shown that cyclic
stretch, such as that induced by mechanical ventilation of the developing lung, may
increase elastin deposition associated with increased tropelastin gene expression.24,25
Alveolarization is mediated by paracrine, autocrine, and juxtacrine communication
between the epithelium and endothelium, and their associated fibroblasts,
modulated by signaling molecules including members of the TGF-E and BMP
pathways. Schwartz et al have shown that increased mechanical forces activate
epithelial cells to produce signals and inflammatory proteins that stimulate the
interstitial fibroblasts to produce collagen, metalloproteins, and other inflammatory
products.26 This process causes remodelling and continued tissue repair as long as
higher airway pressure persists. One might speculate that by removing the pressure
would halt the remodelling and cause regression of the excessive interstitial
collagen.18 Oki et al showed elevated levels of collagen IV, which normally lines the
subepithelial basement membrane of all of the distal airways and saccules, in the
bronchoalveolar lavage fluid of infants who had respiratory distress syndrome in the
first two weeks of life and developed BPD.27 This finding underlines the role of
collagen fibers in the development of BPD.
As mentioned before, elastin deposition and alveolar formation can also be
disrupted by increased elastase activity as seen in lung inflammation during acute
and chronic neonatal respiratory insufficiency.28 Members of the TGF signaling
pathway are known to play a role in inflammatory processes. Bland et al. observed
high expression of TGF-Į and TGF-ǃ in the lung of preterm lambs after one day of
mechanical ventilation.28 This would suggest that these mitogens are involved in
modifying elastin assembly during mechanical ventilation of the developing lung, as
they both induce tropoelastin secretion in lung myofibroblasts in the septal crest.
Thus, increased TGF-Į causes severe remodeling in the premature lung.29,30
Elevated expression of TGF-Į during the saccular phase disrupted lung
morphogenesis, caused mesenchymal and vascular remodeling, and led to neonatal
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mortality within the first week of life in mice. Interestingly, induction of TGF-Į
during the saccular stage of lung development caused a different phenotype and
gene expression profile than did an increase in TGF-Į during the alveolar phase and
in the adult lung. TGF-ǃ will raise, and fibroblast growth factor-ǃ and interleukin-1ǃ,
by transcriptional and post-transcriptional processes, will lower elastin mRNA levels.31
The sustained integrity of alveolar structures requires the maintenance of alveolar
cells and ECM, but the repair capacity of these components in response to injury is
unclear.32,33 Coordinated deposition of new matrix elements such as collagen and
elastin has been proven to be involved in the repair mechanism after alveolar
destruction. Excess deposition of collagen in the lung leads to fibrosis and
dysfunction as seen in infants within the "old-type" of BPD with fibroproliferation.34
During septation, myofibroblasts appear at the edge of the developing septa and
these cells are essential for normal alveoli formation.35,36 They show alpha-smooth
muscle actin (alpha-SMA) expression and synthesize abundant elastin and
collagen.37 Depletion of myofibroblasts from the alveolar wall, as seen in PDGF-A
null mice, results in emphysema secondary to failure of septation. This would seem
to indicate that myofibroblasts are crucial for septation.35 Bland and colleagues
found reduced expression of PDGF-A and its receptor in the lungs of preterm lambs
developing BPD, and suggested a possible role for this growth factor in the
abnormal distribution of elastin.28
Chung Ming and colleagues found that increased levels of lung connective tissue
growth factor (CTGF) mRNA and protein expression were associated with hyperoxia-
induced lung fibrosis in neonatal rats, and that upregulation of CTGF expression
preceded the increase in collagen levels. This suggests that CTGF is involved in the
pathogenesis of hyperoxia-induced lung fibrosis.38
Injury to the developing lung will disrupt critical signaling pathways that regulate
alveolarization, and these pathways are indeed defective in premature infants
developing BPD.10 Elevated levels of TGF-ǃ ligand have been detected in animal
models of BPD, but also in infants with BPD undergoing mechanical ventilation.39
Furthermore, exposure of alveolar ATII cells to hyperoxia promotes association of
Smad2/3/4, TGF-ǃ regulated transcription factors, with DNA, indicating that
hyperoxia upregulates the TGF-ǃ signaling pathways. Under hyperoxia conditions
we demonstrated temporal changes in the expression and localization of key
signaling components of the TGF-ǃ/BMP system.39
Proliferation and differentiation of ATII cells are key steps in alveolarization. It is
known that TGF-ǃ can arrest proliferation of ATII cells and prevent keratinocyte
growth factor-stimulated ATII cell proliferation. Hyperoxia-induced upregulation of
TGF-ǃ signaling in the alveolar epithelium is conductive to apoptosis of ATII cells,
thereby contributing to alveolar hypoplasia in BPD.40
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Deregulation of TGF-ǃ signaling also impacts ECM deposition and remodeling, other
key processes in alveolarization. TGF-ǃ controls the secretion of some matrix
proteases as well as their inhibitors. Three families of proteases and their
corresponding antiproteases play a crucial role in lung destruction and the
development of BPD.41,42 These are the serine proteases (e.g. neutrophil proteases
and trypsin), matrix metalloproteinases (MMPs) and their inhibitors tissue inhibitors
of metalloproteinases (TIMPs), and the papain family (cathepsin B, H, K, L, and S).
Altiok et al. found increase levels of all cathepsins in a baboon model of BPD,
whereas levels of cystatin B and C mRNA were unchanged.42 Cathepsin functionality
in bronchoalveolar fluid and lung tissue homogenate had correspondingly increased.
Levels of cathepsin B, H, S, and K decreased with advancing gestational age.
Recent work implicating a protease-antiprotease imbalance in BPD studied the role
of serine protease inhibitor B1 (SERPINB1), which is a monocyte neutrophil elastase
inhibitor, expressed in neutrophils and macrophages.41 Transcriptional factors that
are prominent in the inflammatory response, such as nuclear factor-kappaB and
PU.1/Spi-1, have been identified as regulatory elements for the SERPINB1 gene.43,44
SERPINB1 protected surfactant protein A and D from degradation by neutrophil
elastase. The findings from Yasumatu et al. suggest that SERPINB1 upregulation in
"new-type" BPD is a part of protection mechanism and that SERPINB1 contributes
to the regulation of neutrophil elastase activity along with other well-known
elastase inhibitors.41
Figure 1 Pathways described in this thesis that are involved in secondary septum formation
and that are deregulated in disturbances of late lung development, which can lead to BPD.
EC: endothelial cells, TGF: Transforming Growth Factor, BMPs: Bone Morphogenetic Proteins.
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Deregulation of TGF-ǃ signaling also impacts ECM deposition and remodeling, other
key processes in alveolarization. TGF-ǃ controls the secretion of some matrix
proteases as well as their inhibitors. Three families of proteases and their
corresponding antiproteases play a crucial role in lung destruction and the
development of BPD.41,42 These are the serine proteases (e.g. neutrophil proteases
and trypsin), matrix metalloproteinases (MMPs) and their inhibitors tissue inhibitors
of metalloproteinases (TIMPs), and the papain family (cathepsin B, H, K, L, and S).
Altiok et al. found increase levels of all cathepsins in a baboon model of BPD,
whereas levels of cystatin B and C mRNA were unchanged.42 Cathepsin functionality
in bronchoalveolar fluid and lung tissue homogenate had correspondingly increased.
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elastase. The findings from Yasumatu et al. suggest that SERPINB1 upregulation in
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elastase inhibitors.41
Figure 1 Pathways described in this thesis that are involved in secondary septum formation
and that are deregulated in disturbances of late lung development, which can lead to BPD.
EC: endothelial cells, TGF: Transforming Growth Factor, BMPs: Bone Morphogenetic Proteins.
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Throughout lung development and alveolarization, MMP1, MMP2, MMP9, and TIMP-2
(tissue inhibitor of metalloprotease-2) are strongly expressed in humans and
mice.45,46 TGF-ǃ stimulation increased TIMP-1 mRNA expression in fibroblast in
hyperoxia conditions, compared to fibroblast in normoxic conditions.
Vascular Development
Various animal models and autopsy studies of humans who died from BPD have
consistently shown fewer small arteries and abnormal distribution of vessels within
the distal lung suggestive of defective vascular development.47,48 Two processes are
involved in vascular development, i.e. vasculogenesis and angiogenesis. The latter
process, by differentiation of angioblasts in the mesoderm, generates new vessels
from pre-existing ones, not only during development but also during tumor growth.
Angiogenesis is distinct from vasculogenesis, which process is prominent in
embryogenesis. Vasculogenesis involves de novo formation of blood vessels from
angioblast or endothelial precursor cells. These cells migrate and differentiate to
form vascular tubes in response to local transcription and growth factors as well as
ECM. The relative contributions of vasculogenesis and angiogenesis to lung vascular
growth at each stage of lung development are being debated and further studies
are needed to better define the underlying mechanisms. In human fetal lungs, the
airways would seem to act as a template for pulmonary artery development, with
endothelial tubes forming around the terminal buds of distal airspaces, suggesting
an inductive influence of the epithelium.49 A study by Parera and colleagues from
our own institution suggested distal angiogenesis as a new mechanism for
pulmonary vascular morphogenesis.50
The bronchial vessels develop with the preacinar airways and are complete by
approximately 16-weeks gestation with further growth in size to match lung growth.
Preacinar pulmonary arteries, supplied by the right heart, grow with the airways
into the intra-acinar region and fuse with peripheral microvasculature that has
arisen from mesenchyme by vasculogenesis.49 The importance of vascular supply
for alveolarization was demonstrated by several studies using antiangiogenic agents
such as a VEGF receptor inhibitor. This agents disrupts vascular development,
leading to reduced pulmonary arterial density and inhibition of alveolar growth. The
VEGF signaling pathway has been shown to play a crucial role in embryonic
vasculogenesis.51
The hypoxia-inducible factors (HIFs) are highly regulated by oxygen tension.52
Molecular oxygen directly regulates HIF-dependent transcription and angiogenic
growth factor expression within the lung. When a fetus is exposed to oxygen at
birth, when breathing starts, steady-state levels of HIF expression within the lung
will rapidly and dramatically decrease. This downregulation is important to control
the production of several growth factors, angiogenic factors, including VEGF and its
receptors, and NO.53,54 Suppression of VEGF and NO production during critical
stages of lung vasculogenesis and alveolar development may lead to long-term
impairment of lung growth.55-57 Nitric oxide as a factor enhancing HIF, and
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subsequently VEGF expression, is inhibited by endogenous arginine metabolites
such as asymmetric dimethylarginine (ADMA). Dimethylarginine
dimethylaminohydrolase (DDAH) selectively degrades ADMA and thus eliminates an
inhibitor for NOS.58-63 DDAH activity in the whole lung substantially increases for 24
hours after birth, and this would be expected to reduce tissue concentrations of
NOS inhibitors and thereby to stimulate NO generation.64 Experimental animals
exposed to hypobaric hypoxia showed markedly suppressed DDAH activity. These
data suggest that DDAH isoforms are developmentally regulated in the lung and
could contribute to pulmonary vascular adaptation and to the dysfunction in
vascular reactivity dysfunction seen in persistent pulmonary hypertension of the
newborn.64
The hypoxic environment of the developing lung favors HIF-1Į-dependent gene
expression. HIF-2Į controls expression of the VEGF isoforms in the developing lung,
thereby preventing disturbed development. HIF-1Į and HIF-2Į levels were found to
decrease following preterm birth of lambs with respiratory distress syndrome
(RDS). This is likely due to suddenly heightened activities of all prolyhydroxylases
(PHDs) caused by the rapid rise in molecular oxygen that is followed by higher
prolylhydroxylase domain containing protein (PHD)-2 expression. With HIF
expression, VEGF mRNA expression declined as well, which therefore may be one of
the factors contributing to the pathophysiologic changes seen in neonatal
respiratory failure.52,65-67
Recent evidence suggests that blood vessels in the lung actively promote normal
alveolar development and thus help maintain alveolar structures throughout life.
Consequently, modulation of angiogenic growth factors and vascular precursor cells
may have therapeutic potential for lung diseases characterized by alveolar
damage.67
The role of the endothelium-dependent relaxing factor NO in the regulation of the
pulmonary vascular tone in the perinatal period has been well established. Recent
studies suggest that inhaled NO may decrease the incidences of death and BPD in
premature infants. Ventilated primates given low-dose inhaled NO have fewer
myofibroblasts and less elastin deposition in alveoli than control animals.68
Endothelial nitric oxide synthetase (eNOS) transgenic animals are less susceptible
to ventilator-induced lung injury and have less fibrosis following injury with
bleomycin.69,70 Patients with interstitial lung diseases, such as idiopathic pulmonary
fibrosis and BPD, suffer from lung fibrosis secondary to myofibroblast-mediated
excessive ECM deposition and destruction of lung architecture.71 TGF-ǃ1 induces
epithelial-mesenchymal transition of alveolar epithelial cells to myofibroblasts.72,73
Read and colleagues suggest a potential mechanism by which NO impacts alveolar
fate and protects against fibrosis. Their findings indicate that NO is important in
preserving an epithelial phenotype and in decreasing epithelial-mesenchymal
transition (EMT) in alveolar epithelial cells.74
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Endothelial progenitor cells (EPCs) have been isolated from the peripheral blood of
humans. Ex vivo, CD34+ EPCs differentiate to an endothelial phenotype and
incorporate into neovessels at sites of ischemia. EPCs can migrate from the bone
marrow to the peripheral circulation, where they contribute to repair of injured
endothelium and the formation of new blood vessels. Lung injury in mice rapidly
released EPCs into the circulation to help repair the lung, together with other bone
marrow derived progenitor cells. In elastase-induced emphysema, cells derived
from the bone marrow develop characteristics of endothelial cells and contribute to
repair of the alveolar capillary wall. A biological role of EPC in lung repair is
suggested by significantly higher numbers of circulating EPCs in patients with
pneumonia, and the fact that patients with low EPC counts tend to have persistent
fibrotic changes in their lungs even after recovery from pneumonia.75,76 Findings
from Balasubramaniam and colleagues in an experimental model of BPD suggest
lowered circulating, lung, and bone marrow EPC levels in BPD.77 Those observations
taken together, one might speculate, that EPCs migrate from the bone marrow to
the peripheral circulation and the lung, to aid in the repair of injured endothelium
and to help restore lung integrity.
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Figure 2 Epithelial-endothelial interactions in pulmonary vascular development showing
pathways involving NO, VEGF and HIF, described in this thesis. See text for details.
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Lung development: Bronchopulmonary dysplasia and chronic obstructive
pulmonary disease
As originally described, BPD is a specific form of chronic lung disease of infancy with
varying degrees of alveolar and vascular growth arrest, airway branching
abnormalities, and peribronchiolar fibrosis.34 Occasionally there may be relentless
progression towards pulmonary fibrosis, with progressive scarring of the fine
structures of the lung parenchyma. Chronic obstructive pulmonary disease (COPD)
is a devastating disorder that causes much human suffering. It is currently the
fourth leading cause of death in the United States.78 Pulmonary emphysema is
classified as a major component of COPD. The pathology of emphysema has been
characterized as loss of respiratory surface area, as evidenced by abnormal,
permanent enlargement of airspaces distal to the terminal bronchioles.71 Both BPD
and COPD lungs show markedly enlarged distal airspaces. There is a difference,
however, in that COPD is related to the destruction of established alveoli, whereas
BPD represents the disruption of normal lung development. In contrast to many
forms of lung disease in adults showing increased angiogenesis is present, COPD is
characterized by a reducted numbers of blood vessels, similar to infant with BPD.79
Liebow as early as 1959 reported, remarkably thin and almost avascular alveolar
septa in lung emphysema underlining that vascular development or impairment of
vasculogenesis is important in the pathophysiology of the disease.80 Confirmation
came from animal models in which VEGF receptor blockade induced alveolar septal
cell apoptosis and airspace enlargement.57,81 Various animal models of BPD and
studies of humans who died from BPD have consistently shown a reduction in the
number of fewer small arteries and abnormally distributed vessels within the distal
lung as well as enlarged distal airspaces resulting from disrupted lung
development.48,56 The response of the developing lung to injury encompasses a
multitude of cellular and molecular interactions. Dependent on these interactions
there will be either regeneration and repair or progression to growth arrest,
irreversible tissue destruction, and/or fibrosis. Injury to an immature or abnormally
developed lung, such as in premature babies or infants with CDH, can eventually
stop alveolar septation and alter pulmonary vascularization.13 Arrest of lung
development is the hallmark of chronic lung disease, the most common
complication in preterm infants, ventilated newborns with ARDS like-disorders, such
as meconium aspiration syndrome or pneumonia, and congenital lung diseases,
such as CDH or CCAM.14
Genetic abnormalities can impact early fetal lung development, postnatal lung
maturation, as well as adult lung injury and repair. Studies suggest that abnormally
developed lung structure and function may contribute as a susceptibility factor for
several adult lung diseases.82,83 In mice, many key genes result in common
phenotypes comprising either neonatal respiratory distress if the structural effect is
severe, or reduced alveolarization and early onset emphysema if the effect is
milder.84,85
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Figure 3 Cell-cell and cell-matrix interactions during disturbance of late lung development and
COPD, described in this thesis. See text for details.
Null mutation of either Fgf10 as well as Fgfr2b completely abrogates lung branching
morphogenesis distal to the carina, whereas hypomorphic or ectopic FGF signaling
results in neonatal lethal alveolar dysplasia.86-88
Null mutation of Smad3, which is a key receptor activated Smad in the TGF-ǃ
signaling pathway, results initially in a rather subtle failure of correct organization of
the matrix, which in turn is an antecedent of subsequent, early onset but still
relatively mild pulmonary emphysema.89 This early onset emphysema in Smad3 null
mutants is also associated with activation of excessive matrix metalloproteinase
(MMP) activity.
Null mutation of lysyl oxidase prevents correct elastin cross-linking, and hence
alveolarization is also incomplete.33,90 Disordered extracellular matrix deposition and
remodeling are key features of arrested alveolarization associated with BPD. The
causes underlying this perturbed ECM remodeling are unknown. Lysyl oxidases,
which catalyse the cross-linking of collagen and elastin fibers, are an important
group of ECM-remodeling enzymes. We observed elevated mRNA and protein
expression of three lysyl oxidases, Lox, LoxL1 and LoxL2, in the lungs of neonatal
mice exposed to chronic hyperoxia, as well as in human patients with BPD
(unpublished data, see Appendix B). Both lysyl oxidase catalytic activity in lung
protein extracts, and staining intensity for lysyl oxidases in the septae and smooth
muscle layers of the developing lung from hyperoxia-exposed mice were
dramatically increased. Lysyl oxidase gene expression and secretion induced by
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transforming growth factor (TGF)-ǃ was also increased in embryonic fibroblast-like
NIH/3T3 cells and human fibroblasts exposed to chronic hyperoxia (unpublished
data). Administration of TGF-ǃ neutralizing antibodies to hyperoxia-exposed
neonatal mice improved alveolarization and restored Lox expression. Our
unpublished data suggest that elevated lysyl oxidase activity in the lungs of mice
exposed to chronic hyperoxia are responsible, at least in part, for the aberrant
elastin and collagen metabolism observed in hyperoxia-induced BPD. This idea is
reinforced by our observation that lungs from mice exposed to chronic hyperoxia
exhibit elevated levels of desmosine, a marker of elastin cross-linking, and that
infants with BPD have elevated desmosine levels in their lung tissue and urine.19,91
Similarly, in mice with the Pdgf-a null mutation, alveolar myofibroblasts fail to
differentiate and produce elastin; hence, alveolar crests also fail to form.35 Failure
to protect elastin from proteolytic degradation in Į1-antitrypsin deficiency, or from
excessive destruction mediated by neutrophil elastase results in emphysema, a
disease characterized by destruction of the alveolar wall.92 Nevertheless,
destruction of elastin through neutrophil elastase is also seen in ventilated preterm
infants developing bronchopulmonary dysplasia.93,94 Elastic complexity of the lung is
important in respiratory physiology. Thus, absence of correctly cross-linked and
oriented elastin containing matrix predisposes to failure of correct establishment of
elastic linkage and alveolarization. Deregulation at several critical points in different
pathways involved in ECM remodeling, angiogenesis and alveolarization in the injured
lung may result in alveolar hypoplasia and fibrosis, and then lead to BPD or COPD.
Lung hypoplasia due to intrauterine growth impairment
Intrauterine growth retardation (IUGR) is a relatively common complication during
pregnancy.95 It occurs when greater placental resistance restrict fetal perfusion or
when specific intrinsic fetal factors are in place, such as chromosomal anomalies.
Decreased tissue perfusion will cause hypoxemia, limit the delivery of nutrients and
raise cortisol concentration, all of which can affect lung development.96-98 High fetal
cortisol levels can cause lung development in preterm fetuses with IUGR to
accelerate, as high cortisol levels induce pneumocytes to secrete more surfactant.
We found higher incidence of BPD, however in premature infants with IUGR as
compared with prematures without IUGR, as compared with prmature without
IUGR, although the rate of RDS did not differ between these groups.99 It would
seem, therefore, that mechanisms other than the pulmonary surfactant system
underlie the development of BPD. On the other hand, long-term prenatal
administration of corticosteroids has been found to decelerate rather than
accelerate of pulmonary development.100 Animal studies have documented that
reduced nutrient availability may impede lung growth.101 Prenatal nutrient and
oxygen restriction in IUGR infants could affect ECM components such as elastin,
which in turn could alter alveolar properties. Epidemiologic studies indicate that
exposure to a suboptimal intrauterine environment that results in IUGR increases
the risk of respiratory illness in infants, children and adults.96,102,103 It is likely that
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undernutrition contributes to neonatal chronic lung disease in preterm infants. With
lung development still ongoing undernutrition, or lack of essential minerals or
micronutrients, could have detrimental effects on lung anti-oxidant and defense
mechanisms and surfactant production, as well as on structural maturation of
alveoli and small airways.104,105 Fetal breathing movements are important for
maintaining the appropriate degree of lung expansion and hence normal lung
growth. Humans fetuses with IUGR, however, show less breathing movements,
perhaps because circulating and/or cerebral adenosine concentrations have
increased.106,107 Experimental studies have clearly shown that nicotine exposure
during gestation interferes with the gas exchanging region of the lungs.108 The
observed effects include decreased pulmonary elastin content, fewer alveoli and
greater alveolar volumes, more alveolar wall fenestrations, and less surface area
available for gas exchange.
Pulmonary Surfactant
Pulmonary surfactant found at the air-liquid interface of the lung functions to
reduce surface tension. It is synthesized by type II pneumocytes, stored in lamellar
bodies, and secreted into the airspace as tubular myelin, from which it is then
absorbed into the air-water interface to form a surfactant monolayer. Pulmonary
surfactant is composed of 80% phospholipids, 8% neutral lipids, and 12% proteins.
The phospholipid components of natural surfactant, especially
dipalmitoylphosphatidylcholine (DPPC), are primarily responsible for lowering
surface tension. Surfactant related proteins, on the other hand, are critical for
surfactant behavior, immune defense, and particle clearance.109,110,111 Members of
the collectin family of host defense proteins, surfactant protein A (SP-A) and SP-D
are hydrophilic oligomers that, play a role in the immune response to microbial
challenge by binding microorganisms and modulating leukocyte function such as
chemotaxis, cytokine function, and phagocytosis.112 SP-D is thought to help reduce
inflammation in the lung. This was postulated from the finding of delayed removal
of apoptoticSP-D deficient mice have delayed removal of apoptotic cells, such as
alveolar macrophages, in SP-D deficient mice, an important step in the resolution of
the inflammation that may contribute to chronic lung disease.113,114 Recombinant
SP-D binds preferentially to these apoptotic cells and may have a role in reducing
inflammation in synthetic surfactant preparations. SP-B and SP-C are critically
important small hydrophobic apoproteins that promote absorption and dynamic
spreading of surfactant to form a phospholipid monolayer that lines the alveoli.
Polymorphisms in the SP-B gene and mutations of SP-C have been associated with
BPD and other interstitial lung diseases. Congenital SP-B deficiency is a lethal cause
of respiratory distress.115, 116
Surfactant replacement therapy for the premature infant with respiratory distress
has now become standard therapy.117 A significant body of evidence supports the
view that surfactant deficiency in neonates with severe respiratory failure either
represents a primary deficiency such as in RDS, or results from surfactant inhibition
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or inactivation, as in pneumonia or meconium aspiration syndrome.118 Endogenous
and exogenous pulmonary surfactant may be inhibited by albumin together with
proteases and coagulation factors present in the alveolar compartment during the
acute phase of respiratory failure. Adding dextran or polymyxin to surfactant
preparations, will counteract this inhibition.119,120 Numerous in vivo studies have
demonstrated that mechanical ventilation of the lung alters the composition and
homeostasis of surfactant.12 Decreased large aggregate surfactant after mechanical
ventilation was found to result in impaired lung function.121 Both rodent and primate
animal studies have reported altered production of surfactant proteins after the
animals' exposure to high oxygen concentrations.122,123 In a rat model of bleomycin-
induced lung injury, respiratory distress was associated with a deficiency of SP-B
and SP-C. Addition of exogenous SP-B in vitro reconstituted the minimum surface
tension to a level seen in the control animals. Bronchial lavage specimens from
human infants with severe BPD have revealed abnormal surface tension, elevated to
the level seen in specimens from infants with inherited SP-B deficiency.124,125,126
Further studies have shown that the gene regulation and release of surfactant
protein B and C are mechanosensitive, suggesting that mechanical ventilation and
stretch may influence the pulmonary surfactant system.127
Additional studies will need to address the question of the usefulness of surfactant
treatment in preterm infants who still show respiratory failure requiring mechanical
ventilation beyond the first week of life. Surfactant therapy ameliorates respiratory
failure in neonatal lung diseases showing surfactant inhibition and dysfunction, so
that less rescue cardiopulmonary bypass are needed and the incidence of chronic
lung disease is brought down. As recombinant SP-C surfactant was found efficient in
premature lambs and rabbits suffering from respiratory distress syndrome as well
as in different models of acute lung injury, Hilgendorff and colleagues addressed its
potencies in a model of lung injury mainly characterized by severe inflammatory
changes.128,129 As recent studies revealed that synthetic SP-C surfactant preparation
shows resistance to inactivation by meconium and that recombinant SP-C possesses
anti-inflammatory potencies of recombinant SP-C, it might well be that synthetic
surfactant exerts a regulatory or protective effect on type II cells or different parts
of the alveolar-capillary compartment.128,129 The future of neonatal medicine
requires designer surfactants that mimic natural surfactant, thereby increasing
resistance to inhibition and improving the clinical response.
In conclusion, many different processes are involved in late lung development, such
as vasculogenesis, septation and alveolarization. Disturbances of these processes
have major impacts on the structure of the developing lung. These processes
nevertheless also offer good starting points for therapeutic interventions. Further
research will have to shed light on the details of these processes and the most
effective ways to implement therapies. The similarities between BPD and COPD may
provide possibilities for combined research.
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Bronchopulmonary dysplasia in CDH
Congenital diaphragmatic hernia (CDH) is a rare congenital anomaly with an
incidence of around 1 in 3,000 live births.130 Over the past 20 years, pulmonary
hypoplasia and pulmonary hypertension haveemerged as the two cornerstones of
the pathophysiology of CDH. More recently, ventilator induced lung injury (VILI)
was recognized as a contributing iatrogenic factor for chronic lung disease in
CDH.131,132 Lung injury secondary to mechanical ventilation certainly is one of the
major contributors to mortality and is a major risk factor for severe morbidity
following initial admission for CDH. Consequently, infants with CDH have a high
mortality risk of up to 30%, depending on case selection. In addition, long-term
pulmonary morbidity is high and is mostly bronchopulmonary dysplasia (BPD),
which develops in 33% of survivors.14 This may extend into infancy.133 The etiology
of BPD in CDH is unknown in a large majority of cases and is thought to be
multifactorial.
BPD is a chronic lung disease characterized by persistent respiratory signs,
prolonged need for mechanical ventilation or oxygen dependency for a longer period
of time. Many infants with BPD have pulmonary hypertension. BPD mostly occurs in
premature infants who have needed mechanical ventilation and oxygen therapy for
acute respiratory distress (proportions are reported to be up to 20%).34
Histologically, BPD is characterized by abnormal lung development with simplified
acinar structures, poorly formed secondary crests, dysmorphic alveolar capillarie,
and expression of angiogenic factors and their receptors. This results in an arrest of
lung and pulmonary vascular development, the so called "new-type" BPD.34
"Gentle mechanical ventilation" with permissive hypercapnia is the initial and only
accepted therapy for infants with respiratory failure due to CDH5. Individually and in
combination, oxygen therapy and mechanical ventilation predispose the newborn to
ventilator-induced lung injury, which can lead to BPD.134 Secondary to mechanical
ventilation, infants can develop lung injury characterized by hyaline membrane
formation, parenchymal hemorrhage, pneumothorax and pulmonary interstitial
emphysema.134 Inflammatory processes as well as endothelial dysfunction play a
role in the development of BPD, as they lead to vascular injury and disturbance of
normal vascular integrity.135 Crucial in this process is, the release of
vasoconstrictors/vasodilators (such as endothelin, nitric oxide and its inhibitors),
adhesion molecules (such as ICAM, VCAM and selectins, e.g.sP-selectin and sE-
selectin), angiogenic factors (such as VEGF) and procoagulants (such as Von
Willebrand factor, thrombomodulin and activated factor VIII:C) play a crucial
role.136 A few studies which suggest that a ventilation strategy using smaller tidal
volumes (high frequency oscillation (HFO)) may reduce the incidence of BPD, seeing
that this strategy will bring down ventilator induced lung injury.137 Thus, HFO would
fit well in the management scheme for neonates with CDH, the more so as it could
prevent the need for ECMO. Clinical studies of HFO and mean airway pressure in
lung injury found that HFO provides better oxygenation and raises this pressure
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without increasing the incidence of barotrauma.138 On the other hand, low mean
airway pressure settings do not allow the alveoli to open in the low-compliance
lung, which causes atelectasis and higher amplitude of swing pressure, and
consequently excessive expression of cytokines in the airway. Studies of this kind
are mainly observational, however, no randomized controlled trials have been
published.139 Having seen that HFO reduces ventilator-induced lung injury, we
might further speculate that HFO gives less damage to the pulmonary vascular
endothelium than does conventional mechanical ventilation. This may also have a
positively influence the development of BPD due to the resolution of the pulmonary
hypertension.
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x Components of the TGF-ǃ signaling pathways are dynamically regulated during
late lung development in the mouse, rat and human. Pronounced changes in
the expression and localization of the TGF-ǃ receptors AcvrII, Tgfbr1, Tgfbr2,
Tgfbr3, and endoglin, and the intracellular messengers Smad2, Smad3, Smad4,
Smad6 and Smad7 were noted through the canalicular, saccular and alveolar
stages of development. TGF-ǃ signaling was detected in the vascular and
airway smooth muscle cells, as well as in the alveolar and airway epithelium
throughout late lung development demonstrating that active TGF-ǃ signaling is
required for normal late lung development
x Hyperoxia exposure of neonatal C57BL/6J mice illustrates that hyperoxia
dysregulates the expression of components of the TGF-ǃ/BMP signaling
pathways. This dysregulated signaling has at least two functional consequences
relevant to hyperoxia-induced arrest of alveolarization and BPD: 1) hyperoxia
increases the sensitivity of alveolar type II cells to TGF-ǃ-induced apoptosis,
and 2) hyperoxia modulates the expression of ECM and ECM-remodeling
components induced by TGF-ǃ in fibroblasts. Abnormal upregulation of the TGF-
ǃ system in the lung upon exposure to hyperoxia swings the balance in favor of
interstitial ECM deposition and prevents turnover or breakdown of ECM
components.
x Chronic hyperoxia leads to restricted lung development togehther with
inflammatory modifications in a critical period of alveolarization.
x SGA neonates below 32 weeks gestation are a high-risk group regarding
neonatal mortality and neonatal pulmonary morbidity.
x Growth restriction leads to reduced expression of surfactant protein mRNA and
could induce increased inflammatory activation.
x Prolonged mechanical ventilation contributes to the development of chronic
lung disease by the induction of lung inflammation without adequate
stimulation of the counter-regulatory cytokine interleukin 10 in preterm infants
with respiratory distress syndrome.
x Surfactant therapy in severe ARDS improves oxygenation immediately after
intratracheal administration. Improvement of oxygenation is sustained only in
the subgroup of patients with mild or moderate ARDS. Ventilator induced lung
injury in children with ARDS can probably be ameliorated with surfactant
treatment.
x In vivo studies concerning the impact of pulmonary surfactant on inflammatory
conditions involving the adhesion of neutrophils to endothelial cells reveal that
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natural surfactant but not synthetic surfactant has pro-inflammatory effects
when higher amounts of the exogenous dose reach the circulation.
x After investigating the impact of a recombinant surfactant protein (SP)-C based
surfactant in a model of meconium aspiration syndrome (MAS), we conclude
that impairment of lung function in MAS, associated with marked changes in
surfactant associated protein messenger RNA, can be sufficiently treated using
recombinant surfactant protein-C or natural surfactant. Surfactant
administration improved pulmonary gas exchange as well as pulmonary
inflammatory cytokine transcription.
x The response to recombinant SP-C surfactant depends on the level of positive
end-expiratory pressure (PEEP) used in ventilated immature rabbits suffering
from respiratory distress syndrome.
x Comparing the effects of an open lung concept positive pressure ventilation
with a conventional ventilation strategy combined with administration of two
different surfactant preparations on lung function and surfactant homeostasis,
we conclude, that both treatment strategies improved gas exchange and lung
function in neonatal ARDS.
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INJURY TO THE DEVELOPING LUNG
Most lung diseases are complex and no single gene or protein alone will either help
us to identify the pathogenesis or result in new approaches of treatment and/or
prevention. The clinical features of acquired lung diseases such as
bronchopulmonary dysplasia, chronic obstructive pulmonary disease, interstitial
pulmonary fibrosis and others are heterogeneous. Understanding the complex
interactions among many genes that result in disease will require a systematic
approach aimed at identifying not only single genes or pathways but also the
networks of genes that interact to produce the disease. It is important to coordinate
research involving different disciplines to begin to "translate" the knowledge of
genomics and proteomics into our understanding of developmental aspects of the
normal human lung, its diseases and its response to injury. Targeted proteomics
will likely assist us in identifying specific genotypes and in understanding
phenotypes of these multifactorial and complex disorders. Both BPD and COPD have
impaired septation as a prominent morphological feature. The similar
pathophysiological features of BPD and COPD may prompt basic scientists and
clinicians (both in adult and pediatric medicine) to combine their research efforts
and focus on the underlying molecular mechanisms. This will lead to a better
understanding of mechanisms of injury, repair and regeneration of the lung. As
COPD is one of the major causes of death in adulthood and as the increasing
number of infants with BPD might form a higher risk group for developing COPD,
research into these underlying processes could have a major impact, not only at an
individual level, but also on public health.1
The data presented in this thesis implicate that the TGF-ǃ/BMP signaling pathway is
relevant in the pathogenesis of BPD. Given that the TGF-ǃ/BMP pathways are also
amenable to pharmacological and genetic manipulation in the lung, they provide
possible avenues for the management of this disease
Today, the importance of ventilator-induced lung injury to the developing lung is
commonly accepted. Mechanotransduction, mechanical force-induced signaling
cascades, has been the focus of several studies.2-5 In addition, research into
mechanosensation, physico-chemical conversion mediated by specific protein-
protein interactions, has provided new insights into cellular and molecular
mechanisms of ventilator-induced lung injury of the developing lung. By knowing
the mechanosensory mechanisms, mechanotransduction pathways and genes
activated by mechanical ventilation and involved in VILI, one might be able to
selectively prevent physical force-induced cell damage. One might speculate that
interfering with these pathways by genetic manipulation, e.g.by small inhibitor
molecules (siRNA's), or by pharmacological interventions may have beneficial
effects on the course of the injury and may enhance recovery. In clinical practice,
reduction of physical force-induced injury to immature as well as hypoplastic lungs
might be achieved by low tidal volume strategies.6-8 However, thus far, current
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treatment strategies have failed to reduce the incidence of BPD.7 In part, this might
be due to the fact that, as a consequence of improved perinatal care, more
premature newborns, who are at high risk of developing BPD, are treated and
survive. Large multicenter studies will have to be conducted to identify which
ventilation strategies lead to the best outcomes in these extremely premature
patients by studying ventilation modalities, such as HFO, as well as additional
therapies such as surfactant, inhaled NO, liquid ventilation, or combinations of
these modalities. A similar approach should be used to study the optimal treatment
modality in patients with hypoplastic lungs, such as in CDH.
In the last 10 years, a number of key control factors have already been identified
determining impaired septation as a crucial feature of BPD. Nevertheless, analyses
of lung transcriptome or proteome offer new prospects in the identification of
candidate genes, pathway and networks and add to a more comprehensive view of
this process. Restoring balance through supply of insufficient factors and inhibition
of excessive factors appears a promising clinical approach for prevention or
treatment of this disease.
Mature differentiated lung epithelial cells, endogenous progenitors, and putative
stem cell niches all appear likely to participate in the response of the lung to injury.
As has recently been suggested for the gut, identification of endogenous lung
progenitors and delivery of exogenous cells are potential therapeutic approaches
that are currently being explored in animal models of lung injury.9 As a detailed
understanding of stem cell biology, lung development, lineage commitment, and
epithelial differentiation emerges, the ability to modulate lung injury and repair will
likely follow. Protecting the alveolar progenitor cell population with small, soluble
molecules or providing the correct exogenous signals can guide alveolar progenitor
cells to maintain or repair the alveolar gas diffusion surface.
Clinically, ventilator-induced lung injury is one of the major contributors to mortality
and morbidity in patients with congenital lung anomalies. The clinical picture has
changed following the application of a lung protective strategy consisting of
preservation of spontaneous ventilation, permissive levels of hypercapnia and
avoidance of high inspiratory airway pressure, increasingly known as the gentle
ventilation concept.10-12 In this concept, high frequency oscillation has been shown
to prevent ventilator-induced lung injury at least in premature infants. There is a
continuing need for international multi-center randomized clinical trials (RCTs) with
enough power to determine the role of HFO compared with conventional ventilation
under a variety of conditions, especially in CDH.
Chapter 19
224
INJURY TO THE DEVELOPING LUNG
Most lung diseases are complex and no single gene or protein alone will either help
us to identify the pathogenesis or result in new approaches of treatment and/or
prevention. The clinical features of acquired lung diseases such as
bronchopulmonary dysplasia, chronic obstructive pulmonary disease, interstitial
pulmonary fibrosis and others are heterogeneous. Understanding the complex
interactions among many genes that result in disease will require a systematic
approach aimed at identifying not only single genes or pathways but also the
networks of genes that interact to produce the disease. It is important to coordinate
research involving different disciplines to begin to "translate" the knowledge of
genomics and proteomics into our understanding of developmental aspects of the
normal human lung, its diseases and its response to injury. Targeted proteomics
will likely assist us in identifying specific genotypes and in understanding
phenotypes of these multifactorial and complex disorders. Both BPD and COPD have
impaired septation as a prominent morphological feature. The similar
pathophysiological features of BPD and COPD may prompt basic scientists and
clinicians (both in adult and pediatric medicine) to combine their research efforts
and focus on the underlying molecular mechanisms. This will lead to a better
understanding of mechanisms of injury, repair and regeneration of the lung. As
COPD is one of the major causes of death in adulthood and as the increasing
number of infants with BPD might form a higher risk group for developing COPD,
research into these underlying processes could have a major impact, not only at an
individual level, but also on public health.1
The data presented in this thesis implicate that the TGF-ǃ/BMP signaling pathway is
relevant in the pathogenesis of BPD. Given that the TGF-ǃ/BMP pathways are also
amenable to pharmacological and genetic manipulation in the lung, they provide
possible avenues for the management of this disease
Today, the importance of ventilator-induced lung injury to the developing lung is
commonly accepted. Mechanotransduction, mechanical force-induced signaling
cascades, has been the focus of several studies.2-5 In addition, research into
mechanosensation, physico-chemical conversion mediated by specific protein-
protein interactions, has provided new insights into cellular and molecular
mechanisms of ventilator-induced lung injury of the developing lung. By knowing
the mechanosensory mechanisms, mechanotransduction pathways and genes
activated by mechanical ventilation and involved in VILI, one might be able to
selectively prevent physical force-induced cell damage. One might speculate that
interfering with these pathways by genetic manipulation, e.g.by small inhibitor
molecules (siRNA's), or by pharmacological interventions may have beneficial
effects on the course of the injury and may enhance recovery. In clinical practice,
reduction of physical force-induced injury to immature as well as hypoplastic lungs
might be achieved by low tidal volume strategies.6-8 However, thus far, current
Future perspectives
225
treatment strategies have failed to reduce the incidence of BPD.7 In part, this might
be due to the fact that, as a consequence of improved perinatal care, more
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ventilation strategies lead to the best outcomes in these extremely premature
patients by studying ventilation modalities, such as HFO, as well as additional
therapies such as surfactant, inhaled NO, liquid ventilation, or combinations of
these modalities. A similar approach should be used to study the optimal treatment
modality in patients with hypoplastic lungs, such as in CDH.
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candidate genes, pathway and networks and add to a more comprehensive view of
this process. Restoring balance through supply of insufficient factors and inhibition
of excessive factors appears a promising clinical approach for prevention or
treatment of this disease.
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likely follow. Protecting the alveolar progenitor cell population with small, soluble
molecules or providing the correct exogenous signals can guide alveolar progenitor
cells to maintain or repair the alveolar gas diffusion surface.
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preservation of spontaneous ventilation, permissive levels of hypercapnia and
avoidance of high inspiratory airway pressure, increasingly known as the gentle
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continuing need for international multi-center randomized clinical trials (RCTs) with
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under a variety of conditions, especially in CDH.
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VASCULOGENESIS DURING LUNG DEVELOPMENT
Lung vasculogenesis, under the influence of the secretion of angiogenic growth
factors, such as VEGF and NO, contributes to normal alveolar development.
Impaired alveolar development in BPD is associated with arrested and dysmorphic
vascular growth and impaired lung angiogenic growth factor expression. Exogenous
VEGF or NO may provide new therapeutic avenues for preserving or enhancing
alveolar structure. Hypoxia-inducible factor (HIF) is a master transcription factor
modulating O2-sensitive gene expression and vessel growth. HIF is activated by
hypoxia and inhibited by increased O2 levels. HIF activation via inhibition of prolyl
hydroxylase domain-containing proteins prevents lung damage, supporting a
potential role in promoting alveolar development. It will be crucial to determine the
appropriate dosing and pre- or postnatal timing of angiogenesis stimulating factors
to avoid abnormal pulmonary vascular proliferation, pulmonary hemorrhage or lung
edema and other problems.
The regenerative potential of stem cells has recently been under intense
investigation.13 However, it is far from clinical application at this moment. In vitro,
stem and progenitor cells have the ability for self-renewal and differentiation into
organ specific cell types. In vivo, transplantation of these cells may reconstitute
organ systems, as shown in animal models of diseases such as ischemic heart
disease.14 Endothelial progenitor cells (EPCs) have been isolated from the peripheral
blood, expanded in vitro and committed to an endothelial lineage in culture. Cell
therapy using EPCs or transfected EPCs that modify their microenvironment to
restore damaged organ integrity might be a future therapeutic option.
As mentioned above, impaired alveolar development in chronic lung disease is
associated with abnormal vascular growth and decreased expression of lung
angiogenic growth factors. Nanotechnology for improving drug delivery may
become of increasing importance in the next decade. A variety of mechanisms
contribute to the potential of nanotechnology. The availability of a number of
different nanoparticle structures, including solid particles, nanoshells, polymeric
micelles and liposomes, provides a flexible range of opportunities that can be
tailored to meet different therapeutic needs. Targeting of nanoparticles with
angiogenic growth factors or HIF stabilizers to specific cell-surface receptors, can
enhance drug delivery to the intended target, reducing systemic load at the same
time. Inhalational delivery offers additional opportunities for nanotechnology to
impact pulmonary disease.
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PULMONARY SURFACTANT
Extensive research has provided increased understanding of molecular mechanisms
involved in the formation and preservation of the surfactant film of the alveolar
lining. These efforts will help to develop stable surfactant associated peptides which
mimic the function of SP-B and -C. Besides treatment of premature infants with
RDS, surfactant might be effective in newborns with inactivated surfactant, as is the
case in inflammatory lung disorders such as meconium aspiration syndrome or in
case of insufficient pool size and inactivation in hypoplastic lungs.15,16 Surfactant
may also be used as a carrier for antibiotics, specific antibodies,
immunosuppressants, vasodilators and other drugs and for treatment of various
lung diseases not primarily related to the surfactant system, such as BPD, lung
fibrosis and COPD.
GENETIC FACTORS OF ADULT-ONSET LUNG DISEASE
In the future, we have to characterize and appreciate genetic and environmental
susceptibility factors that predispose children with impairment of lung development
to apparent adult onset lung disease in more detail. It is equally important to
identify factors that protect against it. Many lung diseases in children and adults are
characterized either by a failure of development and/or by destruction of the alveoli.
In premature neonates, alveolarization may be impaired, resulting in poor lung
function. In contrast, emphysema in adults is characterized by destruction of the
mature alveoli. Understanding the mechanisms that regulate the formation of the
gas exchange surface will enhance development of therapies capable of promoting
alveolarization. Genes that regulate alveolar morphogenesis are differentially
expressed in periods of alveolar formation compared to periods in which no alveoli
are formed. Abnormalities of lung development may contribute to the development
of COPD. The factors that affect pulmonary development in utero and postnatally
are not well understood. Lung morphogenesis is a highly regulated process that can
be impaired in utero by both genetic and environmental factors. One of the best
recognised causes is maternal cigarette smoking, but more work is needed to
identify other causes, both environmental and genetic. This work should involve the
collection of large prospective cohorts of newborn babies, possibly in multicenter
studies, to highlight factors with a role in etiology, using multivariate analysis. In
addition, gene-environment and fetal-maternal interactions have been a focus of
recent research.17 The main targets of identifying gene-environment interactions
are to provide insight into mechanisms of disease development and to identify
patients with an inherent vulnerability to certain conditions based on disease
susceptibility genes. This in turn may allow patients with conditions such as lung
immaturity or hypoplasia or even patients at risk of developing a chronic lung
disease such as BPD or COPD to be treated with targeted and individualised
therapies.
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SUMMARY
Respiratory insufficiency and failure are common problems for many infants in the
neonatal and pediatric intensive care unit. Lung development begins very early in
gestation and continues during pregnancy and after birth into young adulthood.
Injury to the developing lung or disturbance of normal lung development in
different stages may lead to chronic lung disease which can persist into adulthood.
Bronchopulmonary dysplasia (BPD) is a chronic lung disease, characterized by an
arrest of development of the lung and the pulmonary vascular system. It is seen in
around 20% of all ventilated newborns. It often occurs in prematurely born infants,
but it can also be found in term or near-term babies with congenital lung
malformations. Mechanical ventilation, oxygen therapy and inflammation are the
main risk factors for the development of BPD. However, other environmental factors
as well as genetic factors are currently being investigated.
The exact pathogenetic mechanisms of chronic lung disease in general and of BPD
in particular are not fully understood. Identifying and describing pathways that lead
to BPD may provide important clues about the pathophysiology of this condition and
may lead to the development of preventive and therapeutic strategies that may
have implications for long-term outcome.
In Part I of this thesis, an overview of the subject is given. Chapter 1 gives an
introduction to normal and abnormal lung development and possible mechanisms
leading to acute and chronic lung disease in newborns.
Infants born with compromised respiratory status, whether due to immaturity or
other conditions, such as congenital lung hypoplasia, often require mechanical
ventilation and supplemental oxygen to maintain adequate oxygenation and
ventilation. Individually and in combination, these therapies predispose the newborn
to ventilator-induced lung injury. In chapter 2, mechanical ventilation strategies
for congenital lung malformations are discussed.
Part II describes experimental aspects of lung development and BPD. Late lung
development is characterized by progressive subdivision of developing airspaces
into alveoli. An important family of growth factors known to play a role in early lung
development is the TGF-ǃ/BMP (transforming growth factor- ǃ/bone morphogenetic
protein) family. It is unknown if this pathway also has a role in late lung
development. In chapter 3, the expression, tissue localization and activity of
components of the TGF-ǃ signaling pathway during late lung development are
described. We found that these components are dynamically regulated in mouse
and rat, as well as in human lung development. The results of this study suggest
that the TGF-ǃ signaling pathway plays a role in normal late lung development in
rodents and humans.
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Hyperoxic injury is believed to disrupt critical signaling pathways that direct lung
development, which may lead to bronchopulmonary dysplasia. In chapter 4, the
effects of 21% or 85% O2 on TGF-ǃ/BMP superfamily signaling in the lung of
neonatal C57BL/6J mice were investigated. Growth and lung function were
significantly impaired in pups exposed to 85% oxygen. An arrest of lung
development was observed accompanied by a dysregulated expression and
localization of TGF-receptors and their downstream Smad proteins. TGF-ǃ signaling
was potentiated, whereas BMP signaling was impaired, both in the lungs of pups
exposed to hyperoxia and in isolated mouse alveolar type II cells and human
primary lung fibroblasts. After exposure to 85% O2, primary lung alveolar type II
cells were more susceptible to TGF-ǃ-induced apoptosis, whereas primary
pulmonary artery smooth muscle cell were unaffected. In primary lung fibroblasts
exposed to hyperoxia, TGF-ǃ-stimulated production of the Į1-subunit of type I
collagen, tissue inhibitor of metalloproteinase-1, tropoelastin, and tenascin-C is
enhanced. Thus, hyperoxia significantly affects TGF-ǃ/BMP signaling in the lung,
including processes of septation and alveolarization which are disturbed in BPD.
Angiogenic factors, inflammatory cytokines and the nitric oxide system have also
been implicated in the pathogenesis of BPD and play important and interrelated
roles in late lung development. In chapter 5, we demonstrated a pronounced
dysregulation of expression of oxygen-related factors (HIF1-Į and HIF2-Į),
angiogenic factors (VEGF and its receptor Flt-1) and components of the NO-
biosynthetic pathway (NOS-2, NOS-3, DDAH) in a rodent model of hyperoxia-
induced BPD. Furthermore, expression of the pro-inflammatory cytokines tumor
necrosis factor-Į (TNF-Į) and interleukin (IL)-6 was upregulated, and surfactant
proteins (SP)-B and –C were downregulated. Unravelling the interaction of these
differentially regulated factors may contribute to the knowledge of the pathogenesis
of BPD and help to identify new therapeutic targets.
Preterm infants with intrauterine growth retardation (IUGR) have an increased risk
for the development of acute and chronic pulmonary disorders as compared to
preterm infants who are appropriate for gestational age. In chapter 6, the effect of
immaturity and IUGR on pulmonary development was investigated in a hypoxia-
induced intrauterine growth retardation model in mouse pups. Pups born after
hypoxic intrauterine conditions had significantly (P < 0.001) lower birth weights and
body lengths compared to controls born after normoxic intrauterine conditions.
mRNA expression of surfactant protein (SP) -A, -B and C, but not SP-D, could be
shown to be significantly reduced in hypoxic fetuses compared to normoxic controls.
This implicated that low expression of surfactant associated proteins might be a
causal factor for the increased risk of acute and chronic pulmonary disorders in
preterm infants with IUGR.
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The clinical aspects of BPD are discussed in Part III. We studied the association of
IUGR with increased neonatal mortality as well as neonatal pulmonary morbidity in
a large population-based group of infants born below 32 weeks of gestation. The
results of this study are presented and discussed in chapter 7 and chapter 8. We
found significantly increased rates of neonatal mortality [OR 4.54, 95% CI 2.56,
8.0] and BPD [OR 3.80, 95% CI 2.11, 6.84] in those children born below 32 weeks
of gestation that were small for gestational age compared to those who were
appropriate for gestational age.
As mentioned above, inflammatory processes as well as mechanical ventilation play
important roles in the pathogenesis of chronic lung disease in preterm infants. In
chapter 9, we report on a study performed in ventilated preterm infants, who
suffered from respiratory distress syndrome. We analyzed pro- (IL-8, elastase and
epithelial neutrophil-activating peptide 78) and anti-inflammatory (IL-10) mediators
in bronchoalveolar lavage fluid sampled at different time points during ventilatory
treatment. There was a strong correlation between the duration of mechanical
ventilation and the level of the proinflammatory mediators studied. However, levels
of the anti-inflammatory mediator IL-10 did not change during the observation
period. These data support the hypothesis that prolonged mechanical ventilation
contributes to the development of chronic lung disease by the induction of lung
inflammation without adequate stimulation of the counter regulatory cytokine IL-10.
Clinically, BPD can also be associated with increased pulmonary arterial pressure.
One of the factors influencing the pressure in the pulmonary vasculature is the nitric
oxide (NO) pathway. L-Arginine (ARG) is the physiological substrate of the enzyme-
catalyzed synthesis of NO by various NO synthase isoforms. The aim of the study
described in chapter 10 was to determine whether preterm infants with BPD and
increased pulmonary artery pressure had a deficiency of plasma ARG and systemic
NO synthesis. We found no significant differences in total amino acid concentrations
and plasma ARG concentrations between those infants with BPD and increased
pulmonary vascular pressure and those without BPD. Urinary nitrate and nitrite
concentrations, the excreted end-products of the oxidative metabolic pathway of
NO, were not different between groups at day 28, but they were found to be
significantly increased in infants with BPD at 36 weeks. It was concluded that there
was no deficiency of ARG concentrations and systemic NO synthesis in our cases
with BPD.
Surfactant therapy has become the standard therapy for respiratory distress
syndrome in premature infants. Nowadays, there is a significant amount of evidence
that near-term or term infants, as well as children, with acute respiratory failure,
such as in meconium aspiration syndrome or pneumonia, have a profound
functional surfactant deficiency. In these infants, inflammatory processes in the
lungs may lead to inactivation of surfactant. To overcome this, treatment with
exogenous surfactant which is more resistant to inactivation has to be established.
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In Part IV, chapter 11, a randomized multicenter study is described which was
conducted to determine whether tracheal application of bovine surfactant improved
oxygenation in children with acute respiratory distress syndrome. Improved
oxygenation was found in the group that was treated with surfactant, compared to
a control group treated with standard therapy. A sustained improvement was only
found in the subgroup of patients without pneumonia and in that with an initial
PaO2/FiO2 ratio above 65.
Both synthetic and natural surfactants have been well documented to improve
oxygenation in preterm infants with RDS and acute lung injury in adults. A small
proportion of surfactant also enters the circulation in cases of increased
permeability of the alveolar-capillary membrane. In Part V, chapter 12, we
investigate the impact of natural and synthetic surfactant (recombinant SP-C
surfactant) on inflammatory conditions involving the adhesion of neutrophils to
tumor necrosis factor-alpha-activated human umbilical cord vein endothelial cells
(HUVECs) in a flow chamber. Using natural pulmonary surfactant in the
preincubation media, the number of adherent neutrophils increased by 10-20% at
high concentrations of the bovine surfactant compared to controls. This increased
neutrophil adhesion was associated with a significant up-regulation of mRNA levels
for E-selectin and VCAM-1. Interestingly, synthetic surfactant in the same
concentration had no effect on neutrophil adhesion to activated endothelial cells.
One might speculate, that natural surfactant but not synthetic surfactant might
have pro-inflammatory effects when higher amounts of the exogenous dose reach
the circulation.
In chapter 13 and chapter 14, we investigate the effects of the two different
surfactant preparations - recombinant SP-C surfactant and natural bovine surfactant
- on pulmonary gas exchange, inflammatory response and the pulmonary surfactant
system in a piglet model of meconium aspiration syndrome (MAS). Compared to
untreated controls with MAS, improvement of gas exchange and lung function was
observed after surfactant administration in both surfactant treated groups. mRNA
expression of the pro-inflammatory cytokine interleukin (IL)-1ǃ was significantly
lower after administration of recombinant SP-C surfactant than in natural surfactant
and controls whereas IL-10 mRNA expression was significantly induced in both
treatment groups. The exact sequence of the reduced inflammatory response
following surfactant is unclear and further studies are mandatory to address
potential underlying mechanisms.
Compared with healthy (non-MAS) controls, SP-B mRNA expression was
significantly increased in MAS, whereas SP-C mRNA expression was found to be
significantly reduced. Surfactant protein concentrations, however, were not
significantly different between groups. Although a significant improvement of gas
exchange and lung function was observed after surfactant administration in both
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surfactant-treated groups, surfactant mRNA expression and protein concentration
were not significantly altered.
In chapter 15, we describe the effect of positive end expiratory pressure (PEEP) on
lung function in an immature newborn rabbit model for respiratory distress
syndrome. PEEP largely influenced lung function after administration of recombinant
SP-C surfactant, whereas natural surfactant improved lung compliance regardless of
the PEEP applied. Thus, in this model, response to recombinant SP-C surfactant
depends on the PEEP level applied. This observation has to be considered in
treatment strategies with recombinant SP-C surfactants in patients with respiratory
distress syndrome. The study presented in chapter 16 compares the effect of an
open lung concept positive pressure ventilation with a conventional ventilation
strategy combined with administration of two different surfactant preparations on
lung function and surfactant homeostasis in a whole-lung saline-lavaged model.
Each treatment strategy showed improvement of gas exchange and lung function,
although the improvement of PaO2 and pulmonary compliance declined over the
study period in the surfactant groups. Phospholipid and surfactant protein analyses
of the bronchoalveolar lavage fluids showed significant alterations in surfactant
homeostasis in the open lung concept positive pressure ventilation group as
compared to the surfactant groups, whereas IL-10 and SP-C mRNA expression was
tendentially increased in the surfactant groups. Long-term consequences of these
differences need to be further studied.
In Part VI, chapter 17, we discuss different aspects of disturbance of late lung
development as well as their short and long term consequences. We also focus on
aspects of the role of the extracellular matrix in the development of
bronchopulmonary dysplasia and chronic obstructive pulmonary diseases and
discuss similarities between both diseases, which could have a large impact on
future research and treatment strategies.
Samenvatting
235
SAMENVATTING
Respiratoire insufficiëntie is een veel voorkomende probleem bij pasgeborenen en
kinderen op neonatale en pediatrische intensive care afdelingen. Longontwikkeling
is een proces dat vroeg in de zwangerschap begint en dat tijdens de hele
zwangerschap en zelfs na de geboorte doorgaat tot op de jong-volwassen leeftijd.
Schade aan de zich ontwikkelende longen of verstoringen van de verschillende
stadia van de normale longontwikkeling kunnen leiden tot chronische longziekten
die zelfs op de volwassen leeftijd een rol kunnen spelen.
Bronchopulmonale dysplasie (BPD) is een chronische longziekte, waarbij de
ontwikkeling van de longen en de longvaten te vroeg stopt. Het komt voor bij
ongeveer 20% van alle pasgeborenen die beademd moeten worden. Vaak treedt het
op bij prematuur geboren kinderen, maar het kan ook voorkomen bij (bijna) à
terme geboren baby's met aangeboren longafwijkingen. De belangrijkste
risicofactoren voor BPD zijn kustmatige beademing, zuurstoftoediening en
ontstekingsprocessen in de longen, maar ook andere omgevingsfactoren en
genetische factoren zouden een rol kunnen spelen. Op dit moment wordt onderzoek
gedaan naar deze factoren.
De exacte pathogenese van chronische longziekten in het algemeen en van BPD in
het bijzonder is niet bekend. Het identificeren en beschrijven van de mechanismen
die tot BPD leiden kan meer inzicht geven in de pathofysiologie van deze
aandoening en kan leiden tot de ontwikkeling van preventieve en therapeutische
maatregelen, die grote implicaties kunnen hebben voor de lange-termijn prognose.
In Deel I van dit proefschrift wordt een overzicht gegeven van het onderwerp.
Hoofdstuk 1 is een introductie en beschrijft de normale en abnormale
longontwikkeling en mechanismen die kunnen leiden tot acute en chronische
longziekten bij pasgeborenen.
Kinderen die na de geboorte respiratoire insufficiëntie ontwikkelen, of dit nu komt
door immaturiteit of door andere aandoeningen, zoals congenitale longhypoplasie,
hebben vaak kunstmatige beademing en extra zuurstof nodig om de oxygenatie en
ventilatie op peil te houden. Individueel en samen geven deze behandelvormen een
verhoogd risico op "ventilator-induced lung injury". In hoofdstuk 2 worden
beademingsstrategieën besproken voor kinderen met congenitale longafwijkingen.
Deel II beschrijft experimentele aspecten van longontwikkeling en BPD. Tijdens de
late longontwikkeling verdelen de zich ontwikkelende luchtwegen zich verder in
alveoli. Een belangrijke familie van groeifactoren die een rol spelen tijdens de
vroege longontwikkeling is de TGF-ǃ/BMP (transforming growth factor-ǃ/bone
morphogenetic protein) familie. Of deze familie ook een rol speelt tijdens de late
longontwikkeling is onbekend. In hoofdstuk 3 worden de expressie, weefsellocatie
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en activiteit van een aantal onderdelen van de TGF-ǃ pathway tijdens de late
longontwikkeling besproken. Wij hebben gevonden dat deze onderdelen dynamisch
gereguleerd worden, zowel in muizen en ratten als bij de humane longontwikkeling.
Onze resultaten laten zien dat de TGF-ǃ pathway ook een rol speelt tijdens de
normale late longontwikkeling in knaagdieren en mensen.
Men neemt aan dat schade door hyperoxie belangrijke pathways in de
longontwikkeling verstoort, wat kan leiden tot BPD. In hoofdstuk 4 worden de
effecten van 21% of 85% O2 op de signaling van de TGF-ǃ/BMP superfamilie in de
longen van neonatale C57BL/6J muizen beschreven. In pups die blootgesteld waren
aan 85% zuurstof waren de lichaamsgroei en de longfunctie significant verminderd.
We zagen dat de longontwikkeling stopte en dat er een dysregulatie was van de
expressie en de lokalisatie van TGF-receptoren en hun downstream Smad-
proteïnen. De TGF-ǃ signaling was versterkt en de BMP signaling was verminderd,
zowel in de longen van pups blootgesteld aan hyperoxie als in geïsoleerde alveolaire
type II cellen van muizen en in humane primaire longfibroblasten. Na blootstelling
aan 85% O2 vertoonden de alveolaire type-II-cellen meer TGF-ǃ-geïnduceerde
apoptose, terwijl primaire gladde spiercellen uit de longarteriën geen verandering
lieten zien. In primaire longfibroblasten die blootgesteld waren aan hyperoxie was
de TGF-ǃ-gestimuleerde aanmaak van de Į1-subunit van type I collageen, tissue
inhibitor of metalloproteïnase-1, tropoelastine en tenascin-C versterkt. Dit betekent
dat hyperoxie significante veranderingen veroorzaakt in de TGF-ǃ/BMP signaling in
de long. Hierbij kan ook de late longontwikkeling beïnvloed worden, die verstoord is
bij BPD.
Angiogene factoren, cytokinen en het NO (stikstofoxide)-systeem hebben mogelijk
ook een functie in de pathogenese van BPD en spelen een belangrijke rol tijdens de
late longontwikkeling. In hoofdstuk 5 laten we zien dat er een duidelijke
dysregulatie is van de expressie van zuurstofgerelateerde factoren (HIF1-Į en
HIF2-Į), angiogene factoren (VEGF en zijn receptor Flt-1) en van componenten van
de NO-biosynthese pathway (NOS-2, NOS-3, DDAH) in een muismodel van
hyperoxie-geïnduceerde BPD. Daarnaast laten we zien dat de expressie van de pro-
inflammatoire cytokines tumor necrosis factor-Į (TNF-Į) en interleukine (IL)-6
verhoogd is en dat de expressie van de surfactant proteïnen (SP)-B en -C verlaagd
is. Het bestuderen van de interacties tussen deze differentieel-gereguleerde
factoren kan bijdragen aan de kennis over de pathogenese van BPD en kan helpen
bij het vinden van nieuwe therapeutische mogelijkheden en aangrijpingspunten.
Prematuur geboren kinderen met intra-uteriene groeiretardatie (IUGR) hebben een
verhoogd risico op acute en chronische longziekten vergeleken met premature
kinderen die geen groeivertraging hebben. In hoofdstuk 6 hebben we het effect
onderzocht van immaturiteit en IUGR op de longontwikkeling in een muismodel van
hypoxie-geïnduceerde IUGR. Pups die geboren werden na intra-uteriene hypoxie
hadden een significant lager geboortegewicht waren beduidend kleiner dan
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controledieren geboren na intra-uteriene normoxie. De mRNA expressie van SP-A, -
B en -C, maar niet van SP-D, was significant verlaagd in hypoxische foetussen
vergeleken met normoxische controles. Dit betekent dat een lage expressie van
surfactant-geassocieerde proteïnen mogelijk een oorzaak is voor het verhoogde
risico op acute en chronische longziekten bij premature kinderen met IUGR.
De klinische aspecten van BPD worden besproken in Deel III. Wij hebben de relatie
onderzocht tussen IUGR en verhoogde neonatale sterfte en neonatale
longaandoeningen in een grote groep pasgeborenen, geboren na minder dan 32
weken zwangerschapsduur. De resultaten hiervan worden gepresenteerd en
besproken in hoofdstuk 7 en 8. We hebben gevonden dat kinderen geboren na
minder dan 32 weken zwangerschapsduur die small for gestational age (klein voor
de zwangerschapsduur) waren een significant verhoogde neonatale sterfte hadden
[OR 4.54, 95% CI 2.56, 8.0] en significant meer BPD [OR 3.80, 95% CI 2.11, 6.84]
dan kinderen van minder dan 32 weken die een normaal gewicht voor de
zwangerschapsduur hadden.
Zoals hierboven al genoemd is, spelen zowel ontstekingsprocessen als kunstmatige
beademing een belangrijke rol in het ontstaan van chronische longziekten bij
prematuur geboren kinderen. In hoofdstuk 9 beschrijven we een studie uitgevoerd
bij beademde prematuren, die respiratory distress syndrome (RDS) hadden. We
hebben pro- (IL-8, elastase en epithelial neutrophil-activating peptide 78) en anti-
inflammatoire (IL-10) factoren geanalyseerd in vloeistof van bronchoalveolaire
lavages, afgenomen op verschillende momenten tijdens de beademingsperiode. Er
was een sterke correlatie tussen de duur van de beademing en de hoeveelheid pro-
inflammatoire factoren. De hoeveelheid anti-inflammatoire factor (IL-10)
veranderde echter niet tijdens de periode van observatie. Onze data ondersteunen
de hypothese dat langdurige kunstmatige beademing bijdraagt aan de ontwikkeling
van chronische longziekten doordat het ontstekingsprocessen in de long induceert
zonder dat er een adequate stimulatie optreedt van de anti-inflammatoire
tegenhanger IL-10.
BPD kan klinisch samengaan met een verhoogde druk in de longarteriën. Een van
de factoren die de druk in de longvaten beïnvloeden is de NO (stikstofoxide)
pathway. L-Arginine (ARG) is het fysiologische substraat voor de enzym-
gekatalyseerde synthese van NO door verschillende NO-synthase isovormen. Het
doel van de studie die in hoofdstuk 10 beschreven wordt was te bepalen of
prematuur geboren kinderen met BPD en een verhoogde pulmonale arteriële druk
een deficiëntie hadden van plasma ARG en van de systemische NO-synthese. We
hebben geen significante verschillen gevonden in de totale aminozuurconcentratie
en in plasma ARG concentratie tussen kinderen met BPD en een verhoogde
longvaatdruk en kinderen zonder BPD. De urineconcentraties van nitraat en nitriet,
de eindproducten van de oxidatieve metabole pathway van NO, verschilden niet
tussen de groepen op dag 28, maar waren wel significant verhoogd bij kinderen met
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een deficiëntie hadden van plasma ARG en van de systemische NO-synthese. We
hebben geen significante verschillen gevonden in de totale aminozuurconcentratie
en in plasma ARG concentratie tussen kinderen met BPD en een verhoogde
longvaatdruk en kinderen zonder BPD. De urineconcentraties van nitraat en nitriet,
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tussen de groepen op dag 28, maar waren wel significant verhoogd bij kinderen met
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BPD op de leeftijd van 36 weken postconceptioneel. Uit deze resultaten concluderen
wij dat er geen deficiëntie was van ARG en systemische NO synthese in onze
patiënten met BPD.
Behandeling met surfactant is nu standaard therapie voor RDS bij prematuur
geboren kinderen. Er is veel bewijs dat (bijna-) à terme pasgeborenen en ook
andere kinderen met acuut respiratoir falen, bijvoorbeeld bij meconiumaspiratie-
syndroom of pneumonie, een ernstige functionele surfactantdeficiëntie hebben.
Ontstekingsprocessen in de long kunnen bij deze kinderen tot surfactantinactivatie
leiden. Om dit te behandelen moet therapie met exogeen surfactant dat minder
geïnactiveerd wordt gegeven worden.
In Deel IV, hoofdstuk 11, beschrijven wij een gerandomiseerde multicenter studie
die gedaan is om te bepalen of behandeling met bovien surfactant intratracheaal de
oxygenatie bij kinderen met acuut RDS verbetert. We zagen een verbeterde
oxygenatie in de groep die behandeld was met surfactant vergeleken met een
controlegroep, behandeld met standaardtherapie. Een blijvende verbetering trad
alleen op in de subgroep van patiënten zonder pneumonie en in de subgroep met
een initiële PaO2/FiO2 ratio boven de 65.
Zowel synthetisch als natuurlijk surfactant verbeteren de oxygenatie bij prematuren
met RDS en bij volwassenen met acute longschade. Een klein deel van het
surfactant kan in de circulatie terecht komen als de permeabiliteit van het alveolo-
capillaire membraan verhoogd is. In Deel V, hoofdstuk 12, hebben we het effect
onderzocht van natuurlijk en synthetisch surfactant (recombinant SP-C surfactant)
op ontstekingsreacties waarbij er adhesie van neutrofielen optreedt aan tumor
necrosis factor-Į–geactiveerde humane endotheelcellen uit navelstrengvenen
(HUVECs) in een flow chamber. Na toevoeging van hoge concentraties bovien
surfactant aan de preïncubatie media waren er 10 - 20% meer adherente
neutrofielen vergeleken met controles. Deze versterkte neutrofiel-adhesie ging
gepaard met een significante verhoging van het mRNA van E-selectine en VCAM-1.
Synthetisch surfactant in dezelfde concentratie had geen effect op de adhesie van
neutrofielen aan geactiveerde endotheelcellen. Het zou kunnen dat natuurlijk
surfactant, in tegenstelling tot synthetisch surfactant, pro-inflammatoire effecten
heeft wanneer grotere hoeveelheden van de exogene dosis de circulatie bereiken.
In hoofdstuk 13 en hoofdstuk 14 onderzoeken we de effecten van twee
verschillende surfactants – recombinant SP-C surfactant en natuurlijk bovien
surfactant – op de gaswisseling in de long, de inflammatoire respons en het
pulmonale surfactant systeem in een model van meconiumaspiratiesyndroom (MAS)
in biggen. We zagen een verbetering van de gaswisseling en de longfunctie na
toediening van surfactant in beide met surfactant behandelde groepen vergeleken
met onbehandelde controles met MAS. De mRNA expressie van het pro-
inflammatoire cytokine interleukine (IL)-1ǃ was significant lager na toediening van
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recombinant SP-C surfactant dan bij natuurlijk surfactant en controles, terwijl de
mRNA expressie van IL-10 significant verhoogd was in beide behandelde groepen.
Het exacte mechanisme van de verminderde inflammatoire respons na toediening
van surfactant is nog onduidelijk.
De SP-B mRNA expressie was significant verhoogd in de MAS-groep vergeleken met
gezonde controles zonder MAS, terwijl de SP-C mRNA expressie significant verlaagd
was. Er was geen significant verschil tussen de groepen in surfactant proteïne-
concentraties. Hoewel er een significante verbetering van de gaswisseling en de
longfunctie na toediening van surfactant in beide behandelde groepen was, waren
er geen significante veranderingen in surfactant mRNA expressie en
proteïneconcentratie.
In hoofdstuk 15 beschrijven wij het effect van positieve end expiratory pressure
(PEEP) op de longfunctie in een model van RDS in immature konijnen. PEEP had
een grote invloed op de longfunctie na toediening van recombinant SP-C surfactant,
terwijl natuurlijk surfactant onafhankelijk van de gegeven PEEP de longcompliance
verbeterde. In dit model hangt de respons op recombinant SP-C surfactant dus af
van de PEEP die gegeven wordt. Hiermee moet rekening worden gehouden bij de
behandeling van patiënten met RDS met recombinante SP-C surfactant. De studie
die in hoofdstuk 16 beschreven wordt, vergelijkt het effect van een "open lung
concept" met dat van conventionele beademing gecombineerd met de toediening
van twee verschillende surfactants op de longfunctie en de surfactant homeostase
in een diermodel waarin surfactantdeficiëntie geïnduceerd werd door longspoelingen
met zout. Alle behandelmethoden gaven een verbetering van de gaswisseling en de
longfunctie, hoewel de verbetering van PaO2 en longcompliance in de surfactant
groepen afnamen over de studieperiode. Analyse van de fosfolipiden en de
surfactant proteïnen in de bronchoalveolaire lavagevloeistof liet significante
veranderingen zien in de surfactant homeostase in de "open lung concept" groep
vergeleken met de surfactant groepen, terwijl IL-10 en SP-C mRNA een tendens
naar verhoging lieten zien in de surfactant groepen. De lange termijn consequenties
van de gevonden verschillen moeten nog verder bestudeerd worden.
In Deel VI, hoofdstuk 17, bespreken we verschillende aspecten van verstoring
van de late longontwikkeling en de gevolgen hiervan op de korte en lange termijn.
We richten ons ook op aspecten van de rol van de extracellulaire matrix in de
ontwikkeling van bronchopulmonale dysplasie en COPD (chronic obstructive
pulmonary disease) en we bespreken overeenkomsten tussen de beide
ziektebeelden, die van grote invloed zouden kunnen zijn op toekomstig onderzoek
en behandelingsstrategieën.
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Different therapeutic perspectives for novel exogenous surfactant
preparations*
Surfactant replacement therapyhas been established for yearsas one of the most importanttherapeutic interventions in
the management of premature infants
with respiratory distress syndrome. Re-
cently, researchers in the field have fo-
cused on evaluating and comparing not
only different exogenous surfactant com-
positions but also their application in dis-
ease states other than the respiratory dis-
tress syndrome, which could involve a
secondary deficiency of surfactant (1).
Moreover, controversy over the advan-
tages of natural vs. synthetic surfactants
has led to the synthesis of newer surfac-
tants both synthetic and human recom-
binant. Although not yet disseminated,
the emergence of new recombinant for-
mulations of surfactant is promising and
could provide benefits over traditional
synthetic surfactants and natural surfac-
tants.
Investigators have evaluated different
situations in which surfactant therapy
can be beneficial, and several trials have
evaluated the use of exogenous surfactant
in meconium aspiration syndrome
(MAS). MAS is the most common cause of
hypoxemic respiratory failure in full-term
or near-term newborn infants and to-
gether with persistent pulmonary hyper-
tension has been the most frequent indi-
cation for extracorporeal membrane
oxygenation.
Various pathophysiolologic mecha-
nisms are involved in the development of
MAS, including mechanical airway ob-
struction, release of vasoconstrictive and
inflammatory mediators, inflammatory
cell infiltration, proteinaceous exudates,
and surfactant dysfunction and inactiva-
tion (2). The most severe cases of MAS
are usually part of a multiple-system dis-
order including myocardial involvement,
hemodynamic failure, and severe pulmo-
nary hypertension.
Studies in animal models of MAS have
pointed toward an improvement in me-
chanical properties of the respiratory sys-
tem, gaseous exchange, and lung histol-
ogy, after surfactant (3, 4). Additionally,
randomized controlled trials have also
shown improvement in oxygenation and
respiratory morbidity (5) and a decreased
need for extracorporeal membrane oxy-
genation (6) after surfactant replacement
therapy. However, results are still incon-
clusive, and there is much more to learn
regarding this newer indication for exog-
enous surfactant. Besides the need for
stronger evidence on efficacy and safety,
information on other aspects such as dos-
age, response to different surfactant prep-
arations, and ways of administration is
also missing.
In this issue of Critical Care Medicine,
Dr. Hilgendorff and colleagues (7)
present an animal trial focused on the
effect of exogenous surfactant on an ex-
perimental model of MAS in piglets. The
authors not only look for the efficacy of
this strategy but also compare two differ-
ent surfactant preparations, namely Ven-
ticute®, a recombinant human surfac-
tant protein C (rSP-C)-based surfactant,
and Alveofac®, a calf lung lavage natural
surfactant containing both SP-C and
SP-B. Previous evidence from this group
and other researchers suggested an en-
hanced resistance to inactivation by
meconium with the inclusion of hydro-
phobic surfactant proteins (4, 8). In this
study, investigators looked into the pos-
sible mechanisms of action of these com-
pounds by evaluating both surfactant
protein synthesis and morphologic differ-
ences on electron microscopy.
Twenty-three newborn piglets were
randomized after intubation and induc-
tion of MAS to one of three groups re-
ceiving intratracheal saline, rSP-C sur-
factant, or natural surfactant. Surfactant-
treated animals showed a significant
improvement over saline controls in
measurements of gaseous exchange and
lung function. Despite a trend in favor of
rSP-C surfactant, the small number of
animals included precludes any conclu-
sion about potential differences between
both surfactant preparations.
Electron microscopy showed differ-
ences between the MAS control group
and rSP-C surfactant group in regard to
neutrophil infiltration and alveolar septa
thickening as well as cytoplasmic
changes in alveolar epithelial cells that
were prominent in the former and absent
in the latter. No reference is apparent in
the article about the evaluation of ultra-
structural differences between both sur-
factant groups. To evaluate treatment ef-
fects on surfactant protein synthesis,
both SP-B and SP-C messenger RNA and
protein content in lung homogenate were
measured by polymerase chain reaction
and enzyme-linked immunosorbent as-
say, respectively.
To evaluate the effects of MAS over pro-
tein expression, results from the three ex-
perimental groups were referenced to an-
other group of healthy term piglets
provided by one of the authors. MAS plus
mechanical ventilation significantly in-
creased SP-B messenger RNA expression
and decreased SP-C m-RNA compared with
the reference healthy term piglets. No sig-
nificant differences were seen in any of the
treatment groups compared with the MAS
controls. As for SP-B and SP-C content in
lung homogenate, no significant difference
could be found both after the induction of
lung injury or after the treatment with any
of the surfactant preparations. The rele-
vance and potential implications of these
findings remain unclear.
In summary, the authors have estab-
lished an animal model of MAS to evalu-
ate the response to two different surfac-
tant preparations and attempt, at least
partially, to explain its effects by investi-
gating both surfactant protein synthesis
and ultrastructural morphology. The
negative results regarding SP-B and SP-C
synthesis could be attributed to a failure
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of the model or experimental setting or
simply to a lack of that specific action.
Other ways of reversing surfactant inac-
tivation by meconium have been pro-
posed (9, 10). Hypothetically surfactant
proteins could act by a similar mechanis-
tic effect.
It is worth noting that the investiga-
tors delivered surfactant by bolus admin-
istration as opposed to the strategy of
surfactant lavage advocated by some in-
vestigators for MAS and recently ques-
tioned (11, 12). Although this is well sub-
stantiated, other investigators have found
better results with administration by con-
tinuous infusion (3).
As stated, MAS is, especially in its
most severe presentations, a multiple-
system disease, and practitioners should
remain cautious when interpreting ani-
mal model studies. The search for a syn-
thetic surfactant that can compare with
the natural surfactants available is ongo-
ing. This happens mainly because of the
concern about the potential antigenic
and infectious complications that could
be associated with animal products and
because of the potential to reduce man-
ufacturing costs and availability. These
newer synthetic preparations attempt to
overcome the superiority shown by nat-
ural surfactants by incorporating func-
tional synthetic apoproteins, both recom-
binant, as in the preparation used in this
study as totally synthetic as sinapultide, a
polypeptide mimicking SP-B.
This article provides new evidence on
the effect of a novel surfactant formula-
tion on a neonatal animal model of MAS.
It also could motivate the realization of
adequately powered experiments to eval-
uate differential effects on lung function
and gas exchange and either confirm or
refute the trends reported in this setting.
More questions also remain on the differ-
ential effects of the absence of SP-B and
the different concentrations of SP-C be-
tween different preparations of surfactant
both in MAS and in other pathologic en-
tities.
Gabriel Musante;
Eduardo Schnitzler
Department of Pediatrics
Hospital Universitario Austral
Pilar, Argentina
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Figure 1 Assessment of lysyl oxidase expression and activity in the lungs of mice exposed to
normoxia (21% O2) or chronic hyperoxia (85% O2). A. Lysyl oxidase expression was assessed by
reverse-transcription polymerase chain reaction (RT-PCR) in mRNA isolated from the lungs of
mice exposed to different gas mixtures from day P1, at post-natal days P1, P7, P14, P21 and P28.
Expression of the constitutively-expressed hspa8 gene served as a loading control. B. Lysyl
oxidase expression was assessed by immunoblot in protein extracts from lungs from mice
exposed to different gas mixtures from day P1, at post-natal days P1, P7, P14, P21 and P28.
Expression of the constitutively-expressed D-tubulin served as a loading control. C. Assessment of
lung lysyl oxidase activity by the Amplex Red assay, in the lungs of mice at post-natal days P14
and P28. P < 0.05, by ANOVA with Neuman-Keul modification.
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Figure 2 Assessment of elastin expression in the lungs of mice exposed to normoxia (21% O2)
or chronic hyperoxia (85% O2). A. Elastin expression was assessed by immunohistochemical
analysis in paraffin-embedded lung sections, by Hart’s elastin stain. Neonatal mice were exposed
to different gas mixtures from post-natal day P1. B. Assessment of lung elatistin mRNA levels by
semi-quantitative reverse-transcription polymerase chain reaction (RT-PCR) at post-natal days P1,
P7, P14, P21 and P28. Expression of the constitutively-expressed hspa8 gene served as a loading
control. C. Assessment of lung elastin content by dye-binding assay (FASTINTM elastin assay;
BioColor) in mice at post-natal days P14 and P28. D. Assessment of lung desmosine content at
post-natal days P14 and P28. P < 0.05, by ANOVA with Neuman-Keul modification.
eln
hspa8
P28P21P14P7P1 P28P21P14P7
21% O2 85% O2B
21% O2 85% O2 21% O2 85%
O2
Post-natal day P28Post-natal day P7A
0
10
20
30
40
50
60
70C D
21%
85%Elastin
(Pg)
per 200
Pg
protein
0
50
100
150
200
** 21%85%
P14 P28 P14 P28
Desmosine
(pmol)
per mg
protein
Appendices
252
APPENDIX B
Figure 1 Assessment of lysyl oxidase expression and activity in the lungs of mice exposed to
normoxia (21% O2) or chronic hyperoxia (85% O2). A. Lysyl oxidase expression was assessed by
reverse-transcription polymerase chain reaction (RT-PCR) in mRNA isolated from the lungs of
mice exposed to different gas mixtures from day P1, at post-natal days P1, P7, P14, P21 and P28.
Expression of the constitutively-expressed hspa8 gene served as a loading control. B. Lysyl
oxidase expression was assessed by immunoblot in protein extracts from lungs from mice
exposed to different gas mixtures from day P1, at post-natal days P1, P7, P14, P21 and P28.
Expression of the constitutively-expressed D-tubulin served as a loading control. C. Assessment of
lung lysyl oxidase activity by the Amplex Red assay, in the lungs of mice at post-natal days P14
and P28. P < 0.05, by ANOVA with Neuman-Keul modification.
Appendices
253
Figure 2 Assessment of elastin expression in the lungs of mice exposed to normoxia (21% O2)
or chronic hyperoxia (85% O2). A. Elastin expression was assessed by immunohistochemical
analysis in paraffin-embedded lung sections, by Hart’s elastin stain. Neonatal mice were exposed
to different gas mixtures from post-natal day P1. B. Assessment of lung elatistin mRNA levels by
semi-quantitative reverse-transcription polymerase chain reaction (RT-PCR) at post-natal days P1,
P7, P14, P21 and P28. Expression of the constitutively-expressed hspa8 gene served as a loading
control. C. Assessment of lung elastin content by dye-binding assay (FASTINTM elastin assay;
BioColor) in mice at post-natal days P14 and P28. D. Assessment of lung desmosine content at
post-natal days P14 and P28. P < 0.05, by ANOVA with Neuman-Keul modification.
eln
hspa8
P28P21P14P7P1 P28P21P14P7
21% O2 85% O2B
21% O2 85% O2 21% O2 85%
O2
Post-natal day P28Post-natal day P7A
0
10
20
30
40
50
60
70C D
21%
85%Elastin
(Pg)
per 200
Pg
protein
0
50
100
150
200
** 21%85%
P14 P28 P14 P28
Desmosine
(pmol)
per mg
protein
Appendices
254
Figure 3 Assessment of lysyl oxidase gene expression in the lungs of neonates who died from
non-pulmonary causes (open bars) or neonates who died with BPD (dashed boxes). The bars
represent the data range, while the boxes represent lower and upper quartiles. The line within the
quartile box indicates the mean (n = 5, per group). *, P < 0.05, by ANOVA with Neuman-Keul
modification.
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Due to an unfortunate error, Table 2 was misprinted. The
corrected table is printed below.
Table 2 Cytokine mRNA ex-
pression in superior and inferior
left lung lobes and in inferior
left lung lobe; normalization to
HPRT (H) and b-actin (A) and
further to mRNA expression in
control subjects. Data given as
geometric mean and dispersion
factor
Superior, inferior Inferior
Control
(n=3)
rSP-C Surf
(n=5)
nat SF
(n=4)
Control
(n=3)
rSP-C Surf
(n=5)
nat SF
(n=4)
IL-1b/H 1€0.19 0.17€0.30**b 0.77€0.05 1€0.41 0.08€0.37*b 1.76€0.14
IL-1b/A 1€0.33 0.19€0.27**a 0.63€0.1 1€0.75 0.14€0.35a 1.28€0.10
IL-6/H 1€0.19 1.92€0.29 4.61€0.09 1€0.35 0.74€0.27b 17.3€0.27
IL-6/A 1€0.33 2.11€0.38 3.78€0.2 1€0.51 1.31€0.35a 12.6€0.21
IL-8/H 1€0.14 0.35€0.30 1.34€0.07 1€0.41 0.14€0.35 1.49€0.06
IL-8/A 1€0.22 0.38€0.16 1.1€0.11 1€0.70 0.25€0.20 1.08€0.04
IL-10/H 1€0.35 3.19€0.47* 3.61€0.28** 1€0.31 2.23€0.46 3.94€0.46
IL-10/A 1€0.56 3.5€0.54*** 2.96€0.8*** 1€0.48 3.96€0.48* 2.87€0.88
TGF-b/H 1€0.21 0.88€0.4 2.52€0.23 1€0.28 0.62€0.36 1.75€0.59
TGF-b/A 1€0.42 0.97€0.24 2.06€0.58 1€0.55 1.19€0.41 1.28€0.47
*p<0.05; **p<0.02; ***p<0.01 compared to controls
a p<0.05; b p<0.02 compared to natural bovine surfactant (nat SF)

